Form 8-K

8-K — Ensysce Biosciences, Inc.

Accession: 0001493152-26-036268

Filed: 2026-08-06

Period: 2026-08-05

CIK: 0001716947

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Entry into a Material Definitive Agreement

Item: Completion of Acquisition or Disposition of Assets

Item: Unregistered Sales of Equity Securities

Item: Material Modifications to Rights of Security Holders

Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Item: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-2.1 (ex2-1.htm)

EX-3.1 (ex3-1.htm)

EX-3.2 (ex3-2.htm)

EX-10.1 (ex10-1.htm)

EX-10.2 (ex10-2.htm)

EX-10.3 (ex10-3.htm)

EX-10.4 (ex10-4.htm)

EX-99.1 (ex99-1.htm)

EX-99.2 (ex99-2.htm)

GRAPHIC (ex99-2_001.jpg)

GRAPHIC (ex99-2_002.jpg)

GRAPHIC (ex99-2_003.jpg)

GRAPHIC (ex99-2_004.jpg)

GRAPHIC (ex99-2_005.jpg)

GRAPHIC (ex99-2_006.jpg)

GRAPHIC (ex99-2_007.jpg)

GRAPHIC (ex99-2_008.jpg)

GRAPHIC (ex99-2_009.jpg)

GRAPHIC (ex99-2_010.jpg)

GRAPHIC (ex99-2_011.jpg)

GRAPHIC (ex99-2_012.jpg)

GRAPHIC (ex99-2_013.jpg)

GRAPHIC (ex99-2_014.jpg)

GRAPHIC (ex99-2_015.jpg)

GRAPHIC (ex99-2_016.jpg)

GRAPHIC (ex99-2_017.jpg)

GRAPHIC (ex99-2_018.jpg)

GRAPHIC (ex99-2_019.jpg)

GRAPHIC (ex99-2_020.jpg)

GRAPHIC (ex99-2_021.jpg)

GRAPHIC (ex99-2_022.jpg)

GRAPHIC (ex99-2_023.jpg)

GRAPHIC (ex99-2_024.jpg)

GRAPHIC (ex99-2_025.jpg)

GRAPHIC (ex99-2_026.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

--12-31

0001716947

2026-08-05

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

WASHINGTON,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d)

the Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported): August 5, 2026 (August 5, 2026)

Ensysce

Biosciences, Inc.

(Exact

name of registrant as specified in its charter)

Delaware

001-38306

82-2755287

(State

or other jurisdiction

incorporation or organization)

(Commission

File

Number)

(I.R.S.

Employer

Identification

Number)

7946

Ivanhoe Avenue, Suite 201

Jolla, California

92037

(Address

of principal executive offices)

(Zip

Code)

(858)

263-4196

Registrant’s

telephone number, including area code

N/A

(Former

name or former address, if changed since last report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under

any of the following provisions:

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

Stock, par value $0.0001 per share

ENSC

The

Nasdaq Stock Market LLC

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

1.01.

Entry

into a Material Definitive Agreement.

Agreement

and Plan of Merger

August 5, 2026, Ensysce Biosciences, Inc., a Delaware corporation (“we,” “us,” “our,” or

the “Company”), acquired Cy Biopharma, Inc., a Delaware corporation (“Cy”), in accordance with the terms of

an Agreement and Plan of Merger, dated August 5, 2026 (the “Merger Agreement”), by and among the Company, PHRMA Merger

Sub I, Inc., a Delaware corporation (“First Merger Sub”), PHRMA Merger Sub II, LLC, a Delaware limited liability

company (“Second Merger Sub”), and Cy. Pursuant to the Merger Agreement, First Merger Sub merged with and into Cy,

pursuant to which Cy was the surviving corporation and became a wholly owned subsidiary of the Company (the “First

Merger”). Immediately following the First Merger, Cy merged with and into Second Merger Sub, pursuant to which Second Merger

Sub was the surviving entity and a wholly owned subsidiary of the Company (the “Second Merger” and together with the

First Merger, the “Merger”). The Merger is intended to qualify as a tax-free reorganization for U.S. federal income tax

purposes.

Under

the terms of the Merger Agreement, upon the consummation of the Merger on August 5, 2026 (the “Closing”), in exchange for

the outstanding shares of capital stock of Cy immediately prior to the effective time of the First Merger, the Company issued to the

equityholders of Cy the right to receive 282,122 shares of Series C Preferred Stock of the Company, par value $0.0001 per share

(the “Series C Preferred Stock”). Each share of Series C Preferred Stock is convertible into 1,000 shares of common

stock of the Company, par value $0.0001 per share (“Common Stock”), subject to certain conditions described below.

Reference

is made to the discussion of the Series C Preferred Stock in Item 5.03 of this Current Report on Form 8-K (this “Current

Report”), which is incorporated into this Item 1.01 by reference.

Pursuant

to the Merger Agreement, the Company has agreed to hold a stockholders’ meeting to submit the following matters to its

stockholders for their consideration: (i) the approval of the conversion of shares of Series C Preferred Stock into shares

of Common Stock in accordance with the rules of the Nasdaq Stock Market LLC (the “Conversion Proposal”) and (ii) if

deemed necessary or appropriate by the Company or as otherwise required by applicable law or contract, the approval of an amendment

to the Company’s certificate of incorporation, as amended (the “Charter”), to authorize sufficient shares of

Common Stock for the conversion of Series C Preferred Stock issued pursuant to the Merger Agreement and/or to effectuate a reverse

stock split for the purpose of maintaining compliance with Nasdaq listing standards (the “Charter Amendment Proposal”

and together with the Conversion Proposal, the “Meeting Proposals”). In connection with these matters, the Company has

agreed to file a proxy statement on Schedule 14A with the Securities and Exchange Commission (the “SEC”).

The

Board of Directors of the Company (the “Board”) unanimously approved the Merger Agreement and the related transactions, and

the consummation of the Merger and the concurrent Financing (as defined and described below) was not subject to approval of Company stockholders.

The

foregoing description of the Merger and the Merger Agreement does not purport to be complete and is qualified in its entirety by reference

to the full text of the Merger Agreement, a copy of which is filed as Exhibit 2.1 to this Current Report and is incorporated herein

by reference.

The

Merger Agreement has been filed herewith to provide investors and security holders with information regarding its terms. It is not intended

to provide any other factual information about the Company or Cy. The Merger Agreement contains representations, warranties and covenants

that the Company and Cy made to each other as of specific dates. The assertions embodied in those representations, warranties and covenants

were made solely for purposes of the Merger Agreement between the Company and Cy and may be subject to important qualifications and limitations

agreed to by the Company and Cy in connection with negotiating its terms, including being qualified by confidential disclosures exchanged

between the parties in connection with the execution of the Merger Agreement. Moreover, the representations and warranties may be subject

to a contractual standard of materiality that may be different from what may be viewed as material to investors or security holders.

In addition, information concerning the subject matter of the representations and warranties may change after the date of the Merger

Agreement, which subsequent information may or may not be fully reflected in the Company’s public disclosures. For the foregoing

reasons, no person should rely on the representations and warranties as statements of factual information at the time they were made

or otherwise.

Tungsten

Partners LLC (“Tungsten”) acted as financial advisor to the Company in connection with the Merger. As compensation for

services rendered by Tungsten, the Company paid Tungsten $100,000, and issued 100,000 restricted stock units for Common Stock and a

$15,000 monthly advisory fee that has been paid since the engagement in March 2026. H.C. Wainwright & Co., LLC

(“Wainwright”) was engaged by the Company and received an advisory transaction fee of $250,000 and a fairness opinion

delivery fee of $400,000.

Support

Agreements

connection with the execution of the Merger Agreement, the Company and Cy entered into stockholder support agreements (the “Company

Stockholder Support Agreements”) with certain of the Company’s stockholders (solely in their capacity as stockholders of

the Company). Pursuant to the Company Stockholder Support Agreements, among other things, each of the Company stockholder parties thereto

has agreed to vote or cause to be voted all of the shares of Common Stock owned by such stockholder in favor of the Meeting Proposals.

The

foregoing description of the Company Stockholder Support Agreements does not purport to be complete and is qualified in its entirety

by reference to the full text of the form of the Company Stockholder Support Agreement, a copy of which is included as Exhibit D

to the Merger Agreement, which is filed as Exhibit 2.1 to this Current Report and incorporated herein by reference.

connection with the execution of the Merger Agreement, the Company and Cy entered into stockholder support agreements (the “Cy

Stockholder Support Agreements”) with certain Cy stockholders (solely in their capacity as stockholders of Cy). Pursuant to the

Cy Stockholder Support Agreements, among other things, each of the Cy stockholders has agreed to the terms and conditions of the Merger

Agreement, to waive any dissenters’ rights and to release any claims such stockholder may have against the Company and Cy.

The

foregoing description of the Cy Stockholder Support Agreements does not purport to be complete and is qualified in its entirety by reference

to the full text of the form of the Cy Stockholder Support Agreement, a copy of which is included as Exhibit E to the Merger Agreement,

which is filed as Exhibit 2.1 to this Current Report and incorporated herein by reference.

Lock-up

Agreements

Concurrently

and in connection with the execution of the Merger Agreement, certain Cy stockholders as of immediately prior to the Closing, and certain

directors and officers of the Company as of immediately prior to the Closing, entered into lock-up agreements with the Company and Cy,

pursuant to which each such stockholder agreed to be subject to a 180-day lock-up on the sale or transfer of shares of the Company held

by each such stockholder at the Closing, including those shares of Series C Preferred Stock (including the shares of Common Stock

into which such Series C Preferred Stock is convertible) received by each such stockholder in the Merger (the “Lock-up Agreements”).

The

foregoing description of the Lock-up Agreements does not purport to be complete and is qualified in its entirety by reference to the

full text of the form of the Lock-up Agreement, a copy of which is included as Exhibit B to the Merger Agreement, which is filed

as Exhibit 2.1 to this Current Report and incorporated herein by reference.

Private

Placement and Securities Purchase Agreement

August 5, 2026, the Company entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with the purchasers

party thereto (the “Investors”). Pursuant to the Securities Purchase Agreement, the Company agreed to issue and sell an aggregate

of 120,260 shares of Series C Preferred Stock (the “PIPE Securities”) for an aggregate purchase price of approximately

$43 million (the “Financing”) over two tranches. At the initial closing of the Financing (the “Initial Closing”),

the Company will issue to the Investors 66,811 shares of Series C Preferred Stock at a price of $321.79 per share (or $0.32179 per share

on an as-converted basis), and subject to achievement of a clinical trial milestone, the Company will issue to the Investors 53,449 shares

of Series C Preferred Stock at a price of $402.24 per share (or $0.40224 per share on an as-converted basis) (the “Milestone Closing”).

Each share of Series C Preferred Stock is convertible into 1,000 shares of Common Stock, subject to certain conditions described

in this Current Report. The powers, preferences, rights, qualifications, limitations and restrictions applicable to the Series C

Preferred Stock are set forth in the Certificate of Designation (as defined and described below).

The

Initial Closing is expected to occur on August 7, 2026 (the “Financing Closing Date”), and the Milestone Closing will occur

subject to achievement of a clinical trial milestone.

The

foregoing summary of the Securities Purchase Agreement does not purport to be complete and is qualified in its entirety by reference

to the full text of the form of Securities Purchase Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report and

is incorporated herein by reference.

Registration

Rights Agreements

Registration

Rights Agreement with the Investors

August 5, 2026, in connection with the Securities Purchase Agreement, the Company entered into a Registration Rights Agreement (the “PIPE

Registration Rights Agreement”) with the Investors. Pursuant to the PIPE Registration Rights Agreement, the Company is required

to prepare and file a resale registration statement with the SEC within 90 calendar days following the Financing Closing Date (subject

to certain extensions set forth therein), with respect to the shares of Common Stock underlying the PIPE Securities. The Company will

use its commercially reasonable efforts to cause such registration statement to be declared effective by the SEC by the earlier of (i)

five business days after the SEC determines that it will not review the registration statement or will be subject to no further review

or (ii) 90 calendar days following the initial filing date of the registration statement if the SEC reviews the registration statement

(subject to applicable extensions under the PIPE Registration Rights Agreement).

The

Company has also agreed to, among other things, indemnify the Investors, and each of their respective directors, officers, partners,

employees, members, managers, agents, representatives and advisors, each Person who controls any Investor (within the meaning of Section 15

of the Securities Act of 1933, as amended (the “Securities Act”), or Section 20 of the Securities Exchange Act of 1934,

as amended (the “Exchange Act”)) and the directors, officers, partners, employees, members, managers, agents, representatives

and advisors of each such controlling Person under such registration statement from certain liabilities.

Registration

Rights Agreement with Security Holders of the Company and Cy

August 5, 2026, the Company entered into a Registration Rights Agreement (the “3i/Cy Registration Rights Agreement”) with

certain security holders of the Company and Cy as of immediately prior to the Closing. Pursuant to the 3i/Cy Registration Rights Agreement,

the Company is required to prepare and file a resale registration statement with the SEC within 90 calendar days following the Closing

(subject to certain extensions set forth therein), with respect to the shares of Common Stock underlying the Series C Preferred Stock

issued to such security holders. The Company will use its commercially reasonable efforts to cause such registration statement to be

declared effective by the SEC by the earlier of (i) 5 business days after the SEC determines that it will not review the registration

statement or will be subject to no further review or (ii) 90 calendar days following the initial filing date of the registration statement

if the SEC reviews the registration statement (subject to applicable extensions under the 3i/Cy Registration Rights Agreement).

The

Company has also agreed to, among other things, indemnify the holders of the Series C Preferred Stock party to the 3i/Cy Registration

Rights Agreement, and each of their respective partners, members, directors, officers and stockholders; legal counsel and accountants

for each such stockholder; any underwriter (as defined in the Securities Act) for each such stockholder; and each Person, if any, who

controls such stockholder or underwriter within the meaning of the Securities Act or the Exchange Act from certain liabilities.

The

foregoing summaries of the PIPE Registration Rights Agreement and the 3i/Cy Registration Rights Agreement do not purport to be complete

and are qualified in their entirety by reference to the full texts of the form of PIPE Registration Rights Agreement and the form of

3i/Cy Registration Rights Agreement, copies of which are filed as Exhibit 10.2 and Exhibit 10.3, respectively, to this Current Report

and are incorporated herein by reference.

Omnibus

Amendment and Termination Agreement

August 5, 2026, the Company and 3i, LP (“3i”) entered into an Omnibus Amendment and Termination Agreement (the “OATA”)

pursuant to which the Company and 3i agreed, among other things, to terminate all continuing requirements under all agreements and understandings

among the Company, subsidiaries of the Company and 3i, including eliminating by amendment the Company’s Certificate of Designation

of Series B Preferred Stock (the “Series B Preferred Stock”), cancelling the securities purchase agreement entered into by

the Company and 3i on November 13, 2025 and converting any outstanding Series B Preferred Stock into Common Stock. The OATA will have

no effect if the Company does not acquire Cy within 30 days of August 5, 2026. Under the OATA, all outstanding shares of the Series B

Preferred Stock will be converted into 3,229,276 shares of Common Stock, of which 910,905 shares of Common Stock will be issued directly

to 3i and 2,318,371 shares of Common Stock will be issued to a bona fide financial institution to be held in an abeyance account.

addition, all warrants to purchase shares of Common Stock held by 3i will be converted into 7,182.517 shares of Series C Preferred Stock

at an initial conversion ratio of one share of Series C Preferred Stock to 1,000 shares of Common Stock. The OATA also includes a payment

of $250,000 to 3i and the imposition of a beneficial ownership limitation of 4.99% (or up to 9.99%, which increase shall not take effect

until notice of the increase is provided by 3i and 61 days then elapse) of the Company’s then outstanding shares of Common Stock

(the “Beneficial Ownership Limitation”), with the shares exceeding the Beneficial Ownership Limitation held in abeyance for

the benefit of 3i until such time, if ever, as 3i’s right to such shares would not result in 3i exceeding the Beneficial Ownership

Limitation.

The

OATA requires 3i to execute (i) a Company Stockholder Support Agreement and (ii) the 3i/Cy Registration Rights Agreement. The OATA includes

a mutual general release of claims by each of 3i and the Company against the other.

The

foregoing summary of the OATA does not purport to be complete and is qualified in its entirety by reference to the full text of the OATA,

a copy of which is filed as Exhibit 10.4 to this Current Report and is incorporated herein by reference.

Item

2.01

Completion

of Acquisition or Disposition of Assets

August 5, 2026, the Company completed its business combination with Cy. The information contained in Item 1.01 of this Current Report

is hereby incorporated by reference into this Item 2.01.

Item

3.02

Unregistered

Sales of Equity Securities

The

information contained in Item 1.01 and Item 2.01 of this Current Report is incorporated by reference into this Item 3.02.

Pursuant

to the Merger Agreement and the OATA, the Company issued shares of Common Stock and Series C Preferred Stock. The Company issued

the Common Stock and Series C Preferred Stock to 3i pursuant to the OATA as consideration for the transactions contemplated by the Merger

Agreement. Separately, to satisfy a contractual obligation the Company issued 2,175.368 shares of Series C Preferred Stock (the “Galephar

Transaction”). Such issuances were exempt from the registration requirements of the Securities Act in reliance on Section 3(a)(9)

of the Securities Act.

Pursuant

to the Securities Purchase Agreement, the Company issued or will issue the PIPE Securities to the Investors, each of which represented

that it was a sophisticated investor with such knowledge and experience in financial and business matters as to be able to protect its

own interests in connection with the investment, and was acquiring the PIPE Securities for investment only and not with a view towards,

or for resale in connection with, the public sale or distribution thereof. Such issuances were exempt from the registration requirements

of the Securities Act in reliance on Section 4(a)(2) of the Securities Act.

Neither

the shares of Common Stock and Series C Preferred Stock issued in the Merger and in connection with the OATA, the shares of Series

C Preferred Stock issued in the Galephar Transaction, nor the PIPE Securities have been registered under the Securities Act and none

of such securities may be offered or sold in the United States absent registration or an exemption from registration under the Securities

Act and any applicable state securities laws.

Neither

this Current Report nor any of the exhibits attached hereto will constitute an offer to sell or the solicitation of an offer to buy shares

of Common Stock, Series C Preferred Stock or any other securities of the Company.

Item

3.03

Material

Modification to Rights of Security Holders.

the extent required by Item 3.03 of Form 8-K, the information contained in Item 5.03 of this Current Report is incorporated by reference

into this Item 3.03.

Item

5.02

Departure

of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Resignation

of Lynn Kirkpatrick as President and Appointment of James Morrison as President and Director

Pursuant

to the Merger Agreement, on August 5, 2026, Lynn Kirkpatrick resigned from her position as President of the Company, effective immediately

upon the Closing. Dr. Kirkpatrick will continue to serve as the Company’s Chief Executive Officer until stockholder approval of

the Meeting Proposals.

Appointment

of James Morrison as President and Director

Pursuant

to the Merger Agreement, on August 4, 2026, the Board, upon the recommendation of the Nominating and Corporate Governance Committee of

the Board, appointed James Morrison as President and as a director of the Company effective immediately upon the Closing and appointed

Mr. Morrison as Chief Executive Officer effective upon approval of the Meeting Proposals.

James

Morrison is the Founder of Cy and served as President of Cy from October 2019 until the closing of the Merger and as its Chief Executive

Officer from 2021 until the closing of the Merger. Mr. Morrison founded Cy to develop innovative therapies for neurological and neuropsychiatric

disorders and led the company’s scientific, financing and corporate development strategies. Previously, Mr. Morrison worked in

the commodities trading and financial services industries. Mr. Morrison holds a Bachelor of Civil Law degree from the University of Oxford.

There

are no arrangements or understandings between Mr. Morrison and any other person pursuant to which he was selected as a director and an

executive officer other than in connection with the Merger as described herein and his expected appointment as the Company’s Chief

Executive Officer following stockholder approval of the Meeting Proposals, and there are no family relationships between Mr. Morrison

and any of the Company’s directors or executive officers. Mr. Morrison has no direct or indirect material interest in any existing

or currently proposed transaction that would require disclosure under Item 404(a) of Regulation S-K.

connection with his appointment, Mr. Morrison entered into the Company’s standard form of indemnification agreement, a copy of

which was initially filed as Exhibit 10.6 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on November

15, 2021.

Item

5.03.

Amendments

to Articles of Incorporation or Bylaws; Change in Fiscal Year.

Certificate

of Designation (Elimination of Series B Preferred Stock)

August 5, 2026, the Company filed with the Secretary of State of the State of Delaware a Certificate of Elimination of Series B Preferred

Stock (the “Certificate of Elimination”). The Certificate of Elimination has the effect of eliminating from the Company’s

Third Amended and Restated Certificate of Incorporation, as amended, all matters set forth in the Certificate of Designation of Series

B Preferred Stock previously filed by the Company. The sole holder of the Series B Preferred Stock consented to an amendment of the Series

B Preferred Stock to eliminate such certificate.

All

shares of Series B Preferred Stock previously issued or issuable have been converted into shares of Common Stock. The shares of preferred

stock previously designated as Series B Preferred Stock, having been redeemed, purchased or acquired, have been eliminated and returned

to the status of authorized but unissued shares of preferred stock, without designation. No shares of Series B Preferred Stock were issued

and outstanding as of the date of filing of the Certificate of Elimination.

The

foregoing is a summary of the terms of the Certificate of Elimination. The summary does not purport to be complete and is qualified in

its entirety by reference to the Certificate of Elimination, a copy of which is filed with this Form 8-K as Exhibit 3.1 and is incorporated

by reference herein.

Certificate

of Designation (Issuance of Series C Non-Voting Convertible Preferred Stock)

August 5, 2026, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of the Series C Non-Voting

Convertible Preferred Stock (the “Series C Certificate of Designation”) with the Secretary of State of the State of Delaware

in connection with the Merger referenced in Item 1.01 above. The Series C Certificate of Designation provides for the designation of

shares of the Company’s Series C Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the “Series C

Preferred Stock”).

The

Series C Preferred Stock is redeemable for cash at the option of the holder thereof at any time following approval of the Conversion

Proposal if there is any failure to deliver shares of Common Stock in accordance with the terms of the Series C Preferred Stock,

at a price per share equal to the then-current fair value of the Series C Preferred Stock, as described in the Series C Certificate

of Designation.

Holders

of Series C Preferred Stock are entitled to receive dividends on shares of Series C Preferred Stock equal to, on an as-if-converted-to-Common-Stock

basis, and in the same form as dividends actually paid on shares of the Common Stock.

Except

as otherwise required by law, the Series C Preferred Stock does not have voting rights. However, as long as any shares of Series C

Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then-outstanding

shares of the Series C Preferred Stock, (i) alter or change adversely the powers, preferences or rights given to the Series C

Preferred Stock or alter or amend the Series C Certificate of Designation, amend or repeal any provision of, or add any provision to,

the Charter or bylaws of the Company, or file any articles of amendment, certificate of designations, preferences, limitations and relative

rights of any series of preferred stock, in each case if any such action would adversely alter or change the preferences, rights, privileges

or powers of, or restrictions provided for the benefit of the Series C Preferred Stock, regardless of whether any of the foregoing

actions shall be by means of amendment to the Charter or by merger, consolidation, recapitalization, reclassification, conversion or

otherwise, (ii) issue further shares of Series C Preferred Stock, (iii) prior to the earlier of stockholder approval of

the Conversion Proposal or at any time while at least 30% of the originally issued Series C Preferred Stock remains issued and outstanding,

consummate either: (A) any Fundamental Transaction (as defined in the Series C Certificate of Designation) or (B) any stock

sale to, or any merger, consolidation or other business combination of the Company with or into, another entity in which the stockholders

of the Company immediately before such transaction do not hold at least a majority of the capital stock of the Company immediately after

such transaction, (iv) prior to the stockholder approval, authorize or issue any class or series of stock that has powers, preferences

or rights that are senior to those of the Series C Preferred Stock, (v) amend, waive or modify the Merger Agreement in any manner that

would be reasonably likely to prevent, impede or materially delay the stockholder approval or the automatic conversion of the Series

C Preferred Stock into shares of Common Stock or (vi) enter into any agreement with respect to any of the foregoing.

The

Series C Preferred Stock does not have a preference upon any liquidation, dissolution or winding-up of the Company.

Following

stockholder approval of the Conversion Proposal, each share of Series C Preferred Stock will automatically convert into 1,000 shares

of Common Stock, subject to certain limitations, including that a holder of Series C Preferred Stock is prohibited from converting

shares of Series C Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its

affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total

number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion.

The

foregoing description of the Series C Preferred Stock does not purport to be complete and is qualified in its entirety by reference

to the full text of the Series C Certificate of Designation, a copy of which is filed as Exhibit 3.2 to this Current Report and

is incorporated herein by reference.

Item

7.01.

Regulation

FD Disclosure.

Press

Release

August 6, 2026, the Company issued a press release announcing the Merger and the Financing. A copy of the press release is furnished

as Exhibit 99.1 to this Current Report.

copy of the corporate presentation used in connection with the Financing is furnished as Exhibit 99.2 to this Current Report.

The

information in Item 7.01 of this Current Report, including the information in the press release attached as Exhibit 99.1 and the

corporate presentation attached as Exhibit 99.2 to this Current Report, is furnished pursuant to Item 7.01 of Form 8-K and shall

not be deemed “filed” for the purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of

that section. Furthermore, the information in Item 7.01 of this Current Report, shall not be deemed to be incorporated by reference in

the filings of the Company under the Securities Act.

Item

9.01

Financial

Statements and Exhibits.

(a)

Financial statements of business acquired

The

financial statements required by this Item, with respect to the Merger described in Item 2.01 herein, are expected to be filed by amendment

as soon as practicable, and in any event not later than 71 days after the date on which this Current Report on Form 8-K is required

to be filed related to Item 2.01.

(b)

Pro forma financial information

The

pro forma financial information required by this Item, with respect to the Merger described in Item 2.01 herein, is expected to be filed

by amendment as soon as practicable, and in any event not later than 71 days after the date on which this Current Report is required

to be filed related to Item 2.01.

Forward-Looking

Statements

This

Current Report contains certain forward-looking statements within the meaning of Section 27A of the Securities Act, and Section 21E of

the Securities Exchange Act of 1934, as amended. These statements may be made directly in this report. Some of the forward-looking statements

can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words “anticipate,”

“expect,” “suggests,” “plan,” “believe,” “intend,” “estimates,”

“targets,” “projects,” “should,” “could,” “would,” “may,” “will,”

“forecast” and other similar expressions are intended to identify forward-looking statements. These forward-looking statements

include, but are not limited to: statements regarding the Company, Cy, the Financing (including expectations regarding the achievement

of the clinical trial milestone required for the Milestone Closing) and the Merger, and the expected effects, perceived benefits or opportunities

and related timing with respect thereto; statements regarding stockholder approval of the Meeting Proposals and changes in Company management

in connection with such stockholder approval; expectations regarding or plans for the combined company’s pipeline, including clinical

trials and research and development programs; and expectations regarding the use of proceeds from the Financing and cash runway expectations

therefrom, including such proceeds funding the combined company through key clinical milestones and the expected timing of such milestones.

All forward-looking statements are based upon management estimates and forecasts and reflect the views, assumptions, expectations, and

opinions of the Company as of the date of this Current Report, and may include, without limitation, changes in general economic and political

conditions, all of which are accordingly subject to change. Any such estimates, assumptions, expectations, forecasts, views or opinions

set forth in this Current Report constitute the Company’s judgments and should be regarded as indicative, preliminary and for illustrative

purposes only. The forward-looking statements and projections contained in this Current Report are subject to several factors, risks

and uncertainties, some of which are not currently known to the Company, that may cause the Company’s actual results, performance

or financial condition to be materially different from the expectations of future results, performance or financial condition. Although

such forward-looking statements have been made in good faith and are based on assumptions that the Company believes to be reasonable,

there is no assurance that the expected results will be achieved. The Company’s actual results may differ materially from the results

discussed in forward-looking statements. Additional information on factors that may cause actual results and the Company’s performance

to differ materially is included in the Company’s filings with the SEC. Copies of such filings with the SEC are available publicly

on the SEC’s website at www.sec.gov or may be obtained by contacting the Company. Readers are cautioned not to place undue

reliance upon any forward-looking statements, which speak only as of the date made. These forward-looking statements are made only as

of the date hereof, and the Company does not undertake any obligation to update or revise the forward-looking statements, whether as

a result of new information, future events or otherwise, except as required by law.

Offer or Solicitation; Important Information About the Merger and Where to Find It

This

Current Report is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect

of the Merger and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of the Company or Cy, nor

shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful

prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made,

except by means of a prospectus meeting the requirements of Section 10 of the Securities Act or an exemption therefrom.

The

Company expects to file a proxy statement with the SEC relating to the Meeting Proposals. The definitive proxy statement will be sent

to all Company stockholders. Before making any voting decision, investors and security holders of the Company are urged to read the proxy

statement and all other relevant documents filed or that will be filed with the SEC in connection with the Meeting Proposals as they

become available because they will contain important information about the Merger Agreement and related transactions and the Meeting

Proposals to be voted upon. Investors and security holders will be able to obtain free copies of the proxy statement and all other relevant

documents filed or that will be filed with the SEC by the Company through the website maintained by the SEC at www.sec.gov.

Participants

in Solicitation

The

Company, Cy, and their respective directors, executive officers and employees may be deemed to be participants in the solicitation of

proxies in respect of the Merger. Information regarding the persons who may, under the rules of the SEC, be deemed participants

in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained

in the proxy statement and other relevant materials to be filed with the SEC when they become available.

(d)

Exhibits

Exhibit

Number

Description

2.1*

Agreement and Plan of Merger, dated August 5, 2026, by and among Ensysce Biosciences, Inc., PHRMA Merger Sub I, Inc., PHRMA Merger Sub II, LLC and Cy Biopharma, Inc.

3.1

Certificate of Elimination of Series B Preferred Stock of Ensysce Biosciences, Inc., dated August 5, 2026.

3.2

Certificate of Designation of Series C Non-Voting Convertible Preferred Stock of Ensysce Biosciences, Inc., dated August 5, 2026.

10.1*

Form of Securities Purchase Agreement.

10.2*

Form of Registration Rights Agreement with the Investors.

10.3*

Form of Registration Rights Agreement with certain security holders of Ensysce Biosciences, Inc. and Cy Biopharma, Inc.

10.4

Omnibus Amendment and Termination Agreement, dated August 5, 2026, between Ensysce Biosciences, Inc. and 3i, LP.

99.1

Press Release of Ensysce Biosciences, Inc.

99.2

Corporate Presentation, dated July 2026.

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document).

Certain

annexes, schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant agrees to furnish

supplementally a copy of any omitted attachment to the SEC on a confidential basis upon request.

SIGNATURE

Pursuant

to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its

behalf by the undersigned hereunto duly authorized.

Dated: August

6, 2026

Ensysce

Biosciences, Inc.

By:

/s/

Lynn Kirkpatrick

Name:

Dr.

Lynn Kirkpatrick

Title:

Chief

Executive Officer

(Principal

Executive Officer)

EX-2.1

Filename: ex2-1.htm · Sequence: 2

Exhibit

2.1

AGREEMENT

AND PLAN OF MERGER

and among:

ensysce

biosciences, Inc.,

Delaware corporation;

PHRMA

MERGER SUB I, INC.,

Delaware corporation;

PHRMA

MERGER SUB II, LLC,

Delaware limited liability company;

and

Biopharma, Inc.,

Delaware corporation

dated

as of August 5, 2026

TABLE

OF CONTENTS

Page

SECTION 1.

DESCRIPTION

OF TRANSACTION

1.1

The

Merger

1.2

Effects

of the Merger

1.3

Closing;

First Effective Time; Second Effective Time

1.4

Certificate

of Designation; Certificate of Incorporation and Bylaws; Directors and Officers.

1.5

Merger

Consideration; Effect of Merger on Company Capital Stock

1.6

Conversion

of Shares

1.7

Closing

of the Company’s Transfer Books

1.8

Exchange

of Shares

1.9

Appraisal

Rights.

1.10

Further

Action

1.11

Withholding

SECTION 2.

REPRESENTATIONS

AND WARRANTIES OF THE COMPANY

2.1

Due

Organization; Subsidiaries

2.2

Organizational

Documents

2.3

Authority;

Binding Nature of Agreement.

2.4

Vote

Required

2.5

Non-Contravention;

Consents

2.6

Capitalization.

2.7

Financial

Statements

2.8

Absence

of Changes

2.9

Absence

of Undisclosed Liabilities

2.10

Title

to Assets

2.11

Real

Property; Leasehold

2.12

Intellectual

Property; Privacy

2.13

Agreements,

Contracts and Commitments

2.14

Compliance;

Permits; Restrictions

2.15

Legal

Proceedings; Orders

2.16

Tax

Matters

2.17

Employee

and Labor Matters; Benefit Plans

2.18

Environmental

Matters

2.19

Insurance

-i-

TABLE OF CONTENTS

(continued)

Page

2.20

Financial Advisors

2.21

Transactions

with Affiliates

2.22

Anti-Bribery

2.23

Disclaimer

of Other Representations or Warranties

SECTION 3.

REPRESENTATIONS

AND WARRANTIES OF PARENT AND MERGER SUBS

3.1

Due

Organization; Subsidiaries

3.2

Organizational

Documents

3.3

Authority;

Binding Nature of Agreement

3.4

Vote

Required

3.5

Non-Contravention;

Consents

3.6

Capitalization

3.7

SEC

Filings; Financial Statements

3.8

Absence

of Changes

3.9

Absence

of Undisclosed Liabilities

3.10

Title

to Assets

3.11

Real

Property; Leasehold

3.12

Intellectual

Property; Privacy

3.13

Agreements,

Contracts and Commitments

3.14

Compliance;

Permits

3.15

Legal

Proceedings; Orders

3.16

Tax

Matters

3.17

Employee

and Labor Matters; Benefit Plans

3.18

Environmental

Matters

3.19

Transactions

with Affiliates

3.20

Insurance

3.21

Opinion

of Financial Advisor

3.22

Financial Advisors

3.23

Anti-Bribery

3.24

Valid

Issuance

3.25

Agreement

3.26

Disclaimer

of Other Representations or Warranties

-ii-

TABLE OF CONTENTS

(continued)

Page

SECTION 4.

ADDITIONAL

AGREEMENTS OF THE PARTIES

4.1

Parent

Stockholders’ Meeting

4.2

Proxy

Statement

4.3

Reservation

of Parent Common Stock; Issuance of Shares of Parent Common Stock

4.4

Employee

Benefits

4.5

Indemnification

of Officers and Directors

4.6

Additional

Agreements

4.7

Listing

4.8

Tax

Matters

4.9

Legends

4.10

Directors

and Officers

4.11

Section

16 Matters

4.12

Closing

Certificates

4.13

Takeover

Statutes

4.14

Obligations

of Merger Subs

4.15

Private

Placement

4.16

Issuance

of Parent RSUs

4.17

Use

of Proceeds

SECTION 5.

CONDITIONS

PRECEDENT TO OBLIGATIONS OF EACH PARTY

5.1

Restraints

5.2

Certificate

of Designation

5.3

Parent

Financing

SECTION 6.

CLOSING

DELIVERIES OF THE COMPANY

6.1

Documents

6.2

FIRPTA

Certificate

6.3

Company

Lock-Up Agreements

6.4

Company

Stockholder Support Agreements

6.5

Registration

Rights Agreements

SECTION 7.

CLOSING

DELIVERIES OF PARENT

7.1

Documents

7.2

Parent

Lock-Up Agreements

7.3

Registration

Rights Agreements

-iii-

TABLE OF CONTENTS

(continued)

Page

SECTION 8.

MISCELLANEOUS

PROVISIONS

8.1

Non-Survival

of Representations and Warranties

8.2

Amendment

8.3

Waiver

8.4

Entire

Agreement; Counterparts; Exchanges by Electronic Transmission

8.5

Applicable

Law; Jurisdiction

8.6

Attorneys’

Fees

8.7

Assignability

8.8

Notices

8.9

Cooperation

8.10

Severability

8.11

Other

Remedies; Specific Performance

8.12

Third-Party Beneficiaries

8.13

Construction

8.14

Expenses

-iv-

Exhibits:

Exhibit

Definitions

A-1

Exhibit

Form

of Lock-Up Agreement

B-1

Exhibit

Form

of Certificate of Designation

C-1

Exhibit

Form

of Parent Stockholder Support Agreement

D-1

Exhibit

Form

of Company Stockholder Support Agreement

E-1

Exhibit

Letter

of Transmittal

F-1

Exhibit

Registration

Rights Agreement

G-1

-v-

AGREEMENT

AND PLAN OF MERGER

THIS

AGREEMENT AND PLAN OF MERGER (this “Agreement”) is made entered into as of August 5, 2026, by and among ENSYSCE

BIOSCIENCES, INC., a Delaware corporation (“Parent”), PHRMA MERGER SUB I, INC., a Delaware corporation

and wholly owned subsidiary of Parent (“First Merger Sub”), PHRMA MERGER SUB II, LLC, a Delaware limited

liability company and wholly owned subsidiary of Parent (“Second Merger Sub” and together with First Merger

Sub, “Merger Subs”), and CY BIOPHARMA, INC., a Delaware corporation (the “Company”),

(each, a “Party” and collectively, the “Parties”). Certain capitalized terms used

in this Agreement are defined in Exhibit A.

RECITALS

Parent and the Company desire to enter into a business combination as contemplated by this Agreement based on the mutually agreed values

of each of Parent and the Company.

Parent and the Company intend to effect a merger of First Merger Sub with and into the Company (the “First Merger”)

in accordance with this Agreement and the DGCL. Upon consummation of the First Merger, First Merger Sub will cease to exist and the Company

will become a wholly owned subsidiary of Parent.

Immediately following the First Merger and as part of the same overall transaction as the First Merger, the Company will merge with and

into Second Merger Sub (the “Second Merger” and, together with the First Merger, the “Merger”),

with Second Merger Sub being the surviving entity of the Second Merger.

The Parties intend that: (i) the First Merger and the Second Merger, taken together, will constitute an integrated transaction described

in Rev. Rul. 2001-46, 2001-2 C.B. 321, that qualifies as a “reorganization” within the meaning of Section 368(a) of the Code,

and (ii) this Agreement will constitute, and is hereby adopted as, a plan of reorganization within the meaning of Treasury Regulations

Sections 1.368-2(g) and 1.368-3(a).

The Parent Board has: (i) determined that the Contemplated Transactions are fair to, advisable and in the best interests of Parent and

its stockholders (“Parent Stockholders”), (ii) approved and declared advisable this Agreement and the Contemplated

Transactions, including the issuance of the Parent Preferred Stock Payment Shares to the stockholders of the Company (“Company

Stockholders”) pursuant to the terms of this Agreement, and (iii) determined to recommend, upon the terms and subject to

the conditions set forth in this Agreement, that the Parent Stockholders vote to approve the Parent Stockholder Matters at the Parent

Stockholders’ Meeting to be convened following the Closing.

The First Merger Sub Board has: (i) determined that the Contemplated Transactions are fair to, advisable, and in the best interests of

First Merger Sub and its sole stockholder, (ii) approved and declared advisable this Agreement and the Contemplated Transactions, and

(iii) determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the sole stockholder of

First Merger Sub votes to adopt this Agreement and thereby approve the Contemplated Transactions.

The sole member of the Second Merger Sub has (i) determined that the Contemplated Transactions are fair to, advisable, and in the best

interests of Second Merger Sub and its sole member, (ii) approved and

declared advisable this Agreement and the Contemplated Transactions, and (iii) determined to recommend,

upon the terms and subject to the conditions set forth in this Agreement, that the sole member of Second Merger Sub votes to adopt

this Agreement and thereby approve the Contemplated Transactions.

The Company Board has: (i) determined that the Contemplated Transactions are fair to, advisable and in the best interests of the Company

Stockholders, (ii) approved and declared advisable this Agreement and the Contemplated Transactions, and (iii) recommended, upon the

terms and subject to the conditions set forth in this Agreement, that the Company Stockholders vote to approve the Company Stockholder

Matters (collectively, the “Board Approval”).

Subsequent to the Board Approval, but prior to the execution and delivery of this Agreement, Company Stockholders holding a majority

of the outstanding Company Capital Stock, by written consent and in accordance with the Company’s certificate of incorporation,

the Company’s bylaws and the DGCL: (i) approved and adopted this Agreement and the Contemplated Transactions, (ii)

acknowledged that the approval given thereby is irrevocable and that such stockholder is aware of its rights to demand appraisal for

its shares pursuant to Section 262 of the DGCL, a true and correct copy of which was attached thereto, and that such Company Stockholder

has received and read a copy of Section 262 of the DGCL, and (iii) acknowledged that by its approval of the Merger it is not entitled

to appraisal rights with respect to its shares in connection with the Merger and thereby waives any rights to receive payment of the

fair value of its capital stock under the DGCL (such matters, the “Company Stockholder Matters” and the consent,

the “Stockholder Written Consent”), and the Stockholder Written Consent is to become effective by its terms

immediately following the execution of this Agreement by the parties hereto.

Concurrently with the execution and delivery of this Agreement and as a condition and inducement to each of Parent and the Company’s

willingness to enter into this Agreement, the directors and the officers of Parent listed in Section A-1 of the Parent Disclosure

Schedule (solely in their capacity as Parent Stockholders) (the “Parent Signatories”) and the directors and

the officers of the Company listed in Section A-1 of the Company Disclosure Schedule (the “Company Signatories”)

(solely in their capacity as stockholders) are executing lock-up agreements in substantially the form attached as Exhibit B (each,

a “Lock-Up Agreement”).

As a condition and inducement to the Parties’ willingness to enter into this Agreement, concurrently with the execution and delivery

of this Agreement and conditioned solely on Closing, the Parent and certain investors named in that certain purchase agreement (collectively,

the “PIPE Investors”), dated as of the date hereof (the “Securities Purchase Agreement”),

have executed and delivered the Securities Purchase Agreement, pursuant to which the PIPE Investors have agreed to purchase the number

of shares of Parent Convertible Preferred Stock set forth in the Securities Purchase Agreement in connection with the Parent Financing.

Concurrently with the execution and delivery of this Agreement and as a condition and inducement to the Company’s willingness to

enter into this Agreement, certain stockholders set forth on Section A-2 of the Parent Disclosure Schedule (solely in their capacity

as stockholders) are executing support agreements in favor of the Company in substantially the form attached hereto as Exhibit D (the

“Parent Stockholder Support Agreement”), pursuant to which such Persons have, subject to the terms and conditions

set forth in the Parent Stockholder Support Agreement, agreed to vote all of their shares of capital stock of Parent in favor of the

Parent Stockholder Matters.

Concurrently with the execution and delivery of this Agreement and as a condition and inducement to Parent’s willingness to enter

into this Agreement, all of the Company Stockholders are executing Company Stockholder Support Agreements in substantially the form attached

hereto as Exhibit E (the “Company Stockholder Support Agreement”).

Immediately following the execution and delivery of this Agreement, but prior to the filing of the Certificate of Merger, Parent will

file the Certificate of Designation with the office of the Secretary of State of the State of Delaware.

Concurrently with the execution and delivery of this Agreement and as a condition and inducement to the Company’s willingness to

enter into this Agreement, Parent is executing a registration rights agreement in substantially the form attached as Exhibit G

(the “Registration Rights Agreement”).

AGREEMENT

The

Parties, intending to be legally bound, agree as follows:

SECTION 1.

DESCRIPTION OF TRANSACTION

1.1

The Merger. Upon the terms and subject to the conditions set forth in this Agreement, at the First Effective Time, First

Merger Sub shall be merged with and into the Company, and the separate existence of First Merger Sub shall cease. As a result of the

First Merger, the Company will continue as the surviving corporation in the First Merger (the “First Step Surviving Corporation”).

Upon the terms and subject to the conditions set forth in this Agreement, at the Second Effective Time, the First Step Surviving Corporation

will merge with and into Second Merger Sub, and the separate existence of the First Step Surviving Corporation shall cease. As a result

of the Second Merger, Second Merger Sub will continue as the surviving entity in the Second Merger (the “Surviving Entity”).

1.2

Effects of the Merger. At and after the First Effective Time, the First Merger shall have the effects set forth in this

Agreement, the First Certificate of Merger and in the applicable provisions of the DGCL. As a result of the First Merger, the First Step

Surviving Corporation will become a wholly owned subsidiary of Parent. Without limiting the generality of the foregoing, and subject

thereto, at the First Effective Time, all the property, rights, privileges, agreements, powers and franchises, debts, liabilities, duties

and obligations of First Merger Sub and the Company will become the property, rights, privileges, agreements, powers and franchises,

debts, liabilities, duties and obligations of the First Step Surviving Corporation. At and after the Second Effective Time, the Second

Merger shall have the effects set forth in this Agreement, the Second Certificate of Merger and in the applicable provisions of the DGCL

and the DLLCA. Without limiting the generality of the foregoing, and subject thereto, at the Second Effective Time, all the property,

rights, privileges, agreements, powers and franchises, debts, liabilities, duties and obligations of Second Merger Sub and the First

Step Surviving Corporation will become the property, rights, privileges, agreements, powers and franchises, debts, liabilities, duties

and obligations of the Surviving Entity.

1.3

Closing; First Effective Time; Second Effective Time. The consummation of the Merger (the “Closing”)

is being consummated remotely via the electronic exchange of documents and signatures substantially simultaneously with the execution

and delivery of this Agreement, or at such other time, date and place as Parent and the Company may mutually agree in writing. The date

on which the Closing actually takes place is referred to as the “Closing Date. At the Closing: (a) the Parties shall

cause the First Merger to be consummated by executing and filing with

the Secretary of State of the State of Delaware a certificate of merger with respect to the First Merger, satisfying the applicable requirements

of the DGCL and in form and substance to be agreed upon by the Parties (the “First Certificate of Merger”),

and (b) the Parties shall cause the Second Merger to be consummated by executing and filing with the Secretary of State of the State

of Delaware a certificate of merger with respect to the Second Merger, satisfying the applicable requirements of the DGCL and the DLLCA

and in form and substance to be agreed upon by the Parties (the “Second Certificate of Merger” and together

with the First Certificate of Merger, the “Certificates of Merger”). The First Merger shall become effective

at the time of the filing of such First Certificate of Merger with the Secretary of State of the State of Delaware or at such later time

as may be specified in such First Certificate of Merger with the consent of Parent and the Company (the time as of which the First Merger

becomes effective being referred to as the “First Effective Time”). The Second Merger shall become effective

at the time of the filing of such Second Certificate of Merger with the Secretary of State of the State of Delaware or at such later

time as may be specified in such Second Certificate of Merger with the consent of Parent and the Company (the time as of which the Second

Merger becomes effective being referred to as the “Second Effective Time”).

1.4

Certificate of Designation; Certificate of Incorporation

and Bylaws; Directors and Officers.

(a)

Prior to the First Effective Time, Parent will file the Certificate of Designation with the office of the Secretary of State of the State

of Delaware.

(b)

At the First Effective Time:

(i)

the certificate of incorporation of the First Step Surviving Corporation shall be amended and restated as set forth in an exhibit to

the First Certificate of Merger, until thereafter amended as provided by the DGCL and such certificate of incorporation;

(ii)

the bylaws of the First Step Surviving Corporation shall be amended and restated in their entirety to read identically to the bylaws

of the Company as in effect immediately prior to the First Effective Time, until thereafter amended as provided by the DGCL and such

bylaws; and

(iii)

the directors and officers of the First Step Surviving Corporation, each to hold office in accordance with the certificate of incorporation

and bylaws of the First Step Surviving Corporation, shall be such persons as shall be mutually agreed upon by Parent and the Company.

(c)

At the Second Effective Time:

(i)

the certificate of formation of the Surviving Entity shall be the certificate of formation of Second Merger Sub as in effect immediately

prior to the Second Effective Time, until thereafter amended as provided by the DLLCA and such certificate of formation; provided,

however, that at the Second Effective Time (as part of the Second Certificate of Merger), the certificate of formation shall be

amended to: (A) change the name of the Surviving Entity to “Cy Biopharma, LLC,” (B)

comply with Section 4.5, and (C) make such other changes as are mutually agreed to by Parent and the Company;

(ii)

the limited liability company agreement of the Surviving Entity shall be amended and restated in its entirety to read identically to

the limited liability company agreement of Second Merger Sub as in effect immediately prior to the Second Effective Time, until thereafter

amended as provided by the DLLCA and such limited liability company agreement; provided, however, that following the Second

Effective Time (but as soon thereafter as practicable), the limited liability company agreement shall be amended to: (A) comply with

Section 4.5, and (B) change the name of the Surviving Entity to “Cy Biopharma, LLC”;

(iii)

the managers and officers of the Surviving Entity, each to hold office in accordance with the certificate of formation and limited liability

company agreement of the Surviving Entity, shall be such persons as shall be mutually agreed upon by Parent and the Company; and

(iv)

the certificate of incorporation of Parent shall be identical to the certificate of incorporation of Parent immediately prior to the

Second Effective Time, until thereafter amended as provided by the DGCL and such certificate of incorporation; provided, however,

that following the Second Effective Time, the certificate of incorporation may be amended to make such other changes as are mutually

agreed to by Parent and the Company.

1.5

Merger Consideration; Effect of Merger on Company Capital Stock. The aggregate merger consideration (as adjusted for the

final sentence of this Section 1.5, the “Merger Consideration”) to be paid by Parent for all of the

outstanding shares of Company Capital Stock at the Closing shall be 228,923 shares of Parent Convertible Preferred Stock (“Parent

Preferred Stock Payment Shares”). Each Parent Preferred Stock Payment Share shall be convertible into 1,000 shares of Parent

Common Stock, subject to and contingent upon the affirmative vote of a majority of the Parent Common Stock present or represented and

entitled to vote at a meeting of Parent Stockholders to approve, for purposes of Nasdaq Stock Market Rules, the issuance of shares of

Parent Common Stock to the Company Stockholders upon conversion of any and all shares of Parent Convertible Preferred Stock, in accordance

with the terms of the Certificate of Designation in substantially the form attached hereto as Exhibit C (the “Preferred

Stock Conversion Proposal”). In addition, all outstanding convertible notes issued under the Cy Convertible Note Purchase

Agreement shall be converted for an aggregate amount of 53,199 shares of Parent Convertible Preferred Stock, and such issuances of Parent

Convertible Preferred Stock shall be deemed to be Merger Consideration under this Agreement.

1.6

Conversion of Shares.

(a)

At the First Effective Time, by virtue of the First Merger and without any further action on the part of Parent, Merger Subs, the Company

or any stockholder of the Company or Parent:

(i)

any shares of Company Common Stock held as treasury stock or held or owned by the Company or any wholly owned Subsidiary of the Company

immediately prior to the First Effective Time shall be canceled and retired and shall cease to exist, and no consideration shall be delivered

in exchange therefor; and

(ii)

subject to Section 1.5 and Section 1.6(c), each share of Company Capital Stock outstanding immediately prior to the First

Effective Time (excluding shares to be canceled pursuant to Section 1.6(a)(i) and excluding Dissenting Shares) shall be automatically

converted solely into the right to receive the number of Parent Preferred

Stock Payment Shares as set forth on the Allocation Certificate.

(b)

The Company hereby covenants and agrees that, if any shares of Company Common Stock outstanding immediately prior to the First Effective

Time are subject to a repurchase option or a risk of forfeiture under any applicable restricted stock purchase agreement or other similar

agreement with the Company, the Company will cause such shares of Company Common Stock to no longer be subject to any right of repurchase,

risk of forfeiture or other such conditions as of the First Effective Time.

(c)

No fractional shares of Parent Convertible Preferred Stock shall be issued in connection with the First Merger, and no certificates or

scrip for any such fractional shares shall be issued and no cash shall be paid for any such fractional shares. Any fractional shares

of Parent Convertible Preferred Stock that a holder of Company Capital Stock would otherwise be entitled to receive, including without

limitation any conversion of Parent Convertible Preferred Stock into Parent Common Stock, shall be aggregated with all fractional shares

of Parent Convertible Preferred Stock issuable to such holder and any remaining fractional shares shall be rounded down to the nearest

whole share.

(d)

At the First Effective Time, by virtue of the First Merger and without any further action on the part of Parent, Merger Subs, the Company

or any member of the Company or stockholder of Parent, each share of common stock of First Merger Sub issued and outstanding immediately

prior to the First Effective Time shall be converted into and exchanged for one share of common stock of the First Step Surviving Corporation.

If applicable, each stock certificate of First Merger Sub evidencing ownership of any such shares of common stock of First Merger Sub

shall, as of the First Effective Time, evidence ownership of such shares of common stock of the First Step Surviving Corporation.

(e)

If, between the date of this Agreement and the First Effective Time, the outstanding shares of Company Common Stock or Parent Common

Stock or Parent Convertible Preferred Stock shall have been changed into, or exchanged for, a different number of shares or a different

class, by reason of any stock dividend, subdivision, reclassification, recapitalization, split, combination or exchange of shares or

other like change, the Exchange Ratio shall, to the extent necessary, be equitably adjusted to reflect such change to the extent necessary

to provide the holders of Company Common Stock and Parent Convertible Preferred Stock, with the same economic effect as contemplated

by this Agreement prior to such stock dividend, subdivision, reclassification, recapitalization, split, combination or exchange of shares

or other like change; provided, however, that nothing in this Agreement will be construed to permit the Company or Parent to take

any action with respect to Company Common Stock or Parent Convertible Preferred Stock, respectively, that is prohibited or not expressly

permitted by the terms of this Agreement.

(f)

At the Second Effective Time, by virtue of the Second Merger and without any action on the part of Parent, the First Step Surviving Corporation,

Second Merger Sub or their respective stockholders, each share of the First Step Surviving Corporation issued and outstanding immediately

prior to the Second Effective Time shall be canceled and extinguished without any conversion thereof and no payment or distribution shall

be made with respect thereto.

1.7

Closing of the Company’s Transfer Books. At the First Effective Time: (a) all holders of (i) certificates representing

shares of Company Capital Stock, and (ii) book-entry shares representing shares of Company Capital Stock (“Book-Entry Shares”),

in each case, that were outstanding immediately prior to the First Effective Time shall cease to have any rights as Company Stockholders,

and (b) the stock transfer books of the Company shall be closed with respect to all shares of Company Capital Stock outstanding immediately

prior to the First Effective Time. No further transfer of any such shares of Company Capital Stock shall be made on such stock transfer

books after the First Effective Time. If, after the first Effective Time, a valid certificate previously representing any shares of Company

Capital Stock outstanding immediately prior to the First Effective Time (a “Company Stock Certificate”) is

presented to the Exchange Agent or to the Surviving Entity, such Company Stock Certificate shall be canceled and shall be exchanged as

provided in Sections 1.6 and 1.8.

1.8

Exchange of Shares.

(a)

Parent and the Company have selected Continental Stock Transfer & Trust Company, a trust company formed under the banking laws of

the State of New York, to act as exchange agent in the Merger (the “Exchange Agent”). At the First Effective

Time, Parent shall deposit with the Exchange Agent certificates or evidence of book-entry shares representing Parent Convertible Preferred

Stock issuable pursuant to Section 1.6(a). The Parent Convertible Preferred Stock so deposited with the Exchange Agent, together

with any dividends or distributions received by the Exchange Agent with respect to such shares, are referred to collectively as the “Exchange

Fund.”

(b)

Promptly following the First Effective Time, the Parties shall cause the Exchange Agent to email to the Persons who are record holders

of Company Stock Certificates, Book-Entry Shares, or Company SAFEs that will be converted into the right to receive Merger Consideration:

(i) a letter of transmittal in the form attached hereto as Exhibit

F (“Letter of Transmittal”) and an accredited investor questionnaire in customary form and containing such

provisions as Parent may reasonably specify, and (ii) instructions for effecting the surrender of the Company Stock Certificates, Book-Entry

Shares, or Company SAFEs in exchange for book-entry shares of Parent Convertible Preferred Stock representing the Merger Consideration.

Upon surrender of a duly executed Letter of Transmittal, accredited investor questionnaire, and such other documents as may be reasonably

required by the Exchange Agent or Parent, each such former holder of Company Stock Certificates, Book-Entry Shares shall be entitled

to receive, and the Exchange Agent shall issue, in exchange therefor, book-entry shares of Parent Convertible Preferred Stock, as applicable,

representing the Merger Consideration that such holder of Company Capital Stock has the right to receive pursuant to the provisions of

Section 1.6(a), and each Company Stock Certificate or Book-Entry Share shall be canceled. The Merger Consideration and any dividends

or other distributions as are payable pursuant to Section 1.8(d) shall be deemed to have been in full satisfaction of all rights

pertaining to Company Capital Stock formerly represented by such Company Stock Certificates or Book-Entry Shares.

(c)

No dividends or other distributions declared or made with respect to Parent Convertible Preferred Stock with a record date on or after

the First Effective Time shall be paid to the holder of any unsurrendered Company Stock Certificate or Book-Entry Shares with respect

to the shares of Parent Convertible Preferred Stock that such holder has the right to receive in the Merger until such holder surrenders

such Company Stock Certificate or transfers such Book-Entry Shares or provides an affidavit of loss or destruction in lieu thereof in

accordance with this Section 1.8 (at which time (or, if later, on the applicable payment date) such holder shall be entitled,

subject to the effect of applicable abandoned property, escheat or similar

Laws, to receive all such dividends and distributions, without interest).

(d)

Any portion of the Exchange Fund that remains unclaimed by holders of shares of Company Capital Stock as of the date that is one year

after the Closing Date shall be delivered to Parent upon demand, and any holders of Company Stock Certificates or Book-Entry Shares who

have not theretofore surrendered their Company Stock Certificates or transferred their Book-Entry Shares in accordance with this Section

1.8 shall thereafter look only to Parent as general creditors for satisfaction of their claims for Parent Convertible Preferred Stock

and any dividends or distributions with respect to shares of Parent Convertible Preferred Stock.

(e)

No Party shall be liable to any holder of any shares of Company Capital Stock or to any other Person with respect to any shares of Parent

Convertible Preferred Stock (or dividends or distributions with respect thereto) or for any cash amounts delivered to any public official

pursuant to any applicable abandoned property Law, escheat Law or similar Law. Any portion of the Exchange Fund that remains unclaimed

by holders of shares of Company Capital Stock as of the date that is two years after the Closing Date (or immediately prior to such earlier

date on which the related Exchange Funds (and all dividends or other distributions in respect thereof) would otherwise escheat to or

become the property of any Governmental Body) shall, to the extent permitted by applicable Law, become the property of the Surviving

Entity, free and clear of all claims or interest of any Person previously entitled thereto.

1.9

Appraisal Rights.

(a)

Notwithstanding any provision of this Agreement to the contrary, any Company Capital Stock that is outstanding immediately prior to the

First Effective Time and which are held by stockholders who have exercised and perfected appraisal rights for such shares of Company

Capital Stock in accordance with the DGCL (collectively, the “Dissenting Shares” and such stockholders “Dissenting

Stockholders”) shall not be converted into or represent the right to receive the Merger Consideration described in Section

1.5 attributable to such Dissenting Shares. Dissenting Stockholders shall be entitled to receive payment of the appraised value of

such shares of Company Capital Stock held by them in accordance with the DGCL, unless and until Dissenting Stockholders fail to perfect

or effectively withdraw or otherwise lose their appraisal rights under the DGCL. All Dissenting Shares held by Dissenting Stockholders

who shall have failed to perfect or shall have effectively withdrawn or lost their right to appraisal of such shares of Company Capital

Stock under the DGCL (whether occurring before, at or after the First Effective Time) shall thereupon be deemed to be converted into

and to have become exchangeable for, as of the First Effective Time, the right to receive the Merger Consideration, without interest,

attributable to such Dissenting Shares upon their surrender in the manner provided in Section 1.5 and Section 1.7.

(b)

The Company shall give Parent prompt written notice of any demands by Dissenting Stockholders received by the Company, withdrawals of

such demands and any other instruments served on the Company and any material correspondence received by the Company in connection with

such demands, and Parent shall have the right to direct all negotiations and proceedings with respect to such demands; provided that

the Company shall have the right to participate in such negotiations and proceedings. Neither the Parent nor the Company shall, except

with the other party’s prior written consent, voluntarily make any payment with respect to, or settle or offer to settle, any such

demands, or approve any withdrawal of any such demands or agree to do any of the foregoing.

1.10

Further Action. If, at any time after the First Effective Time, any further action is determined by the Surviving Entity

to be necessary or desirable to carry out the purposes of this Agreement or to vest the Surviving Entity with full right, title and possession

of and to all rights and property of the Company, then the officers and directors of the Surviving Entity shall be fully authorized,

and shall use their and its reasonable best efforts (in the name of the Company, in the name of Merger Subs, in the name of the Surviving

Entity and otherwise) to take such action.

1.11

Withholding. The Parties and the Exchange Agent (each, a “Withholding Agent”) shall be entitled

to deduct and withhold from the consideration otherwise payable pursuant to this Agreement to any holder of Company Capital Stock or

any other Person such amounts as such Party or the Exchange Agent is required to deduct and withhold under the Code or any other Law

with respect to the making of such payment; provided, however, that if a Withholding Agent determines that any payment to any stockholder

of the Company hereunder is subject to deduction and/or withholding, then, except with respect to compensatory payments, or as a result

of a failure to deliver the certificate described in Section 6.2, such Withholding Agent shall: (a) provide notice to such stockholder

as soon as reasonably practicable after such determination (and no later than three Business Days prior to undertaking such deduction

and/or withholding), and (b) use commercially reasonable efforts to cooperate with such stockholder prior to Closing to reduce or eliminate

any such deduction and/or withholding. To the extent that amounts are so withheld and paid over to the appropriate Governmental Body,

such withheld amounts shall be treated for all purposes of this Agreement as having been paid to the Person in respect of whom such deduction

and withholding was made.

SECTION 2.

REPRESENTATIONS AND WARRANTIES

OF THE COMPANY

Subject

to Section 8.13(h), except as set forth in the correspondingly numbered Section of the disclosure schedule delivered by the Company

to Parent (the “Company Disclosure Schedule”), the Company represents and warrants to Parent and Merger Subs

as follows:

2.1

Due Organization; Subsidiaries.

(a)

The Company is a corporation duly incorporated, validly existing and in good standing under the Laws of Delaware and has all necessary

corporate power and authority: (i) to conduct its business in the manner in which its business is currently being conducted, (ii) to

own or lease and use its property and assets in the manner in which its property and assets are currently owned or leased and used, and

(iii) to perform its obligations under all Contracts by which it is bound.

(b)

The Company is duly licensed and qualified to do business, and is in good standing (to the extent applicable in such jurisdiction), under

the Laws of all jurisdictions where the nature of its business requires such licensing or qualification other than in jurisdictions where

the failure to be so qualified individually or in the aggregate would not be reasonably expected to have a Company Material Adverse Effect.

(c)

Except as set forth in Section 2.1(c) of the Company Disclosure Schedule: (i) the Company has no Subsidiaries and has never had

any Subsidiaries, and (ii) the Company does not own, and has never owned, any capital stock of, or any equity, ownership or profit-sharing

interest of any nature in, and does not control, and has never controlled, directly or indirectly, any other Entity.

(d)

No Subsidiary of the Company has conducted any clinical trial work.

(e)

The Company is not nor has ever been, directly or indirectly, a party to, member of or participant in any partnership, joint venture

or similar business entity.

(f)

The Company has not agreed to, and is not obligated to make, nor is bound by any Contract under which it may become obligated to make,

any future investment in or capital contribution to any other Entity.

(g)

The Company has not, at any time, been a general partner of, or has otherwise been liable for any of the debts or other obligations of,

any general partnership, limited partnership or other Entity.

2.2

Organizational Documents. The Company has made available to Parent accurate and complete copies of the Organizational Documents

of the Company in effect as of the date of this Agreement. The Company is not in breach or violation of its respective Organizational

Documents.

2.3

Authority; Binding Nature of Agreement.

(a)

The Company has all necessary corporate power and authority to enter into and to perform its obligations under this Agreement and, subject

to receipt of the Required Company Stockholder Vote, to consummate the Contemplated Transactions. The Company Board (at meetings duly

called and held or by unanimous written consent) has: (i) determined that the Contemplated Transactions are fair to, advisable and in

the best interests of the Company and Company Stockholders, (ii) authorized,

approved and declared advisable this Agreement and the Contemplated Transactions, and (iii) determined to recommend, upon the

terms and subject to the conditions set forth in this Agreement, that the Company Stockholders vote in favor of the Company Stockholder

Matters.

(b)

This Agreement has been duly executed and delivered by the Company and, assuming the due authorization, execution and delivery by Parent

and Merger Subs, constitutes the legal, valid and binding obligation of the Company, enforceable against the Company in accordance with

its terms, subject to the Enforceability Exceptions.

2.4

Vote Required. The affirmative vote (or written consent) of the holders of a majority of the shares of Company Common Stock

outstanding on the record date for the Stockholder Written Consent and entitled to vote thereon, with the holders of Company Common Stock

and Company Preferred Stock voting together as a single class (with each share of Company Preferred Stock entitled to the number of votes

equal to the number of shares of Company Common Stock into which it is then convertible), and the separate affirmative vote (or written

consent) of the holders of a majority of the outstanding shares of Company Preferred Stock, voting as a single class on an as-converted

basis (the “Required Company Stockholder Vote”), are the only votes (or written consents) of the holders of

any class or series of Company Capital Stock necessary to adopt and approve this Agreement and approve the Contemplated Transactions.

The Stockholder Written Consent became effective upon the execution of this Agreement by the parties hereto and provided the Required

Company Stockholder Vote. No other corporate proceedings by the Company are necessary to authorize this Agreement or to consummate the

Contemplated Transactions.

2.5

Non-Contravention; Consents. Subject to obtaining the required Company Stockholder Vote, the filing of the Certificates

of Merger required by the DGCL and the filing of the Certificate of Designation, neither (x) the execution, delivery or performance of

this Agreement by the Company, nor (y) the consummation of the Contemplated Transactions, will directly or indirectly (with or without

notice or lapse of time):

(a)

contravene, conflict with or result in a violation of any of the provisions of the Company’s Organizational Documents;

(b)

contravene, conflict with or result in a violation of, or give any Governmental Body or other Person the right to challenge the Contemplated

Transactions or to exercise any remedy or obtain any relief under, any Law or any order, writ, injunction, judgment or decree to which

the Company, or any of the assets owned or used by the Company, is subject, except as would not reasonably be expected to be material

to the Company or its business;

(c)

contravene, conflict with or result in a violation of any of the terms or requirements of, or give any Governmental Body the right to

revoke, withdraw, suspend, cancel, terminate or modify, any Governmental Authorization that is held by the Company, except as would not

reasonably be expected to be material to the Company or its business;

(d)

contravene, conflict with or result in a violation or breach of, or result in a default under, any provision of any Company Material

Contract, or give any Person the right to: (i) declare a default or exercise any remedy under any Company Material Contract,

(ii) any material payment, rebate, chargeback, penalty or change in delivery schedule under any Company Material Contract; (iii)

accelerate the maturity or performance of any Company Material Contract; or (iv) cancel, terminate or modify any term of any Company

Material Contract, except in the case of any non-material breach, default, penalty or modification; or

(e)

result in the imposition or creation of any Encumbrance upon or with respect to any asset owned or used by the Company (except for Permitted

Encumbrances).

Except

for: (i) any Consent set forth in Section 2.5 of the Company Disclosure Schedule under any Company Contract, (ii) the Required

Company Stockholder Vote, (iii) the filing of the Certificates of Merger with the Secretary of State of the State of Delaware pursuant

to the DGCL, (iv) the filing of the Certificate of Designation with the Secretary of State of the State of Delaware pursuant to the DGCL

and (v) such consents, waivers, approvals, orders, authorizations, registrations,

declarations and filings as may be required under applicable federal and state securities Laws, the Company is not required to make any

filing with or give any notice to, or to obtain any Consent from, any Person in connection with: (A) the execution, delivery or performance

of this Agreement, or (B) the consummation of the Contemplated Transactions. The Company Board has taken and will take all actions necessary

to ensure that the restrictions applicable to business combinations contained in Section 203 of the DGCL are, and will be, inapplicable

to the execution, delivery and performance of this Agreement, the Lock-Up Agreements and to the consummation of the Contemplated Transactions.

No other state takeover statute or similar Law applies or purports to apply to the Merger, this Agreement, the Lock-Up Agreements or

any of the Contemplated Transactions.

2.6

Capitalization.

(a)

The authorized Company Capital Stock as of immediately prior to the Closing consists of: (i) 10,870,697 shares of Company Common Stock,

par value $0.00001 per share, of which 6,500,000 shares are issued and outstanding as of immediately prior to the Closing, and (ii)

2,394,207 shares of Preferred Stock, par value $0.00001 per share (the “Company Preferred Stock”), 452,625

of which have been designated Series Seed-1 Preferred Stock and 1,941,582 of which have been designated Series Seed-2 Preferred Stock

and all of which are issued or outstanding as of immediately prior to the Closing. The Company does not hold any shares of its capital

stock in its treasury. Section 2.6(a) of the Company Disclosure Schedule lists, as of immediately prior to the Closing, each record

holder of issued and outstanding Company Capital Stock and the number and type of shares of Company Capital Stock held by such holder.

(b)

All of the outstanding shares of Company Common Stock and Company Preferred Stock have been duly authorized and validly issued, and are

fully paid and nonassessable. Except as set forth in the Investor Agreements, none of the outstanding shares of Company Capital Stock

is entitled or subject to any preemptive right, right of participation, right of maintenance or any similar right and none of the outstanding

shares of Company Capital Stock is subject to any right of first refusal in favor of the Company. Except as contemplated in this Agreement

or as set forth in the Investor Agreements, there is no Company Contract relating to the voting or registration of, or restricting any

Person from purchasing, selling, pledging or otherwise disposing of (or granting any option or similar right with respect to), any shares

of Company Capital Stock. The Company is not under any obligation, nor is it bound by any Contract pursuant to which it may become obligated,

to repurchase, redeem or otherwise acquire any outstanding shares of Company Capital Stock or other securities. Section 2.6(b)

of the Company Disclosure Schedule accurately and completely lists (i) all repurchase rights held by the Company with respect to shares

of Company Capital Stock and specifies which of those repurchase rights are currently exercisable and (ii) whether the holder of such

shares of Company Capital Stock timely filed an election with the relevant Governmental Bodies under Section 83(b) of the Code with respect

to such shares. Each share of Company Preferred Stock is convertible into one share of Company Common Stock.

(c)

Except for the Company’s 2024 Stock Incentive Plan (the “Company Plan”), the Company does not have any

stock option plan or any other plan, program, agreement or arrangement providing for any equity-based compensation for any Person. As

of the date of this Agreement, the Company has reserved 988,245 shares of Company Common Stock for issuance under the Company Plan, all

of which shares remain available for future issuance of awards pursuant to the Company Plan. The Company has made available to Parent

an accurate and complete copy of the Company Plan. In addition, there are no bonds, debentures, notes or other indebtedness involving

the Company having the right to vote (or convertible into, or exchangeable for, securities having the right to vote) on any matters on

which stockholders of the Company may vote.

(d)

There is no: (i) outstanding subscription, option, call, warrant or right (whether or not currently exercisable) to acquire any shares

of the capital stock or other securities of the Company, (ii) outstanding security, instrument or obligation that is or may become convertible

into or exchangeable for any shares of the capital stock or other securities of the Company, or (iii) condition or circumstance that

could be reasonably likely to give rise to or provide a basis for the assertion of a claim by any Person to the effect that such Person

is entitled to acquire or receive any shares of capital stock or other

securities of the Company. There are no outstanding or authorized stock appreciation, phantom stock, profit participation or other similar

rights with respect to the Company.

(e)

All outstanding shares of Company Common Stock, Company Preferred Stock, and other securities of the Company have been issued and granted

in material compliance with (i) the Organizational Documents of the Company

in effect as of the relevant time and all applicable securities Laws and other applicable Law, and (ii) all requirements set forth in

applicable Contracts.

(f)

All distributions, dividends, repurchases and redemptions of the Company Capital Stock or other equity interests of the Company were

undertaken in material compliance with (i) the Organizational Documents of the Company in effect as of the relevant time and all applicable

securities Laws and other applicable Laws, and (ii) all requirements set forth in applicable Contract.

2.7

Financial Statements.

(a)

Prior to the execution hereof, the Company has provided to Parent true and complete copies of (i) the Company’s audited fiscal

year balance sheet (the “Company Balance Sheet”), together with the audited statements of operations and cash

flows of the Company, for the year ended December 31, 2025, and (ii) the Company’s unaudited balance sheet dated as of March 31,

2026, together with the unaudited statements of operations and cash flows of the Company, for the calendar quarter ended March 31, 2026,

each as set forth on Schedule 2.7(a) (collectively, and together with the Company Balance Sheet, the “Company Financials”).

The Company Financials were prepared in accordance with GAAP (except as may be indicated in the notes to such financial statements and

fairly present, in all material respects, the financial position and operating results of the Company as of the dates and for the periods

indicated therein, except in the case of the unaudited financial statements for normal, recurring year end audit adjustments and the

absence of footnotes.

(b)

The Company maintains accurate books and records reflecting its assets and liabilities and maintains a system of internal accounting

controls designed to provide reasonable assurance that: (i) transactions are executed in accordance with management’s general or

specific authorizations, (ii) transactions are recorded as necessary to permit preparation of the financial statements of the Company

in accordance with GAAP and to maintain accountability of the Company’s assets, (iii)

access to the Company’s assets is permitted only in accordance with management’s general or specific authorization, (iv)

the recorded accountability for the Company’s assets is compared with the existing assets at regular intervals and appropriate

action is taken with respect to any differences, and (v) accounts, notes and other receivables and inventory are recorded accurately,

and proper and adequate procedures are implemented which are designed to effect the collection thereof on a current and timely basis.

The Company maintains internal controls consistent with the practices of similarly situated private companies over financial reporting

that provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external

purposes in accordance with GAAP.

(c)

Section 2.7(c) of the Company Disclosure Schedule lists, and the Company has delivered to Parent accurate and complete copies

of the documentation creating or governing, all securitization transactions and “off-balance sheet arrangements” (as defined

in Item 303(c) of Regulation S-K under the Exchange Act) effected by the Company since the Company’s inception.

(d)

Since the Company’s inception, there have been no formal internal investigations regarding financial reporting or accounting policies

and practices discussed with, reviewed by or initiated at the direction

of the chief executive officer, chief financial officer or general counsel of the Company, the Company Board or any committee thereof.

Since the Company’s inception, neither the Company nor its independent auditors have identified: (i) any significant deficiency

or material weakness in the design or operation of the system of internal accounting controls utilized by the Company, (ii) any fraud,

whether or not material, that involves the Company, the Company’s management or other employees who have a role in the preparation

of financial statements or the internal accounting controls utilized by the Company, or (iii) any claim or allegation regarding any of

the foregoing.

2.8

Absence of Changes. Except as set forth in Section 2.8 of the Company Disclosure Schedule, after the date of the

Company Balance Sheet, the Company has conducted its business only in the Ordinary Course of Business (except for the execution and performance

of this Agreement and the discussions, negotiations and transactions related thereto) and there has not been any (x)

Company Material Adverse Effect and (y) the Company has not done any of the following:

(a)

declared, accrued, set aside or paid any dividend or made any other distribution in respect of any shares of its capital stock; or repurchased,

redeemed or otherwise reacquired any shares of its capital stock or other securities (except for shares of Company Common Stock from

terminated employees, directors or consultants of the Company or in connection with the payment of the exercise price and/or withholding

Taxes incurred upon the exercise, settlement or vesting of any award granted under the Company Plan);

(b)

sold, issued, granted, pledged or otherwise disposed of or encumbered or authorized any of the foregoing with respect to: (i) any capital

stock or other security of the Company, (ii) any option, warrant or right

to acquire any capital stock or any other security, other than option grants to employees and service providers in the Ordinary Course

of Business, or (iii) any instrument convertible into or exchangeable for any capital stock or other security of the Company;

(c)

except as required to give effect to anything in contemplation of the Closing, amended any of its Organizational Documents, or effected

or been a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock

split, reverse stock split or similar transaction except, for the avoidance of doubt, the Contemplated Transactions;

(d)

formed any Subsidiary or acquired any equity interest or other interest in any other Entity or entered into a joint venture with any

other Entity;

(e)

either: (i) lent money to any Person (except for the advance of reasonable business expenses to employees, directors and consultants

in the Ordinary Course of Business), (ii) incurred or guaranteed any

indebtedness for borrowed money, or (iii) guaranteed any debt securities of others;

(f)

other than as required by applicable Law or the terms of any Company Benefit Plan as in effect on the date of this Agreement and other

than the Company Plan or any Company Option: (i) adopted, terminated, established or entered into any Company Benefit Plan, (ii) caused

or permitted any Company Benefit Plan to be amended in any material respect, (iii) paid any material bonus or distributed any profit-sharing

account balances or similar payment to, or, other than in the Ordinary Course of Business, increased the amount of the wages, salary,

commissions, benefits or other compensation or remuneration payable to, any of its directors, officers or employees, (iv) increased the

severance or change-of-control benefits offered to any current, former

or new employees, directors or consultants, or (v) hired, terminated or gave notice of termination (other than for cause) to, any (x)

officer or (y) employee whose annual base salary is or is expected to be more than $100,000 per year;

(g)

entered into any collective bargaining agreement or similar agreement with any labor union or similar labor organization;

(h)

entered into any material transaction other than (i) in the Ordinary Course of Business or (ii) in connection with the Contemplated Transactions;

(i)

acquired any material asset or sold, leased or otherwise irrevocably disposed of any of its assets or properties, or granted any Encumbrance

(other than Permitted Encumbrances) with respect to such assets or properties, except in the Ordinary Course of Business;

(j)

sold, assigned, transferred, licensed, sublicensed or otherwise disposed of any material Company IP (other than pursuant to non-exclusive

licenses in the Ordinary Course of Business);

(k)

made, changed or revoked any material Tax election, failed to pay any income or other material Tax as such Tax becomes due and payable,

filed any amendment making any material change to any Tax Return, settled or compromised any income or other material Tax liability,

entered into any Tax allocation, sharing, indemnification or other similar agreement or arrangement (including any “closing agreement”

described in Section 7121 of the Code (or any similar Law) with any Governmental Body, but excluding customary commercial Contracts entered

into in the Ordinary Course of Business the principal subject matter of which is not Taxes), requested or consented to any extension

or waiver of any limitation period with respect to any claim or assessment for any income or other material Taxes (other than pursuant

to an extension of time to file any Tax Return granted in the Ordinary Course of Business of not more than six months), or adopted or

changed any material accounting method in respect of Taxes;

(l)

made any expenditures, incurred any Liabilities or discharged or satisfied any Liabilities, in each case, in amounts that exceed $100,000;

(m)

other than as required by Law or GAAP, taken any action to change accounting policies or procedures;

(n)

initiated or settled any Legal Proceeding; or

(o)

agreed, resolved or committed to do any of the foregoing.

2.9

Absence of Undisclosed Liabilities. As of the date hereof, the Company has no liability, indebtedness, obligation or expense

of any kind, whether accrued, absolute, contingent, matured or unmatured (whether or not required to be reflected in the financial statements

in accordance with GAAP) (each a “Liability”), except for: (a) Liabilities disclosed, reflected or reserved

against in the Company Balance Sheet, (b) Liabilities that have been incurred by the Company since the date of the Company Balance Sheet

in the Ordinary Course of Business and which are not material to the Company, individually or in the aggregate, (c) Liabilities for performance

of obligations under Company Contracts in the Ordinary Course of Business, which, in each case, are not related to any breach or default

of the Company, (d) Liabilities incurred in connection with the Contemplated

Transactions, and (e) Liabilities described in Section 2.9 of the Company Disclosure Schedule.

2.10

Title to Assets. The Company owns, and has good and valid title to, or, in the case of leased properties and assets, valid

leasehold interests in, all tangible properties or tangible assets and equipment used or held for use in its business or operations or

purported to be owned by it that are material to the Company or its business, including: (a) all tangible assets reflected on the Company

Balance Sheet, and (b) all other tangible assets reflected in the books and records of the Company as being owned by the Company. All

of such assets are owned or, in the case of leased assets, leased by the Company free and clear of any Encumbrances, other than Permitted

Encumbrances.

2.11

Real Property; Leasehold. The Company does not own, nor has ever owned, any real property. The Company has made available

to Parent (a) an accurate and complete list of all real properties with respect to which the Company directly or indirectly holds a valid

leasehold interest as well as any other real estate that is in the possession of, or occupied or leased by, the Company, and (b) copies

of all leases under which any such real property is possessed, occupied or leased (the “Company Real Estate Leases”),

each of which is in full force and effect, with no existing material default thereunder by the Company, or to the Knowledge of the Company,

any other party thereto. The Company’s possession, occupancy, lease, use and/or operation of each such leased property and leasehold

interests conforms to all applicable Laws in all material respects, and the Company has exclusive possession of each such leased property

and leasehold interest and has not granted any occupancy rights to tenants or licensees with respect to such leased property or leasehold

interest. In addition, each such leased property and leasehold interest is free and clear of all Encumbrances other than Permitted Encumbrances.

The Company has not received any written notice from its landlords or any Governmental Body that: (i)

relates to violations of building, zoning, safety or fire ordinances or regulations, (ii) claims any defect or deficiency with respect

to any of such leased properties or leaseholder interests, or (iii) requests the performance of any repairs, alterations or other work,

in each case, to such leased property and leaseholder interests.

2.12

Intellectual Property; Privacy.

(a)

Section 2.12(a) of the Company Disclosure Schedule identifies each item of Company Registered IP, including, with respect to each

application and registration: (i) the name of the applicant or registrant and any other co-owner, (ii) the jurisdiction of application

or registration, (iii) the application or registration number, (iv) the date of issue, filing, or registration, as applicable, and (v)

to the extent applicable, the expiration date. To the Knowledge of the Company, each of the Patents and Patent applications included

in Section 2.12(a) of the Company Disclosure Schedule properly identifies by name each and every inventor of the inventions claimed

therein as determined in accordance with applicable Laws of the United States and the applicable foreign jurisdiction. For all Company

Registered IP owned or purported to be owned, in whole or in part, by the Company (the “Owned Company Registered IP”),

and all other Company Registered IP for which the Company has responsibility for prosecution and maintenance activities, all necessary

registration, maintenance, renewal and other relevant filing fees due through the Closing Date have been timely paid and all necessary

documents and certificates in connection therewith have been timely filed with the relevant Patent, Trademark, Copyright, Internet domain

name or other authorities in the United States or the applicable foreign jurisdiction, as the case may be, for the purpose of maintaining

such Company Registered IP in full force and effect and, except as set forth on Section 2.12(a) of the Company Disclosure Schedule,

there are no such filings, payments or other actions that must be made or taken on or before the three-month anniversary

of the Closing Date. As of the date of this Agreement, no cancellation, interference, opposition, reissue, reexamination or other proceeding

of any nature (other than office actions or similar communications issued by any Governmental Body in the ordinary course of prosecution

of any pending applications for registration) is pending or, to the Knowledge of the Company, threatened in writing, in which the scope,

validity, enforceability or ownership of any Company IP is being or has been contested or challenged. To the Knowledge of the Company,

each item of Company IP is valid and enforceable, and with respect to the Company Registered IP, subsisting. The Company has complied

with all Laws regarding the duty of disclosure, candor and good faith in connection with each Patent included in the Owned Company Registered

IP and all other Company Registered IP for which the Company has responsibility for prosecution and maintenance activities.

(b)

The Company (i) exclusively owns or has exclusively licensed all Owned Company Registered IP and all other Company IP (other than as

disclosed in Section 2.12(b) of the Company Disclosure Schedule), and (ii) has valid and continuing rights, pursuant to the Company

In-bound Licenses, to use all other material Intellectual Property Rights as the same are used in or necessary for the conduct of the

business as presently conducted by the Company, in each case, free and clear of all Encumbrances other than Permitted Encumbrances. The

Owned Company Registered IP is currently in compliance in all material respects with all Laws necessary to record and perfect the Company’s

interest in, and the chain of title of, the Owned Company Registered IP and to ensure the ability to claim priority in all jurisdictions.

The Company IP and the Intellectual Property Rights licensed to the Company pursuant to a valid, enforceable written agreement constitute

all Intellectual Property Rights used in, material to or otherwise necessary for the operation of the Company’s business as currently

conducted. Each Company Associate involved in the creation or development of any material Company IP, pursuant to such Company Associate’s

activities on behalf of the Company, has signed a written agreement containing an assignment of such Company Associate’s rights

in such Company IP to the Company. Each Company Associate who has or

has had access to the Company’s trade secrets or confidential information has signed a written agreement containing confidentiality

provisions protecting the Company IP, trade secrets and confidential information. The Company has maintained copies of each such executed

written agreement and, to the Knowledge of the Company, no party thereto is in default or breach of any such agreements. The Company

has taken commercially reasonable steps to protect and preserve the confidentiality of its trade secrets and confidential information.

(c)

No funding, facilities or personnel of any Governmental Body or any university, college, research institute or other educational institution

has been used or is being used to create, in whole or in part, any Company IP that are owned or purported to be owned by Company, except

for any such funding or use of facilities or personnel that does not result in such Governmental Body or institution obtaining ownership

rights, license rights, or any other right to such Company IP (except for use rights during the term of the applicable agreement between

the Company and such Governmental Body or educational institution), including the right to receive royalties for the practice of such

Company IP (other than pursuant to any Company In-bound License disclosed on Section 2.12(d) of the Company Disclosure Schedule).

(d)

Section 2.12(d) of the Company Disclosure Schedule sets forth each license agreement pursuant to which the Company: (i) is granted

a license under any material Intellectual Property Right owned by any third party that is used by the Company in its business as currently

conducted (each a “Company In-bound License”), or (ii) grants to any third party a license under any material

Company IP (each a “Company Out-bound License”) (provided, that, Company In-bound Licenses shall not

include, when entered into in the Ordinary Course of Business, material transfer agreements,

clinical trial agreements, agreements with Company Associates, services agreements, non-disclosure agreements, commercially available

Software-as-a-Service offerings, or off-the-shelf software licenses; and Company Out-bound Licenses shall not include, when entered into

in the Ordinary Course of Business, material transfer agreements, clinical trial agreements, services agreements, or non-disclosure agreements).

All Company In-bound Licenses and Company Out-bound Licenses, to the Knowledge of the Company, are in full force and effect and are valid,

enforceable and binding obligations of the Company and, to the Knowledge of Company, each other party to such Company In-bound Licenses

or Company Out-bound Licenses. Neither the Company, nor to the Knowledge of the Company, any other party to such Company In-bound Licenses

or Company Out-bound Licenses, is in material breach under any Company In-bound Licenses or Company Out-bound Licenses. Except as set

forth in Section 2.12(d) of the Company Disclosure Schedule, none of the terms or conditions of any Company In-bound License or

any Company Out-bound License requires the Company or any of its Affiliates to maintain, develop or prosecute any Intellectual Property

Rights.

(e)

To the Knowledge of the Company: (i) the operation of the business of the Company as currently conducted has not infringed, misappropriated

or otherwise violated and does not infringe, misappropriate or otherwise violate any Intellectual Property Rights of any other Person,

and (ii) no other Person is infringing, misappropriating or otherwise

violating any Company IP. No Legal Proceeding is pending (or, to the Knowledge of the Company, is threatened in writing) (A) against

the Company alleging that the operation of the business of the Company infringes or constitutes the misappropriation or other violation

of any Intellectual Property Rights of another Person, or (B) by the Company alleging that another Person has infringed, misappropriated

or otherwise violated any of the Company IP. Since December 31, 2022, the Company has not received any written notice or other written

communication alleging that the operation of the business of the Company infringes or constitutes the misappropriation or other violation

of any Intellectual Property Right of another Person.

(f)

None of the Company IP owned by the Company or, to the Knowledge of the Company, any Company IP exclusively licensed to the Company is

subject to any pending or outstanding injunction, directive, order, judgment or other disposition of dispute that adversely and materially

restricts the use, transfer, registration or licensing by the Company of any such Company IP.

(g)

To the Knowledge of the Company, the Company and the operation of the Company’s business are and have at all times been, in material

compliance with all applicable Laws and Privacy and Data Processing Requirements. To the Knowledge of the Company, the Company has at

all applicable times provided all notices, and obtained and maintained all rights, consents, and authorizations, to Process Company Data

as Processed by or for the Company. Since December 31, 2022, there have been: (i) no loss or theft or security breach relating to Company

Data, (ii) no violation of any security policy of the Company regarding any such Company Data, and (iii) no unauthorized access to, or

unauthorized, unintended, or improper use disclosure, or other Processing of any Company Data. The Company has taken commercially reasonable

steps and implemented reasonable disaster recovery and security plans and procedures to protect the information technology systems used

in, material to or necessary for operation of the Company’s business as currently conducted and Company Data from unauthorized

use access, or other Processing, and the Company has taken commercially reasonable steps to require that any third party with access

to Company Data collected by or on behalf of the Company has taken commercially reasonable steps to protect the Company Data provided

to them by the Company. The Company has implemented and maintained commercially reasonable policies, procedures and systems for receiving

and appropriately responding to requests from individuals concerning their Company Data where such steps are required by applicable Privacy

and Data Processing Requirements.

(h)

To the Knowledge of the Company, there have been no: (i) material malfunctions or unauthorized intrusions or breaches of the information

technology systems used in, material to or necessary for the operation of the Company’s business, (ii) material unauthorized access

to, or other processing of, Company Data, or (iii) material breaches, security incidents, misuse of or unauthorized access to or disclosure

of any Company Data in the possession or control of the Company, and the Company has not provided or been legally required to provide

any notices to any Person in connection with an unauthorized disclosure of Company Data. To the Knowledge of the Company, the Company

has not been the subject of or received written notice of any complaints, claims or investigations related to their collection, use,

storage or processing of Company Data or alleging any violation of applicable Privacy and Data Processing Requirements.

(i)

The Company has taken reasonable security and other measures, including measures against unauthorized disclosure, to protect and maintain

the secrecy, confidentiality and value of the Know-How and other confidential information included in the Company IP. No trade secret,

Know-How or proprietary information material to the business of the Company as presently conducted, as of the date of this Agreement

has been authorized to be disclosed or, to the Knowledge of the Company, has been actually disclosed by the Company to any Person other

than pursuant to a non-disclosure agreement or other agreement adequately restricting the disclosure and use of such Intellectual Property

Rights or information, and excluding any Know-How or proprietary information disclosed by the Company in publications or public filings,

including as required under applicable securities laws.

(j)

To the Knowledge of the Company, the computer systems, including the software, firmware, hardware, networks, interfaces, platforms and

related systems, owned, leased or licensed by the Company an (collectively, the “Company Systems”) perform

in all material respects as is necessary for the conduct of its business as presently conducted by Company. To the Knowledge of the Company,

in the 12 months immediately prior to the date of this Agreement, (i) there have been no material failures, breakdowns or other adverse

events materially affecting any such Company Systems that have caused a material disruption or interruption to the conduct of the business

of the Company as currently conducted, and (ii) there have not been any material incidents of unauthorized access or other security breaches

of the Company Systems.

2.13

Agreements, Contracts and Commitments.

(a)

Section 2.13(a) of the Company Disclosure Schedule lists the following Company Contracts in effect as of the date of this Agreement

other than any Company Benefit Plans (each, a “Company Material Contract” and collectively, the “Company

Material Contracts”):

(i)

each Company Contract relating to any agreement of indemnification or guaranty not entered into in the Ordinary Course of Business;

(ii)

each Company Contract containing (A) any covenant limiting the freedom of the Company or the Surviving Entity to engage in any line of

business or compete with any Person, (B) any most-favored nation or other preferred pricing arrangement in favor of a Person other than

the Company or any similar term by which any Person is or could become entitled to any benefit, right or privilege that must be at least

as favorable to such Person as those offered to any other Person, (C)

any exclusivity provision, right of first refusal or right of first negotiation or similar covenant in favor of a Person other than the

Company, or (D) any non-solicitation provision not entered into the Ordinary Course of Business;

(iii)

each Company Contract relating to capital expenditures and requiring payments after the date of this Agreement in excess of $100,000

pursuant to its express terms and not cancelable without penalty;

(iv)

each Company Contract relating to the disposition or acquisition of material assets or any ownership interest in any Entity, except as

contemplated hereby;

(v)

each Company Contract relating to any mortgages, indentures, loans, notes or credit agreements, security agreements or other agreements

or instruments relating to the borrowing of money or extension of credit or creating any material Encumbrances with respect to any assets

of the Company or any loans or debt obligations with officers or directors of the Company;

(vi)

each Company Contract requiring payment by or to the Company after the date of this Agreement in excess of $100,000 in the aggregate

in the current calendar year or any future calendar year pursuant to its express terms relating to: (A) any agreement involving the development

or commercialization of any pharmaceutical product (identifying any that contain exclusivity provisions); (B) any agreement involving

provision of services or products with respect to any pre-clinical or clinical development activities of the Company; (C) any dealer,

distributor, joint marketing, alliance, joint venture, cooperation, development or other agreement currently in force under which the

Company has continuing obligations to develop or market any product, technology or service, or any agreement pursuant to which the Company

has continuing obligations to develop any Intellectual Property Rights that will not be owned, in whole or in part, by the Company; or

(D) any Contract with any third party providing any services relating to the manufacture or production of any product, service or technology

of the Company or any Contract to sell, distribute or commercialize any products or service of the Company;

(vii)

each Company Contract with any financial advisor, broker, finder, investment banker or other similar Person providing financial advisory

services to the Company in connection with the Contemplated Transactions;

(viii)

each Company Real Estate Lease;

(ix)

each Company Contract with any Governmental Body;

(x)

each Company Out-bound License and Company In-bound License, and each Company Contract containing a covenant not to sue or otherwise

enforce any Intellectual Property Rights;

(xi)

each Company Contract requiring the payment of any royalty, dividend or similar arrangement based on the revenues or profits of the Company;

(xii)

each Company Contract, offer letter, employment agreement, or independent contractor agreement with any employee, independent contractor

or other natural person service provider that (A) is not immediately terminable at will by the Company without notice, severance or other

cost or payment, except as required under applicable Law, or (B) provides for retention payments, change of control payments, severance,

accelerated vesting, or any similar payment or benefit that may or will become due as a result of the Merger;

(xiii)

each Company Contract providing any option to receive a license or other right, any right of first negotiation, any right of first refusal

or any similar right to any Person related to any material Company IP or material Intellectual Property Right licensed to the Company

under a Company In-bound License;

(xiv)

each Company Contract entered into in settlement of any Legal Proceeding

or other dispute; and

(xv)

any other Company Contract that is not terminable at will (with no penalty or payment or requirement for prior notice, except as required

by applicable Law) by the Company and (A) which involves payment or receipt by the Company after the date of this Agreement under any

such agreement, Contract or commitment of more than $100,000 in the aggregate, or obligations after the date of this Agreement in excess

of $100,000 in the aggregate, or (B) that is material to the business or operations of the Company taken as a whole.

(b)

The Company has delivered or made available to Parent accurate and complete copies of all Company Material Contracts, including all amendments

thereto. There are no Company Material Contracts that are not in written form. Neither the Company nor, to the Company’s Knowledge,

as of the date of this Agreement any other party to a Company Material Contract, has breached, violated or defaulted under, or received

notice that it breached, violated or defaulted under, any of the terms or conditions of any Company Material Contract. As to the Company,

as of the date of this Agreement, each Company Material Contract is valid, binding, enforceable and in full force and effect, subject

to the Enforceability Exceptions. No Person is renegotiating, or has a right pursuant to the terms of any Company Material Contract to

change, any material amount paid or payable to the Company under any Company Material Contract or any other material term or provision

of any Company Material Contract, and no Person has indicated to the Company that it desires to renegotiate, modify, not renew or cancel

any Company Material Contract.

2.14

Compliance; Permits; Restrictions. The Company holds all required Governmental Authorizations which are material to the

operation of the business of the Company as currently conducted (the “Company Permits”). Section 2.14

of the Company Disclosure Schedule identifies each Company Permit. Each such Company Permit is valid and in full force and effect, and

the Company is in material compliance with the terms of the Company Permits. No Legal Proceeding is pending or, to the Knowledge of the

Company, threatened, which seeks to revoke, limit, suspend, or materially modify any Company Permit.

2.15

Legal Proceedings; Orders.

(a)

Except as set forth in Section 2.15(a) of the Company Disclosure Schedule, as of the date of this Agreement, there is no pending

Legal Proceeding and, to the Knowledge of the Company, no Person has threatened in writing to commence any Legal Proceeding: (i) that

involves (A) the Company, (B) any Company Associate (in his or her capacity

as such), or (C) any of the material assets owned or used by the Company, or (ii) that challenges, or that would have the effect of preventing,

delaying, making illegal or otherwise interfering with, the Contemplated Transactions.

(b)

Except as set forth in Section 2.15(b) of the Company Disclosure Schedule, since the Company’s inception through the date

of this Agreement, no Legal Proceeding has been pending against the Company that resulted in material liability to the Company.

(c)

There is no order, writ, injunction, judgment or decree to which the Company, or any of the material assets owned or used by the Company,

is subject. To the Knowledge of the Company, no officer or employees of the Company is subject to any order, writ, injunction, judgment

or decree that prohibits such officer or employee from engaging in or continuing any conduct, activity or practice relating to the business

of the Company or to any material assets owned or used by the Company.

2.16

Tax Matters.

(a)

The Company has timely filed all income and other material Tax Returns that were required to be filed by or with respect to it under

applicable Law. All such Tax Returns are correct and complete in all material respects and have been prepared in compliance with all

applicable Law. No written claim has ever been made by any Governmental Body in any jurisdiction where the Company does not file a particular

Tax Return or pay a particular Tax that the Company is subject to taxation by that jurisdiction.

(b)

All income and other material Taxes due and owing by the Company on or before the date hereof (whether or not shown on any Tax Return)

have been fully and timely paid. The unpaid Taxes of the Company did not, as of the date of the Company Balance Sheet, materially exceed

the reserve for Tax liability (excluding any reserve for deferred Taxes established to reflect timing differences between book and Tax

items) set forth on the face of the Company Balance Sheet. Since the date of the Company Balance Sheet, the Company has not incurred

any material Liability for Taxes outside the Ordinary Course of Business.

(c)

All Taxes that the Company is or was required by Law to withhold or collect have been duly and timely withheld or collected in all material

respects on behalf of its respective employees, independent contractors, stockholders, lenders, customers or other third parties and

have been timely paid to the proper Governmental Body or other Person or properly set aside in accounts for this purpose.

(d)

There are no Encumbrances for material Taxes (other than Permitted Encumbrances) upon any of the assets of the Company.

(e)

No deficiencies for a material amount of Taxes with respect to the Company have been claimed, proposed or assessed by any Governmental

Body in writing. There are no pending or ongoing and, to the Knowledge of the Company, no threatened audits, assessments or other actions

for or relating to any liability in respect of a material amount of Taxes of the Company. The Company nor any of its predecessors has

waived any statute of limitations or agreed to any extension of time with respect to any income or other material Tax assessment or deficiency.

(f)

The Company has not been a United States real property holding corporation within the meaning of Section 897(c)(2) of the Code during

the applicable period specified in Section 897(c)(1)(A)(ii) of the Code.

(g)

The Company is not a party to any Tax allocation agreement, Tax sharing agreement, Tax indemnity agreement, or similar agreement or arrangement,

other than customary commercial Contracts entered into in the Ordinary Course of Business the principal subject matter of which is not

Taxes.

(h)

The Company (nor Parent as a result of the Merger) will not be required to include any item of income in, or exclude any item of deduction

from, taxable income for any Tax period (or portion thereof) ending after the Closing Date as a result of any: (i) change in method of

accounting for Tax purposes for a Tax period ending on or prior to the Closing Date; (ii) use of an improper method of accounting for

a Tax period ending on or prior to the Closing Date; (iii) “closing agreement” as described in Section 7121 of the Code (or

any similar provision of state, local or foreign Law) executed on or prior to the Closing Date; (iv) intercompany transaction or excess

loss account described in Treasury Regulations under Section 1502 of the Code (or any similar provision of state, local or foreign Law);

(v) installment sale or open transaction disposition made on or prior to the Closing Date; or (vi) prepaid amount, advance payment or

deferred revenue received or accrued on or prior to the Closing Date.

(i)

The Company has not ever been: (i) a member of a consolidated, combined or unitary Tax group (other than such a group the common parent

of which is the Company), or (ii) a party to any joint venture, partnership,

or other arrangement that is treated as a partnership for U.S. federal income Tax purposes. The Company has no Liability for any material

Taxes of any Person (other than the Company) under Treasury Regulations Section 1.1502-6 (or any similar provision of state, local, or

foreign Law), as a transferee or successor, by Contract (other than a Contract entered into in the Ordinary Course of Business the principal

subject matter of which is not Taxes) or otherwise by operation of Law.

(j)

The Company has not ever distributed stock of another Person, or had its stock distributed by another Person, in a transaction that was

purported or intended to be governed in whole or in part by Section 355 of the Code or Section 361 of the Code (or any similar provisions

of state, local or foreign Law).

(k)

The Company has not had a permanent establishment (within the meaning of an applicable Tax treaty) or otherwise had an office or fixed

place of business in a country other than the country in which it is organized.

(l)

The Company has not participated in or been a party to a transaction that, as of the date of this Agreement, constitutes a “listed

transaction” within the meaning of Section 6707A(c)(2) of the Code

and Treasury Regulations Section 1.6011-4(b)(2).

(m)

Section 2.16(m) of the Company Disclosure Schedule sets forth the entity classification of the Company for U.S. federal income

tax purposes. The Company has not made an election or taken any other action to change its federal and state income tax classification

from such classification.

For

purposes of this Section 2.16, each reference to the Company shall be deemed to include any Person that was liquidated into, merged

with, or is otherwise a predecessor to, the Company.

2.17

Employee and Labor Matters; Benefit Plans.

(a)

Section 2.17(a) of the Company Disclosure Schedule is a list of all Company Benefit Plans, other than at-will employment offer

letters on the Company’s standard form and other than individual compensatory equity award agreements made pursuant to the Company’s

standard forms, in which case only representative standard forms of such agreements shall be scheduled. “Company

Benefit Plan” means each: (i) “employee benefit plan” as defined in Section 3(3) of ERISA, and (ii) other pension,

retirement, deferred compensation, excess benefit, profit-sharing, bonus, incentive, equity or equity-based, phantom equity, employment,

consulting, severance, change-of-control, retention, health, life, disability, group insurance, paid time off, holiday, welfare and fringe

benefit plan, program, agreement, Contract, or arrangement (whether written or unwritten, qualified or nonqualified, funded or unfunded,

subject or not subject to ERISA and including any that have been frozen), in each case, sponsored, maintained, administered, contributed

to, or required to be contributed to, by the Company for the benefit of any current or former employee, director, officer or independent

contractor of the Company (or beneficiary thereof) or under which the Company has any actual or contingent liability (including, without

limitation, by reason of having a Company ERISA Affiliate).

(b)

As applicable with respect to each material Company Benefit Plan, the Company has made available to Parent, true and complete copies

of: (i) each material Company Benefit Plan, including all amendments thereto, and in the case of an unwritten material Company Benefit

Plan, a written description thereof, (ii) all current trust documents, investment management Contracts, custodial agreements, administrative

services agreements and insurance and annuity Contracts relating thereto, (iii)

the current summary plan description and each summary of material modifications thereto, (iv) the most recently filed annual reports

with any Governmental Body (e.g., Form 5500 and all schedules thereto), (v) the most recent IRS determination, opinion or advisory

letter, (vi) the most recent summary annual reports, nondiscrimination testing reports, actuarial reports, financial statements and trustee

reports, and (vii) all notices and filings from the IRS or Department of Labor or other Governmental Body concerning audits or investigations,

or “prohibited transactions” within the meaning of Section 406 of ERISA or Section 4975 of the Code.

(c)

Each Company Benefit Plan has been maintained, operated and administered in compliance in all material respects with its terms and the

applicable provisions of ERISA, the Code and all other Laws.

(d)

The Company Benefit Plans which are “employee pension benefit plans” within the meaning of Section 3(2) of ERISA and which

are intended to meet the qualification requirements of Section 401(a) of the Code have received determination or opinion letters from

the IRS on which they may currently rely to the effect that such plans are qualified under Section 401(a) of the Code and the related

trusts are exempt from federal income Taxes under Section 501(a) of the Code, respectively, and nothing has occurred that would reasonably

be expected to materially adversely affect the qualification of such Company Benefit Plan or the tax exempt status of the related trust.

(e)

Neither the Company nor any Company ERISA Affiliate maintains, contributes to, is required to contribute to, or has any actual or contingent

liability with respect to, (i) any “employee pension benefit plan” (within the meaning of Section 3(2) of ERISA) that is

subject to Title IV or Section 302 of ERISA or Section 412 of the Code, (ii) any “multiemployer plan” (within the meaning

of Section 3(37) of ERISA), (iii) any “multiple employer plan” (within the meaning of Section 413 of the Code), or (iv) any

“multiple employer welfare arrangement” (within the meaning of Section 3(40) of ERISA).

(f)

There are no pending audits or investigations by any Governmental Body involving any Company Benefit Plan, and no pending or, to the

Knowledge of the Company, threatened claims (except for routine individual claims for benefits payable in the normal operation of the

Company Benefit Plans), suits or proceedings involving any Company Benefit Plan, or, to the Knowledge of the Company,

any fiduciary thereof or service provider thereto, in any case except as would not be reasonably expected to result in material liability

to the Company. All contributions and premium payments required to have been made under any of the Company Benefit Plans or by applicable

Law (without regard to any waivers granted under Section 412 of the Code), have been timely made and the Company has no material liability

for any unpaid contributions with respect to any Company Benefit Plan.

(g)

None of the Company, any Company ERISA Affiliate or, to the Knowledge of the Company, any fiduciary, trustee or administrator of any

Company Benefit Plan, has engaged in, or in connection with the Contemplated Transactions will engage in, any transaction with respect

to any Company Benefit Plan which would subject any such Company Benefit Plan, the Company, or Parent to a material Tax, material penalty

or material liability for a “prohibited transaction” under Section 406 of ERISA or Section 4975 of the Code.

(h)

No Company Benefit Plan provides death, medical, dental, vision, life insurance or other welfare benefits beyond termination of service

or retirement other than coverage mandated by Law and, to the Knowledge of the Company, the Company has not made a written representation

promising the same.

(i)

Neither the execution of this Agreement, nor the performance of the Contemplated Transactions (either alone or when combined with the

occurrence of any other event, including without limitation, a termination of employment), will: (i) result in any payment becoming due

to any current or former employee, director, officer, or independent contractor of the Company thereof, pursuant to any Company Benefit

Plan, (ii) increase any amount of compensation or benefits otherwise payable under any Company Benefit Plan, (iii) result in the acceleration

of the time of payment, funding or vesting of any benefits under any Company Benefit Plan, (iv) require any contribution or payment to

fund any obligation under any Company Benefit Plan, or (v) limit the right to merge, amend or terminate any Company Benefit Plan.

(j)

Except as set forth in Section 2.17(j) of the Company Disclosure Schedule, neither the execution of this Agreement, nor the consummation

of the Contemplated Transactions (either alone or when combined with the occurrence of any other event, including without limitation,

a termination of employment) will result in the receipt or retention by any person who is a “disqualified individual” (within

the meaning of Code Section 280G) with respect to the Company of any payment or benefit that is or could be characterized as a “parachute

payment” (within the meaning of Code Section 280G), determined without regard to the application of Code Section 280G(b)(5).

(k)

No current or former employee, officer, director or independent contractor of the Company has any “gross up” agreements with

the Company or other assurance of reimbursement by the Company for any Taxes imposed under Code Section 409A or Code Section 4999.

(l)

The Company does not maintain any Company Benefit Plan for the benefit of any service providers located outside of the United States.

(m)

The Company has provided to Parent a true and correct list, as of the date of this Agreement, containing the names of all current full-time,

part-time or temporary employees and independent contractors (and indication as such), and, as applicable: (i) the annual dollar amount

of all cash compensation in the form of wages, salary, fees, commissions, or director’s fees payable to each person, (ii) dates

of employment or service, (iii) title and, with respect to independent contractors, a current

written description of such person’s contracting services, (iv) visa status, if applicable, and (v) with respect to employees,

(A) a designation of whether they are classified as exempt or non-exempt for purposes of the Fair Labor Standards Act, as amended (“FLSA”)

and any similar state law, and (B) whether such an employee is on leave and, if so, the expected return

date.

(n)

The Company is not and has never been a party to, bound by, or has a duty to bargain under, any collective bargaining agreement or other

Contract with a labor union or similar labor organization representing any of its employees, and there is no labor union or similar labor

organization representing or, to the Knowledge of the Company, purporting to represent or seeking to represent any employees of the Company,

including through the filing of a petition for representation election. There is not and has not been in the past five years, nor, to

the Knowledge of the Company, is there or has there been since the Company’s inception any threat of, any strike, slowdown, work

stoppage, lockout, union election petition, demand for recognition, or any similar activity or dispute or any union organizing activity,

affecting the Company.

(o)

The Company is, and since the Company’s inception has been, in material compliance with all applicable Laws respecting labor, employment,

employment practices, and terms and conditions of employment, including worker classification, discrimination, harassment and retaliation,

equal employment opportunities, fair employment practices, meal and rest periods, immigration, employee safety and health, payment of

wages (including overtime wages), unemployment and workers’ compensation, leaves of absence, and hours of work. Except as would

not be reasonably likely to result in a material liability to the Company, with respect to employees of the Company, the Company, since

the Company’s inception, has withheld and reported all amounts required by Law to be withheld and reported with respect to wages,

salaries and other payments, benefits, or compensation to employees. There is no material Legal Proceeding pending or, to the Knowledge

of the Company, threatened or reasonably anticipated against the Company relating to any current or former employee, applicant for employment,

or consultant of the Company.

(p)

Within the preceding two years, the Company has complied in all material respects with the WARN Act, and no action that could trigger

the WARN Act has been implemented by the Company without advance notification to and approval of Parent.

2.18

Environmental Matters. The Company is and since inception has complied with all applicable Environmental Laws, which compliance

includes the possession by the Company of all permits and other Governmental Authorizations required under applicable Environmental Laws

and compliance with the terms and conditions thereof, except for any failure to be in such compliance that, either individually or in

the aggregate, would not reasonably be expected to be material to the Company or its business. The Company has not received since inception

any written notice or other communication (in writing or otherwise), whether from a Governmental Body or other Person, that alleges that

the Company is not in compliance with or has liability pursuant to any Environmental Law and, to the Knowledge of the Company, there

are no circumstances that would reasonably be expected to prevent or interfere with the Company’s compliance in any material respects

with any Environmental Law, except where such failure to comply would not reasonably be expected to be material to the Company or its

business. No current or (during the time a prior property was leased or controlled by the Company) prior property leased or controlled

by the Company has had a release of or exposure to Hazardous Materials in material violation of or as would reasonably be expected to

result in any material liability of the Company pursuant to Environmental Law. No consent, approval or Governmental Authorization of

or registration or filing with any Governmental Body is required by Environmental Laws in connection with the execution

and delivery of this Agreement or consummation of the Contemplated Transactions by the Company. Prior to the date hereof, the Company

has provided or otherwise made available to Parent true and correct copies of all material environmental reports, assessments, studies

and audits in the possession or control of the Company with respect to any property leased or controlled by the Company or any business

operated by it.

2.19

Insurance. The Company has delivered or made available to Parent accurate and complete copies of all insurance policies

and all self-insurance programs and arrangements relating to the business, assets, liabilities and operations of the Company. Each of

such insurance policies is in full force and effect and the Company is in compliance in all material respects with the terms thereof.

Other than customary end of policy notifications from insurance carriers, since the Company’s inception, the Company has not received

any notice or other communication regarding any actual or possible: (a)

cancellation or invalidation of any insurance policy, or (b) refusal or denial of any coverage, reservation of rights or rejection of

any material claim under any insurance policy. The Company has provided timely written notice to the appropriate insurance carrier(s)

of each Legal Proceeding that is currently pending against the Company for which the Company has insurance coverage, and no such carrier

has issued a denial of coverage or a reservation of rights with respect to any such Legal Proceeding, or informed the Company of its

intent to do so.

2.20

No Financial Advisors. Except as set forth in Section 2.20 of the Company Disclosure Schedule, no broker, finder

or investment banker is entitled to any brokerage fee, finder’s fee, opinion fee, success fee, transaction fee or other fee or

commission in connection with the Contemplated Transactions based upon arrangements made by or on behalf of the Company.

2.21

Transactions with Affiliates.

(a)

Section 2.21(a) of the Company Disclosure Schedule describes any transactions or relationships, since the Company’s inception,

between, on one hand, the Company and, on the other hand, any: (i) officer or director of the Company or, to the Knowledge of the Company,

any of such officer’s or director’s immediate family members, (ii) owner of more than five percent of the voting power of

the outstanding Company Capital Stock, or (iii) to the Knowledge of the Company, any “related person” (within the meaning

of Item 404 of Regulation S-K under the Securities Act) of any such officer, director or owner (other than the Company) in the case of

each of (i), (ii) or (iii) that is of the type that would be required to be disclosed under Item 404 of Regulation S-K under the Securities

Act.

(b)

Section 2.21(b) of the Company Disclosure Schedule lists each stockholders agreement, voting agreement, registration rights agreement,

co-sale agreement or other similar Contract between the Company and any holders of Company Capital Stock, including any such Contract

granting any Person investor rights, rights of first refusal, rights of first offer, registration rights, director designation rights

or similar rights (collectively, the “Investor Agreements”).

2.22

Anti-Bribery. Neither the Company nor any of its directors, officers, employees or, to the Company’s Knowledge, agents

or any other Person acting on their behalf (in each in their respective capacities as such) has directly or indirectly made any bribes,

rebates, payoffs, influence payments, kickbacks, illegal payments, illegal political contributions, or other payments, in the form of

cash, gifts, or otherwise, or taken any other action, in violation of the Foreign Corrupt Practices Act of 1977, the UK Bribery Act of

2010 or any other anti-bribery or anti-corruption Law (collectively, the “Anti-Bribery

Laws”). The Company is not, nor has ever been, the subject of any investigation or inquiry by any Governmental Body with

respect to potential violations of Anti-Bribery Laws.

2.23

Disclaimer of Other Representations or Warranties.

(a)

Except as previously set forth in this Section 2 or in any certificate delivered by the Company to Parent and/or Merger Subs pursuant

to this Agreement, the Company makes no representation or warranty, express or implied, at law or in equity, with respect to it or any

of its assets, liabilities or operations, and any such other representations or warranties are hereby expressly disclaimed.

(b)

The Company acknowledges and agrees that, except for the representations and warranties of Parent and Merger Subs set forth in Section

3 or in any certificate delivered by Parent and/or Merger Subs to the Company pursuant to this Agreement, neither the Company nor

any of its Representatives is relying on any other representation or warranty of Parent, Merger Subs or any other Person made outside

of Section 3 or such certificate, including regarding the accuracy or completeness of any such other representations or warranties

or the omission of any material information, whether express or implied, in each case, with respect to the Contemplated Transactions.

SECTION 3.

REPRESENTATIONS AND WARRANTIES

OF PARENT AND MERGER SUBS

Subject

to Section 8.13(h), except (a) as set forth in the correspondingly numbered Section of the disclosure schedule delivered by Parent

to the Company (the “Parent Disclosure Schedule”), or (b) as disclosed in the Parent SEC Documents filed with

the SEC after December 31, 2022 and at least 10 Business Days prior to the date hereof, and publicly available on the SEC’s Electronic

Data Gathering Analysis and Retrieval system, and that is reasonably apparent on the face of such disclosure to be applicable to the

representation and warranty set forth herein (but (i) without giving effect to any amendment thereof filed with, or furnished to the

SEC on or after the date hereof, and (ii) excluding any disclosures contained under the heading “Risk Factors,” “Quantitative

and Qualitative Disclosures About Market Risk,” “Forward-Looking Statements,” and any disclosure of risks included

in any “forward-looking statements” disclaimer or in any other section to the extent they are forward-looking statements

or cautionary, predictive or forward-looking in nature), Parent and Merger Subs represent and warrant to the Company as follows:

3.1

Due Organization; Subsidiaries.

(a)

Each of Parent, First Merger Sub, and Second Merger Sub is a company duly incorporated or organized, validly existing and in good standing

under the Laws of the State of Delaware, and each has all necessary corporate or limited liability power and authority: (i) to conduct

its business in the manner in which its business is currently being conducted, (ii) to own or lease and use its property and assets in

the manner in which its property and assets are currently owned or leased and used, and (iii) to perform its obligations under all Contracts

by which it is bound. Since their respective date of incorporation or formation, no Merger Sub has engaged in any activities other than

activities incident to its formation or in connection with or as contemplated by this Agreement.

(b)

Parent is duly licensed and qualified to do business, and is in good standing (to the extent applicable in such jurisdiction), under

the Laws of all jurisdictions where the nature of its business requires such licensing or qualification other than in jurisdictions where

the failure to be so qualified individually or in the aggregate would

not be reasonably expected to have a Parent Material Adverse Effect.

(c)

Parent has no Subsidiaries, except for the Entities identified in Section 3.1(c) of the Parent Disclosure Schedule; and neither

Parent nor any of the Entities identified in Section 3.1(c) of the Company Disclosure Schedule owns any capital stock of, or any

equity, ownership or profit-sharing interest of any nature in, or controls directly or indirectly, any other Entity other than the Entities

identified in Section 3.1(c) of the Company Disclosure Schedule. Each of Parent’s Subsidiaries is a corporation or other

legal entity duly organized, validly existing and, if applicable, in good standing under the Laws of the jurisdiction of its organization

and has all necessary corporate or other power and authority: (i) to conduct its business in the manner in which its business is currently

being conducted, (ii) to own or lease and use its property and assets

in the manner in which its property and assets are currently owned or leased and used, and (iii) to perform its obligations under all

Contracts by which it is bound.

(d)

Neither the Parent nor any of its Subsidiaries is or has otherwise been, directly or indirectly, a party to, member of or participant

in any partnership, joint venture or similar business Entity. Neither the Parent nor any of its Subsidiaries has agreed or is obligated

to make, or is bound by any Contract under which it may become obligated to make, any future investment in or capital contribution to

any other Entity. Neither the Parent nor any of its Subsidiaries has, at any time, been a general partner of, or has otherwise been liable

for, any of the debts or other obligations of, any general partnership, limited partnership or other Entity.

3.2

Organizational Documents. Parent has made available to the Company accurate and complete copies of the Organizational Documents

or Parent and each of its Subsidiaries in effect as of the date of this Agreement. Neither Parent nor any of its Subsidiaries is in breach

or violation of its respective Organizational Documents.

3.3

Authority; Binding Nature of Agreement.

(a)

The Parent and each of its Subsidiaries (including the Merger Subs) have all necessary corporate or limited liability power and authority

to enter into and to perform its obligations under this Agreement, the Registration Rights Agreement, and, subject, with respect to Parent,

to receipt of the Required Parent Stockholder Vote and, with respect to Merger Subs, the adoption of this Agreement by Parent in its

capacity as sole stockholder or sole member of Merger Subs, to perform its obligations hereunder and to consummate the Contemplated Transactions.

The Parent Board (at meetings duly called and held or by unanimous written consent) has: (i) determined that the Contemplated Transactions

are fair to, advisable and in the best interests of Parent Stockholders, (ii) authorized, approved and declared advisable this Agreement

and the Contemplated Transactions, including the issuance of Parent Preferred Stock Payment Shares to the Company Stockholders pursuant

to the terms of this Agreement and the treatment of the Company Options pursuant to this Agreement, and (iii)

determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the Parent Stockholders vote

to approve the Parent Stockholder Matters. The First Merger Sub Board (by unanimous written consent) has: (A) determined that the Contemplated

Transactions are fair to, advisable, and in the best interests of First Merger Sub and its sole stockholder, (B) authorized, approved

and declared advisable this Agreement and the Contemplated Transactions, and (C) determined to recommend, upon the terms and subject

to the conditions set forth in this Agreement, that the stockholder of First Merger Sub vote to adopt this Agreement and thereby approve

the Contemplated Transactions. The Second Merger Sub Board (by unanimous written consent) has: (X) determined that the Contemplated Transactions

are fair to, advisable, and in the best interests of Second Merger Sub and its sole member, (Y) authorized, approved and declared advisable

this Agreement and the Contemplated Transactions; and (Z) determined to recommend, upon the terms and subject to the conditions set forth

in this Agreement, that the sole member of Second Merger Sub vote to adopt this Agreement and thereby approve the Contemplated Transactions.

(b)

This Agreement has been duly executed and delivered by Parent and each Merger Sub and, assuming the due authorization, execution and

delivery by the Company, constitutes the legal, valid and binding obligation of Parent and Merger Subs, enforceable against each of Parent

and Merger Subs in accordance with its terms, subject to the Enforceability Exceptions.

3.4

Vote Required. The approval of holders of Parent Common Stock is not required in order to approve this Agreement or, except

with respect to Parent Stockholder Matters, the transactions contemplated hereby. The affirmative vote of a majority of the votes cast

at the Parent Stockholders’ Meeting by the holders of Parent Common Stock are the only vote of the holders of any class or series

of Parent’s capital stock necessary to approve the proposal described in Section 4.2(a) (“Required Parent Stockholder

Vote”).

3.5

Non-Contravention; Consents. Subject to obtaining the Required Parent Stockholder Vote, the filing of the Certificates

of Merger required by the DGCL and the filing of the Certificate of Designation, neither (x) the execution, delivery or performance of

this Agreement by Parent or Merger Subs, nor (y) the consummation of the Contemplated Transactions, will directly or indirectly (with

or without notice or lapse of time):

(a)

contravene, conflict with or result in a violation of any of the provisions of the Organizational Documents of Parent or Merger Subs;

(b)

contravene, conflict with or result in a violation of, give any Governmental Body or other Person the right to challenge the Contemplated

Transactions or to exercise any remedy or obtain any relief under, any Law or any order, writ, injunction, judgment or decree to which

Parent or its Subsidiaries, or any of the assets owned or used by Parent or its Subsidiaries, is subject, except as would not reasonably

be expected to be material to Parent or its business;

(c)

contravene, conflict with or result in a violation of any of the terms or requirements of, or give any Governmental Body the right to

revoke, withdraw, suspend, cancel, terminate or modify, any Governmental Authorization that is held by Parent, except as would not reasonably

be expected to be material to Parent or its business;

(d)

contravene, conflict with or result in a violation or breach of, or result in a default under, any provision of any Parent Material Contract,

or give any Person the right to: (i) declare a default or exercise any remedy under any Parent Material Contract; (ii) any material payment,

rebate, chargeback, penalty or change in delivery schedule under any Parent Material Contract; (iii) accelerate the maturity or performance

of any Parent Material Contract; or (iv) cancel, terminate or modify any term of any Parent Material Contract, except in the case of

any non-material breach, default, penalty or modification; or

(e)

result in the imposition or creation of any Encumbrance upon or with respect to any asset owned or used by Parent (except for Permitted

Encumbrances).

Except

for (i) any Consent set forth in Section 3.5 of the Parent Disclosure Schedule under any Parent Contract, (ii) the Required Parent

Stockholder Vote, (iii) the filing of the Certificates of Merger with the Secretary of State of the State of Delaware pursuant to the

DGCL, (iv) the filing of the Certificate of Designation with the Secretary of State of the State of Delaware pursuant to the DGCL and

(v) such consents, waivers, approvals, orders, authorizations, registrations,

declarations and filings as may be required under applicable federal and state securities Laws, neither Parent nor any of its Subsidiaries

is or will be required to make any filing with or give any notice to, or to obtain any Consent from, any Person in connection with (A)

the execution, delivery or performance of this Agreement, or (B) the consummation of the Contemplated Transactions. The Parent Board

and the First Merger Sub Board and the Second Merger Sub Board have taken and will take all actions necessary to ensure that the restrictions

applicable to business combinations contained in Section 203 of the DGCL (or analogous provisions) are, and will be, inapplicable to

the execution, delivery and performance of this Agreement, the Lock-Up Agreements and to the consummation of the Contemplated Transactions.

No other state takeover statute or similar Law applies or purports to apply to the Merger, this Agreement or any of the other Contemplated

Transactions.

3.6

Capitalization.

(a)

The authorized capital stock of Parent as of the date of this Agreement consists of 250,000,000 shares of Parent Common Stock, par value

$0.0001 per share, of which 16,227,518 shares have been issued and are outstanding as of the close of business on the Reference Date

and 1,500,000 shares of preferred stock, par value $0.0001 per share, of which 0 shares previously designated as Series A Preferred Stock

are so designated or outstanding as of the date of this Agreement and of the 4,500 shares previously designated as Series B Preferred

Stock, of which 1,233 shares were outstanding the day before the date of this Agreement, 0 shares will be so designated or outstanding

as of the close of business on the date of this Agreement. Parent does not hold any shares of its capital stock in its treasury.

(b)

All of the outstanding shares of Parent Common Stock have been duly authorized and validly issued, and are fully paid and nonassessable.

None of the outstanding shares of Parent Common Stock are entitled or subject to any preemptive right, right of participation, right

of maintenance or any similar right and none of the outstanding shares of Parent Common Stock is subject to any right of first refusal

in favor of Parent. Except as contemplated herein, there is no Parent Contract relating to the voting or registration of, or restricting

any Person from purchasing, selling, pledging or otherwise disposing of (or granting any option or similar right with respect to), any

shares of Parent Common Stock. Parent is not under any obligation, nor is it bound by any Contract pursuant to which it may become obligated,

to repurchase, redeem or otherwise acquire any outstanding shares of Parent Common Stock or other securities. Section 3.6(b) of

the Parent Disclosure Schedule accurately and completely lists all repurchase rights held by Parent with respect to shares of Parent

Common Stock (including shares issued pursuant to the exercise of stock options) and specifies which of those repurchase rights are currently

exercisable and whether the holder of such shares of Parent Common Stock timely filed an election with the relevant Governmental Bodies

under Section 83(b) of the Code with respect to such shares.

(c)

Except for the Parent Stock Plans, and except as set forth in Section

3.6(c) of the Parent Disclosure Schedule, Parent does not have any stock option plan or any other plan, program, agreement or arrangement

providing for any equity-based compensation for any Person. As of the close of business on the Reference Date, Parent has reserved 845,919

shares of Parent Common Stock for issuance under the Parent Stock Plans, of which Parent RSUs and Parent Options to purchase a total

of 86,405 shares, in the aggregate, have been issued and are currently outstanding of, which no shares are subject to Parent’s

right of repurchase, of which (x) 86,405 shares have been reserved for issuance upon exercise of Parent Options previously granted and

currently outstanding under the Parent Stock Plans, (y) zero shares have been reserved for issuance upon the settlement of Parent RSUs

granted under the Parent Stock Plans that are outstanding as of the close of business on the Reference Date, and (z) 759,514 shares remain

available for future issuance pursuant to the Parent Stock Plans. Section 3.6(c) of the Parent Disclosure Schedule sets forth

the following information with respect to each Parent Option and Parent RSU outstanding as of the Reference Date: (i) the name of the

holder, (ii) the number of shares of Parent Common Stock subject to such Parent Option or Parent RSU at the time of grant, (iii) the

number of shares of Parent Common Stock subject to such Parent Option or Parent RSU as of the close of business on the Reference Date,

(iv) the exercise price of such Parent Option, (v) the date on which such Parent Option or Parent RSU was granted, (vi) the applicable

vesting schedule, including the number of vested and unvested shares as of the close of business on the Reference Date and any acceleration

provisions, (vii) the date on which such Parent Option or Parent RSU expires, (viii) whether such Parent Option is intended to constitute

an “incentive stock option” (as defined in the Code) or a non-qualified stock option, and (ix) whether such Parent Option

is “early exercisable”. Parent has made available to the Company accurate and complete copies of the Parent Stock Plans and

the form of the stock option agreements and restricted stock unit agreements evidencing outstanding Parent Options and Parent RSUs granted

thereunder. No vesting of Parent Options or Parent RSUs will be accelerated in connection with the closing of the Contemplated Transactions

other than as set forth on such Section 3.6(c) of the Parent Disclosure Schedule.

(d)

Except for the Parent Options and the Parent RSUs granted pursuant to the Parent Stock Plans, and as otherwise set forth in Section

3.6(d) of the Parent Disclosure Schedule, there is no: (i) outstanding subscription, option, call, warrant or right (whether or not

currently exercisable) to acquire any shares of the capital stock or other securities of Parent or any of its Subsidiaries, (ii) outstanding

security, instrument or obligation that is or may become convertible into or exchangeable for any shares of the capital stock or other

securities of Parent or any of its Subsidiaries, or (iii) condition or

circumstance that could be reasonably likely to give rise to or provide a basis for the assertion of a claim by any Person to the effect

that such Person is entitled to acquire or receive any shares of capital stock or other securities of Parent or any of its Subsidiaries.

There are no outstanding or authorized stock appreciation, phantom stock, profit participation or other similar rights with respect to

Parent or any of its Subsidiaries. In addition, there are no stockholder rights plans (or similar plan commonly referred to as a “poison

pill”) or bonds, debentures, notes or other indebtedness of Parent having the right to vote (or convertible into, or exchangeable

for, securities having the right to vote) on any matters on which stockholders of Parent may vote.

(e)

All outstanding shares of Parent Common Stock, Parent Options, Parent RSUs and other securities of Parent have been issued and granted

in material compliance with: (i) the Organizational Documents of Parent in effect as of the relevant time and all applicable securities

Laws and other applicable Law, and (ii) all requirements set forth in applicable Contracts.

(f)

All distributions, dividends, repurchases and redemptions of Parent Common Stock or other equity interests of Parent were undertaken

in material compliance with (i) the Organizational Documents of Parent in effect as of the relevant time and all applicable securities

Laws and other applicable Laws, and (ii) all requirements set forth in applicable Contracts.

3.7

SEC Filings; Financial Statements.

(a)

Parent has delivered or made available to the Company accurate and complete copies of all registration statements, proxy statements,

Certifications (as defined below) and other statements, reports, schedules, forms and other documents filed by Parent with the SEC since

December 31, 2022 (the “Parent SEC Documents”), other than such documents that can be obtained on the SEC’s

website at www.sec.gov. Since December 31, 2022, all material statements, reports, schedules, forms and other documents, including any

exhibits thereto, required to have been filed by Parent or its officers with the SEC have been so filed on a timely basis. As of the

time it was filed with the SEC (or, if amended or superseded by a filing prior to the date of this Agreement, then on the date of such

filing), each of the Parent SEC Documents complied in all material respects with the applicable requirements of the Securities Act or

the Exchange Act, or the Sarbanes-Oxley Act (as the case may be), and the rules and regulations thereunder, and, as of the time they

were filed, or if amended or superseded by a filing prior to the date of this Agreement, on the date of the last such amendment or superseding

filing prior to the date of this Agreement, none of the Parent SEC Documents contained any untrue statement of a material fact or omitted

to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances

under which they were made, not misleading. The certifications and statements required by (i) Rule 13a-14 under the Exchange Act and

(ii) 18 U.S.C. §1350 (Section 906 of the Sarbanes-Oxley Act) relating

to the Parent SEC Documents (collectively, the “Certifications”) are accurate and complete and comply as to

form and content with all applicable Laws, and no current or former executive officer of Parent has failed to make the Certifications

required of him or her. Parent has made available to the Company true and complete copies of all correspondence, other than transmittal

correspondence or general communications by the SEC not specifically addressed to Parent, between the SEC, on the one hand, and Parent,

on the other, since December 31, 2022, including all SEC comment letters and responses to such comment letters and responses to such

comment letters by or on behalf of Parent except for such comment letters and responses to such comment letters that are publicly accessible

through EDGAR. As of the date of this Agreement, there are no outstanding unresolved comments in comment letters received from the SEC

or Nasdaq with respect to Parent SEC Documents. To the Knowledge of Parent, none of the Parent SEC Documents is the subject of ongoing

SEC review and there are no inquiries or investigations by the SEC or any internal investigations pending or threatened, including with

regards to any accounting practices of Parent. As used in this Section 3.7, the term “file” and variations thereof

shall be broadly construed to include any manner in which a document or information is filed, furnished, supplied or otherwise made available

to the SEC.

(b)

The financial statements (including any related notes) contained or incorporated by reference in the Parent SEC Documents: (i) complied

as to form in all material respects with the published rules and regulations of the SEC applicable thereto, (ii) were prepared in accordance

with GAAP (except as may be indicated in the notes to such financial statements or, in the case of unaudited financial statements, except

as permitted by Form 10-Q of the SEC, and except that the unaudited financial statements may not contain footnotes and are subject to

normal and recurring year-end adjustments) applied on a consistent basis unless otherwise noted therein throughout the periods indicated,

and (iii) fairly present, in all material respects, the financial position of Parent and its consolidated Subsidiaries as of the respective

dates thereof and the results of operations and cash flows of Parent

for the periods covered thereby. Other than as expressly disclosed in the Parent SEC Documents filed prior to the date hereof, there

has been no material change in Parent’s accounting methods or principles that would be required to be disclosed in Parent’s

financial statements in accordance with GAAP.

(c)

Parent’s independent registered public accounting firm has at all times since the date of enactment of the Sarbanes-Oxley Act been:

(i) a registered public accounting firm (as defined in Section 2(a)(12) of the Sarbanes-Oxley Act), (ii) to the Knowledge of Parent,

“independent” with respect to Parent within the meaning of Regulation S-X under the Exchange Act, and (iii) to the Knowledge

of Parent, in compliance with subsections (g) through (l) of Section 10A of the Exchange Act and the rules and regulations promulgated

by the SEC and the Public Company Accounting Oversight Board thereunder.

(d)

Since December 31, 2022, through the date of this Agreement, Parent has not received any comment letter from the SEC or the staff thereof

or any correspondence from officials of Nasdaq or the staff thereof relating to the delisting or maintenance of listing of the Parent

Common Stock on Nasdaq. As of the date of this Agreement, Parent has timely responded to all comment letters of the staff of the SEC

relating to the Parent SEC Documents, and the SEC has not advised Parent that any final responses are inadequate, insufficient or otherwise

non-responsive. Parent has made available to the Company true, correct and complete copies or all comment letters, written inquiries

and enforcement correspondences between the SEC, on the one hand, and Parent, on the other hand, occurring since December 31, 2022 and

will, reasonably promptly following the receipt thereof, make available to the Company any such correspondence sent or received after

the date of this Agreement. To the Knowledge of Parent, as of the date of this Agreement, none of the Parent SEC Documents is the subject

of an ongoing SEC report or outstanding SEC comment.

(e)

Since December 31, 2022, there have been no formal investigations regarding financial reporting or accounting policies and practices

discussed with, reviewed by or initiated at the direction of the chief executive officer, chief financial officer, principal accounting

officer or general counsel of Parent, the Parent Board or any committee thereof, other than ordinary course audits or reviews of accounting

policies and practices or internal controls required by the Sarbanes-Oxley Act.

(f)

Parent is and since its first date of listing on Nasdaq, has been, in compliance in all material respects with the applicable current

listing and governance rules and regulations of Nasdaq.

(g)

Parent maintains, and at all times since December 31, 2022, has maintained, a system of internal control over financial reporting (as

defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that is designed to provide reasonable assurance regarding the reliability

of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP and to provide reasonable

assurance (i) that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, (ii)

that receipts and expenditures are made only in accordance with authorizations of management and the Parent Board, (iii) regarding prevention

or timely detection of the unauthorized acquisition, use or disposition of Parent’s assets that could have a material effect on

Parent’s financial statements and (iv) that Parent maintains records in reasonable detail which accurately and fairly reflect the

transactions and dispositions of the assets of Parent and any of its Subsidiaries. Parent has evaluated the effectiveness of Parent’s

internal control over financial reporting as of December 31, 2022, and, to the extent required by applicable Law, presented in any applicable

Parent SEC Document that is a report on Form 10-K or Form 10-Q (or any

amendment thereto) its conclusions about the effectiveness of the internal control over financial reporting as of the end of the period

covered by such report or amendment based on such evaluation. Parent has disclosed, based on its most recent evaluation of internal control

over financial reporting, to Parent’s auditors and audit committee (and has described in Section 3.7(g) of the Parent Disclosure

Schedule) (A) all material weaknesses and all significant deficiencies, if any, in the design or operation of internal control over financial

reporting that are reasonably likely to adversely affect Parent’s ability to record, process, summarize and report financial information,

(B) any fraud, whether or not material, that involves Parent, any of its Subsidiaries, Parent’s management or other employees who

have a role in the preparation of financial statements or the internal accounting controls utilized by the Parent and its Subsidiaries,

and (C) any claim or allegation regarding any of the foregoing. Parent has not identified, based on its most recent evaluation of internal

control over financial reporting, any significant deficiencies or material weaknesses in the design or operation of Parent’s internal

control over financial reporting.

(h)

Parent maintains “disclosure controls and procedures” (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) that

are reasonably designed to ensure that information required to be disclosed by Parent in the periodic reports that it files or submits

under the Exchange Act is recorded, processed, summarized and reported within the required time periods, and that all such information

is accumulated and communicated to Parent’s management as appropriate to allow timely decisions regarding required disclosure and

to make the Certifications.

(i)

Parent has not been and is not currently a “shell company” as defined under Section 12b-2 of the Exchange Act.

3.8

Absence of Changes. Except as set forth in Section 3.8 of the Parent Disclosure Schedule, after the date of the

Parent Balance Sheet, Parent and its Subsidiaries have conducted its business only in the Ordinary Course of Business (except for the

execution and performance of this Agreement and the discussions, negotiations and transactions related thereto) and there has not been

any (a) Parent Material Adverse Effect and (b) neither Parent nor any

of its Subsidiaries has done any of the following:

(a)

declared, accrued, set aside or paid any dividend or made any other distribution in respect of any shares of its capital stock or repurchased,

redeemed or otherwise reacquired any shares of its capital stock or other securities (except in connection with the payment of the exercise

price and/or withholding Taxes incurred upon the exercise, settlement or vesting of any award granted under the Parent Stock Plans);

(b)

sold, issued, granted, pledged or otherwise disposed of or encumbered or authorized any of the foregoing with respect to: (i) any capital

stock or other security of Parent (except for Parent Common Stock issued upon the valid exercise of outstanding Parent Options), (ii)

any option, warrant or right to acquire any capital stock or any other security, other than option grants to employees in the Ordinary

Course of Business, or (iii) any instrument convertible into or exchangeable for any capital stock or other security of Parent;

(c)

except as required to give effect to anything in contemplation of the Closing, amended any of its Organizational Documents, or effected

or been a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock

split, reverse stock split or similar transaction except, for the avoidance

of doubt, the Contemplated Transactions;

(d)

formed any Subsidiary or acquired any equity interest or other interest in any other Entity or entered into a joint venture with any

other Entity;

(e)

(i) lent money to any Person (except for the advance of reasonable business expenses to employees, directors and consultants in the Ordinary

Course of Business),

(ii)

incurred or guaranteed any indebtedness for borrowed money, or (iii) guaranteed any debt securities of others;

(f)

other than as required by applicable Law or the terms of any Parent Benefit Plan as in effect on the date of this Agreement: (i) adopted,

terminated, established or entered into any Parent Benefit Plan; (ii) caused any Parent Benefit Plan to be amended in any material respect;

(iii) paid any material bonus or distributed any profit-sharing account

balances or similar payment to, or, other than in the Ordinary Course of Business, increased the amount of the wages, salary, commissions,

benefits or other compensation or remuneration payable to, any of its directors, officers or employees; (iv) increased the severance

or change-of-control benefits offered to any current, former or new employees, directors or consultants or (v) hired, terminated or gave

notice of termination (other than for cause) to any (x) officer or (y) employee whose annual base salary is or is expected to be more

than

$100,000

per year;

(g)

entered into any collective bargaining agreement or similar agreement with any labor union, or similar labor organization;

(h)

entered into any material transaction other than (i) in the Ordinary Course of Business or (ii) in connection with the Contemplated Transactions;

(i)

acquired any material asset or sold or otherwise irrevocably disposed of any of its assets or properties, or granted any Encumbrance

(other than a Permitted Encumbrance) with respect to such assets or properties, except in the Ordinary Course of Business;

(j)

sold, assigned, transferred, licensed, sublicensed or otherwise disposed of any material Parent IP;

(k)

made, changed or revoked any material Tax election, failed to pay any income or other material Tax as such Tax becomes due and payable,

filed any amendment making any material change to any Tax Return, settled or compromised any income or other material Tax liability,

entered into any Tax allocation, sharing, indemnification or other similar agreement or arrangement (including any “closing agreement”

described in Section 7121 of the Code (or any similar Law) with any Governmental Body, but excluding customary commercial Contracts entered

into in the Ordinary Course of Business the principal subject matter of which is not Taxes), requested or consented to any extension

or waiver of any limitation period with respect to any claim or assessment for any income or other material Taxes (other than pursuant

to an extension of time to file any Tax Return granted in the Ordinary Course of Business of not more than six months), or adopted or

changed any material accounting method in respect of Taxes;

(l)

made any expenditures, incurred any Liabilities or discharged or satisfied any Liabilities, in each case, in amounts that exceed the

aggregate amount of $100,000;

(m)

other than as required by Law or GAAP, taken any action to change accounting policies or procedures;

(n)

initiated or settled any Legal Proceeding; or

(o)

agreed, resolved or committed to do any of the foregoing.

3.9

Absence of Undisclosed Liabilities. As of the date hereof, neither Parent nor any of its Subsidiaries has any Liability,

individually or in the aggregate, except for: (a) Liabilities disclosed, reflected or reserved against in the Parent Balance Sheet, (b)

Liabilities that have been incurred by Parent or its Subsidiaries since the date of the Parent Balance Sheet in the Ordinary Course of

Business and which are not material to Parent or its Subsidiaries, individually or in the aggregate, (c)

Liabilities for performance of obligations of Parent or any of its Subsidiaries under Parent Contracts in the Ordinary Course of Business,

which, in each case, are not related to any breach or default of Parent or its Subsidiaries, (d) Liabilities incurred in connection with

the Contemplated Transactions, and (e) Liabilities described in Section 3.9 of the Parent Disclosure Schedule.

3.10

Title to Assets. Each of Parent and its Subsidiaries owns, and has good and valid title to, or, in the case of leased properties

and assets, valid leasehold interests in, all tangible properties or tangible assets and equipment used or held for use in its business

or operations or purported to be owned by it that are material to Parent and its Subsidiaries or their business, including: (a) all tangible

assets reflected on the Parent Balance Sheet, and (b) all other tangible assets reflected in the books and records of Parent or any of

its Subsidiaries as being owned by Parent or such Subsidiary. All of such assets are owned or, in the case of leased assets, leased by

Parent or its Subsidiaries free and clear of any Encumbrances, other than Permitted Encumbrances.

3.11

Real Property; Leasehold. Neither Parent nor any of its Subsidiaries own or ever have owned any real property. Parent has

made available to the Company (a) an accurate and complete list of all real properties with respect to which Parent directly or indirectly

holds a valid leasehold interest as well as any other real estate that is in the possession of, or occupied or leased by, Parent or any

of its Subsidiaries, and (b) copies of all leases under which any such real property is possessed, occupied or leased (the “Parent

Real Estate Leases”), each of which is in full force and effect, with no existing material default thereunder by Parent

or any of its Subsidiaries, or to the Knowledge of Parent, any other party thereto. Parent’s possession, occupancy, lease, use

and/or operation of each such leased property conforms to all applicable Laws in all material respects, and Parent has exclusive possession

of each such leased property and leasehold interest and has not granted any occupancy rights to tenants or licensees with respect to

such leased property or leasehold interest. In addition, each such leased property and leasehold interest is free and clear of all Encumbrances

other than Permitted Encumbrances. Parent has not received any written notice from its landlords or any Governmental Body that: (i) relates

to violations of building, zoning, safety or fire ordinances or regulations, (ii) claims any defect or deficiency with respect to any

of such properties, or (iii) requests the performance of any repairs, alterations or other work to such properties.

3.12

Intellectual Property; Privacy.

(a)

Section 3.12(a) of the Parent Disclosure Schedule identifies each item of Parent Registered IP, including, with respect to each

application and registration: (i) the name of the applicant or registrant and any other co-owners, (ii) the jurisdiction of application

or registration, (iii) the application or registration number, (iv) the date of issue, filing, or registration, as applicable, and (v)

to the extent applicable, the expiration date. To the Knowledge of Parent, each of the Patents and Patent applications included in Section

3.12(a) of the Parent Disclosure Schedule properly identifies by name each and every inventor of the inventions claimed therein as

determined in accordance with applicable Laws of the United States and the applicable foreign jurisdiction. For all Parent Registered

IP owned or purported to be owned, in whole or in part, by the Parent (the “Owned Parent Registered IP”), and

all other Parent Registered IP for which the Parent has responsibility for prosecution and maintenance activities, all necessary registration,

maintenance, renewal and other relevant filing fees due through the Closing Date have been timely paid and all necessary documents and

certificates in connection therewith have been timely filed with the relevant Patent, Trademark, Copyright, Internet domain name or other

authorities in the United States or the applicable foreign jurisdiction, as the case may be, for the purpose of maintaining such Parent

Registered IP in full force and effect and, except as set forth on Section

3.12(a) of the Parent Disclosure Schedule, there are no such filings, payments or other actions that must be made or taken on or

before the three-month anniversary of the Closing Date. As of the date of this Agreement, no cancellation, interference, opposition,

reissue, reexamination or other proceeding of any nature (other than office actions or similar communications issued by any Governmental

Body in the ordinary course of prosecution of any pending applications for registration) is pending or, to the Knowledge of Parent, threatened

in writing, in which the scope, validity, enforceability or ownership of any Parent IP is being or has been contested or challenged.

To the Knowledge of Parent, each item of Parent IP is valid and enforceable, and with respect to the material Parent Registered IP, subsisting.

The Parent and its Subsidiaries have complied with all Laws regarding the duty of disclosure, candor and good faith in connection with

each Patent included in the Owned Parent Registered IP and all other Parent Registered IP for which the Parent or its Subsidiaries has

responsibility for prosecution and maintenance activities.

(b)

Parent or its Subsidiaries: (i) exclusively own, are the sole assignee of, or have exclusively licensed all Owned Parent Registered IP

and all other Parent IP (other than as disclosed in Section 3.12(b) of the Parent Disclosure Schedule), and (ii) has valid and

continuing rights, pursuant to the Parent In-bound Licenses, to use all other material Intellectual Property Rights as the same are used

in or necessary for the conduct of the business as presently conducted by the Parent and its Subsidiaries, in each case, free and clear

of all Encumbrances other than Permitted Encumbrances. The Owned Parent Registered IP is currently in compliance in all material respects

with all Laws necessary to record and perfect Parent’s or its Subsidiaries’, as applicable, interest in, and the chain of

title of, the Owned Parent Registered IP and to ensure the ability to claim priority in all jurisdictions. The Parent IP constitute all

Intellectual Property Rights used in, material to or otherwise necessary for the operation of Parent’s and any of its Subsidiaries’

business as currently conducted. Each Parent Associate involved in the creation or development of any material Parent IP, pursuant to

such Parent Associate’s activities on behalf of Parent or any of its Subsidiaries, has signed a written agreement containing an

assignment of such Parent Associate’s rights in such Parent IP to Parent or its Subsidiaries. Each Parent Associate who has or

has had access to Parent’s or any of its Subsidiaries’ trade secrets or confidential information has signed a written agreement

containing confidentiality provisions protecting the Parent IP, trade secrets and confidential information. Parent has maintained copies

of each such executed written agreement and, to the Knowledge of the Parent, no party thereto is in default or breach of any such agreements.

Parent and its Subsidiaries have taken commercially reasonable steps to protect and preserve the confidentiality of their respective

trade secrets and confidential information.

(c)

No funding, facilities or personnel of any Governmental Body or any university, college, research institute or other educational institution

has been used or is being used to create, in whole or in part, any Parent IP that are owned or purported to be owned by Parents or any

of its Subsidiaries, except for any such funding or use of facilities or personnel that does not result in such Governmental Body or

institution obtaining ownership rights, license rights, or any other right to such Parent IP (except for use rights during the term of

the applicable agreement between the Parent or its Subsidiary and such Governmental Body or educational institution), including the right

to receive royalties for the practice of such Parent IP (other than pursuant to any Parent In-bound License disclosed on Section 3.12(d)

of the Parent Disclosure Schedule).

(d)

Section 3.12(d) of Parent Disclosure Schedule sets forth each license agreement pursuant to which Parent (i) is granted a license

under any material Intellectual Property Right owned by any third party that is used by Parent or its Subsidiaries in its business as

currently conducted (each a “Parent In-bound License”), or (ii) grants to any third party a license under any

material Parent IP (each a “Parent Out-bound License”) (provided, that, Parent In-bound Licenses shall

not include, when entered into in the Ordinary Course of Business, material transfer agreements, services agreements, clinical trial

agreements, agreements with Parent Associates, non-disclosure agreements, commercially available Software-as-a-Service offerings, or

off-the-shelf software licenses; and Parent Out-bound Licenses shall not include, when entered into in the Ordinary Course of Business,

material transfer agreements, clinical trial agreements, services agreements, non-disclosure agreements, or non-exclusive outbound licenses).

All Parent In-bound Licenses and Parent Out-bound Licenses, to the Knowledge of Parent, are in full force and effect and are valid, enforceable

and binding obligations of Parent or its Subsidiaries and, to the Knowledge of Parent, each other party to such Parent In-bound Licenses

or Parent Out-bound Licenses. Neither Parent, nor, to the Knowledge of Parent, any other party to such Parent In-bound Licenses or Parent

Out-bound Licenses, is in material breach under any Parent In-bound Licenses or Parent Out-bound Licenses. Except as set forth in Section

3.12(c) of the Parent Disclosure Schedule, none of the terms or conditions of any Parent In-bound License or any Parent Out-bound

License requires Parent or any of its Subsidiaries or any of their Affiliates to maintain, develop or prosecute any Intellectual Property

Rights.

(e)

To the Knowledge of Parent: (i) the operation of the business of Parent and its Subsidiaries as currently conducted has not infringed,

misappropriated or otherwise violated and does not infringe, misappropriate or otherwise violate any Intellectual Property Rights of

any other Person, and (ii) no other Person is infringing, misappropriating or otherwise violating any Parent IP or any Intellectual Property

Rights exclusively licensed to the Parent. No Legal Proceeding is pending (or, to the Knowledge of Parent, is threatened in writing)

(A) against Parent or its Subsidiaries alleging that the operation of the business of Parent or its Subsidiaries infringes or constitutes

the misappropriation or other violation of any Intellectual Property Rights of another Person, or (B) by Parent or its Subsidiaries alleging

that another Person has infringed, misappropriated or otherwise violated any of the Parent IP or any Intellectual Property Rights exclusively

licensed to the Parent. Since December 31, 2022, neither Parent nor its Subsidiaries have received any written notice or other written

communication alleging that the operation of the business of Parent or its Subsidiaries infringes or constitutes the misappropriation

or other violation of any Intellectual Property Right of another Person.

(f)

None of the Parent IP owned by the Parent or, to the Knowledge of Parent, any Parent IP exclusively licensed by Parent or its Subsidiaries,

is subject to any pending or outstanding injunction, directive, order, judgment or other disposition of dispute, that adversely and materially

restricts the use, transfer, registration or licensing by Parent or its Subsidiaries of any such Parent IP.

(g)

To the Knowledge of Parent, Parent and the operation of Parent’s and its Subsidiaries’ business are, and have at all times

been, in material compliance with all applicable Laws and Privacy and Data Processing Requirements. To the knowledge of Parent, Parent

and its Subsidiaries have at all applicable times provided all notices, and obtained and maintained all rights, consents, and authorizations,

to Process Parent Data as Processed by or for Parent or its Subsidiaries. Since December 31, 2022, there have been (i) no loss or theft

of, or security breach relating to. Parent Data, (ii) no violation of any security policy of Parent or its Subsidiaries regarding any

such Parent Data, and (iii) no unauthorized access to, or unauthorized, unintended, or improper use, disclosure, or other Processing

of, any Parent Data. Parent and its Subsidiaries have taken commercially reasonable steps and implemented reasonable disaster recovery

and security plans and procedures to protect the information technology systems used in, material to or necessary for operation of Parent’s

or its Subsidiaries business as currently conducted and Parent Data from unauthorized use, access, or other Processing, and the Parent

has taken commercially reasonable steps to require that any third party with access to Parent Data collected by or on behalf of the Parent

has taken commercially reasonable steps to protect the Parent Data provided to them by the Parent. The Parent has implemented and maintained

commercially reasonable policies, procedures and systems for receiving and appropriately responding to requests from individuals concerning

their Parent Data where such steps are required by applicable Privacy and Data Processing Requirements.

(h)

To the Knowledge of Parent, there have been no (i) material malfunctions or unauthorized intrusions or breaches of the information technology

systems used in, material to or necessary for the operation of Parent’s or its Subsidiaries’ business, (ii) material unauthorized

access to, or other processing of, Parent Data, or (iii) material breaches, security incidents, misuse of or unauthorized access to or

disclosure of any Parent Data in the possession or control of the Parent and the Parent has not provided or been legally required to

provide any notices to any Person in connection with an unauthorized disclosure of Parent Data. To the Knowledge of the Parent, the Parent

has not been the subject of or received written notice of any complaints, claims or investigations related to their collection, use,

storage or processing of Parent Data or alleging any violation of applicable Privacy and Data Processing Requirements.

(i)

The Parent has taken reasonable security and other measures, including measures against unauthorized disclosure, to protect and maintain

the secrecy, confidentiality and value of the Know-How and other confidential information included in the Parent IP. No trade secret,

Know-How or proprietary information material to the business of the Parent as presently conducted, as of the date of this Agreement has

been authorized to be disclosed or, to the Knowledge of the Parent, has been actually disclosed by the Parent or any Subsidiary to any

Person other than pursuant to a non-disclosure agreement or other agreement adequately restricting the disclosure and use of such Intellectual

Property Rights or information, and excluding any Know-How or proprietary information disclosed by the Parent in publications or public

filings, including as required under applicable securities laws.

(j)

To the Knowledge of Parent, the computer systems, including the software, firmware, hardware, networks, interfaces, platforms and related

systems, owned, leased or licensed by the Parent an (collectively, the “Parent Systems”) perform in all material

respects as is necessary for the conduct of its business as presently conducted by Parent. To the Knowledge of the Parent, in the 12

months immediately prior to the date of this Agreement, (i) there have been no material failures, breakdowns or other adverse events

materially affecting any such Parent Systems that have caused a material

disruption or interruption to the conduct of the business of the Parent as currently conducted, and (ii) there have not been any material

incidents of unauthorized access or other security breaches of the Parent Systems.

3.13

Agreements, Contracts and Commitments.

(a)

Section 3.13 of the Parent Disclosure Schedule lists the following Parent Contracts in effect as of the date of this Agreement

other than any Parent Benefit Plans (each, a “Parent Material Contract” and collectively, the “Parent

Material Contracts”):

(i)

a material Contract as defined in Item 601(b)(10) of Regulation S-K as promulgated under the Securities Act;

(ii)

each Parent Contract relating to any agreement of indemnification or guaranty not entered into in the Ordinary Course of Business;

(iii)

each Parent Contract containing: (A) any covenant limiting in any material respect the freedom of Parent or its Subsidiaries to engage

in any line of business or compete with any Person, (B) any most-favored nation or other preferred pricing arrangement in favor of a

Person other than Parent or any similar term by which any Person is or could become entitled to any benefit, right or privilege that

must be at least as favorable to such Person as those offered to any other Person, (C) any exclusivity provision, option to receive a

license, right of first refusal or right of first negotiation or similar covenant in favor of a Person other than Parent, or (D) any

non-solicitation provision not entered into in the Ordinary Course of Business;

(iv)

each Parent Contract relating to capital expenditures and requiring payments after the date of this Agreement in excess of $100,000 pursuant

to its express terms and not cancelable without penalty;

(v)

each Parent Contract relating to the disposition or acquisition of material assets or any ownership interest in any Entity;

(vi)

each Parent Contract relating to any mortgages, indentures, loans, notes or credit agreements, security agreements or other agreements

or instruments relating to the borrowing of money or extension of credit or creating any material Encumbrances with respect to any assets

of Parent or its Subsidiaries or any loans or debt obligations with officers or directors of Parent;

(vii)

each Parent Contract requiring payment by or to Parent after the date of this Agreement in excess of $100,000 in the aggregate in the

current calendar year or any future calendar year pursuant to its express terms relating to: (A) any agreement involving the development

or commercialization of any pharmaceutical product (identifying any that contain exclusivity provisions), (B)

any agreement involving provision of services or products with respect to any pre-clinical or clinical development activities of Parent,

(C) any dealer, distributor, joint marketing, alliance, joint venture, cooperation, development or other agreement currently in force

under which Parent has continuing obligations to develop or market any product, technology or service, or any agreement pursuant to which

Parent has continuing obligations to develop any Intellectual Property Rights that will not be owned, in whole or in part, by Parent,

or (D) any Parent Contract with any third party providing any services relating to the manufacture or production of any product, service

or technology of Parent or any Parent Contract to sell, distribute or commercialize any products or service of Parent;

(viii)

each Parent Contract with any financial advisor, broker, finder, investment banker or other similar Person providing financial advisory

services to Parent in connection with the Contemplated Transactions;

(ix)

each Parent Real Estate Lease;

(x)

each Parent Contract with any Governmental Body;

(xi)

each Parent Out-bound License and Parent In-bound License, and each Parent Contract containing a covenant not to sue or otherwise enforce

any Intellectual Property Rights;

(xii)

each Parent Contract requiring the payment of any royalty, dividend or similar arrangement based on the revenues or profits of Parent

or its Subsidiaries;

(xiii)

each Parent Contract, offer letter, employment agreement, or independent contractor agreement with any employee, independent contractor

or other natural person service provider that: (A) is not immediately terminable by Parent without notice, severance, or other cost or

liability, except as required under applicable Law, or (B) provides for retention payments, change-of-control payments, severance, accelerated

vesting, or any similar payment or benefit that may or will become due as a result of the Merger;

(xiv)

each Parent Contract providing any option to receive a license or other right, any right of first negotiation, any right of first refusal

or any similar right to any Person related to any material Parent IP or material Intellectual Property Right licensed to Parent under

a Parent In-bound License; and

(xv)

each Parent Contract entered into in settlement of any Legal Proceeding or other dispute; and

(xvi)

any other Contract that is not terminable at will (with no penalty or payment or requirement for prior notice, except as required by

applicable law) by Parent or its Subsidiaries, as applicable, and (A) which involves payment or receipt by Parent or its Subsidiaries

after the date of this Agreement under any such agreement, Contract or commitment of more than $100,000 in the aggregate, or obligations

after the date of this Agreement in excess of $100,000 in the aggregate, or (B)

that is material to the business or operations of Parent and its Subsidiaries, taken as a whole.

(b)

Parent has delivered or made available to the Company accurate and complete copies of all Parent Material Contracts, including all amendments

thereto. There are no Parent Material Contracts that are not in written form. Neither Parent nor any of its Subsidiaries has, nor, to

Parent’s Knowledge, as of the date of this Agreement, has any other party to a Parent Material Contract, breached, violated or

defaulted under, or received notice that it breached, violated or defaulted under, any of the terms or conditions of any Parent Material

Contract. As to Parent and its Subsidiaries, as of the date of this Agreement, each Parent Material Contract is valid, binding, enforceable

and in full force and effect, subject to the Enforceability Exceptions. No Person is renegotiating, or has a right pursuant to the terms

of any Parent Material Contract to change, any material amount paid or payable to Parent under any Parent Material Contract or any other

material term or provision of any Parent Material Contract, and no Person has indicated to Parent that it desires to renegotiate, modify,

not renew or cancel any Parent Material Contract.

3.14

Compliance; Permits. Parent or its Subsidiaries hold all required Governmental Authorizations which are material to the

operation of the business of Parent or such Subsidiary as currently conducted (the “Parent Permits”). Section

3.14 of the Parent Disclosure Schedule identifies each Parent Permit. Each such Parent Permit is valid and in full force and effect,

and Parent is in material compliance with the terms of the Parent Permits. No Legal Proceeding is pending or, to the Knowledge of Parent,

threatened, which seeks to revoke, limit, suspend, or materially modify any Parent Permit.

3.15

Legal Proceedings; Orders.

(a)

As of the date of this Agreement, there is no pending Legal Proceeding and, to the Knowledge of Parent, no Person has threatened in writing

to commence any Legal Proceeding:

(i)

that involves (A) Parent, (B) any of its Subsidiaries, (C) any Parent Associate (in his or her capacity as such) or (D) any of the material

assets owned or used by Parent or its Subsidiaries, or (ii) that challenges, or that would have the effect of preventing, delaying, making

illegal or otherwise interfering with, the Contemplated Transactions.

(b)

Except as set forth in Section 3.15(b) of the Parent Disclosure Schedule, since December 31, 2022 through the date of this Agreement,

no Legal Proceeding has been pending against Parent that resulted in material liability to Parent.

(c)

There is no order, writ, injunction, judgment or decree to which Parent or any of its Subsidiaries, or any of the material assets owned

or used by Parent or any of its Subsidiaries, is subject. To the Knowledge of Parent, no officer of Parent or any of its Subsidiaries

is subject to any order, writ, injunction, judgment or decree that prohibits such officer or employee from engaging in or continuing

any conduct, activity or practice relating to the business of Parent or any of its Subsidiaries or to any material assets owned or used

by Parent or any of its Subsidiaries.

3.16

Tax Matters.

(a)

Parent and each of its Subsidiaries have filed all income and other material Tax Returns that were required to be filed by or with respect

to it under applicable Law. All such Tax Returns are correct and complete in all material respects and have been prepared in compliance

with all applicable Law. No written claim has ever been made by any Governmental Body in any jurisdiction where Parent or any of its

Subsidiaries does not file a particular Tax Return or pay a particular Tax that Parent or such Subsidiary is subject to taxation by that

jurisdiction.

(b)

All income and other material Taxes due and owing by Parent or any of its Subsidiaries on or before the date hereof (whether or not shown

on any Tax Return) have been fully and timely paid. The unpaid Taxes of Parent and its Subsidiaries did not, as of the date of the Parent

Balance Sheet, materially exceed the reserve for Tax liability (excluding any reserve for deferred Taxes established to reflect timing

differences between book and Tax items) set forth on the face of the Parent Balance Sheet. Since the Parent Balance Sheet Date, neither

Parent nor any of its Subsidiaries has incurred any material Liability for Taxes outside the Ordinary Course of Business.

(c)

All Taxes that Parent and each of its Subsidiaries is or was required by Law to withhold or collect have been duly and timely withheld

or collected in all material respects on behalf of its respective employees, independent contractors, stockholders, lenders, customers

or other third parties and have been timely paid to the proper Governmental Body or other Person or properly set aside in accounts for

this purpose.

(d)

There are no Encumbrances for material Taxes (other than Permitted Encumbrances) upon any of the assets of Parent or any of its Subsidiaries.

(e)

No deficiencies for a material amount of Taxes with respect to Parent or any of its Subsidiaries have been claimed, proposed or assessed

by any Governmental Body in writing. There are no pending or ongoing and, to the Knowledge of Parent, threatened audits, assessments

or other actions for or relating to any liability in respect of a material amount of Taxes of Parent. Neither Parent nor any of its Subsidiaries

(or predecessors thereof) has waived any statute of limitations or agreed to any extension of time with respect to any income or other

material Tax assessment or deficiency.

(f)

Neither Parent nor any of its Subsidiaries has been a United States real property holding corporation within the meaning of Section 897(c)(2)

of the Code during the applicable period specified in Section 897(c)(1)(A)(ii) of the Code.

(g)

Neither Parent nor any of its Subsidiaries is a party to any Tax allocation agreement, Tax sharing agreement, Tax indemnity agreement,

or similar agreement or arrangement, other than customary commercial Contracts entered into in the Ordinary Course of Business the principal

subject matter of which is not Taxes.

(h)

Neither Parent nor any of its Subsidiaries will be required to include any item of income in, or exclude any item of deduction from,

taxable income for any Tax period (or portion thereof) ending after the Closing Date as a result of any: (i) change in method of accounting

for Tax purposes for a Tax period ending on or prior to the Closing Date, (ii) use of an improper method of accounting for a Tax period

ending on or prior to the Closing Date, (iii) “closing agreement” as described in Section 7121 of the Code (or any similar

provision of state, local or foreign Law) executed on or prior to the Closing Date, (iv) intercompany transaction or excess loss account

described in Treasury Regulations under Section 1502 of the Code (or any similar provision of state, local or foreign Law), (v)

installment sale or open transaction disposition made on or prior to the Closing Date; (vi) prepaid amount, advance payment or deferred

revenue received or accrued on or prior to the Closing Date, (vii) application of Section 367(d) of the Code to any transfer of intangible

property on or prior to the Closing Date, or (viii) application of Sections 951 or 951A of the Code (or any similar provision of state,

local or foreign Law) to any income received or accrued on or prior to the Closing Date. Parent has not made any election under Section

965(h) of the Code.

(i)

Neither Parent nor any of its Subsidiaries has ever been: (i) a member of a consolidated, combined or unitary Tax group (other than such

a group the common parent of which is Parent), or (ii) a party to any joint venture, partnership, or other arrangement that is treated

as a partnership for U.S. federal income Tax purposes. Parent has no Liability for any material Taxes of any Person (other than Parent

and any of its Subsidiaries) under Treasury Regulations Section 1.1502-6 (or any similar provision of state, local, or foreign Law),

as a transferee or successor, by Contract (other than a Contract entered into in the Ordinary Course of Business the principal subject

matter of which is not Taxes) or otherwise by operation of Law.

(j)

Neither Parent nor any of its Subsidiaries has distributed stock of another Person, or had its stock distributed by another Person, in

a transaction that was purported or intended to be governed in whole or in part by Section 355 of the Code or Section 361 of the Code

(or any similar provisions of state, local or foreign Law).

(k)

Parent has never had a permanent establishment (within the meaning of an applicable Tax treaty) or otherwise had an office or fixed place

of business in a country other than the country in which it is organized.

(l)

Neither Parent nor any of its Subsidiaries has participated in or been a party to a transaction that, as of the date of this Agreement,

constitutes a “listed transaction” within the meaning of Section 6707A(c)(2) of the Code and Treasury Regulations Section

1.6011-4(b)(2).

(m)

Section 3.16(m) of the Parent Disclosure Schedule sets forth the entity classification of Parent and each of its Subsidiaries

for U.S. federal income tax purposes. Neither Parent nor any of its Subsidiaries has made an election or taken any other action to change

its federal and state income tax classification from such classification.

For

purposes of this Section 3.16, each reference to Parent or any of its Subsidiaries shall be deemed to include any Person that

was liquidated into, merged with, or is otherwise a predecessor to, Parent.

3.17

Employee and Labor Matters; Benefit Plans.

(a)

Section 3.17(a) of the Parent Disclosure Schedule is a list of all Parent Benefit Plans, other than employment offer letters on

Parent’s standard form and other than individual Parent Options or other compensatory equity award agreements made pursuant to

the Parent’s standard forms, in which case only representative standard forms of such agreements shall be scheduled. “Parent

Benefit Plan” means each: (i) “employee benefit plan” as defined in Section 3(3) of ERISA, and (ii) other pension,

retirement, deferred compensation, excess benefit, profit sharing, bonus, incentive, equity or equity-based, phantom equity, employment,

consulting, severance, change-of-control, retention, health, life, disability, group insurance, paid time off, holiday, welfare and fringe

benefit plan, program, agreement, Contract, or arrangement (whether written or unwritten, qualified or nonqualified, funded or unfunded,

subject or not subject to ERISA and including any that have been frozen), in each case, sponsored, maintained, administered, contributed

to, or required to be contributed to, by Parent or any of its Subsidiaries for the benefit of any current or former employee, director,

officer or independent contractor of Parent or any of its Subsidiaries or under which Parent or any of its Subsidiaries has any actual

or contingent liability (including, without limitation, by reason of having a Parent ERISA Affiliate). Section 3.17(a) of the

Parent Disclosure Schedule indicates which of the Parent Benefit Plans are maintained by a professional employer organization (“Parent

PEO Plans”). Notwithstanding anything herein to the contrary, all representations pursuant to this Section 3.17

in respect of any Parent PEO Plan shall only be made to Parent’s Knowledge.

(b)

As applicable with respect to each material Parent Benefit Plan, and to the extent provided to Parent from the professional employer

organization, Parent has made available to the Company true and complete copies of (i) each material Parent Benefit Plan, including all

amendments thereto, and in the case of an unwritten material Parent Benefit Plan, a written description thereof, (ii) all current trust

documents, investment management Contracts, custodial agreements, administrative services agreements

and insurance and annuity Contracts relating thereto, (iii) the current summary plan description and each summary of material modifications

thereto, (iv) the most recently filed annual reports with any Governmental Body (e.g., Form 5500 and all schedules thereto), (v)

the most recent IRS determination, opinion or advisory letter, (vi) the most recent summary annual reports, nondiscrimination testing

reports, actuarial reports, financial statements and trustee reports, and (vii) all notices and filings from the IRS or Department of

Labor or other Governmental Body concerning audits or investigations, or “prohibited transactions” within the meaning of

Section 406 of ERISA or Section 4975 of the Code.

(c)

Each Parent Benefit Plan has been maintained, operated and administered in compliance in all material respects with its terms and the

applicable provisions of ERISA, the Code and all other Laws.

(d)

The Parent Benefit Plans which are “employee pension benefit plans” within the meaning of Section 3(2) of ERISA and which

are intended to meet the qualification requirements of Section 401(a) of the Code have received determination or opinion letters from

the IRS on which they may currently rely to the effect that such plans are qualified under Section 401(a) of the Code and the related

trusts are exempt from federal income Taxes under Section 501(a) of the Code, respectively, and nothing has occurred that would reasonably

be expected to materially adversely affect the qualification of such Parent Benefit Plan or the tax exempt status of the related trust.

(e)

Neither Parent, any of its Subsidiaries nor any Parent ERISA Affiliate maintains, contributes to, is required to contribute to, or has

any actual or contingent liability with respect to, (i) any “employee pension benefit plan” (within the meaning of Section

3(2) of ERISA) that is subject to Title IV or Section 302 of ERISA or Section 412 of the Code, (ii) any “multiemployer plan”

(within the meaning of Section 3(37) of ERISA), (iii) any “multiple employer plan” (within the meaning of Section 413 of

the Code) or (iv) any “multiple employer welfare arrangement” (within the meaning of Section 3(40) of ERISA).

(f)

There are no pending audits or investigations by any Governmental Body involving any Parent Benefit Plan, and no pending or, to the Knowledge

of Parent, threatened claims (except for routine individual claims for benefits payable in the normal operation of the Parent Benefit

Plans), suits or proceedings involving any Parent Benefit Plan, or, to the Knowledge of Parent, any fiduciary thereof or service provider

thereto, in any case except as would not be reasonably expected to result in material liability to Parent or any of its Subsidiaries.

All contributions and premium payments required to have been made under any of the Parent Benefit Plans or by applicable Law (without

regard to any waivers granted under Section 412 of the Code), have been timely made and neither Parent nor any Parent ERISA Affiliate

has any material liability for any unpaid contributions with respect to any Parent Benefit Plan.

(g)

None of Parent, any of its Subsidiaries or any Parent ERISA Affiliates, or to the Knowledge of Parent, any fiduciary, trustee or administrator

of any Parent Benefit Plan, has engaged in, or in connection with the Contemplated Transactions will engage in, any transaction with

respect to any Parent Benefit Plan which would subject any such Parent Benefit Plan, Parent, any of its Subsidiaries or Parent ERISA

Affiliates to a material Tax, material penalty or material liability for a “prohibited transaction” under Section 406 of

ERISA or Section 4975 of the Code.

(h)

No Parent Benefit Plan provides death, medical, dental, vision, life insurance or other welfare benefits beyond termination of service

or retirement other than coverage mandated by Law and to the Knowledge

of Parent, neither Parent nor any of its Subsidiaries has made a written representation promising the same.

(i)

Except as set forth in Section 3.17(i) of the Parent Disclosure Schedule, neither the execution of this Agreement, nor the performance

of the Contemplated Transactions (either alone or when combined with the occurrence of any other event, including without limitation,

a termination of employment) will: (i) result in any payment becoming due to any current or former employee, director, officer, or independent

contractor of Parent or any Subsidiary thereof pursuant to any Parent Benefit Plan, (ii) increase any amount of compensation or benefits

otherwise payable under any Parent Benefit Plan, (iii) result in the acceleration of the time of payment, funding or vesting of any benefits

under any Parent Benefit Plan, (iv) require any contribution or payment to fund any obligation under any Parent Benefit Plan or (v) limit

the right to merge, amend or terminate any Parent Benefit Plan.

(j)

Except as set forth in Section 3.17(j) of the Parent Disclosure Schedule, neither the execution of, nor the consummation of the

Contemplated Transactions (either alone or when combined with the occurrence of any other event, including without limitation, a termination

of employment) will result in the receipt or retention by any person who is a “disqualified individual” (within the meaning

of Code Section 280G) with respect to Parent and its Subsidiaries of any payment or benefit that is or could be characterized as a “parachute

payment” (within the meaning of Code Section 280G), determined

without regard to the application of Code Section 280G(b)(5).

(k)

No current or former employee, officer, director or independent contractor of Parent or any of its Subsidiaries has any “gross

up” agreements with the Parent or any of its Subsidiaries or other assurance of reimbursement by the Parent or any of its Subsidiaries

for any Taxes imposed under Code Section 409A or Code Section 4999.

(l)

To the Knowledge of Parent, each Parent Benefit Plan maintained for the benefit of service providers located outside of the United States

(each, a “Parent Foreign Plan”) has obtained from the Governmental Body having jurisdiction with respect to

such plan any required determinations that such plan is in compliance with the Laws of any such Governmental Body.

(m)

The assets of each of the Parent Foreign Plans that is similar to an employee pension benefit plan (as defined in Section 3(2) of ERISA

(whether or not subject to ERISA)) or that otherwise provides retirement, medical or life insurance benefits following retirement or

other termination of service or employment are at least equal to the liabilities of such plans.

(n)

Parent has provided to the Company a true and correct list, as of the date of this Agreement, containing the names of all current full-time,

part-time or temporary employees and independent contractors (and indication as such), and, as applicable: (i) the annual dollar amount

of all cash compensation in the form of wages, salary, fees, commissions, or director’s fees payable to each person, (ii) dates

of employment or service, (iii) title and, with respect to independent contractors, a current written description of such person’s

contracting services, (iv) visa status, if applicable; and (v) with respect

to employees, (A) a designation of whether they are classified as exempt or non-exempt for purposes of FLSA and any similar state, federal

or Foreign law and (B) whether such an employee is on leave, and if so, the expected return date.

(o)

Neither Parent nor any of its Subsidiaries is or has ever been a party to, bound by, or has a duty to bargain under, any collective bargaining

agreement or other Contract with a labor union or similar labor organization

representing any of its employees, and there is no labor union or similar labor organization representing or, to the Knowledge of Parent,

purporting to represent or seeking to represent any employees of Parent or its Subsidiaries, including through the filing of a petition

for representation election. There is not and has not been in the past five years, nor, to the Knowledge of Parent, is there or has there

been in the past five years any threat of, any strike, slowdown, work stoppage, lockout, union election petition, demand for recognition,

or any similar activity or dispute, or any union organizing activity, against Parent or any of its Subsidiaries.

(p)

Parent and each of its Subsidiaries is, and since December 31, 2022 has been, in material compliance with all applicable Laws respecting

labor, employment, employment practices, and terms and conditions of employment, including worker classification, discrimination, harassment

and retaliation, equal employment opportunities, fair employment practices, meal and rest periods, immigration, employee safety and health,

payment of wages (including overtime wages), unemployment and workers’ compensation, leaves of absence, and hours of work. Except

as would not be reasonably likely to result in a material liability to Parent or any of its Subsidiaries, with respect to employees of

Parent and its Subsidiaries, each of Parent and its Subsidiaries, since December 31, 2022, has withheld and reported all amounts required

by Law to be withheld and reported with respect to wages, salaries and other payments, benefits, or compensation to employees. There

is no material Legal Proceeding pending or, to the Knowledge of Parent, threatened or reasonably anticipated against Parent or any of

its Subsidiaries relating to any current or former employee, applicant for employment, or consultant of Parent.

(q)

Within the preceding two years, Parent has complied in all material respects with the WARN Act.

3.18

Environmental Matters. Parent and each of its Subsidiaries are in compliance and since December 31, 2022 have complied

with all applicable Environmental Laws, which compliance includes the possession by Parent of all permits and other Governmental Authorizations

required under applicable Environmental Laws and compliance with the terms and conditions thereof, except for any failure to be in such

compliance that, either individually or in the aggregate, would not reasonably be expected to be material to Parent or its business.

Neither Parent nor any of its Subsidiaries has received since December 31, 2022 (or prior to that time, which is pending and unresolved),

any written notice or other communication (in writing or otherwise), whether from a Governmental Body or other Person, that alleges that

Parent or any of its Subsidiaries is not in compliance with or has liability pursuant to any Environmental Law and, to the Knowledge

of Parent, there are no circumstances that would reasonably be expected to prevent or interfere with Parent’s or any of its Subsidiaries’

compliance in any material respects with any Environmental Law, except where such failure to comply would not reasonably be expected

to be material to Parent or its business. No current or (during the time a prior property was leased or controlled by Parent or any of

its Subsidiaries) prior property leased or controlled by Parent or any of its Subsidiaries has had a release of or exposure to Hazardous

Materials in material violation of or as would reasonably be expected to result in any material liability of Parent or any of its Subsidiaries

pursuant to Environmental Law. No consent, approval or Governmental Authorization of or registration or filing with any Governmental

Body is required by Environmental Laws in connection with the execution and delivery of this Agreement or the consummation of the Contemplated

Transactions by Parent or Merger Subs. Prior to the date hereof, Parent has provided or otherwise made available to the Company true

and correct copies of all material environmental reports, assessments, studies and audits in the possession or control of Parent or any

of its Subsidiaries with respect to any property leased or controlled by Parent or any of its Subsidiaries or any business operated by

them.

3.19

Transactions with Affiliates. Except as set forth in the Parent SEC Documents filed prior to the date of this Agreement,

since the date of Parent’s last proxy statement filed in December 2025 with the SEC, no event has occurred that would be required

to be reported by Parent pursuant to Item 404 of Regulation S-K. Section 3.19 of the Parent Disclosure Schedule identifies each

Person who is (or who may be deemed to be) an Affiliate of Parent as of the date of this Agreement.

3.20

Insurance. Parent has delivered or made available to the Company accurate and complete copies of all insurance policies

and all self-insurance programs and arrangements relating to the business, assets, liabilities and operations of Parent and each of its

Subsidiaries. Each of such insurance policies is in full force and effect and Parent and each of its Subsidiaries is in compliance in

all material respects with the terms thereof. Other than customary end of policy notifications from insurance carriers, since December

31, 2022, neither Parent nor any of its Subsidiaries has received any notice or other communication regarding any actual or possible:

(a) cancellation or invalidation of any insurance policy, or (b) refusal or denial of any coverage, reservation of rights or rejection

of any material claim under any insurance policy. Parent and each of its Subsidiaries has provided timely written notice to the appropriate

insurance carrier(s) of each Legal Proceeding that is currently pending against Parent or any of its Subsidiaries for which Parent or

such Subsidiary has insurance coverage, and no such carrier has issued a denial of coverage or a reservation of rights with respect to

any such Legal Proceeding, or informed Parent or any of its Subsidiaries of its intent to do so.

3.21

Opinion of Financial Advisor. The Parent Board has received an opinion of H.C. Wainwright & Co., dated on or about

the date of the Agreement, to the effect that, as of the date of such opinion and subject to the assumptions, qualifications, limitations

and other matters set forth therein, the Transaction (as specified in such opinion) is fair, from a financial point of view, to Parent

Stockholders. It is agreed and understood that such opinion is furnished solely for the use of the Parent Board and may not be relied

upon by the Company or any other party.

3.22

No Financial Advisors. No broker, finder or investment banker, other than Tungsten Partners LLC, H.C. Wainwright &

Co., LLC, UBS Securities LLC, and Cantor Fitzgerald & Co., is entitled to any brokerage fee, finder’s fee, opinion fee, success

fee, transaction fee or other fee or commission in connection with the Contemplated Transactions based upon arrangements made by or on

behalf of Parent or any of its Subsidiaries.

3.23

Anti-Bribery. None of Parent or any of its Subsidiaries nor any of their respective directors, officers, employees or,

to Parent’s Knowledge, agents or any other Person acting on its behalf has directly or indirectly made any bribes, rebates, payoffs,

influence payments, kickbacks, illegal payments, illegal political contributions, or other payments, in the form of cash, gifts, or otherwise,

or taken any other action, in violation of Anti-Bribery Laws. Neither Parent nor any of its Subsidiaries is or has been the subject of

any investigation or inquiry by any Governmental Body with respect to potential violations of Anti-Bribery Laws.

3.24

Valid Issuance. The Parent Common Stock and Parent Convertible Preferred Stock to be issued in the Merger will, when issued

in accordance with the provisions of this Agreement, be validly issued, fully paid and nonassessable. To the Knowledge of Parent as of

the date of this Agreement, no “bad actor” disqualifying event described in Rule 506(d)(1)(i)–(viii) of the Securities

Act (a “Disqualifying Event”) is applicable to Parent or, to Parent’s Knowledge, any Parent Covered Person,

except for a Disqualifying Event as to which Rule 506(d)(2)(ii)–(iv) or (d)(3) of the Securities Act is applicable.

3.25

3i Agreement. Parent represents and warrants that the 3i Agreement has been duly executed and delivered by the parties

thereto and is in full force and effect.

3.26

Disclaimer of Other Representations or Warranties.

(a)

Except as previously set forth in this Section 3 or in any certificate delivered by Parent or Merger Subs to the Company pursuant

to this Agreement, neither Parent nor any Merger Sub makes any representation or warranty, express or implied, at law or in equity, with

respect to it or any of its assets, liabilities or operations, and any such other representations or warranties are hereby expressly

disclaimed.

(b)

Each of Parent, First Merger Sub and Second Merger Sub acknowledges and agrees that, except for the representations and warranties of

the Company set forth in Section 2 or in any certificate delivered by the Company to Parent or the Merger Subs pursuant to this

Agreement, none of Parent, First Merger Sub, Second Merger Sub or any of their respective Representatives is relying on any other representation

or warranty of the Company or any other Person made outside of Section 2 or such certificates, including regarding the accuracy

or completeness of any such other representations or warranties or the omission of any material information, whether express or implied,

in each case, with respect to the Contemplated Transactions.

SECTION 4.

ADDITIONAL AGREEMENTS OF

THE PARTIES

4.1

Parent Stockholders’ Meeting.

(a)

As promptly as practicable following the execution of this Agreement, Parent shall take all action necessary under applicable Law to

call, give notice of and hold a meeting of the holders of Parent Common Stock for the purpose of seeking:

(i)

approval of the Preferred Stock Conversion Proposal;

(ii)

if deemed necessary or appropriate by Parent or as otherwise required by applicable Law or Contract, (a) such additional matters as may

be agreed to by Parent and Company to facilitate approval of the Preferred Stock Conversion Proposal, and (b) as may be agreed to by

Parent and Company to authorize the amendment of Parent’s certificate of incorporation to authorize sufficient Parent Common Stock

in Parent’s certificate of incorporation for the conversion of the Parent Convertible Preferred Stock issued pursuant to this Agreement

and/or to effectuate the Nasdaq Reverse Split (the “Charter Amendment Proposal”) (the matters contemplated

by the clauses 4.1(a)(i) and 4.1(a)(ii) are referred to as the “Parent Stockholder Matters,” and such

meeting, the “Parent Stockholders’ Meeting”).

(b)

Parent agrees to use reasonable best efforts to: (i) call and hold the Parent Stockholders’ Meeting as soon as practicable after

the date hereof, and (ii) to solicit and obtain the Required Parent Stockholder Vote, including without limitation: (A) engaging a nationally

recognized proxy solicitation firm and information agent, (B) actively attempting to contact and obtain votes from the Parent’s

Stockholders (including its retail stockholders with meaningful holdings of Parent Common Stock), and (C) working with the Parent’s

transfer agent and inspector of elections to facilitate an appropriate and straightforward process for obtaining the Required Parent

Stockholder Vote. If the approval of the Parent Stockholder Matters is not obtained at the Parent Stockholders’ Meeting or if on

a date preceding the Parent Stockholders’ Meeting, Parent reasonably

believes that (x) it will not receive proxies sufficient to obtain the Required Parent Stockholder Vote, whether or not quorum would

be present, or (y) it will not have sufficient shares of Parent Common Stock represented (whether in person or by proxy) to constitute

a quorum necessary to conduct the business of the Parent Stockholders’ Meeting, then, in each case, Parent will use its reasonable

best efforts to adjourn the Parent Stockholders’ Meeting one or more times to a date or dates no more than 30 days after the scheduled

date for such meeting, and to obtain such approvals at such time. If the Parent Stockholders’ Meeting is not so adjourned, and/or

if the approval of the Parent Stockholder Matters is not then obtained, Parent will use its reasonable best efforts to obtain such approvals

as soon as practicable thereafter, and in any event to obtain such approvals at the next occurring annual meeting of the Parent Stockholders

or, if such annual meeting is not scheduled to be held within six months after the Parent Stockholders’ Meeting, a special meeting

of the Parent Stockholders to be held within six months after the Parent Stockholders’ Meeting. Parent will hold an annual meeting

or special meeting of Parent Stockholders, at which a vote of the Parent Stockholders to approve the Parent Stockholder Matters will

be solicited and taken, at least once every six months until Parent obtains approval of the Parent Stockholder Matters.

(c)

Parent agrees that: (i) the Parent Board shall recommend that the holders of Parent Common Stock vote to approve the Parent Stockholder

Matters and shall use its reasonable best efforts to solicit and obtain such approval within the time frames set forth in Section

4.2(b), and (ii) the Proxy Statement shall include a statement to the effect that the Parent Board recommends that the Parent Stockholders

vote to approve the Parent Stockholder Matters.

(d)

The Company and Parent acknowledge that, under Nasdaq Stock Market Rules, the Parent Preferred Stock Payment Shares will not be entitled

to vote on the Preferred Stock Conversion Proposal.

4.2

Proxy Statement.

(a)

As promptly as practicable after the Closing Date and subject to Section 4.2(d), Parent and Company shall prepare and Parent shall

file with the SEC a proxy statement relating to the Parent Stockholders’ Meeting to be held in connection with the Parent Stockholder

Matters (together with any amendments thereof or supplements thereto, the “Proxy Statement”). The Proxy Statement

will include AICPA audited financial statements of the Company prepared in accordance with GAAP, pro forma financial statements of the

Company as required by all securities Laws, and, as applicable, reviewed but unaudited interim financial statements of the Company. Parent

shall use its reasonable best efforts to: (i) cause the Proxy Statement to comply with applicable rules and regulations promulgated by

the SEC, and (ii) respond promptly to any comments or requests of the SEC or its staff related to the Proxy Statement. Parent shall not

file the Proxy Statement, or any amendment or supplement thereto, or respond to SEC comments or requests, without providing the Company

a reasonable opportunity to review and comment thereon (which comments shall be reasonably considered by Parent).

(b)

Parent covenants and agrees that the Proxy Statement (and the letters to stockholders, notice of meeting and form of proxy included therewith)

will: (i) comply as to form in all material respects with the requirements of applicable U.S. federal securities Laws and the DGCL, and

(ii) will not contain any untrue statement of a material fact or omit

to state any material fact required to be stated therein or necessary in order to make the statements made therein, in light of the circumstances

under which they were made, not misleading.

(c)

Parent shall use reasonable best efforts to cause the Proxy Statement to be mailed to Parent Stockholders as promptly as practicable

after the Proxy Statement has been filed with the SEC and either: (i) the SEC has indicated that it does not intend to review the Proxy

Statement or that its review of the Proxy Statement has been completed, or (ii) at least ten (10) days shall have passed since the Proxy

Statement was filed with the SEC without receiving any correspondence from the SEC commenting upon, or indicating that it intends to

review, the Proxy Statement, all in compliance with applicable U.S. federal securities laws and the DGCL. If Parent, First Merger Sub,

Second Merger Sub or the Surviving Entity: (A) become aware of any event or information that, pursuant to the Securities Act or the Exchange

Act, should be disclosed in an amendment or supplement to the Proxy Statement, (B)

receives notice of any SEC request for an amendment or supplement to the Proxy Statement or for additional information related thereto,

or (C) receives SEC comments on the Proxy Statement, as the case may be, then such Party, as the case may be, shall promptly inform the

other Parties thereof and shall cooperate and consult with such other Parties in Parent filing such amendment or supplement with the

SEC and, if appropriate, in mailing such amendment or supplement to the Parent Stockholders.

(d)

The Parties shall reasonably cooperate and consult with each other and provide, and shall use reasonable best efforts to cause their

respective Representatives to provide, the other Party and its Representatives, with all true, correct and complete information regarding

such Party that is required by Law to be included in the Proxy Statement or reasonably requested by the other Party to be included in

the Proxy Statement. If at any time the information provided in Proxy Statement has or will become “stale” and new information

should, as determined by Parent acting reasonably, be disclosed in an amendment or supplement to the Proxy Statement, then Parent shall

promptly inform the Company thereof and each such Party shall cooperate and consult with one another, and shall use reasonable best efforts

to cause their accounting and other outside professionals to so cooperate and consult, (i) in providing the financial reporting necessary

for such filing and (ii) in filing such amendment or supplement with the SEC (and, if related to the Proxy Statement, mailing such amendment

or supplement to the Parent Stockholders).

4.3

Reservation of Parent Common Stock; Issuance of Shares of Parent Common Stock. For as long as any Parent Preferred Stock

Payment Shares remain outstanding, Parent shall at all times reserve and keep available, free from preemptive rights, out of its authorized

but unissued Parent Common Stock or shares of Parent Common Stock held in treasury by Parent, for the purpose of effecting the conversion

of the Parent Preferred Stock Payment Shares, the full number of shares of Parent Common Stock then issuable upon the conversion of all

Parent Preferred Stock Payment Shares then outstanding. All shares of Parent Common Stock delivered upon conversion of the Parent Preferred

Stock Payment Shares shall be newly issued shares or shares held in treasury by Parent, shall have been duly authorized and validly issued

and shall be fully paid and nonassessable, and shall be free from preemptive rights and free of any Encumbrance.

4.4

Employee Benefits.

(a)

For purposes of vesting, eligibility to participate, and level of benefits (other than for purposes of determining awards under an equity

incentive plan or accrued benefits under any defined benefit pension plan) under the benefit plans, programs, Contracts or arrangements

of Parent or any of its Subsidiaries (including, following the Closing, the Surviving Entity and its Subsidiaries) (the “Post-Closing

Plans”), Parent shall use reasonable best efforts to cause each employee of the Company who remains employed by Parent

or the Surviving Entity, or any of their respective Subsidiaries following the Closing, (collectively, the “Continuing Employees”)

to be credited with his or her years of service with the Company or any

of its predecessors; provided that the foregoing shall not apply to the extent that its application would result in a duplication

of benefits. In addition, and without limiting the generality of the foregoing, for purposes of each Post-Closing Plan providing medical,

dental, pharmaceutical and/or vision benefits to a Continuing Employee, Parent shall use reasonable best efforts to cause all pre-existing

condition exclusions and actively-at-work requirements of such Post-Closing Plan to be waived for such Continuing Employee and his or

her covered dependents to the extent and unless such conditions would have been waived or satisfied under the employee benefit plan whose

coverage is being replaced under the Post-Closing Plan, and Parent shall use its reasonable best efforts to cause any eligible expenses

incurred by a Continuing Employee and his or her covered dependents during the portion of such plan year in which coverage is replaced

with coverage under a Post-Closing Plan to be taken into account under such Post-Closing Plan with respect to the plan year in which

participation in such Post-Closing Plan begins for purposes of satisfying all deductible, coinsurance and maximum out-of-pocket requirements

applicable to such Continuing Employee and his or her covered dependents for such plan year as if such amounts had been paid in accordance

with such Post-Closing Plan.

(b)

The provisions of this Section 4.4 are for the sole benefit of Parent and the Company and no provision of this Agreement shall:

(i) create any third-party beneficiary or other rights in any Person, including rights in respect of any benefits that may be provided,

directly or indirectly, under any Company Benefit Plan, Parent Benefit Plan or Post-Closing Plan or rights to continued employment or

service with the Company or the Parent (or any Subsidiary thereof), (ii) be construed as an amendment, waiver or creation of or limitation

on the ability to terminate any Company Benefit Plan, Parent Benefit Plan or Post-Closing Plan, or (iii) limit the ability of the Parent

to terminate the employment of any Continuing Employee or modify the at-will status of any Continuing Employees.

4.5

Indemnification of Officers and Directors.

(a)

From the First Effective Time through the sixth anniversary of the date on which the First Effective Time occurs, each of Parent and

the Surviving Entity shall indemnify and hold harmless each person who is now, or has been at any time prior to the date hereof, or who

becomes prior to the First Effective Time, a director or officer of Parent or the Company or any of their respective Subsidiaries, respectively

(the “D&O Indemnified Parties”), against all claims, losses, liabilities, damages, judgments, fines and

reasonable fees, costs and expenses, including attorneys’ fees and disbursements, incurred in connection with any claim, action,

suit, proceeding or investigation, whether civil, criminal, administrative or investigative, arising out of or pertaining to the fact

that the D&O Indemnified Party is or was a director or officer of Parent or of the Company, or any Subsidiary thereof, asserted or

claimed prior to the First Effective Time, in each case, to the fullest extent permitted under applicable Law. Except in the case of

fraud, each D&O Indemnified Party will be entitled to advancement of expenses incurred in the defense of any such claim, action,

suit, proceeding or investigation from each of Parent and the Surviving Entity, jointly and severally, upon receipt by Parent or the

Surviving Entity from the D&O Indemnified Party of a request therefor; provided that any such person to whom expenses are

advanced provides an undertaking to Parent, to the extent then required by the DGCL and DLLCA, as applicable, to repay such advances

if it is ultimately determined that such person is not entitled to indemnification.

(b)

The provisions of the certificate of incorporation and bylaws of Parent with respect to indemnification, advancement of expenses and

exculpation of present and former directors and officers of Parent that are presently set forth in the certificate of incorporation and

bylaws of Parent shall not be amended, modified or repealed for a period of six years from the First Effective Time in a manner

that would adversely affect the rights thereunder of individuals who, at or prior to the First Effective Time, were officers or directors

of Parent, unless such modification is required by applicable Law. The certificate of formation and limited liability company agreement

of the Surviving Entity shall contain, and Parent shall cause the certificate of formation and limited liability company agreement of

the Surviving Entity to so contain, provisions no less favorable with respect to indemnification, advancement of expenses and exculpation

of present and former directors and officers as those presently set forth in the certificate of incorporation and bylaws of Parent.

(c)

From and after the First Effective Time: (i) the Surviving Entity shall fulfill and honor in all respects the obligations of the Company

to its D&O Indemnified Parties as of immediately prior to the Closing pursuant to any indemnification provisions under the Company’s

Organizational Documents and pursuant to any indemnification agreements between the Company and such D&O Indemnified Parties set

forth on Schedule 4.5(c)(i) hereto, with respect to claims arising out of matters occurring at or prior to the First Effective

Time, and (ii) Parent shall fulfill and honor in all respects the obligations of Parent to its D&O Indemnified Parties as of immediately

prior to the Closing pursuant to any indemnification provisions under Parent’s Organizational Documents and pursuant to any indemnification

agreements between Parent and such D&O Indemnified Parties set forth on Schedule 4.5(c)(ii) hereto, with respect to

claims arising out of matters occurring at or prior to the First Effective Time.

(d)

From and after the First Effective Time, Parent shall continue to maintain directors’ and officers’ liability insurance policies,

with an effective date as of the Closing Date, on commercially available terms and conditions and with coverage limits customary for

U.S. public companies similarly situated to Parent. From and after the First Effective Time, Parent shall pay all expenses, including

reasonable attorneys’ fees, that are incurred by the persons referred to in this Section

4.5 in connection with their successful enforcement of the rights provided to such persons in this Section 4.5.

(e)

The provisions of this Section 4.5 are intended to be in addition to the rights otherwise available to the current and former

officers and directors of Parent and the Company by Law, charter, statute, bylaw or agreement, and shall operate for the benefit of,

and shall be enforceable by, each of the D&O Indemnified Parties, their heirs and their representatives.

(f)

In the event Parent or the Surviving Entity or any of their respective successors or assigns (i) consolidates with or merges into any

other Person and shall not be the continuing or surviving corporation or entity of such consolidation or merger, or (ii) transfers all

or substantially all of its properties and assets to any Person, then, and in each such case, proper provision shall be made so that

the successors and assigns of Parent or the Surviving Entity, as the case may be, shall succeed to the obligations set forth in this

Section 4.5. Parent shall cause the Surviving Entity to perform all of the obligations of the Surviving Entity under this Section

4.5.

4.6

Additional Agreements. The Parties shall use reasonable best efforts to cause to be taken all actions necessary to consummate

the Contemplated Transactions. Without limiting the generality of the foregoing, each Party to this Agreement: (a) shall make all filings

and other submissions (if any) and give all notices (if any) required to be made and given by such Party in connection with the Contemplated

Transactions; (b) shall use reasonable best efforts to obtain each Consent (if any) reasonably required to be obtained (pursuant to any

applicable Law or Contract, or otherwise) by such Party in connection with the Contemplated Transactions or for such Contract to remain

in full force and effect; (c) shall use reasonable best efforts to lift

any injunction prohibiting, or any other legal bar to, the Contemplated Transactions; and (d) shall use reasonable best efforts to satisfy

the conditions precedent to the consummation of this Agreement.

4.7

Listing. Parent shall use its reasonable best efforts to (a) maintain its existing listing on Nasdaq, (b) prepare and submit

to Nasdaq a notification form for the listing of the shares of the Parent Common Stock to be issued upon conversion of the Parent Preferred

Stock Payment Shares in connection with the Contemplated Transactions, to cause such shares to be approved for listing (subject to official

notice of issuance), (c) effect the Nasdaq Reverse Split, if deemed necessary, and (d) to the extent required by Nasdaq rules and regulations,

file an initial listing application for the Parent Common Stock on Nasdaq (the “Nasdaq Listing Application”),

which Nasdaq Listing Application shall be prepared in cooperation with the Company, and to cause such Nasdaq Listing Application to be

conditionally approved prior to the First Effective Time. The Parties will use reasonable best efforts to coordinate with respect to

compliance with Nasdaq rules and regulations. Each Party will promptly inform the other Party of all verbal or written communications

between Nasdaq and such Party or its representatives. The Company will cooperate with Parent as reasonably requested by Parent with respect

to the Nasdaq Listing Application and promptly furnish to Parent all information concerning the Company Stockholders that may be required

or reasonably requested in connection with any action contemplated by this Section 4.7.

4.8

Tax Matters.

(a)

For U.S. federal income Tax purposes: (i) the Parties intend that the First Merger and the Second Merger, taken together, constitute

an integrated transaction described in Rev. Rul. 2001-46, 2001-2 C.B. 321 that qualifies as a “reorganization” within the

meaning of Section 368(a) of the Code and the Treasury Regulations promulgated thereunder (the “Intended Tax Treatment”),

and (ii) this Agreement is intended to be, and is hereby adopted as, a “plan of reorganization” for purposes of Sections

354 and 361 of the Code and Treasury Regulations Sections 1.368-2(g) and 1.368-3(a), to which the Parent, Merger Subs and the Company

are parties under Section 368(b) of the Code. The Parties shall treat and shall not take any tax reporting position (including during

the course of any audit, litigation or other proceeding with respect to Taxes) inconsistent with the treatment of the Merger as a reorganization

within the meaning of Section 368(a) of the Code for U.S. federal, state and other relevant Tax purposes, unless otherwise required pursuant

to a “determination” within the meaning of Section 1313(a) of the Code. The Parties shall (and shall cause their Affiliates

to) not take any action or cause any action to be taken, or fail to take or cause to be taken any action, which action or failure to

act would reasonably be expected to prevent the Merger from qualifying, for the Intended Tax Treatment.

4.9

Legends. Parent shall be entitled to place appropriate legends, including the legend noted in Section 4.15, on the

book entries and/or certificates evidencing any shares of Parent Common Stock or Parent Convertible Preferred Stock to be received in

the Merger by equity holders of the Company who may be considered “affiliates” of Parent for purposes of Rules 144 and 145

under the Securities Act reflecting the restrictions set forth in Rules 144 and 145 and to issue appropriate stop transfer instructions

to the transfer agent for Parent Common Stock and Parent Convertible Preferred Stock.

4.10

Directors and Officers. The Parties shall take all necessary action so that immediately after the Second Effective Time,

(a) the Parent Board is comprised of six members, with five such members designated by Parent, and one such members designated by the

Company, as set forth on Schedule 4.10(a) hereto, which includes a majority of independent directors (in accordance with

Nasdaq requirements) and (b) the Person set forth on Schedule 4.10(b)

hereto under the heading “Officer” is elected or appointed, as applicable, to the position of officer of Parent, as set forth

therein, to serve in such positions effective as of the Second Effective Time until a successor is duly appointed and qualified in accordance

with applicable Law.

4.11

Section 16 Matters. Prior to the First Effective Time, Parent and the Company shall take all such steps as may be required

(to the extent permitted under applicable Laws) to cause any acquisitions of Parent Common Stock, restricted stock awards to acquire

Parent Common Stock and any Parent Options to purchase Parent Common Stock in connection with the Contemplated Transactions, by each

individual who is reasonably expected to become subject to the reporting requirements of Section

16(a) of the Exchange Act with respect to Parent, to be exempt under Rule 16b-3 promulgated under the Exchange Act.

4.12

Closing Certificates.

(a)

The Company will prepare and deliver to Parent prior to the Closing a certificate signed by the Chief Financial Officer of the Company

(“Company Closing Certificate”) in a form reasonably acceptable to Parent setting forth, as of immediately

prior to the First Effective Time: (i) each holder of Company Common

Stock, Company Preferred Stock and Company Options, (ii) such holder’s name and address, (iii) the number and type of Company Common

Stock held and/or underlying the Company Options as of immediately prior to the First Effective Time for each such holder, and the number

and type of Company Preferred Stock held, and (iv) the number of shares of Parent Common Stock and/or Parent Convertible Preferred Stock

to be issued to such holder, or to underlie any Parent Option to be issued to such holder, pursuant to this Agreement in respect of the

Company Capital Stock, Company Preferred Stock or Company Options held by such holder as of immediately prior to the First Effective

Time, which shall be calculated using the Exchange Ratio (the “Allocation Certificate”).

(b)

Parent will prepare and deliver to the Company prior to the Closing a certificate signed by the Chief Financial Officer of Parent (“Parent

Closing Certificate”) in a form reasonably acceptable to the Company, setting forth, as of immediately prior to the Reference

Date: (i) the number of Parent Common Stock outstanding and (ii) (A) each record holder of Parent Options or Parent RSUs, (B) such record

holder’s name, (C) the number of shares of Parent Common Stock underlying the Parent Options or Parent RSUs as of the First Effective

Time for such holder (the “Parent Outstanding Shares Certificate”).

4.13

Takeover Statutes. If any Takeover Statute is or may become applicable to the Contemplated Transactions, each of the Company,

the Company Board, Parent and the Parent Board, as applicable, shall grant such approvals and take such actions as are necessary so that

the Contemplated Transactions may be consummated as promptly as practicable on the terms contemplated by this Agreement and otherwise

act to eliminate or minimize the effects of such statute or regulation on the Contemplated Transactions.

4.14

Obligations of Merger Subs. Parent will take all action necessary to cause Merger Subs to perform their obligations under

this Agreement and to consummate the Merger on the terms and conditions set forth in this Agreement.

4.15

Private Placement. Each of the Company and Parent shall take all reasonably necessary action on its part such that the

issuance of Parent Common Stock and Parent Preferred Stock Payment Shares

pursuant to this Agreement and the 3i Agreement constitutes a transaction exempt from registration under the Securities Act in compliance

with Rule 506 of Regulation D promulgated thereunder. Each certificate representing Parent Common Stock Payment Shares and the Parent

Preferred Stock Payment Shares comprising Merger Consideration shall, until such time that such shares are not so restricted under the

Securities Act, bear a legend identical or similar in effect to the following legend (together with any other legend or legends required

by applicable state securities applicable Law or otherwise, if any):

“THE

SHARES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE “ACT”) AND MAY NOT

BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED UNLESS REGISTERED UNDER THE ACT OR UNLESS AN EXEMPTION FROM

THE REGISTRATION REQUIREMENTS OF THE ACT IS AVAILABLE.”

4.16

Issuance of Parent RSUs. Parent agrees to take all necessary steps, including obtaining approval from the Parent Board

and increasing the share available for future grant under the Parent Stock Plans, as necessary, to grant 1,786,402 Parent RSUs to Roger

Sawhney and 2,353,883 Parent RSUs to Richard Langford, as soon as practicable following the Closing. Such Parent RSUs shall be subject

to the terms and conditions of the applicable Parent Stock Plans and standard vesting provisions as determined by James Morrison and

the compensation committee of the Parent Board.

4.17

Use of Proceeds. Parent covenants and agrees that the proceeds from the Parent Financing and the Cy Convertible Note Financing

shall be used primarily to support and fund the development of the Company’s lead drug candidate, CY-201, and other drug candidates

developed by or on behalf of the Company.

SECTION 5.

CONDITIONS PRECEDENT TO OBLIGATIONS

OF EACH PARTY

The

obligations of each Party to effect the Merger and otherwise consummate the Contemplated Transactions to be consummated at the Closing

are subject to the satisfaction or, to the extent permitted by applicable Law, the written waiver by each of the Parties, at or prior

to the Closing Date, of each of the following conditions:

5.1

No Restraints. No temporary restraining order, preliminary or permanent injunction or other order preventing the consummation

of the Contemplated Transactions shall have been issued by any court of competent jurisdiction or other Governmental Body of competent

jurisdiction and remain in effect and there shall not be any Law which has the effect of making the consummation of the Contemplated

Transactions illegal.

5.2

Certificate of Designation. Parent shall have filed the Certificate of Designation with the Secretary of State of the State

of Delaware.

5.3

Parent Financing. The Securities Purchase Agreement shall be in full force and effect and cash proceeds not less than the

Concurrent Investment Amount shall have been received by Parent, or will be received by Parent substantially simultaneously with the

Closing, in connection with the consummation of the transactions contemplated by the Securities Purchase Agreement, and Parent shall

have received confirmation of the Parent Financing.

SECTION 6.

CLOSING DELIVERIES OF THE

COMPANY

The

obligations of Parent and Merger Subs to effect the Merger and otherwise consummate the transactions to be consummated at the Closing

are subject to the satisfaction or the written waiver by Parent, at or prior to the Closing, of each of the following conditions:

6.1

Documents. Parent shall have received the following documents, each of which shall be in full force and effect:

(a)

a written resignation, in a form reasonably satisfactory to Parent, dated as of the Closing Date and effective as of the Closing,

executed by each of the directors of the Company listed on Schedule 6.1(a) hereto;

(b)

the Company Closing Certificate; and

(c)

the Allocation Certificate.

6.2

FIRPTA Certificate. Parent shall have received: (i) an original signed statement from the Company that the Company is not,

and has not been at any time during the applicable period specified in Section 897(c)(1)(A)(ii) of the Code, a “United States real

property holding corporation,” as defined in Section 897(c)(2) of the Code, conforming to the requirements of Treasury Regulations

Section 1.1445-2(c)(3) and 1.897-2(h), and (ii) an original signed notice

to be delivered to the IRS in accordance with the provisions of Treasury Regulations Section 1.897-2(h)(2), together with written authorization

for Parent to deliver such notice to the IRS on behalf of the Company following the Closing, each dated as of the Closing Date, duly

executed by an authorized officer of the Company, and in form and substance reasonably acceptable to Parent; provided, that the

Parent’s sole remedy for the Company’s failure to deliver such documentation shall be to withhold pursuant to Section

1.11.

6.3

Company Lock-Up Agreements. Parent shall have received the Lock-Up Agreements duly executed by each of the Company Signatories,

each of which shall be in full force and effect.

6.4

Company Stockholder Support Agreements. Parent shall have received the Company Stockholder Support Agreements duly executed

by each of the Company Stockholders, each of which shall be in full force and effect.

6.5

Registration Rights Agreements. Parent shall have received the Registration Rights Agreement duly executed by each of the

Purchasers under the Securities Purchase Agreement.

SECTION 7.

CLOSING DELIVERIES OF PARENT

The

obligations of the Company to effect the Merger and otherwise consummate the transactions to be consummated at the Closing are subject

to the satisfaction or the written waiver by the Company, at or prior to the Closing, of each of the following conditions:

7.1

Documents. The Company shall have received the following documents, each of which shall be in full force and effect:

(a)

the Parent Outstanding Shares Certificate;

(b)

Parent Closing Certificate; and

(c)

certified copies of the resolutions duly adopted by the Parent Board and in full force and effect as of the Closing authorizing the appointment

of the directors and officers set forth in Section 4.10.

7.2

Parent Lock-Up Agreements. The Company shall have received the Lock-Up Agreements duly executed by each of the Parent Signatories,

each of which shall be in full force and effect.

7.3

Registration Rights Agreements. The Company shall have received the Registration Rights Agreement duly executed by Parent.

SECTION 8.

MISCELLANEOUS PROVISIONS

8.1

Non-Survival of Representations and Warranties. The representations and warranties of the Company, Parent and Merger Subs

contained in this Agreement or any certificate or instrument delivered pursuant to this Agreement shall terminate at the First Effective

Time, and only the covenants that by their terms survive the First Effective Time and this Section 8 shall survive the First Effective

Time.

8.2

Amendment. This Agreement may be amended with the approval of the respective boards of directors (or managers as applicable)

of the Surviving Entity and Parent at any time; provided, however, that after any such approval of this Agreement by a

Party’s stockholders, no amendment shall be made which by Law requires further approval of such stockholders without the further

approval of such stockholders. This Agreement may not be amended except by an instrument in writing signed on behalf of each of the Surviving

Entity and Parent.

8.3

Waiver.

(a)

No failure on the part of any Party to exercise any power, right, privilege or remedy under this Agreement, and no delay on the part

of any Party in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver of such power, right,

privilege or remedy; and no single or partial exercise of any such power, right, privilege or remedy shall preclude any other or further

exercise thereof or of any other power, right, privilege or remedy.

(b)

No Party shall be deemed to have waived any claim arising out of this Agreement, or any power, right, privilege or remedy under this

Agreement, unless the waiver of such claim, power, right, privilege or remedy is expressly set forth in a written instrument duly executed

and delivered on behalf of such Party and any such waiver shall not be applicable or have any effect except in the specific instance

in which it is given.

8.4

Entire Agreement; Counterparts; Exchanges by Electronic Transmission. This Agreement and the other schedules, exhibits,

certificates, instruments and agreements referred to in this Agreement constitute the entire agreement and supersede all prior agreements

and understandings, both written and oral, among or between any of the Parties with respect to the subject matter hereof and thereof;

provided, however, that the Confidentiality Agreement shall not be superseded and shall remain in full force and effect

in accordance with its terms. This Agreement may be executed in several counterparts, each of which shall be deemed an original and all

of which shall constitute one and the same instrument. Counterparts may be delivered via electronic mail (including pdf or any electronic

signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart

so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

8.5

Applicable Law; Jurisdiction. This Agreement shall be governed by, and construed in accordance with, the Laws of the State

of Delaware, regardless of the Laws that might otherwise govern under applicable principles of conflicts of laws. In any action or proceeding

between any of the Parties arising out of or relating to this Agreement or any of the Contemplated Transactions, each of the Parties:

(a) irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Courts of Chancery of the State

of Delaware, or to the extent such court does not have subject matter jurisdiction, the United States District Court for the District

of Delaware, or, to the extent that neither of the foregoing courts has jurisdiction, the Superior Court of the State of Delaware; (b)

agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with clause (a)

of this Section 8.5, (c) waives any objection to laying venue in any such action or proceeding in such courts, (d) waives any

objection that such courts are an inconvenient forum or do not have jurisdiction over any Party, (e) agrees that service of process upon

such Party in any such action or proceeding shall be effective if notice is given in accordance with Section 8.8 of this Agreement,

and (f) irrevocably and unconditionally waives the right to trial by jury.

8.6

Attorneys’ Fees. In any action at law or suit in equity to enforce this Agreement or the rights of any of the Parties,

the prevailing Party in such action or suit (as determined by a court of competent jurisdiction) shall be entitled to recover its reasonable

out-of-pocket attorneys’ fees and all other reasonable costs and expenses incurred in such action or suit.

8.7

Assignability. This Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit of, the

Parties and their respective successors and permitted assigns; provided, however, that neither this Agreement nor any of

a Party’s rights or obligations hereunder may be assigned or delegated by such Party without the prior written consent of the other

Party, and any attempted assignment or delegation of this Agreement or any of such rights or obligations by such Party without the other

Party’s prior written consent shall be void and of no effect.

8.8

Notices. All notices and other communications hereunder shall be in writing and shall be deemed to have been duly delivered

and received hereunder (a) one Business Day after being sent for next Business Day delivery, fees prepaid, via a reputable international

overnight courier service, (b) upon delivery in the case of delivery

by hand, or (c) on the date delivered in the place of delivery if sent by email (with a written or electronic confirmation of delivery)

prior to 5:00 p.m. Eastern Time, otherwise on the next succeeding Business Day, in each case to the intended recipient as set forth below:

to Parent or Merger Subs:

Ensysce

Biosciences, Inc.

7946

Ivanhoe Avenue, Suite 201

Jolla, CA 92037

Attention:

Dr. Lynn Kirkpatrick

Address: lkirkpatrick@ensysce.com

with

a copy to (which shall not constitute notice):

Troutman

Pepper Locke, LLP

Union

Trust Building

501

Grant Street

Pittsburg,

PA 15219

Attention:

Eric Kline

Email:

Eric.kline@troutman.com

to the Company:

Biopharma, Inc.

Oberneuhofstrasse

Baar

6340, Switzerland

Attention:

James Morrison

Email:

james@cybiopharma.com

with

a copy to (which shall not constitute notice):

Orrick,

Herrington & Sutcliffe LLP

The

Orrick Building

405

Howard Street

San

Francisco, CA 94105-2669

United

States

Attention:

Edward Dyson, Niki Fang, David Schulman

Email:

edyson@orrick.com; nfang@orrick.com; dschulman@orrick.com

8.9

Cooperation. Each Party agrees to cooperate fully with the other Party and to execute and deliver such further documents,

certificates, agreements and instruments and to take such other actions as may be reasonably requested by the other Party to evidence

or reflect the Contemplated Transactions and to carry out the intent and purposes of this Agreement and the Registration Rights Agreement.

8.10

Severability. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction

shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability

of the offending term or provision in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction

declares that any term or provision of this Agreement is invalid or unenforceable, the Parties agree that the court making such determination

shall have the power to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a

term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term

or provision, and this Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted

to it in the prior sentence, the Parties agree to replace such invalid or unenforceable term or provision with a valid and enforceable

term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable

term or provision.

8.11

Other Remedies; Specific Performance. Except as otherwise provided herein, any and all remedies herein expressly conferred

upon a Party will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such Party,

and the exercise by a Party of any one remedy will not preclude the exercise of any other remedy. The Parties agree that irreparable

damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that any Party does not

perform the provisions of this Agreement (including failing to take such actions as are required of it hereunder to consummate this Agreement)

in accordance with its specified terms or otherwise breaches such provisions. Accordingly, the Parties acknowledge and agree that the

Parties shall be entitled to seek an injunction, specific performance and other equitable relief to prevent breaches of this Agreement

and to enforce specifically the terms and provisions hereof, in addition to any other remedy to which they are entitled at law or in

equity. Each of the Parties agrees that it will not oppose the granting of an injunction, specific performance or other equitable relief

on the basis that any other Party has an adequate remedy at law or that any award of specific performance is not an appropriate remedy

for any reason at law or in equity. Any Party seeking an injunction or injunctions to prevent breaches of this Agreement shall not be

required to provide any bond or other security in connection with any such order or injunction.

8.12

No Third-Party Beneficiaries. Nothing in this Agreement, express or implied, is intended to or shall confer upon any Person

(other than the Parties and the D&O Indemnified Parties to the extent of their respective rights pursuant to Section 4.5)

any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.

8.13

Construction.

(a)

References to “cash,” “dollars” or “$” are to U.S. dollars.

(b)

For purposes of this Agreement, whenever the context requires: the singular number shall include the plural, and vice versa; the masculine

gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter

gender shall include masculine and feminine genders.

(c)

The Parties have participated jointly in the negotiating and drafting of this Agreement and agree that any rule of construction to the

effect that ambiguities are to be resolved against the drafting Party shall not be applied in the construction or interpretation of this

Agreement, and no presumption or burden of proof shall arise favoring or disfavoring any Party by virtue of the authorship of any provision

of this Agreement.

(d)

As used in this Agreement, the words “include” and “including,” and variations thereof, shall not be deemed to

be terms of limitation, but rather shall be deemed to be followed by the words “without limitation.”

(e)

Except as otherwise indicated, all references in this Agreement to “Sections,” “Exhibits” and “Schedules”

are intended to refer to Sections of this Agreement and Exhibits and Schedules to this Agreement, respectively.

(f)

Any reference to legislation or to any provision of any legislation shall include any modification, amendment, re-enactment thereof,

any legislative provision substituted therefore and all rules, regulations, and statutory instruments issued or related to such legislations.

All references to legislation or to any provision of any legislation

in this Agreement are to those of the United States, unless the contrary is indicated.

(g)

The bold-faced headings and table of contents contained in this Agreement are for convenience of reference only, shall not be deemed

to be a part of this Agreement and shall not be referred to in connection with the construction or interpretation of this Agreement.

(h)

The inclusion of any information in the Company Disclosure Schedule or Parent Disclosure Schedule shall not be deemed an admission or

acknowledgment to any third party, in and of itself and solely by virtue of the inclusion of such information in the Company Disclosure

Schedule or Parent Disclosure Schedule, as applicable, that such information is required to be listed in the Company Disclosure Schedule

or Parent Disclosure Schedule, as applicable, that such items are material to the Company and its Subsidiaries, taken as a whole, or

Parent and its Subsidiaries, taken as a whole, as the case may be, or that such items have resulted in a Company Material Adverse Effect

or a Parent Material Adverse Effect. The Parties agree that each of the Company Disclosure Schedule and the Parent Disclosure Schedule

shall be arranged in sections and subsections corresponding to the numbered and lettered sections and subsections contained in this Agreement.

The disclosures in any section or subsection of the Company Disclosure Schedule or the Parent Disclosure Schedule shall qualify other

sections and subsections in this Agreement to the extent it is readily apparent on its face from a reading of the disclosure that such

disclosure is applicable to such other sections and subsections.

(i)

Each of “delivered” or “made available” means, with respect to any documentation, that: (i) prior to 11:59 p.m.

(Eastern Time) on the date that is two Business Days prior to the date of this Agreement: (A) a copy of such material has been posted

to and made available by a Party to the other Party and its Representatives in the electronic data room maintained by such disclosing

Party, or (B) such material is disclosed in the Parent SEC Documents filed with the SEC prior to the date hereof and publicly made available

on the SEC’s Electronic Data Gathering Analysis and Retrieval system, or (ii)

delivered by or on behalf of a Party or its Representatives via electronic mail or in hard copy form prior to the execution of this Agreement.

(j)

Whenever the last day for the exercise of any privilege or the discharge of any duty hereunder shall fall upon a Saturday, Sunday, or

any date on which banks in New York, NY, are authorized or obligated by Law to be closed, the Party having such privilege or duty may

exercise such privilege or discharge such duty on the next succeeding day which is a regular Business Day.

8.14

Expenses. Except as otherwise expressly provided in this Agreement, all expenses incurred in connection with this Agreement

and the Contemplated Transactions will be paid by the Party incurring such expenses.

(Remainder

of page intentionally left blank)

WITNESS WHEREOF, the Parties have caused this Agreement to be executed as of the date first above written.

ENSYSCE BIOSCIENCES, INC.

By:

/s/

Dr. Lynn Kirkpatrick

Name:

Dr.

Lynn Kirkpatrick

Title:

Chief

Executive Officer

PHRMA MERGER SUB I, INC.

By:

/s/

Dr. Lynn Kirkpatrick

Name:

Title:

Chief

Executive Officer

PHRMA MERGER SUB II, LLC

By: Ensysce Bioscience, Inc.

Its: Sole member

By:

/s/

Dr. Lynn Kirkpatrick

Name:

Title:

Chief

Executive Officer

[Signature

Page to Agreement and Plan of Merger Agreement]

WITNESS WHEREOF, the Parties have caused this Agreement to be executed as of the date first above written.

CY BIOPHARMA, INC.

By:

/s/

James Morrison

Name:

James Morrison

Title:

Chief

Executive Officer

[Signature

Page to Agreement and Plan of Merger Agreement]

EXHIBIT

CERTAIN

DEFINITIONS

For

purposes of this Agreement (including this Exhibit A):

“3i

Agreement” means the Omnibus Amendment and Termination Agreement, dated August 5, 2026, by and between the Parent and 3i,

LP.

“Act”

has the meaning set forth in Section 4.15.

“Affiliate”

of a Person means any other Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is

under common control with, such Person. The term “control” (including the terms “controlled by” and “under

common control with”) means the possession, directly or indirectly, of the power to direct or cause the direction of the management

and policies of a Person, whether through the ownership of voting securities, by Contract or otherwise.

“Agreement”

has the meaning set forth in the Preamble.

“Allocation

Certificate” has the meaning set forth in Section 4.13.

“Anti-Bribery

Laws” has the meaning set forth in Section 2.22.

“Board

Approval” has the meaning set forth in the Recitals.

“Book-Entry

Shares” has the meaning set forth in Section 1.7.

“Business

Day” means any day other than a Saturday, Sunday or other day on which banks in New York, NY, are authorized or obligated

by Law to be closed.

“Certificate

of Designation” means the Certificate of Designation of Preferences, Rights and Limitations of Series C Non-Voting Convertible

Preferred Stock in the form attached hereto as Exhibit C.

“Certificates

of Merger” has the meaning set forth in Section 1.3.

“Certifications”

has the meaning set forth in Section 3.7(a).

“Charter

Amendment Proposal” has the meaning set forth in Section 4.1(a)(ii).

“Closing”

has the meaning set forth in Section 1.3.

“Closing

Date” has the meaning set forth in Section 1.3.

“Code”

means the Internal Revenue Code of 1986, as amended.

“Company” has the meaning set forth in the Preamble.

A-1

“Company

Associate” means any current or former employee, consultant, independent contractor, officer or director of the Company.

“Company

Benefit Plan” has the meaning set forth in Section 2.17(a).

“Company

Balance Sheet” has the meaning set forth in Section 2.7(a).

“Company

Board” means the board of directors of the Company.

“Company

Capital Stock” means the Company Common Stock and the Company Preferred

Stock.

“Company

Common Stock” means the Common Stock, $0.00001 par value per share, of the

Company.

“Company

Closing Certificate” has the meaning set forth in Section 4.12(a).

“Company

Contract” means any Contract: (a) to which the Company or any of its Subsidiaries is a Party, (b) by which the Company

or any of its Subsidiaries or any Company IP or any other asset of the Company or its Subsidiaries is or may become bound or under which

the Company or any of its Subsidiaries has, or may become subject to, any obligation, or (c) under which the Company or any of its Subsidiaries

has or may acquire any right or interest.

“Company

Data” means all data and information Processed by or for the Company or any of its Subsidiaries, including any Personal

Information.

“Company

Disclosure Schedule” has the meaning set forth in Section 2.

“Company

ERISA Affiliate” means any corporation or trade or business (whether or not incorporated) which is (or at any relevant

time was) treated with the Company as a single employer within the meaning of Section 414 of the Code.

“Company

Financials” has the meaning set forth in Section 2.7(a).

“Company

In-bound License” has the meaning set forth in Section 2.12(d).

“Company

IP” means all Intellectual Property Rights that are owned or purported to be owned by, assigned to, or exclusively licensed

by, the Company, including without limitation, all Company Registered IP.

A-2

“Company

Material Adverse Effect” means any Effect that, considered together with all other Effects that have occurred prior to

the date of determination of the occurrence of a Company Material Adverse Effect, has or would reasonably be expected to have a material

adverse effect on the business, condition (financial or otherwise), assets, liabilities or results of operations of the Company, taken

as a whole; provided, however, that Effects arising or resulting from the following shall not be taken into account in

determining whether there has been a Company Material Adverse Effect: (a) general business or economic conditions affecting the industry

in which the Company and its Subsidiaries operate, (b) acts of war, armed hostilities or terrorism, acts of God or comparable events,

epidemic, pandemic or disease outbreak (including the COVID-19 virus)

or any worsening of the foregoing, or any declaration of martial law, quarantine or similar directive, policy or guidance or Law or other

action by any Governmental Body in response thereto, (c) changes in financial, banking or securities markets, (d) any change in, or any

compliance with or action taken for the purpose of complying with, any Law or GAAP (or interpretations of any Law or GAAP), (e) resulting

from the announcement of this Agreement or the pendency of the Contemplated Transactions; provided, that this clause (e) shall

not apply to any representation or warranty (or condition to the consummation of the Merger relating to such representation or warranty)

to the extent the representation and warranty expressly addresses the consequences resulting from the execution and delivery of this

Agreement or the consummation of the Contemplated Transactions, or (f) resulting from the taking of any action required to be taken by

this Agreement; except in each case with respect to clauses (a) through (c), to the extent disproportionately affecting the Company,

taken as a whole, relative to other similarly situated companies in the industries in which the Company operates.

“Company

Material Contract(s)” has the meaning set forth in Section 2.13(a).

“Company

Out-bound License” has the meaning set forth in Section 2.12(d).

“Company

Permits” has the meaning set forth in Section 2.14.

“Company

Plan” has the meaning set forth in Section 2.6(c).

“Company

Preferred Stock” has the meaning set forth in Section 2.6(a).

“Company

Real Estate Leases” has the meaning set forth in Section 2.11.

“Company

Registered IP” means all Registered IP owned or purported to be owned, in whole or in part, or exclusively licensed by

the Company.

“Company

Signatories” has the meaning set forth in the Recitals.

“Company

Stock Certificate” has the meaning set forth in Section 1.7.

“Company

Stockholder Matters” has the meaning set forth in the Recitals.

“Company

Stockholder Support Agreement” has the meaning set forth in the Recitals.

“Company

Stockholders” has the meaning set forth in the Recitals.

“Company

Systems” has the meaning set forth in Section 2.12(j).

“Concurrent

Investment Amount” means $21,500,000 as contemplated by the Securities Purchase Agreement.

“Confidentiality

Agreement” means that certain non-disclosure agreement by and between the parties dated as of June 2, 2026, between Parent

and Company.

“Consent”

means any approval, consent, ratification, permission, waiver or authorization (including any Governmental Authorization).

A-3

“Contemplated

Transactions” means the Merger, the Nasdaq Reverse Split (if deemed necessary), Parent Stockholder Support Agreements and

the other transactions and actions contemplated by this Agreement to be consummated at or prior to the Closing (but not, for the avoidance

of doubt, the actions proposed to be taken as the Parent Stockholders’ Meeting following the Closing pursuant to Section 4.2).

“Continuing

Employees” has the meaning set forth in Section 4.4(a).

“Contract”

means, with respect to any Person, any written or oral agreement, contract, subcontract, lease (whether for real or personal property),

mortgage, license, sublicense or other legally binding commitment or undertaking of any nature to which such Person is a party or by

which such Person or any of its assets are bound or affected under applicable Law.

“Cy

Convertible Note Financing” means that certain convertible note financing completed between Cy Biopharma, Inc. and certain

accredited investors on August 4, 2026.

“Data

Processing Policy” means each policy, statement, representation, or notice of the Company, Parent or their respective Subsidiaries

relating to the Processing of Company Data or Parent Data (as applicable), privacy, data protection, or security.

“DGCL”

means the General Corporation Law of the State of Delaware.

“DLLCA”

means the Delaware Limited Liability Company Act.

“D&O

Indemnified Parties” has the meaning set forth in Section 4.5(a).

“Disqualifying

Event” has the meaning set forth in Section 3.24.

“Dissenting

Shares” has the meaning set forth in Section 1.9(a).

“Effect”

means any effect, change, event, circumstance, or development.

“Encumbrance” means any lien, pledge, hypothecation,

charge, mortgage, security interest, lease, license, option, easement,

reservation, servitude, adverse title, claim, infringement, interference, option, right of first refusal, preemptive right, community

property interest or restriction or encumbrance of any nature (including any restriction on the voting of any security, any restriction

on the transfer of any security or other asset, any restriction on the receipt of any income derived from any asset, any restriction

on the use of any asset and any restriction on the possession, exercise or transfer of any other attribute of ownership of any asset).

“Enforceability

Exceptions” means the (a) Laws of general application relating to bankruptcy, insolvency and the relief of debtors, and

(b) rules of law governing specific performance, injunctive relief and other equitable remedies.

“Entity”

means any corporation (including any non-profit corporation), partnership (including any general partnership, limited partnership or

limited liability partnership), joint venture, estate, trust, company (including any company limited by shares, limited liability company

or joint stock company), firm, society or other enterprise, association, organization or entity, and each of its successors.

A-4

“Environmental

Law” means any federal, state, local or foreign Law relating to pollution or protection of human health (as it relates

to exposure to Hazardous Materials) or the environment (including ambient air, surface water, ground water, land surface or subsurface

strata), including any Law or regulation relating to emissions, discharges, releases or threatened releases of Hazardous Materials, or

otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous

Materials.

“ERISA”

means the Employee Retirement Income Security Act of 1974, as amended.

“Exchange

Act” means the Securities Exchange Act of 1934.

“Exchange

Agent” has the meaning set forth in Section 1.8.

“Exchange

Fund” has the meaning set forth in Section 1.8.

“Exchange

Ratio” means 23.8187 shares of Parent Common Stock for each share of Company Common Stock (each as calculated on a fully-diluted

basis).

“First

Certificate of Merger” has the meaning set forth in

Section 1.3.

“First

Effective Time” has the meaning set forth in Section 1.3.

“First

Merger” has the meaning set forth in the Recitals.

“First Merger Sub” has the meaning set forth

in the Preamble.

“First

Merger Sub Board” means the board of directors of First Merger Sub.

“First

Step Surviving Corporation” has the meaning set forth in Section 1.1.

“FLSA”

has the meaning set forth in Section 2.17(m).

“GAAP”

means generally accepted accounting principles and practices in effect from time to time within the United States applied consistently

throughout the period involved.

“Governmental

Authorization” means any: (a) permit, license, certificate, franchise, permission, variance, exception, approval, exemption,

order, clearance, registration, qualification or authorization issued, granted, given or otherwise made available by or under the authority

of any Governmental Body or pursuant to any Law, or (b) right under any Contract with any Governmental Body.

“Governmental

Body” means any: (a) nation, state, commonwealth, province, territory, county, municipality, district or other jurisdiction

of any nature, (b) federal, state, local, municipal, foreign or other government, (c) governmental or quasi-governmental authority of

any nature (including any governmental division, department, agency, commission, bureau, instrumentality, official, ministry, fund, foundation,

center, organization, unit, body or Entity and any court or other tribunal, and for the avoidance of doubt, any taxing authority), or

(d) self-regulatory organization (including Nasdaq).

A-5

“Hazardous

Materials” means any pollutant, chemical, substance and any toxic, infectious, carcinogenic, reactive, corrosive, ignitable

or flammable chemical, or chemical compound, or hazardous substance, material or waste, whether solid, liquid or gas, that is subject

to regulation, control or remediation under any Environmental Law, including without limitation, crude oil or any fraction thereof, and

petroleum products or byproducts.

“Intellectual

Property Rights” means any and all of the following arising pursuant to the Laws of any jurisdiction throughout the world,

including without limitation: (a) copyrights, applicable to copyrightable works, original works of authorship fixed in any tangible medium

of expression, including literary works (including all forms and types of computer software, including all source code, object code,

firmware, development tools, files, records and data, and all documentation related to any of the foregoing), pictorial and graphic works,

database and design rights, whether or not registered or published, including all data collections, “moral” rights, mask

works and copyright registrations and applications in any of the foregoing and corresponding rights in works of authorship (collectively,

“Copyrights”), (b) all trademarks, service marks, trade names, service names, brand names, trade dress rights,

and rights, logos, corporate names, and other source or business identifiers, together with the goodwill associated with any of the foregoing,

along with all applications, registrations, renewals and extensions thereof (collectively, “Trademarks”), (c)

registration right to Internet domain names, URLs, and similar rights, (d) rights under applicable trade secret Laws arising with respect

to know how, inventions (including conceptions and/or reductions to practice), invention disclosures, methods, processes, protocols,

specifications, techniques, discoveries and improvements, formulae, confidential and proprietary information, technical information,

designs, drawings, procedures, models, formulations, manuals and systems, including all biological, chemical, biochemical, toxicological,

pharmacological and metabolic material and information and data relating thereto and formulation, clinical, analytical and stability

information and data, in each case which are not available in the public domain and have actual or potential commercial value that is

derived, in whole or in part, from such secrecy (collectively, “Know-How”), (e) all patents, industrial property

rights, patent applications, provisional patent applications and similar instruments (including any and all substitutions, revisions,

divisions, continuations, continuations-in-part, divisions, reissues, renewals, re-examinations and extensions and any foreign equivalents

of the foregoing (including certificates of invention and any applications therefor)) (collectively, “Patents”),

and (f) all rights to prosecute and perfect any of the foregoing through

administrative prosecution, registration, recordation or other administrative proceeding, and all causes of action and rights to sue

or seek other remedies arising from or relating to any of the foregoing.

“Intended

Tax Treatment” has the meaning set forth in Section 4.8(a).

“Investor

Agreements” has the meaning set forth in Section 2.21(b).

“IRS”

means the United States Internal Revenue Service.

“Knowledge”

means, with respect to an individual, that such individual is actually aware of the relevant fact or such individual would reasonably

be expected to know such fact in the ordinary course of the performance of such individual’s employment responsibilities. Any Person

that is an Entity shall have Knowledge if any officer or director of such Person as of the date such knowledge is imputed has Knowledge

of such fact or other matter.

“Law”

means any federal, state, national, foreign, material local or municipal or other law, statute, constitution, principle of common law,

resolution, ordinance, code, edict, decree, rule, regulation, ruling

or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental

Body (including under the authority of Nasdaq or the Financial Industry Regulatory Authority).

A-6

“Legal

Proceeding” means any action, suit, litigation, arbitration, proceeding (including any civil, criminal, administrative,

investigative or appellate proceeding), hearing, inquiry, audit, examination or investigation commenced, brought, conducted or heard

by or before, or otherwise involving, any court or other Governmental Body or any arbitrator or arbitration panel.

“Letter

of Transmittal” has the meaning set forth in Section 1.8(b).

“Liability”

has the meaning set forth in Section 2.9.

“Lock-Up

Agreement” has the meaning set forth in the Recitals.

“Merger” has the meaning set forth in the

Recitals.

“Merger

Consideration” has the meaning set forth in Section 1.5.

“Merger

Subs” has the meaning set forth in the Preamble.

“Nasdaq”

means the Nasdaq Stock Market, including the Nasdaq Global Select Market or such other Nasdaq market on which shares of Parent Common

Stock are then listed .

“Nasdaq

Listing Application” has the meaning set forth in Section 4.7.

“Nasdaq

Reverse Split” means a reverse stock split of all outstanding shares of Parent Common Stock at a reverse stock split ratio

to be reasonably determined by Parent for the purpose of maintaining compliance with Nasdaq listing standards.

“Ordinary

Course of Business” means, in the case of each of the Company and Parent, such actions taken in the ordinary course of

its normal operations and consistent with its past practices.

“Organizational

Documents” means, with respect to any Person (other than an individual): (a) the certificate or certificate of association

or incorporation or organization or limited partnership or limited liability company, and any joint venture, limited liability company,

operating or partnership agreement and other similar documents adopted or filed in connection with the creation, formation or organization

of such Person, and (b) all bylaws, regulations and similar documents or agreements relating to the organization or governance of such

Person, in each case, as amended or supplemented.

“Owned

Company Registered IP” has the meaning set forth in Section 2.12(a).

“Owned

Parent Registered IP” has the meaning set forth in Section 3.12(a).

“Parent”

has the meaning set forth in the Preamble.

“Parent

Associate” means any current or former employee, independent contractor, officer or director of Parent.

A-7

“Parent

Balance Sheet” means the audited balance sheet of Parent as of December 31, 2025 (the “Parent Balance Sheet

Date”) provided to the Company prior to the date of this Agreement.

“Parent

Benefit Plan” has the meaning set forth in Section 3.17(a).

“Parent

Board” means the board of directors of Parent.

“Parent

Closing Certificate” has the meaning set forth in Section 4.12(b).

“Parent

Common Stock” means the Common Stock, $0.0001 par value per share, of Parent.

“Parent

Contract” means any Contract: (a) to which Parent or any of its Subsidiaries is a party, (b) by which Parent or any of

its Subsidiaries or any Parent IP or any other asset of Parent or any of its Subsidiaries is or may become bound or under which Parent

or any of its Subsidiaries has, or may become subject to, any obligation, or (c) under which Parent or any of its Subsidiaries has or

may acquire any right or interest.

“Parent

Convertible Preferred Stock” means Parent’s non-voting convertible preferred stock, par value $0.0001 per share,

with the rights, preferences, powers and privileges specified in the Certificate of Designation.

“Parent

Covered Person” means, with respect to Parent as an “issuer” for purposes of Rule 506 promulgated under the

Securities Act, any Person listed in the first paragraph of Rule 506(d)(1).

“Parent

Data” means all data and information Processed by or for Parent or any of its Subsidiaries, including any Personal Information.

“Parent

Disclosure Schedule” has the meaning set forth in Section 3.

“Parent

ERISA Affiliate” means any corporation or trade or business (whether or not incorporated) which is (or at any relevant

time was) treated with Parent or any of its Subsidiaries as a single employer within the meaning of Section 414 of the Code.

“Parent

Financing” means an acquisition of shares of Parent Common Stock and Parent Convertible Preferred Stock to be consummated

concurrently with the Closing pursuant to the Securities Purchase Agreement with aggregate gross cash proceeds to Parent of at least

the Concurrent Investment Amount.

“Parent

Foreign Plan” has the meaning set forth in Section 3.17(l).

“Parent

In-bound License” has the meaning set forth in Section 3.12(d).

“Parent

IP” means all Intellectual Property Rights that are owned or purported to be owned by, assigned to, or exclusively licensed

by, Parent or its Subsidiaries, including without limitation, all Parent Registered IP.

A-8

“Parent

Material Adverse Effect” means any Effect that, considered together with all other Effects that have occurred prior to

the date of determination of the occurrence of a Parent Material Adverse Effect, has or would reasonably be expected to have a material

adverse effect on the business, condition (financial or otherwise), assets, liabilities or results of operations of Parent; provided,

however, that Effects arising or resulting from the following shall not be taken into account in determining whether there has

been a Parent Material Adverse Effect: (a) general business or economic conditions affecting the industry in which Parent operates, (b)

acts of war, armed hostilities or terrorism, acts of God or comparable events, epidemic, pandemic or disease outbreak (including the

COVID-19 virus) or any worsening of the foregoing, or any declaration of martial law, quarantine or similar directive, policy or guidance

or Law or other action by any Governmental Body in response thereto, (c) changes in financial, banking or securities markets, (d) the

taking of any action required to be taken by this Agreement, (e) any change in the stock price or trading volume of Parent Common Stock

(it being understood, however, that any Effect causing or contributing to any change in stock price or trading volume of Parent Common

Stock may be taken into account in determining whether a Parent Material Adverse Effect has occurred, unless such Effects are otherwise

excepted from this definition), (f) any change in, or any compliance with or action taken for the purpose of complying with, any Law

or GAAP (or interpretations of any Law or GAAP), (g) resulting from the announcement of this Agreement or the pendency of the Contemplated

Transactions; provided, that this clause (g) shall not apply to any representation or warranty (or condition to the consummation

of the Merger relating to such representation or warranty) to the extent the representation and warranty expressly addresses the consequences

resulting from the execution and delivery of this Agreement or the consummation of the Contemplated Transactions, or (h) resulting from

the taking of any action or the failure to take any action, by Parent that is required to be taken by this Agreement, except in each

case with respect to clauses (a) through (c), to the extent disproportionately affecting Parent relative to other similarly situated

companies in the industries in which Parent operates.

“Parent

Material Contract(s)” has the meaning set forth in Section 3.13(a).

“Parent

Options” means options or other rights to purchase shares of Parent Common Stock issued by Parent.

“Parent

Out-bound License” has the meaning set forth in Section 3.12(c).

“Parent

Outstanding Shares Certificate” has the meaning set forth in Section 4.12(b).

“Parent

PEO Plans” has the meaning set forth in Section 3.17(a).

“Parent

Permits” has the meaning set forth in Section 3.14.

“Parent

Preferred Stock Payment Shares” has the meaning set forth in Section 1.5.

“Parent

Real Estate Leases” has the meaning set forth in Section 3.11.

“Parent

Registered IP” means all Registered IP owned or purported to be owned, in whole or in part, or exclusively licensed by

the Parent.

“Parent

RSUs” means any restricted stock unit award granted pursuant to the Parent Stock

Plans.

A-9

“Parent

SEC Documents” has the meaning set forth in Section 3.7(a).

“Parent

Signatories” has the meaning set forth in the Recitals.

“Parent

Stock Plans” means the Amended and Restated 2021 Omnibus Incentive Plan and the Amended and Restated 2021 Omnibus Incentive

Plan Form of Stock Option Grant Notice and Award Agreement.

“Parent

Stockholder Matters” has the meaning set forth in Section 4.1(a)(ii).

“Parent

Stockholder Support Agreement” has the meaning set forth in the Recitals.

“Parent

Stockholders” has the meaning set forth in the Recitals.

“Parent

Stockholders’ Meeting” has the meaning set forth in Section 4.1(a)(ii).

“Parent

Systems” has the meaning set forth in Section 3.12(j).

“Party”

or “Parties” has the meaning set forth in the Preamble.

“Permitted

Encumbrance” means: (a) any Encumbrance for current Taxes not yet due and payable or for Taxes that are being contested

in good faith and for which adequate reserves have been made on the Company Balance Sheet or the Parent Balance Sheet, as applicable,

in accordance with GAAP, (b) minor liens that have arisen in the Ordinary Course of Business and that do not (in any case or in the aggregate)

materially detract from the value of the assets or properties subject thereto or materially impair the operations of the Company or any

of its Subsidiaries or Parent, as applicable, (c) liens to secure obligations to landlords, lessors or renters under leases or rental

agreements, (d) deposits or pledges made in connection with, or to secure payment of, workers’ compensation, unemployment insurance

or similar programs mandated by Law, (e) non-exclusive licenses of Intellectual Property Rights granted by the Company or any of its

Subsidiaries or Parent, as applicable, in the Ordinary Course of Business and that do not (in any case or in the aggregate) materially

detract from the value of the Intellectual Property Rights subject thereto, (f) statutory liens in favor of carriers, warehousemen, mechanics

and materialmen, to secure claims for labor, materials or supplies the payment for which is not delinquent, and (g) obligations of the

Company or any of its Subsidiaries or Parent under Company In-bound Licenses disclosed in Section 2.12(d) with respect to Company

or any of its Subsidiaries or under Parent In-bound Licenses disclosed in Section 3.12(d) with respect to Parent, as the case

may be.

“Person”

means any individual, Entity or Governmental Body.

“Personal

Information” means all information in any form or media that identifies, could be used to identify or is otherwise related

to an individual person (including any current, prospective, or former customer, end user or employee), in addition to any definition

for “personal information” or any similar term provided by applicable Law or by the Company or any of its Subsidiaries in

any of its privacy policies, notices or contracts (e.g., “personal data,” “personally identifiable information”

or “PII”).”

“PIPE

Investors” has the meaning set forth in the Recitals.

A-10

“Post-Closing

Plans” has the meaning set forth in Section 4.4(a).

“Preferred

Stock Conversion Proposal” has the meaning set forth in Section 1.5.

“Privacy

and Data Processing Requirements” means any applicable (i) Law (including of any applicable foreign jurisdiction) relating

to privacy, data protection, security, or Personal Information, including, the Federal Trade Commission Act, California Consumer Privacy

Act (CCPA), HIPAA, EU General Data Protection Regulation (GDPR), any applicable Law relating to breach notification, and any laws relating

to the use of biometric identifiers, (ii) Data Processing Policy, or (iii)

requirement of any self-regulatory organization, industry standard (including, as applicable, the Payment Card Industry Data Security

Standard), or Contract by which the Company, Parent or their respective Subsidiaries are bound relating to the Processing of Company

Data or Parent Data (as applicable), privacy, data protection, or security, including, in each case of (i) through (iii), in connection

with direct marketing or the initiation, transmission, monitoring, interception, recording, or receipt of communications.

“Process”

means, with respect to any data, information, or information technology system, any operation or set of operations performed thereon,

whether or not by automated means, including access, adaptation, alignment, alteration, collection, combination, compilation, consultation,

creation, derivation, destruction, disclosure, disposal, dissemination, erasure, interception, maintenance, making available, organization,

recording, restriction, retention, retrieval, storage, structuring, transmission, and use, and security measures with respect thereto.

“Proxy

Statement” has the meaning set forth in Section 4.2.

“Reference

Date” means August 5, 2026.

“Registered

IP” means all Intellectual Property Rights that are registered or issued under the authority of, with or by any Governmental

Body or Internet domain registrar, including all Patents, registered Copyrights, registered Trademarks, Internet domain names, and all

applications for registration of any of the foregoing.

“Registration

Rights Agreement” has the meaning set forth in the Recitals.

“Representatives” means directors,

officers, employees, agents, attorneys, accountants, investment bankers,

advisors and representatives.

“Required

Company Stockholder Vote” has the meaning set forth in Section 2.4.

“Required

Parent Stockholder Vote” has the meaning set forth in Section 3.4.

“Sarbanes-Oxley

Act” means the Sarbanes-Oxley Act of 2002.

“SEC” means the United States Securities and Exchange

Commission.

“Second

Certificate of Merger” has the meaning set forth in Section 1.3.

“Second

Effective Time” has the meaning set forth in Section 1.3.

A-11

“Second

Merger” has the meaning set forth in the Recitals.

“Second

Merger Sub” has the meaning set forth in the Preamble.

“Second

Merger Sub Board” means the board of managers of Second Merger Sub.

“Securities Act” means the

Securities Act of 1933, as amended.

“Securities

Purchase Agreement” has the meaning set forth in the Recitals.

“Series

A Preferred Stock” means shares of the Parent’s Series A preferred stock, par value $0.0001 per share.

“Series

B Preferred Stock” means shares of the Parent’s Series B preferred stock, par value $0.0001 per share.

“Series

C Preferred Stock” means shares of the Parent’s Series C preferred stock, par value $0.0001 per share.

“Stockholder

Written Consent” has the meaning set forth in the Recitals.

“Subsidiary” means an entity shall

be deemed to be a ‘subsidiary’ of a Person if such Person

directly or indirectly owns or purports to own, beneficially or of record: (a) an amount of voting securities or other interests in such

entity that is sufficient to enable such Person to elect at least a majority of the members of such entity’s board of directors

or other governing body, or (b) at least 50% of the outstanding equity, voting, beneficial or financial interests in such Entity.

“Surviving

Entity” has the meaning set forth in Section 1.1.

“Takeover

Statute” means any “fair price,” “moratorium,” “control share acquisition” or other

similar anti-takeover Law.

“Tax”

means any: (i) federal, state, local, foreign or other tax, including any income, capital gain, gross receipts, capital stock, profits,

transfer, estimated, registration, stamp, premium, escheat, unclaimed property, customs duty, ad valorem, occupancy, occupation, alternative,

add-on, windfall profits, value added, severance, property, business, production, sales, use, license, excise, franchise, employment,

payroll, social security, disability, unemployment, workers’ compensation, national health insurance, withholding or other taxes,

duties, fees, assessments or governmental charges, surtaxes or deficiencies thereof in the nature of a tax, however denominated (whether

imposed directly or through withholding and whether or not disputed), and including any fine, penalty, addition to tax, or interest or

additional amount imposed by a Governmental Body with respect thereto (or attributable to the nonpayment thereof), and (ii) any liability

for payment of amounts described in clause (i) whether as a result of transferee or successor liability, of being a member of an affiliated,

consolidated, combined or unitary group for any period, pursuant to a Contract, through operation of Law or otherwise.

“Tax

Return” means any return (including any information return), report, statement, declaration, claim for refund, estimate,

schedule, notice, notification, form, election, certificate or other document, and any amendment or supplement to any of the foregoing,

filed with or submitted to, or required to be filed with or submitted

to, any Governmental Body (or provided to a payee) in connection with the determination, assessment, collection or payment of any Tax

or in connection with the administration, implementation or enforcement of or compliance with any Law relating to any Tax.

“Treasury

Regulations” means the United States Treasury regulations promulgated under

the Code.

“U.S.”

or “United States” means the United States of America, its states, territories and possessions.

“WARN

Act” means the Worker Adjustment Retraining and Notification Act of 1988, as amended, or any similar state or local plant

closing mass layoff statute, rule or regulation.

“Withholding

Agent” has the meaning set forth in Section 1.11.

A-12

EX-3.1

Filename: ex3-1.htm · Sequence: 3

Exhibit

3.1

ENSYSCE

BIOSCIENCES, INC.

CERTIFICATE

OF ELIMINATION

SERIES

B PREFERRED STOCK

Pursuant

to Section 151(g) of the General Corporation Law

the State of Delaware

Ensysce

Biosciences, Inc. (the “Company”), a corporation organized and existing under and by virtue of the General

Corporation Law of the State of Delaware (“DGCL”), DOES HEREBY CERTIFY:

FIRST.

Pursuant to the authority expressly vested in the Board of Directors of the Company (the “Board”) by the Third

Amended and Restated Certificate of Incorporation of the Company, as amended, the Board previously adopted resolutions creating and authorizing

the issuance of 4,500 shares of Series B Preferred Stock (the “Series B Preferred Stock”) in accordance with

the provisions of the Certificate of Designation of Series B Preferred Stock as filed with the Delaware Secretary of State on November

14, 2025, as corrected by those Certificates of Correction to the Certificate of Designation of Series B Preferred Stock as filed with

the Delaware Secretary of State on November 14, 2025 and March 18, 2026, as amended by that certain Certificate of Amendment to Certificate

of Designation of Series B Preferred Stock filed with the Delaware Secretary of State on April 2, 2026.

SECOND.

The sole holder of Series B Preferred Stock has consented to amend the Certificate of Designation of Series B Preferred Stock to eliminate

the Certificate of Designation of Series B Preferred Stock upon the conversion or cancellation of the shares of Series B Preferred Stock,

and the outstanding shares of Series B Preferred Stock have been converted or cancelled.

THIRD.

Pursuant to Section 151(g) of the DGCL, the Board adopted the following resolutions respecting the Company’s Series B Preferred

Stock, which resolutions have not been amended or rescinded:

NOW,

THEREFORE, BE IT HEREBY RESOLVED, that the Chief Executive Officer and Chief Financial Officer (each an “Authorized Officer,”

and collectively, the “Authorized Officers”) be, and each of them individually hereby is, authorized and empowered,

in the name and on behalf of the Company, to prepare and file with the Secretary of State of the State of Delaware (the “Delaware

Secretary”) a Certificate of Elimination or other certificate to remove the designation and other references to the Series

B Preferred Stock from the Company’s Third Amended and Restated Certificate of Incorporation, as amended, that are contained in

the Certificate of Designation of Series B Preferred Stock, as amended, and will eliminate and return the 4,500 shares of preferred stock

previously designated as Series B Preferred Stock to the status of authorized but unissued shares of preferred stock, without designation,

in a form approved by the Authorized Officer executing the same, such approval to be conclusively evidenced by the Authorized Officer’s

execution thereof, and one or more amendments thereto, as such Authorized Officer may deem necessary, advisable, or appropriate or as

may be required by the Delaware Secretary; and be it further

RESOLVED,

that effective on and after the date of effectiveness of the Certificate of Elimination, none of the authorized shares of Series B Preferred

Stock are outstanding, and none will be issued subject to the Certificate of Designation of Series B Preferred Stock, as amended, previously

filed with the Delaware Secretary with respect to the Series B Preferred Stock, in accordance with Section 103 of the DGCL.

FOURTH.

In accordance with Section 151(g) of the DGCL, all matters set forth in the previously filed Certificate of Designation of Series B Preferred

Stock are hereby eliminated.

*****

EX-3.2

Filename: ex3-2.htm · Sequence: 4

Exhibit

3.2

ENSYSCE

BIOSCIENCES, inc.

CERTIFICATE

OF DESIGNATION OF PREFERENCES,

RIGHTS AND LIMITATIONS

SERIES C NON-VOTING CONVERTIBLE PREFERRED STOCK

Pursuant

to Section 151 of the

General Corporation Law of the State of Delaware

THE

UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Ensysce Biosciences, Inc., a Delaware corporation (the “Corporation”),

that the following resolution was duly adopted by the Board of Directors of the Corporation (the “Board of Directors”),

in accordance with the provisions of Section 151 of the General Corporation Law of the State of Delaware (the “DGCL”),

at a meeting duly called and held on August 4, 2026, which resolution provides for the creation of a series of the Corporation’s

Preferred Stock, par value $0.0001 per share, which is designated as “Series C Non-Voting Convertible Preferred Stock,” with

the preferences, rights and limitations set forth therein relating to dividends, conversion, redemption, dissolution and distribution

of assets of the Corporation.

WHEREAS:

the Third Amended and Restated Certificate of Incorporation of the Corporation, as amended (the “Certificate of Incorporation”),

provides for a class of its authorized stock known as Preferred Stock, consisting of 1,500,000 shares, $0.0001 par value per share (the

“Preferred Stock”), issuable from time to time in one or more series.

RESOLVED:

that, pursuant to authority conferred upon the Board of Directors by the Certificate of Incorporation, (i) a series of Preferred Stock

of the Corporation be, and hereby is authorized by the Board of Directors; (ii) the Board of Directors hereby authorizes the issuance

of 454,295 shares of “Series C Non-Voting Convertible Preferred Stock” pursuant to the terms of (a) the Securities Purchase

Agreement, dated as of the date hereof, by and among the Corporation and the initial Holders (as defined below) (the “Purchase

Agreement”), (b) the Agreement and Plan of Merger, dated as of the date hereof, by and among the Corporation, PHRMA Merger

Sub I, Inc., a Delaware corporation and wholly owned subsidiary of the Corporation, PHRMA Merger Sub II, LLC, a Delaware limited liability

company and wholly owned subsidiary of the Corporation and Cy Biopharma, Inc., a Delaware corporation (the “Merger Agreement”),

(c) and certain agreements with existing equityholders; and (iii) the Board of Directors hereby fixes the designations, powers, preferences

and relative, participating, optional or other special rights, and the qualifications, limitations or restrictions thereof, of such shares

of Preferred Stock, in addition to any provisions set forth in the Certificate of Incorporation that are applicable to the Preferred

Stock of all classes and series, as follows:

TERMS

OF SERIES C NON-VOTING CONVERTIBLE PREFERRED STOCK

Definitions. For the purposes hereof, the following terms shall have the following meanings:

“Business

Day” means any day other than a Saturday, Sunday or other day on which banks in New York, NY, are authorized or obligated

by Law to be closed.

“Buy-In”

shall have the meaning set forth in Section 6.5.4.

“Closing

Sale Price” means, for any security as of any date, the last closing trade price for such security immediately prior to

4:00 p.m., New York City time, on the principal Trading Market where such security is listed or traded, as reported by Bloomberg, L.P.

(or an equivalent, reliable reporting service), or if the foregoing do not apply, the last trade price of such security in the over-the-counter

market on the electronic bulletin board for such security as reported by Bloomberg, L.P., or, if no last trade price is reported for

such security by Bloomberg, L.P., the average of the bid prices of any market makers for such security as reported on the OTCID Basic

Market or other market by OTC Markets Group, Inc. If the Closing Sale Price cannot be calculated for a security on a particular date

on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair market value as determined in good

faith by the Board of Directors of the Corporation.

“Commission”

means the United States Securities and Exchange Commission.

“Common

Stock” means the Corporation’s common stock, par value $0.0001 per share, and stock of any other class of securities

into which such securities may hereafter be reclassified or changed.

“Conversion

Shares” means, collectively, the shares of Common Stock issuable upon conversion of the shares of Series C Non-Voting Preferred

Stock in accordance with the terms hereof.

“Exchange

Act” means the Securities Exchange Act of 1934.

“Holder”

means a holder of shares of Series C Non-Voting Preferred Stock.

“Person”

means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability

company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

“Trading

Day” means a day on which the principal Trading Market is open for business.

“Trading

Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the

date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New

York Stock Exchange (or any successors to any of the foregoing).

Designation, Amount and Par Value. The series of Preferred Stock shall be designated as the Corporation’s Series C Non-Voting

Convertible Preferred Stock (the “Series C Non-Voting Preferred Stock”) and the number of shares so designated

shall be 454,295. Each share of Series C Non-Voting Preferred Stock shall have a par value of $0.0001 per share.

Dividends. Holders shall be entitled to receive, and the Corporation shall pay, dividends on shares of the Series C Non-Voting

Preferred Stock (on an as-if-converted-to-Common-Stock basis, without regard to the Beneficial Ownership Limitation (as defined below))

equal to and in the same form, and in the same manner, as dividends (other than dividends on shares of the Common Stock payable in the

form of Common Stock) actually paid on shares of the Common Stock when, as and if such dividends (other than dividends payable in the

form of Common Stock) are paid on shares of the Common Stock. No dividends shall be paid on shares of Series C Non-Voting Preferred Stock,

and the Corporation shall pay no dividends (other than dividends payable in the form of Common Stock) on shares of the Common Stock unless

it simultaneously complies with the previous sentence.

C-2

Voting Rights.

4.1

Except as otherwise provided herein or as otherwise required by the DGCL, the Series C Non-Voting Preferred Stock shall have no voting

rights. However, as long as any shares of Series C Non-Voting Preferred Stock are outstanding, the Corporation shall not, without the

affirmative vote of the holders of a majority of the then outstanding shares of the Series C Non-Voting Preferred Stock: (i) alter or

change adversely the powers, preferences or rights given to the Series C Non-Voting Preferred Stock or alter or amend this Certificate

of Designation, amend or repeal any provision of, or add any provision to, the Certificate of Incorporation or Amended and Restated Bylaws

of the Corporation, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any

series of Preferred Stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions

provided for the benefit of the Series C Non-Voting Preferred Stock, regardless of whether any of the foregoing actions shall be by means

of amendment to the Certificate of Incorporation or by merger, consolidation, recapitalization, reclassification, conversion or otherwise,

(ii) issue further shares of Series C Non-Voting Preferred Stock or increase or decrease (other than by conversion) the number of authorized

shares of Series C Non-Voting Preferred Stock, (iii) other than the transactions contemplated by the Merger Agreement, prior to the Stockholder

Approval (as defined below) or at any time while at least 30% of the originally issued Series C Non-Voting Preferred Stock remains issued

and outstanding, consummate either: (A) any Fundamental Transaction (as defined below) or (B) any merger or consolidation of the Corporation

with or into another entity or any stock sale to, or other business combination in which the stockholders of the Corporation immediately

before such transaction do not hold at least a majority of the capital stock of the Corporation immediately after such transaction, (iv)

prior to the Stockholder Approval, authorize or issue any class or series of stock that has powers, preferences or rights that are senior

to those of the Series C Non-Voting Preferred Stock, (v) amend, waive or modify the Merger Agreement in any manner that would be reasonably

likely to prevent, impede or materially delay the Stockholder Approval or the Automatic Conversion (as defined below) or (vi) enter into

any agreement with respect to any of the foregoing. Holders of shares of Common Stock acquired upon the conversion of shares of Series

C Non-Voting Preferred Stock shall be entitled to the same voting rights as each other holder of Common Stock, except that such holders

may not vote such shares upon the proposal for Stockholder Approval in accordance with Rule 5635 of the listing rules of The Nasdaq Stock

Market LLC.

4.2

Any vote required or permitted under Section 4.1 may be taken at a meeting of the Holders or through the execution of an action

by written consent in lieu of such meeting, provided that the consent is executed by Holders representing a majority of the outstanding

shares of Series C Non-Voting Preferred Stock.

Rank; Liquidation.

5.1

The Series C Non-Voting Preferred Stock shall rank on parity with the Common Stock as to distributions of assets upon liquidation, dissolution

or winding up of the Corporation, whether voluntarily or involuntarily.

5.2

Upon any liquidation, dissolution or winding-up of the Corporation, whether voluntary or involuntary (a “Liquidation”),

each Holder shall be entitled to receive out of the assets, whether capital or surplus, of the Corporation the same amount that a holder

of Common Stock would receive if the Series C Non-Voting Preferred Stock were fully converted (disregarding for such purpose any Beneficial

Ownership Limitations) to Common Stock which amounts shall be paid pari passu with all holders of Common Stock, plus an additional

amount equal to any dividends declared on but unpaid to such shares. If, upon any such Liquidation, the assets of the Corporation shall

be insufficient to pay the Holders of shares of the Series C Non-Voting Preferred Stock the amount required under the preceding sentence,

then all remaining assets of the Corporation shall be distributed ratably to the Holders and the holders of Common Stock in accordance

with the respective amounts that would be payable on all such securities if all amounts payable thereon were paid in full. For the avoidance

of any doubt, a Fundamental Transaction shall not be deemed a Liquidation unless the Corporation expressly declares that such Fundamental

Transaction shall be treated as if it were a Liquidation.

C-3

Conversion.

6.1

Automatic Conversion on Stockholder Approval. Effective as of 5:00 p.m. Eastern time on the third Business Day after the date

that the Corporation’s stockholders approve the conversion of the Series C Non-Voting Preferred Stock into shares of Common Stock

in accordance with the listing rules of the Nasdaq Stock Market, as set forth in Section 4.1 of the Merger Agreement (the “Stockholder

Approval”), each share of Series C Non-Voting Preferred Stock then outstanding shall automatically convert into a number

of shares of Common Stock equal to the Conversion Ratio (as defined below), subject to the Beneficial Ownership Limitation (the “Automatic

Conversion”). In determining the application of the Beneficial Ownership Limitations solely with respect to the Automatic

Conversion, the Corporation shall calculate beneficial ownership for each Holder assuming beneficial ownership by such Holder of: (x)

the number of shares of Common Stock issuable to such Holder in such Automatic Conversion, plus (y) any additional shares of Common Stock

for which a Holder has provided the Corporation with prior written notice of beneficial ownership within 30 days prior to the date of

Stockholder Approval (a “Beneficial Ownership Statement”) and assuming the conversion of all shares of Series

C Non-Voting Preferred Stock held by all other Holders less the aggregate number of shares of Series C Non-Voting Preferred Stock held

by all other Holders that will not convert into shares of Common Stock on account of the application of any Beneficial Ownership Limitations

applicable to any such other Holders. If a Holder fails to provide the Corporation with a Beneficial Ownership Statement within 30 days

prior to the date of Stockholder Approval, then the Corporation shall presume the Holder’s beneficial ownership of Common Stock

(excluding the Conversion Shares) to be zero. The shares of Series C Non-Voting Preferred Stock that are converted in the Automatic Conversion

are referred to as the “Converted Stock”. For the avoidance of doubt, any shares of Series C Non-Voting Preferred

Stock that are not automatically converted pursuant to the Automatic Conversion as a result of a Beneficial Ownership Limitation shall

remain outstanding until such shares of Series C Non-Voting Preferred Stock are converted pursuant to Section 6.2. The Conversion Shares

shall be issued as follows:

6.1.1

Converted Stock that is registered in book entry form shall be automatically cancelled upon the Automatic Conversion and converted into

the corresponding Conversion Shares, which shares shall be issued in book entry form and shall be delivered to the Holders within one

Business Day of the effectiveness of the Automatic Conversion without any action on the part of the Holders.

6.1.2

Converted Stock that is issued in certificated form shall be deemed converted into the corresponding Conversion Shares on the date of

Automatic Conversion and the Holder’s rights as a holder of such shares of Converted Stock shall cease and terminate on such date,

excepting only the right to receive the Conversion Shares within one (1) Business Day of the effectiveness of the Automatic Conversion.

Without delaying the delivery of the Conversion Shares, the Holder shall as soon as practicable following the effectiveness of the Automatic

Conversion, tender to the Corporation (or its designated agent) the stock certificate(s) (duly endorsed) representing such certificated

Converted Stock.

6.1.3

Notwithstanding the cancellation of the Converted Stock upon the Automatic Conversion, Holders of Converted Stock shall continue to have

any remedies provided herein or otherwise available at law or in equity to such Holder because of a failure by the Corporation to comply

with the terms of this Certificate of Designation. In all cases, the Holder shall retain all of its rights and remedies for the Corporation’s

failure to convert the Converted Stock.

C-4

6.2

Conversion at Option of Holder. Subject to Section 6.1, Section 6.4 and Section 6.5.3, each share of Series

C Non-Voting Preferred Stock then outstanding shall be convertible, at any time and from time to time following 5:00 p.m. Eastern time

on the third Business Day after the date that the Stockholder Approval is obtained by the Corporation, at the option of the Holder thereof,

into a number of shares of Common Stock equal to the Conversion Ratio, subject to the Beneficial Ownership Limitation (each, an “Optional

Conversion”). Holders shall effect conversions by providing the Corporation with the form of conversion notice attached

hereto as Annex A (a “Notice of Conversion”), duly completed and executed. Provided the Corporation’s

transfer agent is participating in the Depository Trust Company (“DTC”) Fast Automated Securities Transfer

program, the Notice of Conversion may specify, at the Holder’s election, whether the applicable Conversion Shares shall be credited

to the account of the Holder’s prime broker with DTC through its Deposit Withdrawal Agent Commission system (a “DWAC

Delivery”). The date on which an Optional Conversion shall be deemed effective (the “Conversion Date”)

shall be the Trading Day that the Notice of Conversion, completed and executed, is sent via email to, and received during regular business

hours by, the Corporation. The Holder shall not be required to physically surrender any stock certificate to the Corporation until the

Holder has converted all of the Series C Non-Voting Preferred Stock represented by such certificate in full without regard to the Beneficial

Ownership Limitation, in which case, the Holder shall surrender its stock certificate to the Corporation for cancellation within three

(3) Trading Days of the date the final Notice of Conversion is delivered to the Corporation. Execution and delivery of a Notice of Conversion

shall have the same effect as cancellation of the original stock certificate and issuance of a new stock certificate evidencing the right

to purchase the remaining number of Conversion Shares, if any. The calculations set forth in the Notice of Conversion shall control in

the absence of manifest or mathematical error.

6.3

Conversion Ratio. The “Conversion Ratio” for each share of Series C Non-Voting Preferred Stock shall

be shares of Common Stock issuable upon the conversion (the “Conversion”) of each share of Series C Non-Voting

Preferred Stock, subject to adjustment as provided herein.

6.4

Beneficial Ownership Limitation. Notwithstanding anything herein to the contrary, the Corporation shall not effect any conversion

of any share of Series C Non-Voting Preferred Stock, including pursuant to Section 6.1, and a Holder shall not have the right

to convert any portion of the Series C Non-Voting Preferred Stock pursuant to Section 6.2, to the extent that, after giving effect

to such attempted conversion set forth on an applicable Notice of Conversion (as defined in the Certificate of Designation) with respect

to the Series C Preferred Stock, such Holder (or any of such Holder’s affiliates or any other Person who would be a beneficial

owner of Common Stock beneficially owned by the Holder for purposes of Section 13(d) or Section 16 of the Exchange Act and the applicable

rules and regulations of the Commission, including any “group” of which the Holder is a member (the foregoing, “Attribution

Parties”)) would beneficially own a number of shares of Common Stock in excess of the Beneficial Ownership Limitation.

For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by such Holder and its Attribution

Parties shall include the number of shares of Common Stock issuable upon conversion of the Series C Non-Voting Preferred Stock subject

to the Notice of Conversion or the Automatic Conversion, as applicable, with respect to which such determination is being made, but shall

exclude the number of shares of Common Stock which are issuable upon (A) conversion of the remaining, unconverted Series C Non-Voting

Preferred Stock beneficially owned by such Holder or any of its Attribution Parties, and (B) exercise or conversion of the unexercised

or unconverted portion of any other securities of the Corporation (including any warrants) beneficially owned by such Holder or any of

its Attribution Parties that are subject to and would exceed a limitation on conversion or exercise similar to the limitation contained

herein. Except as set forth in the preceding sentence, for purposes of this Section 6.4, beneficial ownership shall be calculated

in accordance with Section 13(d) of the Exchange Act and the applicable rules and regulations of the Commission, and the terms “beneficial

ownership” and “beneficially own” have the meanings ascribed to such terms therein. In addition, for purposes hereof,

“group” has the meaning set forth in Section 13(d) of the Exchange Act and the applicable rules and regulations of the Commission.

For purposes of this Section 6.4, in determining the number of outstanding shares of Common Stock, a Holder may rely on the number

of outstanding shares of Common Stock as stated in the most recent of the following: (A) the Corporation’s most recent periodic

or annual filing with the Commission, as the case may be, (B) a more recent public announcement by the Corporation that is filed with

the Commission, or (C) a more recent notice by the Corporation or the Corporation’s transfer agent to the Holder setting forth

the number of shares of Common Stock then outstanding. Upon the written request of a Holder (which may be by email), the Corporation

shall, within two (2) Trading Days thereof, confirm in writing to such Holder (which may be via email) the number of shares of Common

Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to any

actual conversion or exercise of securities of the Corporation, including shares of Series C Non-Voting Preferred Stock, by such Holder

or its Attribution Parties since the date as of which such number of outstanding shares of Common Stock was last publicly reported or

confirmed to the Holder. The “Beneficial Ownership Limitation” shall initially be set at 19.9% for each Holder

and its Attribution Parties and (A) at any time by written notice to the Corporation may be adjusted at the discretion of the Holder

to a percentage between 4.9% and 19.9% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance

of shares of Common Stock pursuant to the Automatic Conversion or such Notice of Conversion (as applicable), to the extent permitted

by this Section 6.3, and (B) at any time following Stockholder Approval, by written notice to the Corporation, may be adjusted at the

discretion of the Holder to any percentage at or above 4.9% of the number of shares of Common Stock outstanding immediately after giving

effect to the issuance of shares of Common Stock pursuant to the Second Automatic Conversion or such Notice of Optional Conversion (as

applicable); provided, that to the extent such adjustment is solely permitted in accordance with (A) and (B), such notice must

be delivered not less than sixty (60) days prior to the effectiveness of such adjustment. The Corporation shall be entitled to rely on

representations made to it by the Holder in any Notice of Conversion regarding its Beneficial Ownership Limitation. Notwithstanding the

foregoing, by written notice to the Corporation, (i) which will not be effective until the sixty-first (61st) day after such written

notice is delivered to the Corporation, the Holder may reset the Beneficial Ownership Limitation percentage to a higher percentage, which

prior to Stockholder Approval shall not exceed 19.9%, to the extent then applicable and (ii) which will be effective immediately after

such notice is delivered to the Corporation, the Holder may reset the Beneficial Ownership Limitation percentage to a lower percentage

(but in no event less than 4.9%) provided that such decrease shall not become effective until the later of (x) 5:00 p.m. Eastern time

on the third Business Day after the date of the Stockholder Approval and (y) if Stockholder Approval is not obtained within six months

after the initial issuance of the Series C Non-Voting Preferred Stock, the date that is three Business Days after the date that is six

months after the initial issuance of the Series C Non-Voting Preferred Stock. Upon such a change by a Holder of the Beneficial Ownership

Limitation, which prior to Stockholder Approval shall not exceed 19.9%, the Beneficial Ownership Limitation may not be further amended

by such Holder without first providing the minimum notice required by this Section 6.4. Notwithstanding the foregoing, at any

time following notice of a Fundamental Transaction, the Holder may waive and/or change the Beneficial Ownership Limitation effective

immediately upon written notice to the Corporation and may reinstitute a Beneficial Ownership Limitation at any time thereafter effective

immediately upon written notice to the Corporation. The provisions of this Section 6.4 shall be construed, corrected and implemented

in a manner so as to effectuate the intended Beneficial Ownership Limitation herein contained and the shares of Common Stock underlying

the securities in excess of the Beneficial Ownership Limitation shall not be deemed to be beneficially owned by the Holder for any purpose

including for purposes of Section 13(d) or Rule 16a-1(a)(1) of the Exchange Act.

C-5

6.5

Mechanics of Conversion.

6.5.1

Delivery of Certificate or Electronic Issuance. Upon Conversion not later than two (2) Trading Days after the applicable Conversion

Date, or if the Holder requests the issuance of physical certificate(s), two (2) Trading Days after receipt by the Corporation of the

original certificate(s) representing such shares of Series C Non-Voting Preferred Stock being converted, duly endorsed, and the accompanying

Notice of Conversion (the “Share Delivery Date”), the Corporation shall either: (a) deliver, or cause to be

delivered, to the converting Holder a physical certificate or certificates representing the number of Conversion Shares being acquired

upon the conversion of shares of Series C Non-Voting Preferred Stock, or (b) in the case of a DWAC Delivery (if so requested by the Holder),

electronically transfer such Conversion Shares by crediting the account of the Holder’s prime broker with DTC through its DWAC

system. If in the case of any Notice of Conversion such certificate or certificates for the Conversion Shares are not delivered to or

as directed by or, in the case of a DWAC Delivery, such shares are not electronically delivered to or as directed by, the applicable

Holder by the Share Delivery Date, the applicable Holder shall be entitled to elect to rescind such Notice of Conversion by written notice

to the Corporation at any time on or before its receipt of such certificate or certificates for Conversion Shares or electronic receipt

of such shares, as applicable, in which event the Corporation shall promptly return to such Holder any original Series C Non-Voting Preferred

Stock certificate delivered to the Corporation and such Holder shall promptly return to the Corporation any Common Stock certificates

or otherwise direct the return of any shares of Common Stock delivered to the Holder through the DWAC system, representing the shares

of Series C Non-Voting Preferred Stock unsuccessfully tendered for conversion to the Corporation.

6.5.2

Obligation Absolute. Subject to Section 6.4 and subject to Holder’s right to rescind a Notice of Conversion pursuant

to Section 6.5.1, the Corporation’s obligation to issue and deliver the Conversion Shares upon conversion of Series C Non-Voting

Preferred Stock in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by a Holder

to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any

action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by such

Holder or any other Person of any obligation to the Corporation or any violation or alleged violation of law by such Holder or any other

Person, and irrespective of any other circumstance which might otherwise limit such obligation of the Corporation to such Holder in connection

with the issuance of such Conversion Shares. Subject to Section 6.4 and subject to Holder’s right to rescind a Notice of

Conversion pursuant to Section 6.5.1, in the event a Holder shall elect to convert any or all of its Series C Non-Voting Preferred

Stock, the Corporation may not refuse conversion based on any claim that such Holder or anyone associated or affiliated with such Holder

has been engaged in any violation of law, agreement or for any other reason, unless an injunction from a court, on notice to Holder,

restraining and/or enjoining conversion of all or part of the Series C Non-Voting Preferred Stock of such Holder shall have been sought

and obtained by the Corporation, and the Corporation posts a surety bond for the benefit of such Holder in the amount of 150% of the

value of the Conversion Shares into which would be converted the Series C Non-Voting Preferred Stock which is subject to such injunction,

which bond shall remain in effect until the completion of arbitration/litigation of the underlying dispute and the proceeds of which

shall be payable to such Holder to the extent it obtains judgment. In the absence of such injunction, the Corporation shall, subject

to Section 6.4 and subject to Holder’s right to rescind a Notice of Conversion pursuant to Section 6.5.1, issue Conversion

Shares upon a properly noticed conversion.

C-6

6.5.3

Cash Settlement. If at any time after Stockholder Approval after the initial issuance of the Series C Non-Voting Preferred Stock,

the Corporation fails to deliver to a Holder such certificate or certificates, or electronically deliver (or cause its transfer agent

to electronically deliver) such shares in the case of a DWAC Delivery, pursuant to Section 6.5.1 on or prior to the third (3rd)

Trading Day after the Share Delivery Date applicable to such conversion (other than a failure caused by (i) materially incorrect or incomplete

information provided by Holder to the Corporation or (ii) the application of the Beneficial Ownership Limitation), then, unless the Holder

has rescinded the applicable Notice of Conversion pursuant to Section 6.5.1, the Corporation shall, at the request of the Holder,

pay an amount equal to the Fair Value (as defined below) of such undelivered shares, with such payment to be made within two Business

Days from the date of request by the Holder, whereupon the Corporation’s obligations to deliver such shares underlying the Notice

of Conversion shall be extinguished upon payment in full of the Fair Value of such undelivered shares. For purposes of this Section

6.5.3, the “Fair Value” of shares shall be fixed with reference to the last reported Closing Sale Price on the principal

Trading Market on which the Common Stock is listed as of the Trading Day immediately prior to, in the case of the Automatic Conversion,

the date of the Stockholder Approval, and in the case of an Optional Conversion, the Conversion Date. For the avoidance of doubt, the

cash settlement provisions set forth in this Section 6.5.3 shall be available irrespective of the reason for the Corporation’s

failure to timely deliver Conversion Shares (other than a failure caused by (i) materially incorrect or incomplete information provided

by Holder to the Corporation or (ii) the application of the Beneficial Ownership Limitation), including due to limitations set forth

in Section 6.5.6 or due to applicable Trading Market rules.

6.5.4

Buy-In on Failure to Timely Deliver Certificates. If the Corporation fails to deliver to a Holder the applicable certificate or

certificates or to effect a DWAC Delivery, as applicable, by the Share Delivery Date pursuant to Section 6.5.1 (other than a failure

caused by materially incorrect or incomplete information provided by Holder to the Corporation or the application of the Beneficial Ownership

Limitation), and if after such Share Delivery Date such Holder is required by its brokerage firm to purchase (in an open market transaction

or otherwise), or the Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale

by such Holder of the Conversion Shares which such Holder was entitled to receive upon the conversion relating to such Share Delivery

Date (a “Buy-In”), then the Corporation shall (A) pay in cash to such Holder (in addition to any other remedies

available to or elected by such Holder) the amount by which (x) such Holder’s total purchase price (including any brokerage commissions)

for the shares of Common Stock so purchased exceeds (y) the product of (1) the aggregate number of shares of Common Stock that such Holder

was entitled to receive from the conversion at issue multiplied by (2) the actual sale price at which the sell order giving rise to such

purchase obligation was executed (including any brokerage commissions) and (B) at the option of such Holder, either reissue (if surrendered)

the shares of Series C Non-Voting Preferred Stock equal to the number of shares of Series C Non-Voting Preferred Stock submitted for

conversion or deliver to such Holder the number of shares of Common Stock that would have been issued if the Corporation had timely complied

with its delivery requirements under Section 6.5.1. For example, if a Holder purchases shares of Common Stock having a total purchase

price of $11,000 to cover a Buy-In with respect to an attempted conversion of shares of Series C Non-Voting Preferred Stock with respect

to which the actual sale price (including any brokerage commissions) giving rise to such purchase obligation was a total of $10,000 under

clause (A) of the immediately preceding sentence, the Corporation shall be required to pay such Holder $1,000. The Holder shall provide

the Corporation written notice, within three (3) Trading Days after the occurrence of a Buy-In, indicating the amounts payable to such

Holder in respect of such Buy-In together with applicable confirmations and other evidence reasonably requested by the Corporation. Nothing

herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without

limitation, a decree of specific performance and/or injunctive relief with respect to the Corporation’s failure to timely deliver

certificates representing shares of Common Stock upon conversion of the shares of Series C Non-Voting Preferred Stock as required pursuant

to the terms hereof or the cash settlement remedy set forth in Section 6.5.3; provided, however, that the Holder shall not be

entitled to both (i) require the reissuance of the shares of Series C Non-Voting Preferred Stock submitted for conversion for which such

conversion was not timely honored and (ii) receive the number of shares of Common Stock that would have been issued if the Corporation

had timely complied with its delivery requirements under Section 6.5.1.

C-7

6.5.5

Reservation of Shares Issuable Upon Conversion. The Corporation covenants that at all times it will reserve and keep available

out of its authorized and unissued shares of Common Stock for the sole purpose of issuance upon conversion of the Series C Non-Voting

Preferred Stock, free from preemptive rights or any other actual contingent purchase rights of Persons other than the Holders of the

Series C Non-Voting Preferred Stock, not less than such aggregate number of shares of the Common Stock as shall be issuable (taking into

account the adjustments of Section 7) upon the conversion of all outstanding shares of Series C Non-Voting Preferred Stock. The

Corporation covenants that all shares of Common Stock that shall be so issuable shall, upon issue, be duly authorized, validly issued,

fully paid and non-assessable.

6.5.6

Fractional Shares. No fractional shares of Common Stock shall be issued upon conversion of the Series C Non-Voting Preferred Stock,

no certificates or scrip for any such fractional shares shall be issued and no cash shall be paid for any such fractional shares. Any

fractional shares of Common Stock that a Holder of Series C Non-Voting Preferred Stock would otherwise be entitled to receive shall be

aggregated with all fractional shares of Common Stock issuable to such Holder and any remaining fractional shares shall be rounded up

to the nearest whole share. Whether or not fractional shares would be issuable upon such conversion shall be determined on the basis

of the total number of shares of Series C Non-Voting Preferred Stock the Holder is at the time converting into Common Stock and the aggregate

number of shares of Common Stock issuable upon such conversion.

6.5.7

Transfer Taxes. The issuance of certificates for shares of the Common Stock upon conversion of the Series C Non-Voting Preferred

Stock shall be made without charge to any Holder for any documentary stamp or similar taxes that may be payable in respect of the issue

or delivery of such certificates, provided that the Corporation shall not be required to pay any tax that may be payable in respect of

any transfer involved in the issuance and delivery of any such certificate upon conversion in a name other than that of the registered

Holder(s) of such shares of Series C Non-Voting Preferred Stock and the Corporation shall not be required to issue or deliver such certificates

unless or until the Person or Persons requesting the issuance thereof shall have paid to the Corporation the amount of such tax or shall

have established to the satisfaction of the Corporation that such tax has been paid.

6.6

Status as Stockholder. Upon each Conversion Date, (i) the shares of Series C Non-Voting Preferred Stock being converted shall

be deemed converted into shares of Common Stock and (ii) the Holder’s rights as a holder of such converted shares of Series C Non-Voting

Preferred Stock shall cease and terminate, excepting only the right to receive certificates for such shares of Common Stock and to any

remedies provided herein or otherwise available at law or in equity to such Holder because of a failure by the Corporation to comply

with the terms of this Certificate of Designation. In all cases, the Holder shall retain all of its rights and remedies for the Corporation’s

failure to convert Series C Non-Voting Preferred Stock. In no event shall the Series C Non-Voting Preferred Stock convert into shares

of Common Stock prior to the Stockholder Approval.

Certain Adjustments.

7.1

Stock Dividends and Stock Splits. If the Corporation, at any time while this Series C Non-Voting Preferred Stock is outstanding:

(A) pays a stock dividend or otherwise makes a distribution or distributions payable in shares of Common Stock (which, for avoidance

of doubt, shall not include any shares of Common Stock issued by the Corporation upon conversion of this Series C Non-Voting Preferred

Stock) with respect to the then outstanding shares of Common Stock; (B) subdivides outstanding shares of Common Stock into a larger number

of shares; or (C) combines (including by way of a reverse stock split) outstanding shares of Common Stock into a smaller number of shares,

then the Conversion Ratio shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding

any treasury shares of the Corporation) outstanding immediately after such event and of which the denominator shall be the number of

shares of Common Stock outstanding immediately before such event (excluding any treasury shares of the Corporation). Any adjustment made

pursuant to this Section 7.1 shall become effective immediately after the record date for the determination of stockholders entitled

to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision

or combination.

C-8

7.2

Fundamental Transaction. If, at any time while this Series C Non-Voting Preferred Stock is outstanding, (A) the Corporation effects

any merger or consolidation of the Corporation with or into another Person or any stock sale to, or other business combination (including,

without limitation, a reorganization, recapitalization, spin-off, share exchange or scheme of arrangement) with or into another Person

(other than such a transaction in which the Corporation is the surviving or continuing entity and its Common Stock is not exchanged for

or converted into other securities, cash or property), (B) the Corporation effects any sale, lease, transfer or exclusive license of

all or substantially all of its assets in one transaction or a series of related transactions, (C) any tender offer or exchange offer

(whether by the Corporation or another Person) is completed pursuant to which more than 50% of the Common Stock not held by the Corporation

or such Person is exchanged for or converted into other securities, cash or property, or (D) the Corporation effects any reclassification

of the Common Stock or any compulsory share exchange pursuant (other than as a result of a dividend, subdivision or combination covered

by Section 7.1) to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (in

any such case, a “Fundamental Transaction”), then, upon any subsequent conversion of this Series C Non-Voting

Preferred Stock the Holders shall have the right to receive, in lieu of the right to receive Conversion Shares, for each Conversion Share

that would have been issuable upon such conversion immediately prior to the occurrence of such Fundamental Transaction (without regard

to any Beneficial Ownership Limitation), the same kind and amount of securities, cash or property as it would have been entitled to receive

upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of

one share of Common Stock (the “Alternate Consideration”). For purposes of any such subsequent conversion,

the determination of the Conversion Ratio shall be appropriately adjusted to apply to such Alternate Consideration based on the amount

of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Corporation shall

adjust the Conversion Ratio in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration.

If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then

the Holders shall be given the same choice as to the Alternate Consideration it receives upon any conversion of this Series C Non-Voting

Preferred Stock following such Fundamental Transaction. To the extent necessary to effectuate the foregoing provisions, any successor

to the Corporation or surviving entity in such Fundamental Transaction shall file a new certificate of designations with the same terms

and conditions and issue to the Holders new preferred stock consistent with the foregoing provisions and evidencing the Holders’

right to convert such preferred stock into Alternate Consideration. The terms of any agreement to which the Corporation is a party and

pursuant to which a Fundamental Transaction is effected shall include terms requiring any such successor or surviving entity to comply

with the provisions of this Section 7.2 and insuring that this Series C Non-Voting Preferred Stock (or any such replacement security)

will be similarly adjusted upon any subsequent transaction analogous to a Fundamental Transaction. The Corporation shall cause to be

delivered to each Holder, at its last address as it shall appear upon the stock books of the Corporation, written notice of any Fundamental

Transaction at least 20 calendar days prior to the date on which such Fundamental Transaction is expected to become effective or close.

7.3

Calculations. All calculations under this Section 7 shall be made to the nearest cent or the nearest 1/100th of a share,

as the case may be. For purposes of this Section 7, the number of shares of Common Stock deemed to be issued and outstanding as

of a given date shall be the sum of the number of shares of Common Stock (excluding any treasury shares of the Corporation) issued and

outstanding.

C-9

Redemption. The shares of Series C Non-Voting Preferred Stock shall not be redeemable; provided, however, that the foregoing shall

not limit the ability of the Corporation to purchase or otherwise deal in such shares to the extent otherwise permitted hereby and by

law, nor shall the foregoing limit the Holder’s rights under Section 6.5.3.

Transfer. A Holder may transfer any shares of Series C Non-Voting Preferred Stock together with the accompanying rights set forth

herein, held by such holder without the consent of the Corporation; provided that such transfer is in compliance with applicable securities

laws. The Corporation shall in good faith (a) do and perform, or cause to be done and performed, all such further acts and things, and

(b) execute and deliver all such other agreements, certificates, instruments and documents, in each case, as any holder of Series C Non-Voting

Preferred Stock may reasonably request in order to carry out the intent and accomplish the purposes of this Section 9. The transferee

of any shares of Series C Non-Voting Preferred Stock shall be subject to the Beneficial Ownership Limitation applicable to the transferor

as of the time of such transfer.

10.

Series C Non-Voting Preferred Stock Register. The Corporation shall maintain at its principal executive offices (or such other

office or agency of the Corporation as it may designate by notice to the Holders in accordance with Section 11), a register for

the Series C Non-Voting Preferred Stock, in which the Corporation shall record (a) the name, address, and electronic mail address of

each holder in whose name the shares of Series C Non-Voting Preferred Stock have been issued and (b) the name, address, and electronic

mail address of each transferee of any shares of Series C Non-Voting Preferred Stock. The Corporation may deem and treat the registered

Holder of shares of Series C Non-Voting Preferred Stock as the absolute owner thereof for the purpose of any conversion thereof and for

all other purposes. The Corporation shall keep the register open and available at all times during business hours for inspection by any

holder of Series C Non-Voting Preferred Stock or his, her or its legal representatives.

11.

Notices. Any notice required or permitted by the provisions of this Certificate of Designation to be given to a Holder of shares

of Series C Non-Voting Preferred Stock shall be mailed, postage prepaid, to the post office address last shown on the records of the

Corporation, or given by electronic communication in compliance with the provisions of the Delaware General Corporation Law, and shall

be deemed sent upon such mailing or electronic transmission.

12.

Book-Entry; Certificates. The Series C Non-Voting Preferred Stock will be issued in book-entry form; provided that, if a Holder

requests that such Holder’s shares of Series C Non-Voting Preferred Stock be issued in certificated form, the Corporation will

instead issue a stock certificate to such Holder representing such Holder’s shares of Series C Non-Voting Preferred Stock. To the

extent that any shares of Series C Non-Voting Preferred Stock are issued in book-entry form, references herein to “certificates”

shall instead refer to the book-entry notation relating to such shares.

13.

Waiver. Any waiver by the Corporation or a Holder of a breach of any provision of this Certificate of Designation shall not operate

as or be construed to be a waiver of any other breach of such provision or of any breach of any other provision of this Certificate of

Designation or a waiver by any other Holders, other than as expressly set forth herein. The failure of the Corporation or a Holder to

insist upon strict adherence to any term of this Certificate of Designation on one or more occasions shall not be considered a waiver

or deprive that party (or any other Holder) of the right thereafter to insist upon strict adherence to that term or any other term of

this Certificate of Designation. Any waiver by the Corporation or a Holder must be in writing. Notwithstanding any provision in this

Certificate of Designation to the contrary, any provision contained herein and any right of the Holders of Series C Non-Voting Preferred

Stock granted hereunder may be waived as to all shares of Series C Non-Voting Preferred Stock (and the Holders thereof) upon the written

consent of the Holders of not less than a majority of the shares of Series C Non-Voting Preferred Stock then outstanding, provided, however,

that the Beneficial Ownership Limitation applicable to a Holder, and any provisions contained herein that are related to such Beneficial

Ownership Limitation, cannot be modified, waived or terminated without the consent of such Holder, provided further, that any proposed

waiver that would, by its terms, have a disproportionate and materially adverse effect on any Holder shall require the consent of such

Holder(s).

14.

Severability. Whenever possible, each provision hereof shall be interpreted in a manner as to be effective and valid under applicable

law, but if any provision hereof is held to be prohibited by or invalid under applicable law, then such provision shall be ineffective

only to the extent of such prohibition or invalidity, without invalidating or otherwise adversely affecting the remaining provisions

hereof.

15.

Status of Converted Series C Non-Voting Preferred Stock. If any shares of Series C Non-Voting Preferred Stock shall be converted

or redeemed by the Corporation, such shares shall, to the fullest extent permitted by applicable law, be retired and cancelled upon such

acquisition, and shall not be reissued as a share of Series C Non-Voting Preferred Stock. Any share of Series C Non-Voting Preferred

Stock so acquired shall, upon its retirement and cancellation, and upon the taking of any action required by applicable law, resume the

status of authorized but unissued shares of preferred stock and shall no longer be designated as Series C Non-Voting Preferred Stock.

[Remainder

of Page Intentionally Left Blank]

C-10

WITNESS WHEREOF, Ensysce Biosciences, Inc. has caused this Certificate of Designation of Preferences, Rights and Limitations of Series

C Non-Voting Convertible Preferred Stock to be duly executed by its Chief Executive Officer on August 5, 2026.

ENSYSCE BIOSCIENCES, INC.

By:

/s/

Dr. Lynn Kirkpatrick

Name:

Dr.

Lynn Kirkpatrick

Title:

Chief

Executive Officer

ANNEX

NOTICE

OF CONVERSION

(TO

BE EXECUTED BY THE REGISTERED HOLDER IN ORDER TO CONVERT SHARES OF SERIES C NON-VOTING CONVERTIBLE PREFERRED STOCK)

The

undersigned Holder hereby irrevocably elects to convert the number of shares of Series C Non-Voting Preferred Stock indicated below,

represented in book-entry form, into shares of common stock, par value $0.0001 per share (the “Common Stock”),

of Ensysce Biosciences, Inc., a Delaware corporation (the “Corporation”), as of the date written below. If

securities are to be issued in the name of a Person other than the undersigned, the undersigned will pay all transfer taxes payable with

respect thereto. Capitalized terms utilized but not defined herein shall have the meaning ascribed to such terms in that certain Certificate

of Designation of Preferences, Rights and Limitations of Series C Non-Voting Convertible Preferred Stock (the “Certificate

of Designation”) filed by the Corporation with the Secretary of State of the State of Delaware on August 5, 2026.

of the date hereof, the number of shares of Common Stock beneficially owned by the undersigned Holder (together with such Holder’s

Attribution Parties), including the number of shares of Common Stock issuable upon conversion of the Series C Non-Voting Preferred Stock

subject to this Notice of Conversion, but excluding the number of shares of Common Stock which are issuable upon (A) conversion of the

remaining, unconverted Series C Non-Voting Preferred Stock beneficially owned by such Holder or any of its Attribution Parties, and (B)

exercise or conversion of the unexercised or unconverted portion of any other securities of the Corporation (including any warrants)

beneficially owned by such Holder or any of its Attribution Parties that are subject to a limitation on conversion or exercise similar

to the limitation contained in Section 6.4 of the Certificate of Designation, is _____. For purposes hereof, beneficial ownership

shall be calculated in accordance with Section 13(d) of the Exchange Act and the applicable regulations of the Commission. In addition,

for purposes hereof, “group” has the meaning set forth in Section 13(d) of the Exchange Act and the applicable regulations

of the Commission.

CONVERSION

CALCULATIONS:

Date

to Effect Conversion:

Number

of shares of Series C Non-Voting Preferred Stock owned prior to Conversion:

Number

of shares of Series C Non-Voting Preferred Stock to be Converted:

Number

of shares of Common Stock to be Issued:

Address

for delivery of physical certificates:

For

DWAC Delivery, please provide the following:

Broker

No.: ________________

Account

No.: _______________

[HOLDER]

By:

Name:

Title:

EX-10.1

Filename: ex10-1.htm · Sequence: 5

Exhibit

10.1

FORM

OF SECURITIES PURCHASE AGREEMENT

This

SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of August 5, 2026, by and among Ensysce Biosciences,

Inc., a Delaware corporation (the “Company”), and each purchaser listed on Exhibit A attached to this Agreement

(each, including its successors and assigns, an “Investor” and together, the “Investors”).

WHEREAS,

the Company and the Investors are executing and delivering this Agreement in reliance upon the exemption from securities registration

afforded by Section 4(a)(2) of the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder (the “Securities

Act”);

WHEREAS,

the Company desires to sell to the Investors, and each Investor desires to purchase from the Company, severally and not jointly, upon

the terms and subject to the conditions stated in this Agreement, an aggregate of 120,260 shares

of Series C Non-Voting Convertible Preferred Stock, par value $0.0001 per share (and including any other class of securities into which

the Series C Non-Voting Convertible Preferred Stock may hereafter be reclassified or changed into (the “Preferred Shares”)),

of the Company, having the designation, preferences, conversion or other rights, voting powers,

restrictions, limitations as to dividends, qualifications and terms and conditions as specified in the Certificate of Designation attached

hereto as Exhibit B (the “Certificate of Designation”), at a per

share purchase price equal to the Initial Share Price or the Milestone Share Price (as applicable), which Preferred Shares will be convertible

into shares (the “Conversion Shares”) of the Company’s common stock, par value $0.0001 per share (“Common

Stock”);

WHEREAS,

the Company has engaged Cantor Fitzgerald & Co.

and UBS Securities LLC as its exclusive placement agents (each, a “Placement Agent”

and together, the “Placement Agents”) for the offering of the Preferred Shares on a “best efforts” basis;

WHEREAS,

contemporaneously with the sale of the Preferred Shares, the Company and the Investors will execute and deliver a Registration Rights

Agreement, in the form attached hereto as Exhibit

C (the “Registration Rights Agreement”), pursuant to which the Company will

agree to provide certain registration rights, including in respect of the Conversion Shares, under the Securities Act and applicable

state securities laws;

WHEREAS,

concurrently with, or promptly after, the execution and delivery of this Agreement, the Company

is entering into an Agreement and Plan of Merger (the “Merger Agreement”) by

and among the Company, PHRMA Merger Sub I, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“First

Merger Sub”), PHRMA Merger Sub II, LLC, a Delaware limited liability company and wholly-owned subsidiary of the Company (“Second

Merger Sub”), and Cy Biopharma, Inc., a Delaware corporation (the “Target”), pursuant to which the Company

and the Target intend to effect a merger of First Merger Sub with and into the Target (the “First Merger”). Upon consummation

of the First Merger, First Merger Sub will cease to exist and the Target will become a wholly-owned subsidiary of the Company. Immediately

following the First Merger and as part of the same overall transaction as the First Merger, the Target will merge with and into Second

Merger Sub (the “Second Merger” and, together with the First Merger, the “Merger”), with Second

Merger Sub being the surviving entity of the Second Merger; and

WHEREAS,

pursuant to the terms and conditions of the Certificate of Designation, the conversion of the Preferred Shares into Conversion Shares

shall be subject to receipt of the Required Parent Stockholder Vote (as defined in the Merger Agreement).

NOW

THEREFORE, in consideration of the mutual agreements, representations, warranties and covenants herein contained, the Company and

each Investor, severally and not jointly, agree as follows:

1. Definitions.

As used in this Agreement, the following terms shall have the following respective meanings:

“Affiliate”

means, with respect to any Person, any other Person that, directly or indirectly through one or more intermediates, controls, is controlled

by or is under common control with such Person, as such terms are used in and construed under Rule 405 under the Securities Act.

“Aggregate

Initial Purchase Amount” has the meaning set forth in Section 2.2(a) hereof.

“Aggregate

Milestone Purchase Amount” has the meaning set forth in Section 2.2(b) hereof.

“Agreement”

has the meaning set forth in the recitals.

“Amended

and Restated Bylaws” means the Second Amended and Restated Bylaws of the Company, as currently in effect.

“Benefit

Plan” means employee benefit plans as defined in Section 3(3) of ERISA and all other employee benefit practices or arrangements,

including, without limitation, any such practices or arrangements providing severance pay, sick leave, vacation pay, salary continuation

for disability, retirement benefits, deferred compensation, bonus pay, incentive pay, stock options or other stock-based compensation,

hospitalization insurance, medical insurance, life insurance, scholarships or tuition reimbursements, maintained by the Company or to

which the Company or any of its subsidiaries is obligated to contribute for employees or former employees of the Company and its subsidiaries.

“Board

of Directors” means the board of directors of the Company.

“Business

Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day

on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.

“Certificate

of Designation” has the meaning set forth in the recitals.

“Certificate

of Incorporation” means the Certificate of Incorporation of the Company, as currently in effect.

“Closing”

has the meaning set forth in Section 2.2(b).

“Closing

Date” has the meaning set forth in Section 2.2(b).

“Code”

means the U.S. Internal Revenue Code of 1986, as amended.

“Common

Stock” has the meaning set forth in the recitals.

“Common

Stock Equivalents” means any securities of the Company that would entitle the holder thereof to acquire at any time Common

Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible

into or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.

“Company”

has the meaning set forth in the recitals.

“Confidential

Data” has the meaning set forth in Section 3.30.

“Conversion

Shares” has the meaning set forth in the recitals.

“Disclosure

Document” has the meaning set forth in Section 5.3(a).

“Disclosure

Schedules” means the disclosure schedules of the Company delivered concurrently herewith.

“Disqualification

Event” has the meaning set forth in Section 4.14.

“Drug

Regulatory Agency” means the U.S. Food and Drug Administration (“FDA”) or other foreign, state, local or

comparable governmental authority responsible for regulation of the research, development, testing, manufacturing, processing, storage,

labeling, sale, marketing, advertising, distribution and importation or exportation of drug or biological products and drug or biological

product candidates.

“Environmental

Laws” has the meaning set forth in Section 3.15.

“ERISA”

means the U.S. Employee Retirement Income Security Act of 1974, as amended.

“Exchange

Act” means the U.S. Securities Exchange Act of 1934, as amended, and all of the rules and regulations promulgated thereunder.

“Financial

Statements” has the meaning set forth in Section 3.8(b).

“First

Merger Sub” has the meaning set forth in the recitals hereof.

“GAAP”

has the meaning set forth in Section 3.8(b).

“GDPR”

has the meaning set forth in Section 3.31.

“Governmental

Authorizations” has the meaning set forth in Section 3.11.

“Health

Care Laws” has the meaning set forth in Section 3.21.

“HIPAA”

has the meaning set forth in Section 3.30.

“Indemnified

Persons” has the meaning set forth in Section 5.9(a).

“Initial

Closing” has the meaning set forth in Section 2.2(a).

“Initial

Funding Notice” has the meaning set forth in Section 2.2(a).

“Initial

Share Price” means $321.79.

“Initial

Closing Date” has the meaning set forth in Section 2.2(a).

“Intellectual

Property” has the meaning set forth in Section 3.12.

“Investor”

and “Investors” have the meanings set forth in the recitals.

“IT

Systems” has the meaning set forth in Section 3.30.

“Material

Adverse Effect” means any change, event, circumstance, development, condition, occurrence or effect that, individually or in

the aggregate, (a) was, is, or would reasonably be expected to be, materially adverse to the business, financial condition, properties,

assets, liabilities, stockholders’ equity or results of operations of the Company and its subsidiaries, taken as a whole, or (b)

materially delays or materially impairs the ability of the Company to comply, or prevents the Company from complying, with its obligations

under this Agreement, the other Transaction Agreements, or with respect to the Closing, or would reasonably be expected to do so.

“Merger”

has the meaning set forth in the recitals.

“Merger

Agreement” has the meaning set forth in the recitals.

“Milestone

Closing” has the meaning set forth in Section 2.2(b).

“Milestone

Closing Date” has the meaning set forth in Section 2.2(b).

“Milestone

Funding Notice” has the meaning set forth in Section 2.2(b).

“Milestone

Phase 2 Clinical Achievement Event” means, with respect to a Phase 2 Clinical Trial for the Company’s CY200 pharmaceutical

drug candidate, that the top-line data readout for such Phase 2 Clinical Trial demonstrates that the reduction from baseline in the mean

NRS (0-10 Numeric Rating Scale for Pain) score at days 14-20 among participants who received CY200 25mg is greater than the corresponding

reduction from baseline in the mean NRS score at days 14-20 among participants who received placebo, and that such difference is statistically

significant in favor of CY200 25mg at a two-sided p-value of less than 0.05, and the placebo-adjusted mean reduction from baseline for

CY200 25mg (being the CY200 25mg mean reduction minus the placebo mean reduction) is at least 1.0 points on the NRS, in each case as

determined under the pre-specified primary efficacy analysis and analysis population (intent-to-treat or modified intent-to-treat) set

forth in the statistical analysis plan for such Phase 2 Clinical Trial.

“Milestone

Share Price” means a price equal to 125% of the Initial Share Price.

“National

Exchange” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the

date in question, together with any successor thereto: the Nasdaq Capital Market, The New York Stock Exchange, The Nasdaq Global Market,

The Nasdaq Global Select Market and The Nasdaq Capital Market.

“Nasdaq

Capital Market” means the trading market on which the Company is listed.

“Person”

means an individual, partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated

association, joint venture or any other entity or organization.

“Personal

Data” has the meaning set forth in Section 3.30.

“Phase

2 Clinical Trial” means a clinical study of a pharmaceutical drug candidate, the principal purpose of which is a determination

of safety and efficacy in the target patient population, which is prospectively designed to generate sufficient data that may permit

commencement of pivotal clinical trials or a similar clinical study prescribed by the FDA and other regulatory authorities throughout

the world, from time to time, pursuant to applicable laws or otherwise, including the trials referred to in 21 C.F.R. § 312.21(b),

as amended.

“Preferred

Shares” has the meaning set forth in the recitals.

“Privacy

Laws” has the meaning set forth in Section 3.31.

“Privacy

Statements” has the meaning set forth in Section 3.31.

“Process”

or “Processing” has the meaning set forth in Section 3.31.

“Registration

Rights Agreement” has the meaning set forth in the recitals.

“Regulatory

Agencies” has the meaning set forth in Section 3.20.

“Rule

144” means Rule 144 promulgated by the SEC pursuant to the Securities Act, as such Rule may be amended from time to time, or

any similar rule or regulation hereafter adopted by the SEC having substantially the same effect as such Rule.

“SEC”

means the U.S. Securities and Exchange Commission.

“SEC

Reports” means (a) the Company’s most recently filed Annual Report on Form 10-K and (b) all Quarterly Reports on Form

10-Q or Current Reports on Form 8-K filed or furnished (as applicable) by the Company following the end of the most recent fiscal year

for which an Annual Report on Form 10-K has been filed and prior to the execution of this Agreement, together in each case with any documents

incorporated by reference therein or exhibits thereto.

“Second

Merger Sub” has the meaning set forth in the recitals.

“Securities”

means the Preferred Shares and the Conversion Shares.

“Securities

Act” has the meaning set forth in the recitals.

“Short

Sales” include, without limitation, (a) all “short sales” as defined in Rule 200 promulgated under Regulation SHO

under the Exchange Act, whether or not against the box, and all types of direct and indirect stock pledges, forward sale contracts, options,

puts, calls, short sales, swaps, “put equivalent positions” (as defined in Rule 16a-1(h) under the Exchange Act) and similar

arrangements (including on a total return basis), and (b) sales and other transactions through non-U.S. broker dealers or non-U.S. regulated

brokers (but shall not be deemed to include the location and/or reservation of borrowable shares of Common Stock).

“Studies”

has the meaning set forth in Section 3.20.

“Target”

has the meaning set forth in the recitals.

“Tax”

or “Taxes” means any and all federal, state, local, foreign and other taxes, levies, fees, imposts, duties and charges

of whatever kind (including any interest, penalties or additions to the tax imposed in connection therewith or with respect thereto),

whether or not imposed on the Company or its subsidiaries (if any) including, without limitation, taxes imposed on, or measured by, income,

franchise, profits or gross receipts, and also ad valorem, value added, sales, use, service, real or personal property, capital stock,

license, payroll, withholding, employment, social security, workers’ compensation, unemployment compensation, utility, severance,

production, excise, stamp, occupation, premium, windfall profits, transfer and gains taxes and customs duties.

“Tax

Returns” means returns, reports, information statements and other documentation (including any additional or supporting material)

filed or maintained, or required to be filed or maintained, in connection with the calculation, determination, assessment or collection

of any Tax and shall include any amended returns required as a result of examination adjustments made by the Internal Revenue Service

or other Tax authority.

“Transaction

Agreements” means this Agreement, the Certificate of Designation, the Registration Rights

Agreement, and any other documents or agreements explicitly contemplated hereunder.

“Transfer

Agent” means Equiniti Trust Company, LLC or such other financial institution that provides transfer agent services as the Company

may engage from time to time.

2. Purchase

and Sale of Securities.

2.1 Purchase

and Sale. Upon the terms and subject to the conditions set forth herein, the Company agrees to sell, and the Investors,

severally and not jointly, agree to purchase, at the applicable Closing, the number of Preferred Shares, for the aggregate purchase

price, set forth opposite the Investor’s name on Exhibit A.

2.2 Closing.

(a) Initial

Closing. Subject to the satisfaction or waiver of the conditions set forth in Section 6.1, the initial closing of the

purchase and sale of the Preferred Shares (the “Initial Closing” and, the date on which the Initial Closing

occurs, the “Initial Closing Date”) shall occur remotely via the exchange of documents and signatures

simultaneously with the execution and delivery of this Agreement, or at such other time and place as mutually agreed by the Company

and the Investors, but in no event later than the fifth (5th) Business Day after the date of fulfillment of all of the

conditions set forth in this Agreement. Concurrently with or prior to the execution and

delivery hereof, the Company has provided written notice to the Investors (the “Initial Funding Notice”) of the

anticipated Initial Closing Date and the wire instructions for delivery of the Aggregate Initial Purchase Amount. At the

Initial Closing, the Preferred Shares shall be issued and registered in the name of the Investor, or in such nominee name(s) as

designated by such Investor, representing the number of Preferred Shares to be purchased by the Investor at such Initial Closing, as

set forth in Exhibit A, in each case against payment to the Company of the purchase price therefor (the “Aggregate

Initial Purchase Amount”) in full, by wire transfer to the Company of immediately available funds, at or prior to the

Initial Closing, in accordance with wire instructions provided by the Company to the Investors in the Initial Funding Notice at

least one (1) Business Day prior to the Initial Closing. On the Initial Closing Date, the Company will cause the Transfer Agent to

issue the Preferred Shares in book-entry form, free and clear of all restrictive and other legends (except as expressly provided in Section

4.10) and the Company shall provide evidence of such issuance from the Company’s Transfer Agent as soon as reasonably

practical following the Initial Closing Date to each Investor. In the event that the Initial Closing has not occurred within five

(5) Business Days after the expected Initial Closing Date, unless otherwise agreed by the Company and such Investor, the Company

shall promptly (but no later than one (1) Business Day thereafter) return the previously wired Aggregate Initial Purchase Amount to

each respective Investor by wire transfer of United States dollars in immediately available funds to the account specified by each

Investor, and any book entries for the Preferred Shares shall be deemed cancelled; provided that, unless this Agreement has been

terminated pursuant to Section 7, such return of funds shall not terminate this Agreement or relieve such Investor of its

obligation to purchase, or the Company of its obligation to issue and sell, the Preferred Shares at the Initial Closing. Notwithstanding

the foregoing and anything in this Agreement to the contrary, the Company may amend Exhibit A following

the Initial Closing, without the consent of the other parties hereto, to reflect the number of Preferred Shares actually purchased

and the Aggregate Initial Purchase Amount paid at the Initial Closing in accordance with this Section 2.2(a), in each case,

by each such applicable Investor, and shall provide such updated Exhibit A to an

Investor upon request.

(b) Milestone

Closing. Subject to the satisfaction or waiver of the conditions set forth in Section 6.1, the milestone closing of the

purchase and sale of the Preferred Shares (the “Milestone Closing” and, the date on which the Milestone Closing

occurs, the “Milestone Closing Date”) shall occur remotely via the exchange of documents and signatures

simultaneously with the execution and delivery of this Agreement, or at such other time and place as mutually agreed by the Company

and the Investors, but in no event later than the fifth (5th) Business Day after the date of fulfillment of all of the

conditions set forth in this Agreement. The term “Closing” shall apply to both the Initial Closing and the

Milestone Closing, and the term “Closing Date” shall apply to both the Initial Closing Date and the Milestone

Closing Date. Five (5) Business Days prior to the Milestone Closing Date, the Company will

provide written notice to the Investors (the “Milestone Funding Notice”) of the anticipated Milestone Closing

Date and the wire instructions for delivery of the Aggregate Milestone Purchase Amount. At the Milestone Closing, the

Preferred Shares shall be issued and registered in the name of the Investor, or in such nominee name(s) as designated by such

Investor, representing the number of Preferred Shares to be purchased by the Investor at such Milestone Closing, as set forth in Exhibit

A, in each case against payment to the Company of the purchase price therefor (the “Aggregate Milestone Purchase

Amount”) in full, by wire transfer to the Company of immediately available funds, at or prior to the Milestone Closing, in

accordance with wire instructions provided by the Company to the Investors in the Milestone Funding Notice at least one (1) Business

Day prior to the Milestone Closing. On the Milestone Closing Date, the Company will cause the Transfer Agent to issue the Preferred

Shares in book-entry form, free and clear of all restrictive and other legends (except as expressly provided in Section 4.10)

and the Company shall provide evidence of such issuance from the Company’s Transfer Agent as soon as reasonably practical

following the Milestone Closing Date to each Investor. In the event that the Milestone Closing has not occurred within five (5)

Business Days after the expected Milestone Closing Date, unless otherwise agreed by the Company and such Investor, the Company shall

promptly (but no later than one (1) Business Day thereafter) return the previously wired Aggregate Milestone Purchase Amount to each

respective Investor by wire transfer of United States dollars in immediately available funds to the account specified by each

Investor, and any book entries for the Preferred Shares shall be deemed cancelled; provided that, unless this Agreement has been

terminated pursuant to Section 7, such return of funds shall not terminate this Agreement or relieve such Investor of its

obligation to purchase, or the Company of its obligation to issue and sell, the Preferred Shares at the Milestone Closing. Notwithstanding

the foregoing and anything in this Agreement to the contrary, the Company may amend Exhibit A following

the Milestone Closing, without the consent of the other parties hereto, to reflect the number of Preferred Shares actually purchased

and the Aggregate Milestone Purchase Amount paid at the Milestone Closing in accordance with this Section 2.2(b), in each

case, by each such applicable Investor, and shall provide such updated Exhibit A to

an Investor upon request.

3. Representations

and Warranties of the Company. Except as set forth in the SEC Reports or the Disclosure Schedules, which Disclosure Schedules

shall be deemed a part hereof and shall qualify any representation or otherwise made herein to the extent of the disclosure

contained in the corresponding section of the Disclosure Schedules, the Company hereby represents and warrants to each of the

Investors and the Placement Agents that the statements contained in this Section 3 are true and correct as of the date of

this Agreement and as of the applicable Closing Date (except for the representations and warranties that speak as of a specific

date, which shall be made as of such date).

3.1 Organization

and Power. The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of

Delaware, has the requisite power and authority to own, lease and operate its properties and to carry on its business as now

conducted and described in the SEC Reports and is qualified to do business in each jurisdiction in which the character of its

properties or the nature of its business requires such qualification, except where such failure to be in good standing or to have

such power and authority or to so qualify would not reasonably be expected to have a Material Adverse Effect. Each of the

Company’s subsidiaries is (i) duly incorporated and validly existing and in good standing under the laws of the jurisdiction

of its incorporation and has the requisite power and authority to carry on its business as now conducted and to own or lease its

properties and (ii) qualified to do business as a foreign corporation and in good standing in each jurisdiction in which such

qualification is required, except in each case as would not reasonably be expected to cause a Material Adverse Effect.

3.2 Capitalization.

The Company’s disclosure of its authorized, issued and outstanding capital stock in the SEC Reports containing such disclosure

was accurate in all material respects as of the date indicated in such SEC Reports. All of the issued and outstanding shares of

Common Stock have been duly authorized and validly issued and are fully paid and non-assessable. None of the outstanding shares of

capital stock of the Company were issued in violation of any preemptive or other similar rights of any securityholder of the Company

which have not been waived, and such shares were issued in compliance in all material respects with applicable state and federal

securities law and any rights of third parties. Except as set forth in the SEC Reports and as contemplated by the Merger Agreement,

there are no outstanding rights (including, without limitation, pre-emptive rights), warrants or options to acquire, or instruments

convertible into or exchangeable for, any shares of capital stock or other equity interest in the Company or any of its

subsidiaries, or any contract, commitment, agreement, understanding or arrangement of any kind relating to the issuance of any

capital stock of the Company or any such subsidiary, any such convertible or exchangeable securities or any such rights, warrants or

options; the capital stock of the Company conforms in all material respects to the description thereof contained in the SEC Reports;

and all the outstanding shares of capital stock or other equity interests of each subsidiary owned, directly or indirectly, by the

Company have been duly and validly authorized and issued, are fully paid and non-assessable (except, in the case of any foreign

subsidiary, for directors’ qualifying shares) and are owned directly or indirectly by the Company, free and clear of any lien,

charge, encumbrance, security interest, restriction on voting or transfer or any other claim of any third party. There are no

securities or instruments issued by or to which the Company is a party containing anti-dilution, rights of first refusal, rights of

participation or similar provisions that will be triggered (which, for the avoidance of doubt, excludes any such anti-dilution,

rights of first refusal, rights of participation or similar provision that will be waived in connection with the transactions

contemplated by this Agreement and the Merger Agreement) by the issuance of the Securities pursuant to this Agreement.

3.3 Registration

Rights. Except as set forth in the Transaction Agreements, contemplated by the Merger Agreement or as disclosed in the SEC Reports,

the Company is presently not under any obligation, and has not granted any rights, to register under the Securities Act any of the Company’s

presently outstanding securities or any of its securities that may hereafter be issued, other than such rights and obligations that have

expired or been satisfied or waived.

3.4 Authorization.

The Company has all requisite corporate power and authority to enter into the Transaction Agreements and to carry out and perform its

obligations under the terms of the Transaction Agreements, including the issuance and sale of the Preferred Shares and,

subject to obtaining the Required Parent Stockholder Vote (as defined in the Merger Agreement) of the Parent Stockholder Matters (as

defined in the Merger Agreement) at the Parent Stockholders’ Meeting (as defined in the Merger Agreement) and the related filing

and effectiveness of an amendment to the Certificate of Incorporation approved at such Parent Stockholders’ Meeting, the

issuance of the Conversion Shares. Except for the Required Parent Stockholder Vote of the Parent

Stockholder Matters at the Parent Stockholder’s Meeting and the related filing and effectiveness of an amendment to the Certificate

of Incorporation approved at such Parent Stockholders’ Meeting, all corporate action on the part of the Company, its officers,

directors and stockholders necessary for the authorization of the Securities, the authorization, execution, delivery and performance

of the Transaction Agreements and the consummation of the transactions contemplated herein and therein, including the issuance and sale

of the Preferred Shares has been taken, including, without limitation, the approval of the Board of Directors (or a committee thereof)

in accordance with Section 144(a)(1) of the DGCL (as defined below). This Agreement has been duly executed and delivered by the Company

and, assuming the due authorization, execution and delivery by each Investor of this Agreement and that this Agreement constitutes the

legal, valid and binding agreement of each Investor, this Agreement constitutes a legal, valid and binding obligation of the Company,

enforceable against the Company in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency,

reorganization, moratorium and similar laws relating to or affecting creditors generally or by general equity principles (regardless

of whether such enforceability is considered in a proceeding in equity or at law). Upon its execution by the Company and the other parties

thereto and assuming that it constitutes legal, valid and binding agreements of the other parties thereto, the Registration Rights Agreement

will constitute a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except

as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium and similar laws relating to or affecting

creditors generally or by general equity principles (regardless of whether such enforceability is considered in a proceeding in equity

or at law).

3.5 Valid

Issuance. The Preferred Shares being purchased by the Investors hereunder have been duly and validly authorized and, upon issuance

pursuant to the terms of this Agreement against full payment therefor in accordance with the terms of this Agreement, will be duly and

validly issued, fully paid and non-assessable and will be issued free and clear of any liens or other restrictions (other than those

as provided in the Transaction Agreements or restrictions on transfer under applicable state and federal securities laws), and the holder

of the Preferred Shares shall be entitled to all rights accorded to a holder of Preferred Shares. Subject

to obtaining Required Parent Stockholder Vote of the Parent Stockholder Matters at the Parent Stockholders’ Meeting and the related

filing and effectiveness of an amendment to the Certificate of Incorporation approved at such Parent Stockholders’ Meeting, the

Conversion Shares will be duly and validly authorized and reserved for issuance and, upon issuance in accordance with the Certificate

of Designation, will be duly and validly issued, fully paid and non-assessable and will be issued free and clear of any liens or other

restrictions (other than restrictions on transfer under applicable state and federal securities laws) and the holder of the Conversion

Shares shall be entitled to all rights accorded to a holder of Common Stock. Subject to the accuracy of the representations and warranties

made by the Investors in Section 4 hereof, the offer and sale of the Preferred Shares to the Investors is and will be, and the

issuance of the Conversion Shares will be, in compliance with applicable exemptions from (i) the registration and prospectus delivery

requirements of the Securities Act and (ii) the registration and qualification requirements of applicable securities laws of the states

of the United States.

3.6 No

Conflict. Subject to obtaining Required Parent Stockholder Vote of the Parent Stockholder Matters

at the Parent Stockholders’ Meeting, approval of the Nasdaq Listing of Additional Shares Notification Form and, to the extent required

by Nasdaq rules and regulations, the Nasdaq Listing Application (as defined in the Merger Agreement), as applicable, and the related

filing and effectiveness of an amendment to the Certificate of Incorporation approved at the Parent Stockholders’ Meeting, the

execution, delivery and performance of the Transaction Agreements by the Company, the issuance and sale of the Securities and the consummation

of the other transactions contemplated by the Transaction Agreements will not (i) violate any provision of the Certificate of Incorporation

or Amended and Restated Bylaws of the Company, (ii) conflict with or result in a violation of or default (with or without notice or lapse

of time, or both) under, or give rise to a right of termination, cancellation or acceleration of any obligation, a change of control

right or to a loss of a benefit under any agreement or instrument, credit facility, franchise, license, judgment, order, statute, law,

ordinance, rule or regulations, applicable to the Company or any of its subsidiaries or their respective properties or assets, or (iii)

result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental

authority to which the Company or any of its subsidiaries is subject (including federal and state securities laws and regulations) and

the rules and regulations of any self-regulatory organization to which the Company or its securities are subject, or by which any property

or asset of the Company or any of its subsidiaries is bound or affected, except, in the case of clauses (ii) and (iii), as would not,

individually or in the aggregate, be reasonably expected to have a Material Adverse Effect.

3.7 Consents.

Assuming the accuracy of the representations and warranties of each Investor set forth in Section 4 hereof, no consent, approval,

authorization, filing with or order of or registration with, any court or governmental agency or body is required in connection with

the authorization, execution or delivery by the Company of the Transaction Agreements, the issuance and sale of the Securities and the

performance by the Company of its other obligations under the Transaction Agreements, except (a) as have been or will be obtained or

made under the Securities Act or the Exchange Act, (b) the filing of any requisite notices and/or application(s), including without limitation

the requisite Nasdaq Listing of Additional Shares Notification Form, as applicable, with respect

to the Conversion Shares, with Nasdaq Capital Market for the listing of the Conversion Shares for trading or quotation, as the

case may be, thereon in the time and manner required thereby, (c) customary post-Closing filings with the SEC or pursuant to state securities

laws in connection with the offer and sale of the Securities by the Company in the manner contemplated herein, which will be filed on

a timely basis, (d) the filing of the registration statement required to be filed by the Registration Rights Agreement, (e) the

Required Parent Stockholder Vote of the Parent Stockholder Matters at the Parent Stockholders’ Meeting, the approval of the listing

of the Conversion Shares by Nasdaq Capital Market, and the related filing and effectiveness of an amendment to the Certificate of Incorporation

approved at the Parent Stockholders’ Meeting or (f) such that the failure of which to obtain would not have a Material Adverse

Effect. All notices, consents, authorizations, orders, filings and registrations which the Company is required to deliver or obtain prior

to the applicable Closing pursuant to the preceding sentence have been obtained or made or will be delivered or obtained or effected,

and shall remain in full force and effect, on or prior to the applicable Closing.

3.8 SEC

Filings; Financial Statements.

(a) The

Company has filed all forms, statements, certifications, reports and documents required to be filed by it with the SEC under Section

13, 14(a) and 15(d) of the Exchange Act for the one year preceding the date of this Agreement and is in compliance with General Instruction

I.A.3 of Form S-3. As of the time it was filed with the SEC (or, if amended or superseded by a filing prior to the date of this Agreement,

then on the date of such filing), each of the filed SEC Reports complied in all material respects with the applicable requirements of

the Exchange Act, and, as of the time they were filed, none of the filed SEC Reports contained any untrue statement of a material fact

or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the

circumstances under which they were made, not misleading. There are no outstanding or unresolved comments from the SEC staff with respect

to the SEC Reports. To the Company’s knowledge, none of the SEC Reports are the subject of an ongoing SEC review. The interactive

data in eXtensible Business Reporting Language included in the SEC Reports fairly presents the information called for in all material

respects and has been prepared in accordance with the SEC’s rules and guidelines applicable thereto. The Company is not, and has

never been, an issuer subject to Rule 144(i) under the Securities Act.

(b) The

consolidated financial statements of the Company included in the SEC Reports (collectively, the “Financial Statements”)

comply in all material respects with applicable accounting requirements and the rules and regulations of the SEC with respect thereto

as in effect at the time of filing (or to the extent corrected by a subsequent restatement) and fairly present in all material respects

the consolidated financial position of the Company and its subsidiaries as of the dates indicated, and the results of its operations

and cash flows for the periods therein specified, and have been prepared in accordance with United States generally accepted accounting

principles (“GAAP”) applied on a consistent basis throughout the periods therein specified (except as otherwise noted

therein, and except that any unaudited financial statements may not contain certain footnotes and are subject to normal and recurring

year-end adjustments). Except as set forth in the Financial Statements filed prior to the date of this Agreement, the Company has not

incurred any liabilities, contingent or otherwise, except (i) those incurred in the ordinary course of business, consistent with past

practices since the date of such financial statements or (ii) liabilities not required under GAAP to be reflected in the Financial Statements,

in either case, none of which, individually or in the aggregate, have had or would reasonably be expected to have a Material Adverse

Effect.

3.9 Absence

of Changes. Since December 31, 2025, (a) the Company has conducted its business only in the ordinary course of business and there

have been no material transactions entered into by the Company or any of its subsidiaries (except for the execution and performance of

this Agreement and the discussions, negotiations and transactions related thereto); (b) no material change to any material contract or

arrangement by which the Company or any of its subsidiaries is bound or to which any of its assets or properties is subject has been

entered into that has not been disclosed in the SEC Reports; and (c) there has not been any other event or condition of any character

that has had or would reasonably be expected to have a Material Adverse Effect; provided, however, that none of the following will be

deemed in themselves, either alone or in combination, to constitute, and that none of the following will be taken into account in determining

whether there has been or will be, a Material Adverse Effect under this Section 3.9:

(i) any

change generally affecting the economy, financial markets or political, economic or regulatory conditions in the United States or any

other geographic region in which the Company conducts business, provided that the Company is not disproportionately affected thereby;

(ii) general

financial, credit or capital market conditions, including interest rates or exchange rates, or any changes therein, provided that the

Company is not disproportionately affected thereby;

(iii) any

change that generally affects industries in which the Company and its subsidiaries conduct business, provided that the Company is not

disproportionately affected thereby;

(iv) earthquakes,

hurricanes, tsunamis, tornadoes, floods, mudslides, fires or other natural disasters, weather conditions, global pandemics, epidemic

or similar health emergency, and other force majeure events in the United States or any other location, provided that the Company is

not disproportionately affected thereby;

(v) national

or international political or social conditions (or changes in such conditions), whether or not pursuant to the declaration of a national

emergency or war, or the occurrence of any military or terrorist attack, provided that the Company is not disproportionately affected

thereby;

(vi) material

changes in laws after the date of this Agreement; and

(vii) in

and of itself, any material failure by the Company to meet any published or internally prepared estimates of revenues, expenses, earnings

or other economic performance for any period ending on or after the date of this Agreement (it being understood that the facts and circumstances

giving rise to such failure may be deemed to constitute, and may be taken into account in determining whether there has been, a Material

Adverse Effect to the extent that such facts and circumstances are not otherwise described in clauses (i)-(vi) of this definition).

3.10 Absence

of Litigation. There is no action, suit, proceeding, arbitration, claim, investigation, charge, complaint or inquiry pending or,

to the Company’s knowledge, threatened against the Company or any of its subsidiaries which, individually or in the aggregate,

has had or would reasonably be expected to have a Material Adverse Effect, nor are there any orders, writs, injunctions, judgments or

decrees outstanding of any court or government agency or instrumentality and binding upon the Company or any of its subsidiaries that

have had or would reasonably be expected to have a Material Adverse Effect. Neither the Company nor any subsidiary, nor to the knowledge

of the Company, any director or officer of the Company or any subsidiary, is, or within the last ten years has been, the subject of any

action involving a claim of violation of or liability under federal or state securities laws relating to the Company or such subsidiary

or a claim of breach of fiduciary duty relating to the Company or such subsidiary.

3.11 Compliance

with Law; Permits. Neither the Company nor any of its subsidiaries is in violation of, or has received any notices of violations

with respect to, any laws, statutes, ordinances, rules or regulations of any governmental body, court or government agency or instrumentality,

except for violations which, individually or in the aggregate, have not had and would not reasonably be expected to have a Material Adverse

Effect. The Company and its subsidiaries have all required licenses, permits, certificates and other authorizations (collectively, “Governmental

Authorizations”) from such federal, state or local government or governmental agency, department or body that are currently

necessary for the operation of the business of the Company and its subsidiaries as currently conducted, except where the failure to possess

currently such Governmental Authorizations has not had and is not reasonably expected to have a Material Adverse Effect. Neither the

Company nor any subsidiary has received any written (or, to the Company’s knowledge, oral) notice regarding any revocation or material

modification of any such Governmental Authorization, which, individually or in the aggregate, if the subject of an unfavorable decision,

ruling or finding, has or would reasonably be expected to result in a Material Adverse Effect.

3.12 Intellectual

Property. The Company and its subsidiaries own, or have rights to use, all material inventions, patent applications, patents, trademarks,

trade names, service names, service marks, copyrights, trade secrets, know how (including unpatented and/or unpatentable proprietary

or confidential information, systems or procedures) and other intellectual property as described in the SEC Reports necessary for, or

used in the conduct of their respective businesses (including as described in the SEC Reports) (collectively, “Intellectual

Property”), except where any failure to own, possess or acquire such Intellectual Property has not had, and would not, individually

or in the aggregate, reasonably be expected to have a Material Adverse Effect. The Intellectual Property of the Company and its subsidiaries

has not been adjudged by a court of competent jurisdiction to be invalid or unenforceable, in whole or in part. To the Company’s

knowledge: (i) there are no third parties who have rights to any Intellectual Property, including no liens, security interests, or other

encumbrances; and (ii) there is no infringement by third parties of any Intellectual Property, except, in each case, which, individually

or in the aggregate, have not had and would not reasonably be expected to have a Material Adverse Effect. No action, suit, or other proceeding

is pending, or, to the Company’s knowledge, is threatened: (A) challenging the Company’s or its subsidiaries’ rights

in or to any Intellectual Property; (B) challenging the validity, enforceability or scope of any Intellectual Property; or (C) alleging

that the Company or any of its subsidiaries infringes, misappropriates, or otherwise violates any patent, trademark, trade name, service

name, copyright, trade secret or other proprietary rights of others, except, in each case, which, individually or in the aggregate, have

not had and would not reasonably be expected to have a Material Adverse Effect. The Company and its subsidiaries have complied in all

material respects with the terms of each agreement pursuant to which Intellectual Property has been licensed to the Company or any of

its subsidiaries in all material respects, and to the Company’s knowledge all such agreements are in full force and effect. To

the Company’s knowledge, there are no material defects in any of the patents or patent applications included in the Intellectual

Property. The Company and its subsidiaries have taken all reasonable steps to protect, maintain and safeguard their Intellectual Property.

3.13 Employee

Benefits. Except as would not be reasonably likely to result in a Material Adverse Effect, each Benefit Plan has been established

and administered in accordance with its terms and in compliance with the applicable provisions of ERISA, the Code, the Patient Protection

and Affordable Care Act of 2010, as amended, and other applicable laws, rules and regulations. The Company and its subsidiaries are in

compliance with all applicable federal, state and local laws, rules and regulations regarding employment, except for any failures to

comply that are not reasonably likely, individually or in the aggregate, to have a Material Adverse Effect. There is no labor dispute,

strike or work stoppage against the Company or its subsidiaries pending or, to the knowledge of the Company, threatened which may interfere

with the business activities of the Company, except where such dispute, strike or work stoppage is not reasonably likely, individually

or in the aggregate, to have a Material Adverse Effect.

3.14 Taxes.

The Company and its subsidiaries have filed all federal, state and foreign income Tax Returns and other Tax Returns required to have

been filed under applicable law (or extensions have been duly obtained) and have paid all Taxes required to have been paid by them, except

for those which are being contested in good faith and except where failure to file such Tax Returns or pay such Taxes would not, individually

or in the aggregate, reasonably be expected to have a Material Adverse Effect. No assessment in connection with United States federal

tax returns has been made against the Company. The charges, accruals and reserves on the books of the Company in respect of any income

and corporation tax liability for any years not finally determined are adequate to meet any assessments or reassessments for additional

income tax for any years not finally determined, except to the extent of any inadequacy that would not result in a Material Adverse Effect.

No audits, examinations, or other proceedings with respect to any material amounts of Taxes of the Company and its subsidiaries are presently

in progress or have been asserted or proposed in writing without subsequently being paid, settled or withdrawn. There are no liens on

any of the assets of the Company. At all times since inception, the Company has been and continues to be classified as a corporation

for U.S. federal income tax purposes. Neither the Company nor any of its subsidiaries has been a United States real property holding

corporation within the meaning of Code Section 897(c)-2 during the period specified in Code Section 897(c)(1)(A)(ii).

3.15 Environmental

Laws. The Company and its subsidiaries (i) are in compliance with any and all applicable foreign, federal, state and local laws and

regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants

or contaminants (“Environmental Laws”), (ii) have received all permits and other Governmental Authorizations required

under applicable Environmental Laws to conduct their business and (iii) are in compliance with all terms and conditions of any such permit,

license or approval, except where such noncompliance with Environmental Laws, failure to receive required permits, licenses or other

approvals or failure to comply with the terms and conditions of such permits, licenses or approvals would not, individually or in the

aggregate, reasonably be expected to have a Material Adverse Effect. None of the Company nor any of its subsidiaries has received since

January 1, 2025, any written notice or other communication (in writing or otherwise), whether from a governmental authority or other

Person, that alleges that the Company or any subsidiary is not in compliance with any Environmental Law and, to the knowledge of the

Company, there are no circumstances that may prevent or interfere with the Company’s or any subsidiary’s compliance in any

material respects with any Environmental Law in the future, except where such failure to comply would not reasonably be expected to have

a Material Adverse Effect. To the knowledge of the Company: (i) no current or (during the time a prior property was leased or controlled

by the Company) prior property leased or controlled by the Company or any subsidiary has received since July 1, 2024, any written notice

or other communication relating to property owned or leased at any time by the Company, whether from a governmental authority, or other

Person, that alleges that such current or prior owner or the Company or any subsidiary is not in compliance with or violated any Environmental

Law relating to such property and (ii) the Company has no material liability under any Environmental Law.

3.16 Title.

Each of the Company and its subsidiaries has good and marketable title to all personal property owned by it that is material to the business

of the Company, free and clear of all liens, encumbrances and defects except such as do not materially and adversely affect the value

of such property and do not materially and adversely interfere with the use made and proposed to be made of such property by the Company

or its subsidiaries, as the case may be. Any real property and buildings held under lease by the Company or its subsidiaries is held

under valid, subsisting and enforceable leases with such exceptions as are not material and do not interfere with the use made and proposed

to be made of such property and buildings by the Company or its subsidiaries, as the case may be. The Company does not own any real property.

3.17 Insurance.

The Company carries or is entitled to the benefits of insurance in such amounts and covering such risks that is customary for comparably

situated companies and is adequate for the conduct of its business and the value of its real and personal properties (owned or leased)

and tangible assets, and each of such insurance policies is in full force and effect and the Company is in compliance in all material

respects with the terms of such insurance policies. Other than customary end-of-policy notifications from insurance carriers, since July

1, 2024, the Company has not received any notice or other communication regarding any actual or possible: (i) cancellation or invalidation

of any material insurance policy or (ii) refusal or denial of any coverage, reservation of rights or rejection of any material claim

under any insurance policy.

3.18 Nasdaq

Capital Market. The issued and outstanding shares of Common Stock are registered pursuant to Section 12(b) of the Exchange Act and

are listed for trading on the Nasdaq Capital Market under the symbol “ENSC”. The Company is in compliance with all listing

requirements of the Nasdaq Capital Market applicable to the Company. As of the date of this Agreement, there is no suit, action, proceeding

or investigation pending or, to the knowledge of the Company, threatened against the Company by Nasdaq Capital Market or the SEC, respectively,

to prohibit or terminate the listing of the Common Stock on the Nasdaq Capital Market or to deregister the Common Stock under the Exchange

Act. The Company has taken no action as of the date of this Agreement that is designed to terminate the registration of the Common Stock

under the Exchange Act.

3.19 Sarbanes-Oxley

Act. The Company is, and since January 1, 2025 has been, in compliance in all material respects with all applicable requirements

of the Sarbanes-Oxley Act of 2002 and applicable rules and regulations promulgated by the SEC thereunder.

3.20 Clinical

Data and Regulatory Compliance. Except as would not reasonably be expected to result in a Material Adverse Effect: (i) the preclinical

tests and clinical trials and other studies used to support regulatory approval (collectively, “Studies”) being conducted

by or on behalf of, or sponsored by, the Company or its subsidiaries that are described in, or the results of which are referred to in,

the SEC Reports were (and, if still pending, are being) conducted in all material respects in accordance with the protocols, procedures

and controls designed and approved for such Studies and with standard medical and scientific research procedures; (ii) each description

of the results of such Studies is accurate and complete in all material respects and fairly presents the data derived from such Studies,

and the Company and its subsidiaries have no knowledge of any other studies the results of which are inconsistent with, or otherwise

call into question, the results described or referred to in the SEC Reports; (iii) the Company and its subsidiaries have made all such

filings and obtained all such approvals as may be required by the FDA or from any other U.S. federal, state or local government or foreign

government or Drug Regulatory Agency, or Institutional Review Board, each having jurisdiction over biopharmaceutical products (collectively,

the “Regulatory Agencies”) for the conduct of its business as described in the SEC Reports; (iv) neither the Company

nor any of its subsidiaries has received any notice of, or correspondence from, any of the Regulatory Agencies requiring the termination

or suspension of or imposing any clinical hold on any clinical trials that are described or referred to in the SEC Reports; and (v) the

Company and its subsidiaries have each operated and currently are in compliance in all material respects with all applicable rules, regulations

and policies of the Regulatory Agencies.

3.21 Compliance

with Health Care Laws. The Company and its subsidiaries are in compliance in all material respects with all Health Care Laws to the

extent applicable to the current business of the Company and its subsidiaries or any of their respective activities. For purposes of

this Agreement, “Health Care Laws” means: (i) the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Section 301 et seq.)

and the Public Health Service Act (42 U.S.C. Section 201 et seq.), and the regulations promulgated thereunder; (ii) all applicable federal,

state, local and foreign health care fraud and abuse laws, including, without limitation, the Anti-Kickback Statute (42 U.S.C. Section

1320a-7b(b)); (iii) HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. Section 17921

et seq.); (iv) the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act

of 2010; (v) the European Union (“EU”) Clinical Trials Regulation (Regulation (EU) No. 536/2014); (vi) the EU Regulation

regarding community procedures for authorization and supervision of medicinal products for human and veterinary use and establishing

a European Medicines Agency (Regulation (EC) No. 726/2004); (vii) licensure, quality, safety and accreditation requirements under applicable

federal, state, local or foreign laws or regulatory bodies; (viii) all other local, state, federal, national, supranational and foreign

laws, relating to the regulation of the Company or its subsidiaries, and (ix) the regulations promulgated pursuant to such statutes and

any state or non-U.S. counterpart thereof. Neither the Company nor any of its subsidiaries has received written or, to the Company’s

knowledge, oral notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from

any court or arbitrator or governmental or regulatory authority or third party alleging that any product operation or activity is in

material violation of any Health Care Laws nor, to the Company’s knowledge, is any such claim, action, suit, proceeding, hearing,

enforcement, investigation, arbitration or other action threatened. The Company and its subsidiaries have filed, maintained or submitted

all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required

by any Health Care Laws, and all such reports, documents, forms, notices, applications, records, claims, submissions and supplements

or amendments were complete and accurate on the date filed in all material respects (or were corrected or supplemented by a subsequent

submission). Neither the Company nor any of its subsidiaries is a party to any corporate integrity agreements, monitoring agreements,

consent decrees, settlement orders, or similar agreements with or imposed by any governmental or regulatory authority. Additionally,

neither the Company nor any of its subsidiaries nor any of their respective employees, officers, directors, or, to the knowledge of the

Company, agents has been excluded, suspended or debarred from participation in any U.S. federal health care program or human clinical

research or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action

that would reasonably be expected to result in debarment, suspension, or exclusion.

3.22 Accounting

Controls and Disclosure Controls and Procedures. The Company maintains a system of internal control over financial reporting (as

defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that is designed to comply with the requirements of the Exchange Act applicable

to the Company and provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements

for external purposes in accordance with GAAP, including policies and procedures sufficient to provide reasonable assurance (i) that

the Company maintains records that in reasonable detail accurately and fairly reflect the Company’s transactions and dispositions

of assets, (ii) that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, (iii)

that receipts and expenditures are made only in accordance with authorizations of management and the Board of Directors and (iv) regarding

prevention or timely detection of the unauthorized acquisition, use or disposition of the Company’s assets that could have a material

effect on the Company’s financial statements. Except as disclosed in the Company’s SEC Reports filed prior to the date of

this Agreement, the Company has not identified any material weaknesses in the design or operation of the Company’s internal control

over financial reporting. The Company’s “disclosure controls and procedures” (as defined in Rules 13a-15(e) and 15d-15(e)

of the Exchange Act) are designed to provide reasonable assurance that all information (both financial and non-financial) required to

be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported

within the time periods specified in the rules and forms of the SEC, and that all such information is accumulated and communicated to

the Company’s management as appropriate to allow timely decisions regarding required disclosure.

3.23 Price

Stabilization of Common Stock. The Company has not taken, nor will it take, directly or indirectly, any action designed to stabilize

or manipulate the price of the Common Stock to facilitate the sale or resale of the Securities.

3.24 Investment

Company Act. The Company is not, and immediately after receipt of payment for the Securities will not be, an “investment company”

within the meaning of the U.S. Investment Company Act of 1940, as amended.

3.25 General

Solicitation; No Integration or Aggregation. Neither the Company nor any other person or entity authorized by the Company to act

on its behalf has engaged in a general solicitation or general advertising of investors with respect to offers or sales of Securities

pursuant to this Agreement. Except with respect to the capital stock of the Company to be issued pursuant to the Merger Agreement, the

Company has not, directly or indirectly, sold, offered for sale, solicited offers to buy or otherwise negotiated in respect of, any security

(as defined in the Securities Act) which, to its knowledge, is or will be (i) integrated with the offer and sale of the Securities pursuant

to this Agreement for purposes of the Securities Act or (ii) aggregated with prior offerings by the Company for the purposes of the rules

and regulations of the Nasdaq Capital Market. Assuming the accuracy of the representations and warranties of the Investors set forth

in Section 4, neither the Company nor any of its Affiliates, its subsidiaries nor any Person acting on their behalf has, directly

or indirectly, made any offers or sales of any Company security or solicited any offers to buy any Company security, under circumstances

that would adversely affect reliance by the Company on Section 4(a)(2) for the exemption from registration for the transactions contemplated

hereby.

3.26 Brokers

and Finders. Other than the Placement Agents, neither the Company nor any other Person authorized by the Company to act on its behalf

has retained, utilized or been represented by any broker or finder in connection with the transactions contemplated by this Agreement.

3.27 Reliance

by the Investors. The Company has a reasonable basis for making each of the representations set forth in this Section 3. The

Company acknowledges that each of the Investors will rely upon the truth and accuracy of, and the Company’s compliance with, the

representations, warranties, agreements, acknowledgements and understandings of the Company set forth herein.

3.28 No

Additional Agreements. There are no agreements or understandings between the Company and any Investor with respect to the transactions

contemplated by the Transaction Agreements other than (i) as specified in the Transaction Agreements and (ii) any side letter agreements

with any of the Investors, which side letters the Company has shared with all Investors.

3.29 Anti-Bribery

and Anti-Money Laundering Laws. Each of the Company, its subsidiaries and, to the knowledge of the Company, any of their respective

officers, directors, supervisors, managers, agents, or employees are and have at all times been in compliance with and its participation

in the offering will not violate: (A) anti-bribery laws, including but not limited to, any applicable law, rule, or regulation of any

locality, including but not limited to any law, rule, or regulation promulgated to implement the OECD Convention on Combating Bribery

of Foreign Public Officials in International Business Transactions, signed December 17, 1997, including the U.S. Foreign Corrupt Practices

Act of 1977, as amended, the U.K. Bribery Act 2010, or any other law, rule or regulation of similar purposes and scope; (B) anti-money

laundering laws, including, but not limited to, applicable federal, state, international, foreign or other laws, regulations or government

guidance regarding anti-money laundering, including, without limitation, Title 18 US. Code sections 1956 and 1957, the Patriot Act, the

Bank Secrecy Act, and international anti-money laundering principles or procedures by an intergovernmental group or organization, such

as the Financial Action Task Force on Money Laundering, of which the United States is a member and with which designation the United

States representative to the group or organization continues to concur, all as amended, and any executive order, directive, or regulation

pursuant to the authority of any of the foregoing, or any orders or licenses issued thereunder; or (C) except as would not reasonably

be expected, individually or in the aggregate, to result in a Material Adverse Effect, any laws with respect to import and export control

and economic sanctions, including the U.S. Export Administration Regulations, the U.S. International Traffic in Arms Regulations, and

economic sanctions regulations and executive orders administered by the U.S. Department of the Treasury Office of Foreign Asset Control.

3.30 Cybersecurity.

The Company and its subsidiaries’ information technology assets and equipment, computers, systems, networks, hardware, software,

websites, applications, and databases (collectively, “IT Systems”) are adequate for, and operate and perform in all

material respects as required in connection with the operation of the business of the Company and its subsidiaries as currently conducted,

and are free and clear of all material Trojan horses, time bombs, malware and other malicious code. The Company and its subsidiaries

have implemented and maintained commercially reasonable physical, technical and administrative controls designed to maintain and protect

the confidentiality, integrity, availability, privacy and security of all sensitive, confidential or regulated data (“Confidential

Data”) used or maintained in connection with their businesses and Personal Data (defined below), and the integrity, availability

continuous operation, redundancy and security of all IT Systems. “Personal Data” means the following data used in

connection with the Company’s and its subsidiaries’ businesses and in their possession or control: (i) a natural person’s

name, street address, telephone number, e-mail address, photograph, social security number or other tax identification number, driver’s

license number, passport number, credit card number or bank information; (ii) information that identifies or may reasonably be used to

identify an individual; (iii) any information that would qualify as “protected health information” under the Health Insurance

Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act (collectively,

“HIPAA”); and (iv) any information that would qualify as “personal data,” “personal information”

(or similar term) under the Privacy Laws. To the Company’s knowledge, there have been no breaches, outages or unauthorized uses

of or accesses to the Company’s IT Systems, Confidential Data, or Personal Data that would require notification under Privacy Laws

(as defined below).

3.31 Compliance

with Data Privacy Laws. The Company and its subsidiaries are, and at all prior times were, in material compliance with all applicable

state, federal and foreign data privacy and security laws and regulations regarding the collection, use, storage, retention, disclosure,

transfer, disposal, or any other processing (collectively “Process” or “Processing”) of Personal

Data, including without limitation HIPAA, the EU General Data Protection Regulation (“GDPR”) (Regulation (EU) No.

2016/679), all other local, state, federal, national, supranational and foreign laws relating to the regulation of the Company or its

subsidiaries, and the regulations promulgated pursuant to such statutes and any state or non-U.S. counterpart thereof (collectively,

the “Privacy Laws”). To ensure material compliance with the Privacy Laws, the Company and its subsidiaries have in

place, comply with, and take all appropriate steps necessary to ensure compliance in all material respects with their policies and procedures

relating to data privacy and security, and the Processing of Personal Data and Confidential Data (the “Privacy Statements”).

The Company and its subsidiaries have, except as would not reasonably be expected, individually or in the aggregate, to result in a Material

Adverse Effect, at all times since inception provided accurate notice of their Privacy Statements then in effect to its customers, employees,

third party vendors and representatives. None of such disclosures made or contained in any Privacy Statements have been materially inaccurate,

misleading, incomplete, or in material violation of any Privacy Laws.

3.32 Transactions

with Affiliates and Employees. No relationship, direct or indirect, exists between or among the Company or any of its subsidiaries,

on the one hand, and the directors, officers, stockholders, customers or suppliers of the Company, on the other hand, that is required

to be described in the SEC Reports that is not so described.

3.33 Disclosure.

The Company confirms that it has not provided, and to the Company’s knowledge, none of its officers or directors nor any other

Person acting on its or their behalf (including, without limitation, the Placement Agents) has provided, and it has not authorized the

Placement Agents to provide, any Investor or its respective agents or counsel with any information that it believes constitutes material,

non-public information except insofar as the existence, provisions and terms of the Transaction Agreements, the Merger Agreement, and

the proposed transactions hereunder and thereunder may constitute such information, all of which will be disclosed by the Company in

the Disclosure Document as contemplated by Section 5.3 hereof. The Company understands and confirms that the Investors will rely on the

foregoing representations in effecting transactions in securities of the Company.

4. Representations

and Warranties of Each Investor. Each Investor, severally for itself and not jointly with any other Investor, represents and warrants

to the Company and the Placement Agents that the statements contained in this Section 4 are true and correct as of the date of

this Agreement and the applicable Closing Date:

4.1 Organization.

The Investor, if a corporation, partnership, limited liability company, association, joint stock company, trust, unincorporated organization

or other entity, is duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization and

has the requisite power and authority to own, lease and operate its properties and to carry on its business as now conducted.

4.2 Authorization.

The Investor has all requisite corporate or similar power and authority to enter into this Agreement and the other Transaction Agreements

to which it will be a party and to carry out and perform its obligations hereunder and thereunder. All corporate, member or partnership

action on the part of such Investor or its stockholders, members or partners necessary for the authorization, execution, delivery and

performance of this Agreement and the other Transaction Agreements to which it will be a party and the consummation of the other transactions

contemplated in this Agreement has been taken. The execution, delivery and performance by such Investor of the Transaction Agreements

to which such Investor is a party has been duly authorized and each has been duly executed. Assuming this Agreement constitutes the legal

and binding agreement of the Company, this Agreement constitutes a legal, valid and binding obligation of such Investor, enforceable

against such Investor in accordance with its terms, except as such enforceability may be limited or otherwise affected by bankruptcy,

insolvency, fraudulent conveyance, reorganization, moratorium and/or similar laws relating to or affecting the rights of creditors generally

or by general equity principles (regardless of whether such enforceability is considered in a proceeding in equity or at law).

4.3 No

Conflicts. The execution, delivery and performance of the Transaction Agreements by the Investor, the purchase of the Securities

in accordance with their terms and the consummation by the Investor of the other transactions contemplated hereby will not conflict with

or result in any violation of, breach or default by such Investor (with or without notice or lapse of time, or both) under, conflict

with, or give rise to a right of termination, cancellation or acceleration of any obligation, a change of control right or to a loss

of a material benefit under (i) any provision of the organizational documents of the Investor, including, without limitation, its incorporation

or formation papers, bylaws, indenture of trust or partnership or operating agreement, as may be applicable or (ii) any agreement or

instrument, undertaking, credit facility, franchise, license, judgment, order, ruling, statute, law, ordinance, rule or regulations,

applicable to such Investor or its respective properties or assets, except, in the case of clause (ii), as would not, individually or

in the aggregate, be reasonably expected to materially delay or hinder the ability of the Investor to perform its obligations under the

Transaction Agreements.

4.4 Residency.

The Investor’s residence (if an individual) or offices in which its investment decision with respect to the Securities was made

(if an entity) are located at the address immediately below the Investor’s name on the pertinent signature page of this Agreement,

except as otherwise communicated by the Investor to the Company.

4.5 Brokers

and Finders. The Investor has not retained, utilized or been represented by any broker or finder in connection with the transactions

contemplated by this Agreement whose fees the Company would be required to pay.

4.6 Investment

Representations and Warranties. The Investor hereby represents and warrants that, it is a sophisticated investor with such knowledge

and experience in financial and business matters as to be able to protect its own interests in connection with an investment in the Securities.

The Investor further represents and warrants that (x) it is capable of evaluating the merits and risk of such investment, and (y) that

it has not been organized for the purpose of acquiring the Securities and is an “institutional account” as defined by FINRA

Rule 4512(c). The Investor understands and agrees that the offering and sale of the Securities has not been registered under the Securities

Act or any applicable state securities laws and is being made in reliance upon federal and state exemptions for transactions not involving

a public offering which depend upon, among other things, the bona fide nature of the investment intent and the accuracy of the Investor’s

representations as expressed herein.

4.7 Intent.

The Investor is purchasing the Preferred Shares solely for the Investor’s own account and not for the account of others, and not

with a view to the resale or distribution of any part thereof in violation of the Securities Act, and the Investor has no present intention

of selling, granting any participation in, or otherwise distributing the same in violation of the Securities Act without prejudice, however,

to the Investor’s right at all times to sell or otherwise dispose of all or any part of such Securities in compliance with applicable

federal and state securities laws. Notwithstanding the foregoing, if the Investor is purchasing the Preferred Shares as a fiduciary or

agent for one or more investor accounts, the Investor has full investment discretion with respect to each such account, and the full

power and authority to make the acknowledgements, representations and agreements herein on behalf of each owner of each such account.

The Investor has no present arrangement to sell the Preferred Shares to or through any person or entity. The Investor understands that

the Securities must be held indefinitely unless such Conversion Shares are resold pursuant to a registration statement under the Securities

Act or an exemption from registration is available. Nothing contained herein shall be deemed a representation or warranty by the Investor

to hold the Securities for any period of time.

4.8 Investment

Experience; Ability to Protect Its Own Interests and Bear Economic Risks. The Investor acknowledges that it can bear the economic

risk and complete loss of its investment in the Securities and has knowledge and experience in finance, securities, taxation, investments

and other business matters as to be capable of evaluating the merits and risks of investments of the kind described in this Agreement

and contemplated hereby, and the Investor has had an opportunity to seek, and has sought, such accounting, legal, business and tax advice

as the Investor has considered necessary to make an informed investment decision. The Investor acknowledges that the Investor (i) is

a sophisticated investor, experienced in investing in private placements of equity securities and capable of evaluating investment risks

independently, both in general and with regard to all transactions and investment strategies involving a security or securities and (ii)

has exercised independent judgment in evaluating its participation in the purchase of the Securities, and (iii) is not acting in concert

with any other Investor in the offering, such the investors would constitute a group for purposes of the federal securities laws. The

Investor acknowledges that the Investor is aware that there are substantial risks incident to the purchase of the Preferred Shares and

ownership of the Securities, including those set forth in the Company’s filings with the SEC. Alone, or together with any professional

advisor(s), the Investor has adequately analyzed and fully considered the risks of an investment in the Securities and determined that

the Securities are a suitable investment for the Investor. The Investor is, at this time and in the foreseeable future, able to afford

the loss of the Investor’s entire investment in the Securities and the Investor acknowledges specifically that a possibility of

total loss exists.

4.9 Independent

Investment Decision. The Investor understands that nothing in the Transaction Agreements or any other materials presented by or on

behalf of the Company to the Investor in connection with the purchase of the Securities constitutes legal, tax or investment advice.

The Investor has consulted such legal, tax and investment advisors as it, in such Investor’s sole discretion, has deemed necessary

or appropriate in connection with its purchase of the Securities. In connection with the offer and sale of Securities, none of the Placement

Agents has acted as the Investor’s financial advisor or fiduciary. The Investor understands that the Placement Agents and their

respective directors, officers, employees, representatives and controlling person have made no independent investigation with respect

to the Company or the Securities or the accuracy, completeness or adequacy of any information supplied to the Investors by the Company.

4.10 Securities

Not Registered; Legends. The Investor acknowledges and agrees that the Preferred Shares are being offered in a transaction not involving

any public offering within the meaning of the Securities Act, and the Investor understands that the Securities have not been registered

under the Securities Act, by reason of their issuance by the Company in a transaction exempt from the registration requirements of the

Securities Act, and that the Securities must continue to be held and may not be offered, resold, transferred, pledged or otherwise disposed

of by the Investor unless a subsequent disposition thereof is registered under the Securities Act or is exempt from such registration

and in each case in accordance with any applicable securities laws of any state of the United States. The Investor understands that the

exemptions from registration afforded by Rule 144 (the provisions of which are known to it) promulgated under the Securities Act depend

on the satisfaction of various conditions including, but not limited to, the time and manner of sale, the holding period and on requirements

relating to the Company which are outside of the Investor’s control and which the Company may not be able to satisfy, and that,

if applicable, Rule 144 may afford the basis for sales only in limited amounts. The Investor acknowledges and agrees that it has been

advised to consult legal counsel prior to making any offer, resale, transfer, pledge or disposition of any of the Securities. The Investor

acknowledges that no federal or state agency has passed upon or endorsed the merits of the offering of the Preferred Shares or made any

findings or determination as to the fairness of this investment.

The

Investor understands that any certificates or book entry notations evidencing the Securities may bear one or more legends in substantially

the following form and substance:

“THE

SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”),

OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED

OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT, (II) SUCH SECURITIES MAY BE SOLD

PURSUANT TO RULE 144, (III) THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO IT THAT SUCH TRANSFER MAY BE LAWFULLY

MADE WITHOUT REGISTRATION, OR (IV) THE SECURITIES ARE TRANSFERRED WITHOUT CONSIDERATION TO AN AFFILIATE OF SUCH HOLDER OR A CUSTODIAL

NOMINEE (WHICH FOR THE AVOIDANCE OF DOUBT SHALL REQUIRE NEITHER CONSENT NOR THE DELIVERY OF AN OPINION).”

addition, the Securities may contain a legend regarding affiliate status of the Investor, if applicable.

4.11 No

General Solicitation. The Investor acknowledges and agrees that the Investor is purchasing the Preferred Shares directly from the

Company. Investor became aware of this offering of the Securities solely by means of direct contact from the Placement Agents or directly

from the Company as a result of a pre-existing, substantive relationship with the Company or the Placement Agents, and/or their respective

advisors (including, without limitation, attorneys, accountants, bankers, consultants and financial advisors), agents, control persons,

representatives, Affiliates, directors, officers, managers, members, and/or employees, and/or the representatives of such persons. The

Preferred Shares were offered to Investor solely by direct contact between Investor and the Company, the Placement Agents and/or their

respective representatives. Investor did not become aware of this offering of the Preferred Shares, nor were the Preferred Shares offered

to Investor, by any other means, and none of the Company, the Placement Agents and/or their respective representatives acted as investment

advisor, broker or dealer to Investor. The Investor is not purchasing the Preferred Shares as a result of any general or public solicitation

or general advertising, or publicly disseminated advertisement, article, notice or other communication regarding the Preferred Shares

published in any newspaper, magazine or similar media or broadcast over television, radio or the internet or presented at any seminar

or any other general solicitation or general advertisement.

4.12 Access

to Information. In making its decision to purchase the Preferred Shares, such Investor has relied solely upon independent investigation

made by such Investor, upon the SEC Reports and upon the representations, warranties and covenants set forth herein. Such Investor acknowledges

and agrees that such Investor and the Investor’s professional advisor(s), if any, have had the opportunity to ask such questions,

receive such answers and obtain such information from the Company regarding the Company, its business and the terms and conditions of

the offering of the Preferred Shares as the Investor and the Investor’s professional advisor(s), if any, have deemed necessary

to make an investment decision with respect to the Securities and that the Investor has independently made its own analysis and decision

to invest in the Company. Neither such inquiries nor any other due diligence investigation conducted by the Investor shall modify, limit

or otherwise affect the Investor’s right to rely on the Company’s representations and warranties contained in this Agreement.

4.13 Certain

Trading Activities. Other than consummating the transaction contemplated hereby, the Investor has not, nor has any Person acting

on behalf of or pursuant to any understanding with the Investor, directly or indirectly executed any purchases or sales, including Short

Sales, of the securities of the Company during the period commencing as of the time that the Investor was first contacted by the Company

or any other Person regarding the transaction contemplated hereby and ending immediately prior to the date of this Agreement. Notwithstanding

the foregoing, in the case of an Investor that is a multi-managed investment vehicle whereby separate portfolio managers manage separate

portions of such Investor’s assets and the portfolio managers have no direct knowledge of the investment decisions made by the

portfolio managers managing other portions of such Investor’s assets, the representation set forth above shall only apply with

respect to the portion of the assets managed by the portfolio manager that made the investment decision to purchase the Securities covered

by this Agreement. Furthermore, in the case of an Investor whose investment advisor utilized an information barrier with respect to the

information regarding the transactions contemplated hereunder after first being contacted by the Company or its representatives, the

representation set forth above shall only apply after the point in time when the portfolio manager who manages such Investor’s

assets was informed of the information regarding the transactions contemplated hereunder and, with respect to the Investor’s investment

advisor, the representation set forth above shall only apply with respect to any purchases or sales, including Short Sales, of the securities

of the Company on behalf of other funds or investment vehicles for which the Investor’s investment advisor is also an investment

advisor or sub-advisor after the point in time when the portfolio manager who manages the assets of such other funds or investment vehicles

for which the Investor’s investment advisor is also an investment advisor or sub-advisor was informed of the information regarding

the transactions contemplated hereunder. Other than to other Persons party to this Agreement and to its advisors and agents who had a

need to know such information, the Investor has maintained the confidentiality of all disclosures made to it in connection with this

transaction (including the existence and terms of this transaction). Notwithstanding the foregoing, for avoidance of doubt, nothing contained

herein shall constitute a representation or warranty, or preclude any actions, with respect to the identification of the availability

of, or securing of, available shares to borrow in order to effect Short Sales or similar transactions in the future.

4.14 Disqualification

Event. To the extent the Investor is one of the covered persons identified in Rule 506(d)(1), the Investor represents that no disqualifying

event described in Rule 506(d)(1)(i-viii) of the Securities Act (a “Disqualification Event”) is applicable to the

Investor or any of its Rule 506(d) Related Parties (as defined below), except, if applicable, for a Disqualification Event as to which

Rule 506(d)(2)(ii) or (iii) or (d)(3) is applicable. The Investor hereby agrees that it shall notify the Company promptly in writing

in the event a Disqualification Event becomes applicable to the Investor or any of its Rule 506(d) Related Parties, except, if applicable,

for a Disqualification Event as to which Rule 506(d)(2)(ii) or (iii) or (d)(3) is applicable. For purposes of this Section, “Rule

506(d) Related Party” means a person or entity that is a beneficial owner of the Investor’s securities for purposes of

Rule 506(d) of the Securities Act.

5. Covenants.

5.1 Further

Assurances. Each party agrees to cooperate with each other and their respective officers, employees, attorneys, accountants and other

agents, and, generally, do such other reasonable acts and things in good faith as may be necessary to effectuate the intents and purposes

of this Agreement, subject to the terms and conditions of this Agreement and compliance with applicable law, including taking reasonable

action to facilitate the filing of any document or the taking of reasonable action to assist the other parties hereto in complying with

the terms of this Agreement. The Investor acknowledges that the Company and the Placement Agents will rely on the acknowledgments, understandings,

agreements, representations and warranties contained in this Agreement. Prior to the applicable Closing, the Investor agrees to promptly

notify the Company if any of the acknowledgments, understandings, agreements, representations and warranties set forth in Section

4 are no longer accurate and the Company agrees to promptly notify each Investor and the Placement Agents if any of the acknowledgements,

understandings, agreements, representations and warranties set forth in Section 3 are no longer accurate.

5.2 Listing.

The Company shall use commercially reasonable efforts to maintain the listing and trading of its Common Stock on the Nasdaq Capital Market

and, in accordance therewith, will use reasonable efforts to comply in all material respects with the Company’s reporting, filing

and other obligations under the rules and regulations of Nasdaq Capital Market, except in the case of a sale of all or substantially

all of the assets of the Company, a merger or reorganization of the Company with one or more other entities in which the Company is not

the surviving entity or any transaction or series of related transactions as a result of which any Person (together with its Affiliates)

acquires then outstanding securities of the Company representing more than fifty percent (50%) of the voting control of the Company.

5.3 Disclosure

of Transactions.

(a) The

Company shall, by 9:00 a.m., New York City time, on the first (1st) Business Day immediately following the date of this Agreement, issue

a press release and/or file with the SEC a Current Report on Form 8-K (including, if applicable, all exhibits thereto, the “Disclosure

Document” and the actual filing of such press release and/or Current Report on Form 8-K, the “Disclosure Time”)

disclosing (i) all material terms of the transactions contemplated hereby and by the other Transaction Agreements and the

Merger Agreement, if the Disclosure Document is a Current Report on Form 8-K, as

exhibits to such Disclosure Document and (ii) all material non-public information concerning the Company, Target, the transactions contemplated

hereby or the transactions contemplated by the Merger Agreement disclosed to the Investors prior to the Disclosure Time. Following the

issuance or filing of the Disclosure Document, no Investor shall be in possession of any material non-public information concerning the

Company disclosed to the Investors by the Company or its representatives. Without limiting the terms of the Registration Rights Agreement,

from and after the issuance of the Disclosure Document, the Company shall not provide material non-public information to any Investor,

unless otherwise specifically agreed in writing by such Investor prior to any such disclosure. The Company understands and confirms that

the Investors will rely on the foregoing representation in effecting securities transactions. Notwithstanding anything in this Agreement

to the contrary, the Company shall not publicly disclose the name of any Investor or any of its Affiliates or advisors, or include the

name of any Investor or any of its Affiliates or advisors in any press release or filing with the SEC (other than any registration statement

contemplated by the Registration Rights Agreement) or any regulatory agency, without the prior written consent of the Investor, except

(i) as required by the federal securities law in connection with (A) any registration statement contemplated by the Registration Rights

Agreement and (B) the filing of final Transaction Agreements with the SEC or pursuant to other routine proceedings of regulatory authorities,

or (ii) to the extent such disclosure is required by law, at the request of the staff of the SEC or regulatory agency or under the regulations

of the Nasdaq Capital Market.

5.4 Integration.

The Company shall not, and shall use its commercially reasonable efforts to ensure that no Affiliate of the Company shall, sell, offer

for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the Securities Act) that

will be integrated with the offer or sale of the Securities in a manner that would require the registration under the Securities Act

of the sale of the Securities to the Investors, or that will be integrated with the offer or sale of the Securities for purposes of the

rules and regulations of any National Exchange such that it would require stockholder approval prior to the closing of such other transaction

unless stockholder approval is obtained before the closing of such subsequent transaction; provided, however, that this Section

5.4 shall not limit the Company’s right to issue shares of capital stock pursuant to the Merger Agreement.

5.5 Removal

of Legends.

(a) Once

a registration statement covering the resale of the Conversion Shares is declared effective, the Company shall use its reasonable best

efforts to promptly remove all restrictive legends following any sale of Conversion Shares, including the legend set forth in Section

4.10 above. Further, conditioned upon the prior completion and submission by the Investor or its broker, as applicable, of customary

certificates or representation letters, the Company shall use its reasonable best efforts to remove all restrictive legends, including

the legend set forth in Section 4.10 above, (i) following any transfer or sale of such Preferred Shares or Conversion Shares once

such Securities are eligible for transfer or sale pursuant to Rule 144 or any other applicable exemption from the registration requirements

of the Securities Act, or (ii) if such Conversion Shares are eligible for resale under Rule 144(b)(1) or any successor provision (or,

in the event that Conversion Shares are issued upon conversion after the conditions set forth in clauses (i) and (ii) above, the Conversion

Shares shall be issued without restrictive legends). Without limiting the foregoing, upon request of an Investor and upon receipt by

the Company of an opinion of counsel reasonably satisfactory to the Company to the effect that such legend is no longer required under

the Securities Act and applicable state securities laws, the Company shall promptly cause the legend to be removed from any certificate

for any Preferred Shares or Conversion Shares in accordance with the terms of this Agreement and deliver, or cause to be delivered, to

any Investor new certificate(s) representing the Preferred Shares or Conversion Shares that are free from all restrictive and other legends

or, at the request of such Investor, via DWAC transfer to such Investor’s account.  In connection with any sale, assignment,

transfer or other disposition of the Preferred Shares or Conversion Shares by an Investor pursuant to Rule 144 or pursuant to any other

exemption under the Securities Act such that the purchaser acquires freely tradable shares and upon compliance by the Investor with the

requirements of this Agreement, if requested by the Investor by notice to the Company, the Company shall request the Transfer Agent to

remove any restrictive legends related to the book entry account holding such shares and make a new, unlegended entry for such book entry

shares sold or disposed of without restrictive legends as soon as reasonably practicable following any such request therefor from the

Investor, provided that the Company has timely received from the Investor customary representations and other documentation reasonably

acceptable to the Company in connection therewith. The Company shall be responsible for the fees of its Transfer Agent and its legal

counsel associated with such legend removal.

(b) Subject

to receipt from the Investor by the Company and the Transfer Agent of customary representations and other documentation reasonably acceptable

to the Company and the Transfer Agent in connection therewith, upon the earliest of such time as the Securities (i) have been registered

and sold under the Securities Act pursuant to an effective registration statement; (ii) have been sold pursuant to Rule 144, or (iii)

are eligible for resale under Rule 144(b)(1) without the requirement for the Company to be in compliance with the current public information

requirements under Rule 144(c)(1) (or any successor provision), the Company shall, in accordance with the provisions of this Section

5.5(b) and as soon as reasonably practicable following any request therefor from an Investor accompanied by such customary and reasonably

acceptable documentation acceptable to the Company and its counsel, (A) deliver to the Transfer Agent irrevocable instructions that the

Transfer Agent shall make a new, unlegended entry for such book entry shares, and (B) cause its counsel to deliver to the Transfer Agent

one or more opinions to the effect that the removal of such legends in such circumstances may be effected under the Securities Act if

required by the Transfer Agent to effect the removal of the legend in accordance with the provisions of this Agreement.

5.6 Withholding

Taxes. Each Investor agrees to furnish the Company with any information, representations and forms as shall reasonably be requested

by the Company from time to time to assist the Company in complying with any applicable tax law (including any withholding obligations).

5.7 Fees

and Commissions. The Company shall be solely responsible for the payment of any Placement Agent fees, financial advisory fees, or

broker’s commissions (other than for Persons engaged by an Investor) relating to or arising out of the transactions contemplated

hereby, including, without limitation, any fees or commissions payable to the Placement Agents.

5.8 No

Conflicting Agreements. The Company will not take any action, enter into any agreement or make any commitment that would conflict

or interfere in any material respect with the Company’s obligations to the Investors under the Transaction Agreements.

5.9 Indemnification.

(a) The

Company agrees to indemnify and hold harmless each Investor and its Affiliates and each Person who controls such Investor (within the

meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and their respective directors, officers, trustees,

members, managers, employees, investment advisors and agents (collectively, the “Indemnified Persons”), from and against

any and all losses, claims, damages, liabilities and expenses (including without limitation reasonable and documented attorney fees and

disbursements and other documented out-of-pocket expenses reasonably incurred in connection with investigating, preparing or defending

any action, claim or proceeding, pending or threatened and the costs of enforcement thereof) to which such Person may become subject

(i) as a result of any breach of representation, warranty, covenant or agreement made by or to be performed on the part of the Company

under the Transaction Agreements, (ii) as a result of or arising out of any action, claim or proceeding, pending or threatened, against

an Indemnified Person in any capacity by any stockholder of the Company who is not an Affiliate of the Indemnified Person, whether directly

or in a derivative capacity, with respect to the transactions contemplated by the Transaction Agreements (unless such action, claim or

proceeding is based upon a breach of such Investor’s representations, warranties or covenants under the Transaction Agreements),

and in each case will reimburse any such Indemnified Person for all such amounts as they are incurred by such Indemnified Person, and

will, in each case, reimburse any such Person for all such amounts as they are incurred by such Person solely to the extent such amounts

have been finally judicially determined not to have resulted from such Person’s fraud or willful misconduct.

(b) Any

person entitled to indemnification hereunder shall (i) give prompt written notice to the indemnifying party of any claim with respect

to which it seeks indemnification and (ii) permit such indemnifying party to assume the defense of such claim with counsel reasonably

satisfactory to the indemnified party; provided that any person entitled to indemnification hereunder shall have the right to employ

separate counsel and to participate in the defense of such claim, but the fees and expenses of such counsel shall be at the expense of

such person unless (a) the indemnifying party has agreed in writing to pay such fees or expenses, (b) the indemnifying party shall have

failed to assume the defense of such claim and employ counsel reasonably satisfactory to such person or (c) in the reasonable judgment

of any such person, based upon written advice of its counsel, a conflict of interest exists between such person and the indemnifying

party with respect to such claims (in which case, if the person notifies the indemnifying party in writing that such person elects to

employ separate counsel at the expense of the indemnifying party, the indemnifying party shall not have the right to assume the defense

of such claim on behalf of such person); and provided, further, that the failure of any indemnified party to give written notice as provided

herein shall not relieve the indemnifying party of its obligations hereunder, except to the extent that such failure to give notice shall

materially adversely affect the indemnifying party in the defense of any such claim or litigation. It is understood that the indemnifying

party shall not, in connection with any proceeding in the same jurisdiction, be liable for fees or expenses of more than one separate

firm of attorneys at any time for all such indemnified parties. No indemnifying party will, except with the consent of the indemnified

party, which consent shall not be unreasonably withheld, conditioned or delayed, consent to entry of any judgment or enter into any settlement

unless such judgment or settlement (i) imposes no liability or obligation on, (ii) includes as an unconditional term thereof the giving

of a complete, explicit and unconditional release from the party bringing such indemnified claims of all liability of the indemnified

party in respect of such claim or litigation in favor of, and (iii) does not include any admission of fault, culpability, wrongdoing

or malfeasance by or on behalf of, the indemnified party. No indemnified party will, except with the consent of the indemnifying party,

which consent shall not be unreasonably withheld, conditioned or delayed, consent to entry of any judgment or enter into any settlement.

5.10 Subsequent

Equity Sales. From the date of this Agreement until the earlier of (a) sixty (60) days after the Initial Closing Date and (b) the

Business Day immediately following the effective date of the registration statement filed pursuant to the Registration Rights Agreement,

the Company shall not (A) issue shares of Common Stock or Common Stock Equivalents, or (B) file with the SEC a registration statement

under the Securities Act relating to any shares of Common Stock or Common Stock Equivalents, except pursuant to the terms of the Registration

Rights Agreement. Notwithstanding the foregoing, the provisions of this Section 5.10 shall not apply to (i) the issuance of the

Securities hereunder, (ii) the issuance of Common Stock or Common Stock Equivalents upon the conversion, exercise or vesting of any securities

of the Company outstanding on the date of this Agreement or outstanding pursuant to clause (iii) below, (iii) the issuance of any Common

Stock or Common Stock Equivalents pursuant to any Company stock-based compensation plans or in accordance with Nasdaq Stock Market Rule

5635(c)(4), (iv) the issuance and sale of shares of Common Stock or Common Stock Equivalents pursuant to an at-the-market offering program

pursuant to Rule 415(a)(4) under the Securities Act, (v) the filing of a registration statement on Form S-8 under the Securities Act

to register the offer and sale of securities on an equity incentive plan or employee stock purchase plan, (vi) securities issued pursuant

to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that such securities

are issued as “restricted securities” (as defined in Rule 144) and carry no registration rights that require or permit the

filing of any registration statement in connection therewith during the prohibition period in this Section 5.10, and provided

that any such issuance shall only be to a Person (or to the equityholders of a Person) which is, itself or through its subsidiaries,

an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company

additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities

primarily for the purpose of raising capital or to an entity whose primary business is investing in securities, or (vii) issued pursuant

to the Merger Agreement.

5.11 Reservation

of Common Stock. As of the date of this Agreement, the Company has reserved and the Company shall continue to reserve and keep available

at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue

the Conversion Shares issuable to the Investors.

5.12 No

Amendment or Waiver of Merger Agreement Terms. The Company shall not, and shall not permit any of its subsidiaries to, amend, modify,

supplement, terminate or waive (or fail to contest an action regarding a breach of or agree to amend, modify, supplement, terminate or

waive) any provision of the Merger Agreement or any other Transaction Agreement in a manner that would reasonably be expected to materially

and adversely affect the benefits that an Investor would reasonably expect to receive pursuant to this Agreement without the prior written

consent of the Investors representing a majority in interest of the Securities then held by the Investors, it being agreed that any amendment

or modification to the definition of “Exchange Ratio” shall be deemed to materially and adversely affect the benefits that

the Investors would reasonably expect to receive under this Agreement.

5.13 Stockholder

Approval. The Company shall use its reasonable efforts to obtain the Required Parent Stockholder Vote (as defined in the Merger Agreement)

to approve the Parent Stockholder Matters (as defined in the Merger Agreement), including without limitation the issuance of the Conversion

Shares for purposes of the listing rules of Nasdaq Capital Market at the Parent Stockholders’ Meeting (as defined in the Merger

Agreement), which shall be held as promptly as practicable after the filing of the Proxy Statement (as defined in the Merger Agreement)

in accordance with the terms and conditions of the Merger Agreement. The Company shall use its reasonable efforts to solicit its stockholders’

approval of such resolution and shall cause the Board of Directors to recommend to the stockholders that they approve such resolution.

If the Required Parent Stockholder Vote is not obtained, the Company shall use its reasonable efforts to obtain such approvals as soon

as reasonably practicable thereafter, including to (i) obtain such approvals at the next occurring annual meeting of the stockholders

of the Company or, if such annual meeting is not scheduled to be held within six months, a special meeting of the stockholders of the

Company to be held within six months, and (ii) hold an annual meeting or special meeting of its stockholders, at which a vote of the

stockholders of the Company to approve the Parent Stockholder Matters (as defined in the Merger Agreement) will be solicited and taken,

at least once every six months until the Company obtains approval of the Parent Stockholder Matters, in each case, in accordance with

Section 4.2 of the Merger Agreement.

5.14 Lock-Up

Agreements. The Company shall not consent or agree to amend, alter, waive or otherwise modify the terms of any of the Lock-Up Agreements

(as defined in the Merger Agreement) without the written consent of each of Cantor Fitzgerald & Co. and UBS Securities LLC.

5.15 Equal

Treatment of Investors. No consideration shall be offered or paid to any Investor to amend or consent to a waiver or modification

of any provision of this Agreement unless the same consideration is also offered to all of the Investors. The Company further confirms

that there are no side letters or other agreements giving any Investor any additional rights or benefits other than as set forth in the

Transaction Agreements (other than confidentiality, nondisclosure, or similar agreements). The Company shall not be entitled to redeem

or repurchase any of the Securities unless such redemption or repurchase is on a pro-rata basis amongst the Investors. For clarification

purposes, this provision constitutes a separate right granted to each Investor by the Company and negotiated separately by each Investor

and shall not in any way be construed as the Investors acting in concert or as a group with respect to the purchase, disposition or voting

of shares of Common Stock or otherwise.

6. Conditions

of Closing.

6.1 Conditions

to the Obligation of the Investors. The several obligations of each Investor to consummate the transactions to be consummated at

the applicable Closing, and to purchase and pay for the Securities being purchased by it at the applicable Closing pursuant to this Agreement,

are subject to the satisfaction or waiver in writing of the following conditions precedent:

(a) Representations

and Warranties. The representations and warranties of the Company contained herein shall be true and correct in all material respects,

except for those representation and warranties qualified by materiality or Material Adverse Effect, which shall be true and correct in

all respects, as of the date of this Agreement and as of the applicable Closing Date, as though made on and as of such date, except to

the extent any such representation or warranty expressly speaks as of an earlier date, in which case such representation or warranty

shall be true and correct in all material respects as of such earlier date, except for those representations and warranties qualified

by materiality or Material Adverse Effect, which shall be true and correct in all respects as of such earlier date.

(b) Performance.

The Company shall have performed in all material respects the obligations and conditions herein required to be performed or observed

by the Company on or prior to the applicable Closing Date.

Injunction. The purchase of and payment for the Securities by each Investor shall not be prohibited or enjoined by any law or governmental

or court order or regulation and no such prohibition shall have been threatened in writing.

(d) Consents.

The Company shall have obtained any and all consents, permits, approvals, registrations and waivers necessary for the consummation of

the purchase and sale of the Securities (except for the Required Parent Stockholder Vote and approvals required by the Nasdaq Capital

Market for the issuance of the Conversion Shares), all of which shall be in full force and effect.

(e) Transfer

Agent. The Company shall have furnished all required materials to the Transfer Agent to reflect the issuance of the Preferred Shares

at the applicable Closing.

(f) Adverse

Changes. Since the date of this Agreement, no event or series of events shall have occurred that has had or would reasonably be expected

to have a Material Adverse Effect.

(g) Opinion

of Company Counsel. The Company shall have delivered to the Investors and the Placement Agents the opinion of Troutman Pepper Locke

LLP, dated as of the Initial Closing Date, in customary form and substance to be reasonably agreed upon with the Investors and addressing

such legal matters as the Investors and the Company reasonably agree.

(h) Compliance

Certificate. An authorized officer of the Company shall have delivered to the Investors at the applicable Closing Date a certificate

certifying that the conditions specified in Sections 6.1(a) (Representations and Warranties), 6.1(b) (Performance), 6.1(c)

(No Injunction), 6.1(d) (Consents), 6.1(e) (Transfer Agent), 6.1(f) (Adverse Changes), 6.1(k) (Listing Requirements),

6.1(l) (No Injunction), and solely with respect to the Milestone Closing 6.1(q) (Achievement of Milestone) have been fulfilled.

(i) Secretary’s

Certificate. The Secretary of the Company shall have delivered to the Investors at the applicable Closing Date a certificate certifying

(i) the Certificate of Incorporation; (ii) the Amended and Restated Bylaws; and (iii) resolutions of the Company’s Board of Directors

(or an authorized committee thereof) approving this Agreement, the other Transaction Agreements, the transactions contemplated by this

Agreement and the issuance of the Securities.

(j) Registration

Rights Agreement. The Company shall have executed and delivered the Registration Rights Agreement to the Investors.

(k) Listing

Requirements. No stop order or suspension of trading shall have been imposed by Nasdaq Capital Market, the SEC or any other governmental

or regulatory body with respect to public trading in the Common Stock. The Company shall have filed

with Nasdaq Capital Market a Listing of Additional Shares Notification Form for the listing of the Conversion Shares that do not require

stockholder approval and are issuable prior to the Company’s receipt of the Required Parent Stockholder Vote and shall not have

received any objections to the transactions contemplated in this Agreement, the other Transaction Agreements or the Merger Agreement.

(l) No

Injunction. No judgment, writ, order, injunction, award or decree of or by any court, or judge, justice or magistrate, including

any bankruptcy court or judge, or any order of or by any governmental entity, shall have been issued, and no action or proceeding shall

have been instituted by any governmental entity, enjoining or preventing the consummation of the transactions contemplated hereby or

in the other Transaction Agreements.

(m) Minimum

Financing Amount. The Company shall receive at Initial Closing aggregate proceeds from the purchase of Securities pursuant to this

Agreement of not less than $15,000,000, together with approximately $15,000,000 of Target’s cash and cash equivalents comprised

primarily of proceeds from a convertible note financing completed with certain accredited investors prior to the Merger.

(n) Merger.

The closing of the Merger shall have occurred in accordance with the terms of the Merger Agreement.

(o) Certificate

of Designation. The Company shall have received a certified copy of the Certificate of Designation, as filed with the Secretary of

State of the State of Delaware.

(p) Lock-Up

Agreements. The officers and directors of the Company who are continuing in such roles following the Closing Date shall have executed

the Lock-Up Agreements.

(q) Achievement

of Milestone. Solely with respect to the Milestone Closing, the Milestone Phase 2 Clinical Achievement Event shall have occurred.

6.2 Conditions

to the Obligation of the Company. The obligation of the Company to consummate the transactions to be consummated at the applicable

Closing, and to issue and sell to each Investor the Preferred Shares to be purchased by it at the applicable Closing pursuant to this

Agreement, is subject to the satisfaction or waiver in writing of the following conditions precedent:

(a) Representations

and Warranties. The representations and warranties of each Investor in Section 4 hereto shall be true and correct on and as

of the applicable Closing Date, with the same force and effect as though made on and as of the applicable Closing Date and consummation

of the applicable Closing shall constitute a reaffirmation by the Investor of each of the representations, warranties, covenants and

agreements of the Investor contained in this Agreement as of the applicable Closing Date.

(b) Performance.

Each Investor shall have performed or complied with in all material respects all obligations and conditions herein required to be performed

or observed by such Investor on or prior to the applicable Closing Date.

The purchase of and payment for the Securities by each Investor shall not be prohibited or enjoined by any law or governmental or court

order or regulation.

(d) Registration

Rights Agreement. Each Investor shall have executed and delivered the Registration Rights Agreement to the Company in the form attached

as Exhibit C.

(e) Payment.

Except as may be agreed to among the Company and each Investor in accordance with Section 2.2, the Company shall have received

payment, by wire transfer of immediately available funds, in the full amount of the purchase price for the number of Preferred Shares

being purchased by each Investor at the applicable Closing as set forth in Exhibit A.

7. Termination.

7.1 Termination.

The obligations of the Company, on the one hand, and the Investors, on the other hand, to effect the applicable Closing shall terminate

as follows:

(i) Upon

the mutual written consent of the Company and the Investors that agreed to purchase a majority of the Securities in such Closing prior

to the applicable Closing;

(ii) By

the Company if any of the conditions set forth in Section 6.2 shall have become incapable of fulfillment, and shall not have been

waived by the Company;

(iii) By

an Investor (with respect to itself only) if any of the conditions set forth in Section 6.1 shall have become incapable of fulfillment,

and shall not have been waived by such Investor; or

(iv) By

either the Company or an Investor (with respect to itself only) if the applicable Closing has not occurred on or prior to the fifth (5th)

Business Day following the date of this Agreement;

provided,

however, that, in the case of clauses (ii) and (iii) above, the party seeking to terminate its obligation to effect the applicable Closing

shall not then be in breach of any of its representations, warranties, covenants or agreements contained in the Transaction Agreements

if such breach has resulted in the circumstances giving rise to such party’s seeking to terminate its obligation to effect the

applicable Closing.

7.2 Notice.

In the event of termination by the Company or the Investor of its obligations to effect the applicable Closing pursuant to Section

7.1(i), written notice thereof shall be given to the other Investors by the Company. Nothing in this Section 7 shall be deemed

to release any party from any liability for any breach by such party of the other terms and provisions of the Transaction Agreements

or to impair the right of any party to compel specific performance by any other party of its other obligations under the Transaction

Agreements.

8. Miscellaneous

Provisions.

8.1 Public

Statements or Releases. Except as set forth in Section 5.3, neither the Company nor any Investor shall make any public announcement

with respect to the existence or terms of this Agreement or the transactions provided for herein without the prior consent of the other

party (which consent shall not be unreasonably withheld) other than filings pursuant to Section 13 and/or Section 16 of the Exchange

Act or as otherwise required by law, rule or regulation, which, for avoidance of doubt, shall not require the Company’s consent.

Notwithstanding the foregoing, and subject to compliance with Section 5.3, nothing in this Section 8.1 shall prevent any

party from making any public announcement it considers necessary in order to satisfy its obligations under the law, including applicable

securities laws, or under the rules of any national securities exchange or securities market, in which case the Company shall, to the

extent reasonably practicable, allow the Investors reasonable time to comment on such release or announcement in advance of such issuance,

and the Company will consider in good faith any Investor comments. The Company shall not include the name of the Investor in any press

release or public announcement (which, for the avoidance of doubt, shall not include any filing with the SEC if so required by the applicable

rules of the SEC) without the prior written consent of such Investor, except as otherwise required by law or the applicable rules or

regulations of any securities exchange or securities market, in which case the Company shall allow the Investors, to the extent reasonably

practicable in the circumstances, reasonable time to comment on such release or announcement in advance of such issuance. Notwithstanding

anything to the contrary in this Section 8.1, Investor review shall not be required for Company disclosures that are substantially

consistent with prior Company disclosures.

8.2 Notices.

Any notices or other communications required or permitted to be given hereunder shall be in writing and shall be deemed to be given (a)

when delivered if personally delivered to the party for whom it is intended, (b) when delivered, if sent by electronic mail during normal

business hours of the recipient, and if not sent during normal business hours, then on the recipient’s next Business Day, (c) three

(3) calendar days after having been sent by certified or registered mail, return-receipt requested and postage prepaid, or (d) one (1)

Business Day after deposit with a nationally recognized overnight courier, freight prepaid, specifying next Business Day delivery, with

written verification of receipt:

(a) If

to the Company, addressed as follows:

Ensysce

Biosciences, Inc.

7946

Ivanhoe Avenue, Suite 201

Jolla, CA 92037

Attention:

Dr. Lynn Kirkpatrick

Email:

with

a copy (which shall not constitute notice):

Troutman

Pepper Locke LLP

Union

Trust Building

501

Grant Street, Suite 300

Pittsburgh,

PA 15219

Attention:

Eric D. Kline

Email:

(b) If

to any Investor, at its address or e-mail address set forth on Exhibit A, or such address as subsequently modified by written

notice given in accordance with this Section 8.2.

Any

Person may change the address to which notices and communications to it are to be addressed by notification as provided for herein.

8.3 Consent

to Electronic Notice. Each Investor consents to the delivery of any stockholder notice pursuant to Section 232 of the Delaware General

Corporation Law, as amended or superseded from time to time (the “DGCL”), at the e-mail address set forth below the

Investor’s name on the signature page or Exhibit A, as updated from time to time by notice to the Company. To the extent

that any notice given by means of electronic mail is returned or undeliverable for any reason, the foregoing consent shall be deemed

to have been revoked until a new or corrected e-mail address has been provided, and such attempted electronic notice shall be ineffective

and deemed to not have been given. Each party agrees to promptly notify the other parties of any change in its e-mail address, and that

failure to do so shall not affect the foregoing.

8.4 Severability.

If any part or provision of this Agreement is held unenforceable or in conflict with the applicable laws or regulations of any jurisdiction,

the invalid or unenforceable part or provisions shall be replaced with a provision which accomplishes, to the extent possible, the original

business purpose of such part or provision in a valid and enforceable manner, and the remainder of this Agreement shall remain binding

upon the parties hereto.

8.5 Governing

Law; Submission to Jurisdiction; Venue; Waiver of Trial by Jury.

(a) This

Agreement shall be governed by, and construed in accordance with, the laws of the State of New York without regard to choice of laws

or conflicts of laws provisions thereof that would require the application of the laws of any other jurisdiction, except to the extent

that mandatory principles of Delaware law may apply.

(b) The

Company and each of the Investors hereby irrevocably and unconditionally:

(i) submits

for itself and its property in any legal action or proceeding relating solely to this Agreement or the transactions contemplated hereby,

to the general jurisdiction of any state court or United States Federal court sitting in the Borough of Manhattan, City of New York in

the State of New York;

(ii) consents

that any such action or proceeding may be brought in such courts, and waives any objection that it may now or hereafter have to the venue

of any such action or proceeding in any such court or that such action or proceeding was brought in an inconvenient court and agrees

not to plead or claim the same to the extent permitted by applicable law;

(iii) agrees

that service of process in any such action or proceeding may be effected by mailing a copy thereof by registered or certified mail (or

any substantially similar form of mail), postage prepaid, to the party, as the case may be, at its address set forth in Section 8.2

or at such other address of which the other party shall have been notified pursuant thereto;

(iv) agrees

that nothing herein shall affect the right to effect service of process in any other manner permitted by law or shall limit the right

to sue in any other jurisdiction for recognition and enforcement of any judgment or if jurisdiction in the courts referenced in the foregoing

clause (i) are not available despite the intentions of the parties hereto;

(v) agrees

that final judgment in any such suit, action or proceeding brought in such a court may be enforced in the courts of any jurisdiction

to which such party is subject by a suit upon such judgment, provided that service of process is effected upon such party in the manner

specified herein or as otherwise permitted by law;

(vi) agrees

that to the extent that such party has or hereafter may acquire any immunity from jurisdiction of any court or from any legal process

with respect to itself or its property, such party hereby irrevocably waives such immunity in respect of its obligations under this Agreement,

to the extent permitted by law; and

(vii) irrevocably

and unconditionally waives trial by jury in any legal action or proceeding in relation to this Agreement.

8.6 Waiver.

No waiver of any term, provision or condition of this Agreement, whether by conduct or otherwise, in any one or more instances, shall

be deemed to be, or be construed as, a further or continuing waiver of any such term, provision or condition or as a waiver of any other

term, provision or condition of this Agreement.

8.7 Expenses.

Except as expressly set forth in the Transaction Agreements to the contrary, each party shall pay its own out-of-pocket fees and expenses,

including the fees and expenses of attorneys, accountants and consultants employed by such party, incurred in connection with the proposed

investment in the Securities and the consummation of the transactions contemplated thereby; provided, however, that the Company shall

pay all Transfer Agent fees (including, without limitation, any fees required for same-day processing of any instruction letter delivered

by the Company), stamp taxes and other taxes (other than income taxes) and duties levied in connection with the delivery of any Securities

to the Investors. The Company shall pay all Placement Agent expenses up to $240,000 relating to or arising out of the transactions contemplated

by this Agreement.

8.8 Assignment.

None of the parties may assign its rights or obligations under this Agreement or designate another person (i) to perform all or part

of its obligations under this Agreement or (ii) to have all or part of its rights and benefits under this Agreement, in each case without

the prior written consent of (x) the Company, in the case of an Investor, and (y) the Investors, in the case of the Company, provided

that an Investor may, without the prior consent of the Company, assign its rights to purchase the Securities hereunder to any of its

Affiliates or to any other investment funds or accounts managed or advised by the investment manager who acts on behalf of such Investor

(provided each such assignee agrees to be bound by the terms of this Agreement and makes the same representations and warranties set

forth in Section 4). In the event of any assignment in accordance with the terms of this Agreement, the assignee shall specifically

assume and be bound by the provisions of this Agreement by executing a writing agreeing to be bound by and subject to the provisions

of this Agreement and shall deliver an executed counterpart signature page to this Agreement and, notwithstanding such assumption or

agreement to be bound hereby by an assignee, no such assignment shall relieve any party assigning any interest hereunder from its obligations

or liability pursuant to this Agreement.

8.9 Confidential

Information.

(a) Each

Investor covenants that until such time as the transactions contemplated by this Agreement and any material non-public information provided

to such Investor are publicly disclosed by the Company, such Investor will maintain the confidentiality of all disclosures made to it

in connection with this transaction (including the existence and terms of this transaction), other than to such Investor’s outside

attorney, accountant, auditor or investment advisor only to the extent necessary to permit evaluation of the investment, and the performance

of the necessary or required tax, accounting, financial, legal, or administrative tasks and services and other than as may be required

by law.

(b) The

Company may request from the Investors such reasonable and customary additional information as the Company may deem necessary to evaluate

the eligibility of the Investor to acquire the Securities, and the Investor shall promptly provide such information as may reasonably

be requested to the extent readily available; provided, that the Company agrees to keep any such information provided by the Investor

confidential, except (i) as required by the federal securities laws, rules or regulations and (ii) to the extent such disclosure is required

by other laws, rules or regulations, at the request of the staff of the SEC or regulatory agency or under the regulations of Nasdaq Capital

Market. The Investor acknowledges that the Company may file a copy of this Agreement and the Registration Rights Agreement with the SEC

as exhibit to a periodic report or a registration statement of the Company.

8.10 Reliance

by and Exculpation of Placement Agents.

(a) Each

Investor agrees for the express benefit of each Placement Agent, its affiliates and its representatives that (i) it is not relying upon,

and has not relied upon, any statement, representation or warranty made by either Placement Agent, any of its affiliates or any of its

or its representatives, in making its investment or decision to invest in the Company, (ii) each Placement Agent is acting solely as

placement agent in connection with the transactions contemplated hereby and is not acting as an underwriter, initial purchaser, dealer

or in any other such capacity and is not and shall not be construed as a fiduciary for such Investor, (iii) each Placement Agent, its

affiliates and representatives have not made, and will not make, any representations or warranties with respect to the Company or the

offer and sale of the Securities or any other matter concerning the Company or the transactions contemplated hereby, and the Investor

will not rely on any statements made by either Placement Agent, orally or in writing, to the contrary, (iv) the Investor will be responsible

for conducting its own due diligence investigation with respect to the Company and the offer and sale of the Securities, (v) the Investor

will be purchasing Securities based on the results of its own due diligence investigation of the Company and the Placement Agents and

each of its directors, officers, employees, representatives, and controlling persons have made no independent investigation with respect

to the Company, the Securities, or the accuracy, completeness, or adequacy of any information supplied to the Investor by the Company,

(vi) the Investor has negotiated the offer and sale of the Securities directly with the Company, and the Placement Agents will not be

responsible for the ultimate success of any such investment and (vii) the decision to invest in the Company will involve a significant

degree of risk, including a risk of total loss of such investment. Each Investor further represents and warrants to the Placement Agents

that it, including any fund or funds that it manages or advises that participates in the offer and sale of the Securities, is permitted

under its constitutive documents (including, without limitation, all limited partnership agreements, charters, bylaws, limited liability

company agreements, all applicable side letters with investors, and similar documents) to make investments of the type contemplated by

this Agreement. This Section 8.10 shall survive any termination of this Agreement.

(b) The

Company agrees and acknowledges that each Placement Agent may rely on its representations, warranties, agreements and covenants contained

in this Agreement and each Investor agrees that each Placement Agent may rely on such Investor’s representations and warranties

contained in this Agreement as if such representations and warranties, as applicable, were made directly to the Placement Agent.

the Placement Agents nor any of their respective Affiliates or representatives (1) shall be liable for any improper payment made in accordance

with the information provided by the Company; (2) makes any representation or warranty, or has any responsibilities as to the validity,

enforceability, accuracy, value or genuineness of any information, certificates or documentation delivered by or on behalf of the Company

pursuant to the Transaction Agreements or in connection with any of the transactions contemplated therein; or (3) shall be liable (x)

for any action taken, suffered or omitted by any of them in good faith and reasonably believed to be authorized or within the discretion

or rights or powers conferred upon it by the Transaction Agreements or (y) for anything which any of them may do or refrain from doing

in connection with the Transaction Agreements, except in each case for such party’s own gross negligence or willful misconduct.

(d) The

Company agrees that each Placement Agent, its affiliates and representatives shall be entitled to (1) rely on, and shall be protected

in acting upon, any certificate, instrument, notice, letter or any other document or security delivered to any of them by or on behalf

of the Company, and (2) be indemnified by the Company for acting as a Placement Agent hereunder pursuant to the indemnification provisions

set forth in the applicable letter agreement between the Company and the Placement Agents.

8.11 Third

Parties. Nothing in this Agreement, express or implied, is intended to confer on any Person other than the parties to this Agreement

any rights, remedies, claims, benefits, obligations or liabilities under or by reason of this Agreement, and no Person that is not a

party to this Agreement (including, without limitation, any partner, member, shareholder, director, officer, employee or other beneficial

owner of any party to this Agreement, in its own capacity as such or in bringing a derivative action on behalf of a party to this Agreement)

shall have any standing as a third party beneficiary with respect to this Agreement or the transactions contemplated hereby. Notwithstanding

the foregoing, (i) each Placement Agent is an intended third-party beneficiary of the representations and warranties of the Company and

of each Investor set forth in Section 3, Section 4 and Section 6.1(h) and Section 8.10 respectively, of this

Agreement and (ii) the Indemnified Persons are intended third-party beneficiaries of Section 5.9.

8.12 Independent

Nature of Investors’ Obligations and Right. The obligations of each Investor under this Agreement are several and not joint

with the obligations of any other Investor, and no Investor shall be responsible in any way for the performance obligations of any other

Investor under this Agreement. Nothing contained herein, and no action taken by any Investor pursuant hereto, shall be deemed to constitute

the Investors as, and the Company acknowledges that the Investors do not so constitute, a partnership, an association, a joint venture

or any other kind of entity, or create a presumption that the Investors are in any way acting in concert or as a group, and the Company

will not assert any such claim with respect to such obligations or the transactions contemplated by this Agreement and the Company acknowledges

that the Investors are not acting in concert or as a group with respect to such obligations or the transactions contemplated by this

Agreement. It is expressly understood that each provision contained in this Agreement is between the Company and an Investor, solely,

and not between the Company and the Investors collectively and not between and among the Investors. The Company acknowledges and each

Investor confirms that it has independently participated in the negotiation of the transaction contemplated hereby with the advice of

its own counsel and advisors. Each Investor also acknowledges that Troutman Pepper Locke LLP has not rendered legal advice to such Investor.

Each Investor shall be entitled to independently protect and enforce its rights, including, without limitation, the rights arising out

of this Agreement, and it shall not be necessary for any other Investor to be joined as an additional party in any proceeding for such

purpose. The Company has elected to provide all Investors with the same terms and Transaction Agreements for the convenience of the Company

and not because it was required or requested to do so by any Investor.

8.13 Headings.

The titles, subtitles and headings in this Agreement are for convenience of reference and shall not form part of, or affect the interpretation

of, this Agreement.

8.14 Counterparts.

This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and

shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile or

pdf signature including any electronic signatures complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com shall be

considered due execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original,

not a facsimile or pdf (or other electronic reproduction of a) signature.

8.15 Entire

Agreement; Amendments. This Agreement and the other Transaction Agreements (including all schedules and exhibits hereto and thereto),

together with any side letter agreements with any of the Investors, constitute the entire agreement between the parties hereto respecting

the subject matter of this Agreement and supersedes all prior agreements, negotiations, understandings, representations and statements

respecting the subject matter of this Agreement, whether written or oral. No amendment, modification, alteration, or change in any of

the terms of this Agreement shall be valid or binding upon the parties hereto unless made in writing and duly executed by the Company

and the Investors of at least a majority in interest of the Securities then held by the Investors, provided that prior to the Milestone

Closing the consent of all Investors shall be required. Notwithstanding the foregoing, (i) this Agreement may not be amended and the

observance of any term of this Agreement may not be waived with respect to any Investor without the written consent of such Investor

unless such amendment or waiver applies to all Investors in the same fashion and (ii) any amendment to Section 2.1, Section

2.2, Section 5.5, Section 5.9, Section 6.1, Section 7.1 or this Section 8.15 shall require the

consent of each Investor. The Company, on the one hand, and each Investor, on the other hand, may by an instrument signed in writing

by such parties waive the performance, compliance or satisfaction by such Investor or the Company, respectively, with any term or provision

of this Agreement or any condition hereto to be performed, complied with or satisfied by such Investor or the Company, respectively.

Notwithstanding the foregoing or anything else herein to the contrary, no amendment, modification, alteration, change or waiver of this

Section 8.15 shall be valid without the prior written consent of the Placement Agents, which consent may be granted or withheld

in the sole discretion of the Placement Agents.

8.16 Survival.

The covenants, representations and warranties made by each party hereto contained in this Agreement shall survive the Closing and the

delivery of the Securities in accordance with their respective terms. Each Investor shall be responsible only for its own representations,

warranties, agreements and covenants hereunder.

8.17 Contract

Interpretation. This Agreement is the joint product of each Investor and the Company and each provision of this Agreement has been

subject to the mutual consultation, negotiation and agreement of such parties and shall not be construed for or against any party hereto.

8.18 Arm’s

Length Negotiations. For the avoidance of doubt, the parties acknowledge and confirm that the terms and conditions of the Securities

were determined as a result of arm’s-length negotiations.

8.19 Interpretation.

Unless the context otherwise requires, references in this Agreement to “Section” or “Sections” shall refer to

a Section or Sections of this Agreement.

[Remainder

of Page Intentionally Left Blank.]

WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above written.

COMPANY:

Ensysce Biosciences, INC.

By:

Name:

Dr. Lynn Kirkpatrick

Title:

President and Chief Executive Officer

[Signature

Page to Securities Purchase Agreement]

WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above written.

INVESTOR:

[NAME]

By:

Name:

Title:

Address:

[●]

Email:

[●]

[Signature

Page to Securities Purchase Agreement]

Exhibit

INVESTORS

Initial

Closing

Investor Name Preferred

Initial

Share Price

Conversion Shares

Underlying

Preferred Shares

Aggregate

Initial

Purchase Price

Milestone

Closing

Investor Name Preferred

Milestone

Share Price

Conversion Shares Underlying Preferred Shares

Aggregate Milestone

Purchase Price

Exhibit

FORM

OF CERTIFICATE OF DESIGNATION

Exhibit

FORM

OF REGISTRATION RIGHTS AGREEMENT

EX-10.2

Filename: ex10-2.htm · Sequence: 6

Exhibit 10.2

FORM

OF REGISTRATION RIGHTS AGREEMENT

THIS

REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of August 5, 2026, is entered into by and among Ensysce

Biosciences, Inc., a Delaware corporation (the “Company”), and the several investors signatory hereto (individually

as an “Investor” and collectively together with their respective permitted assigns, the “Investors”).

Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Purchase Agreement

(as defined below).

WHEREAS:

Upon the terms and subject to the conditions set forth in that Securities Purchase Agreement, dated as of the date hereof, by and

among the Company and the parties hereto (as amended, restated, supplemented or otherwise modified from time to time, the

“Purchase Agreement”), the Company has agreed to issue to the Investors that are party to the Purchase Agreement,

and such Investors have agreed to purchase, severally and not jointly, an aggregate of 120,260 shares of the Company’s Series

C Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the “Preferred Shares”), pursuant to the

Purchase Agreement;

B. Upon

the terms and subject to the conditions set forth in that Agreement and Plan of Merger, dated as of the date hereof, by and among the

Company, Cy Biopharma, Inc., a Delaware corporation (“Cy Biopharma”), and certain other parties thereto (as amended,

restated, supplemented or otherwise modified from time to time, the “Merger Agreement”), as consideration for the

transactions contemplated by the Merger Agreement (collectively, the “Merger”), the Company has agreed to issue Preferred

Shares to the equityholders of Cy Biopharma;

C. Pursuant

to the terms and conditions of the Certificate of Designation of the Series C Non-Voting Convertible Preferred Stock, dated as of August

5, 2026 (the “Certificate of Designation”), subject to the limitations set forth therein, including without limitation

receipt of the Required Parent Stockholder Vote (as defined in the Merger Agreement), the Preferred Shares will be convertible into shares

(the “Conversion Shares”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”);

and

D. To

induce the Investors to enter into the Purchase Agreement, the Company has agreed to provide certain registration rights under the Securities

Act of 1933, as amended, and the rules and regulations promulgated thereunder (the “Securities Act”), and applicable

state securities laws.

NOW,

THEREFORE, in consideration of the promises and the mutual covenants contained herein and other good and valuable consideration,

the receipt and sufficiency of which are hereby acknowledged, the Company and the Investors hereby agree as follows:

1. DEFINITIONS.

For

purposes of this Agreement, the following terms shall have the following meanings:

(a) “Person”

means an individual, partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated

association, joint venture or any other entity or organization.

(b) “Prospectus”

means (i) the prospectus included in any Registration Statement, as amended or supplemented by any prospectus supplement, with respect

to the terms of the offering of any portion of the Registrable Securities covered by such Registration Statement and by all other amendments

and supplements to the prospectus, including post-effective amendments and all material incorporated by reference in such prospectus,

and (ii) any “free writing prospectus” as defined in Rule 405 under the Securities Act, relating to the terms of the offering

of any portion of the Registrable Securities.

“Registered,” and “Registration” refer to a registration effected by preparing and filing one or

more registration statements of the Company in compliance with the Securities Act and providing for offering securities on a continuous

basis, and the declaration or ordering of effectiveness of such registration statement(s) by the SEC.

(d) “Registrable

Securities” means the Conversion Shares issuable upon conversion of the Preferred Shares issued or to be issued pursuant to

the Purchase Agreement and any shares of Common Stock issued or issuable with respect to the Conversion Shares as a result of any stock

split or subdivision, stock dividend, recapitalization, exchange or similar event; provided, however, that any such Registrable Securities

shall cease to be Registrable Securities (and the Company shall not be required to maintain the effectiveness of any, or file another,

Registration Statement hereunder with respect thereto) for so long as (a) a Registration Statement with respect to the sale of such Registrable

Securities is declared effective by the SEC under the Securities Act and such Registrable Securities have been disposed of by the Investors

in accordance with such effective Registration Statement, (b) such Registrable Securities have been previously sold in accordance with

Rule 144, or (c) such securities become eligible for resale without volume or manner-of-sale restrictions and without current public

information pursuant to Rule 144 as set forth in a written opinion letter to such effect, addressed, delivered and acceptable to the

Transfer Agent and the affected Investors (assuming that such securities and any securities issuable upon exercise, conversion or exchange

of which, or as a dividend upon which, such securities were issued or are issuable, were at no time held by any Affiliate of the Company).

(e) “Registration

Expenses” means all registration and filing fee expenses incurred by the Company in effecting any registration pursuant to

this Agreement, including (i) all registration, qualification, and filing fees, printing expenses, and any other fees and expenses associated

with filings required to be made with the SEC, FINRA or any other regulatory authority, (ii) all fees and expenses in connection with

compliance with or clearing the Registrable Securities for sale under any securities or “Blue Sky” laws, (iii) all printing,

duplicating, word processing, messenger, telephone and delivery expenses, and (iv) all fees and disbursements of counsel for the Company

and of all independent certified public accountants of the Company (including the expenses of any special audit and cold comfort letters

required by or incident to such performance).

(f) “Registration

Statement” means any registration statement of the Company filed with, or to be filed with, the SEC under the Securities Act,

that Registers Registrable Securities, including the related Prospectus, amendments and supplements to such registration statement, including

pre- and post-effective amendments, and all exhibits and all material incorporated by reference in such registration statement as may

be necessary to comply with applicable securities laws. “Registration Statement” shall also include a New Registration Statement,

as amended, when each became effective, including all documents filed as part thereof or incorporated by reference therein, and including

any information contained in a Prospectus subsequently filed with the SEC.

(g) “Required

Investors” means the Investors holding a majority of the Registrable Securities outstanding from time to time.

(h) “Rule

415” means Rule 415 promulgated by the SEC pursuant to the Securities Act, as such Rule may be amended from time to time, or

any similar rule or regulation hereafter adopted by the SEC having substantially the same effect as such Rule.

(i) “Rule

416” means Rule 416 promulgated by the SEC pursuant to the Securities Act, as such Rule may be amended from time to time, or

any similar rule or regulation hereafter adopted by the SEC having substantially the same effect as such Rule.

(j) “Rule

424” means Rule 424 promulgated by the SEC pursuant to the Securities Act, as such Rule may be amended from time to time, or

any similar rule or regulation hereafter adopted by the SEC having substantially the same effect as such Rule.

(k) “Rule

172” means Rule 172 promulgated by the SEC pursuant to the Securities Act, as such Rule may be amended from time to time, or

any similar rule or regulation hereafter adopted by the SEC having substantially the same effect as such Rule.

(l) “SEC”

means the U.S. Securities and Exchange Commission.

(m) “Selling

Expenses” means all underwriting discounts and selling commissions applicable to the sale of Registrable Securities and all

similar fees and commissions relating to the Investors’ disposition of the Registrable Securities.

2. REGISTRATION.

(a) Mandatory

Registration. The Company shall, as promptly as reasonably practicable and in any event no later than ninety (90) calendar days after

the Closing Date (the “Filing Deadline”), prepare and file with the SEC an initial Registration Statement (the “Initial

Registration Statement”) covering the resale of all Registrable Securities; provided, however, if Cy Biopharma has not delivered

the financial statements required to be included in the Initial Registration Statement pursuant to the rules and regulations of the SEC

to Company by seventy-five (75) days after closing of the Merger, such Filing Deadline shall be extended by one calendar day for each

day that Cy Biopharma has not delivered such financial statements. Before filing the Registration Statement, the Company shall furnish

to the Investors a copy of the Registration Statement. The Investors and their counsel shall have at least three (3) Business Days prior

to the anticipated filing date of a Registration Statement to review and comment upon such Registration Statement and any amendment or

supplement to such Registration Statement and any related Prospectus, prior to its filing with the SEC. Subject to any SEC comments,

such Registration Statement shall include the plan of distribution substantially in the form attached hereto as Exhibit A. Such

Registration Statement also shall cover, to the extent allowable under the Securities Act and the rules promulgated thereunder (including

Rule 416), such indeterminate number of additional shares of Common Stock resulting from stock splits, stock dividends or similar transactions

with respect to the Registrable Securities. Such Registration Statement shall not include any shares of Common Stock or other securities

for the account of any other holder of securities of the Company without the prior written consent of the Required Investors; provided,

however, that such Registration Statement may also include the Conversion Shares issuable upon conversion of the shares of Preferred

Stock issued to the equityholders of Cy Biopharma pursuant to the Merger Agreement without the need to obtain prior written consent of

the Required Investors. The Company shall (a) use commercially reasonable efforts to address in each such document prior to being so

filed with the SEC such reasonable comments as the Investor or its counsel reasonably proposed by the Investor, and (b) not file any

Registration Statement or Prospectus or any amendment or supplement thereto containing information regarding the Investor to which Investor

reasonably objects, unless such information is required to comply with any applicable law or regulation. The Investors shall furnish

all information reasonably requested by the Company and as shall be reasonably required in connection with any registration referred

to in this Agreement.

(b) Effectiveness.

The Company shall use its commercially reasonable efforts to have the Initial Registration Statement and any amendment declared effective

by the SEC at the earliest possible date but no later than the earlier of (1) the ninetieth (90th) calendar day following

the initial filing date of the Initial Registration Statement if the SEC notifies the Company that it will “review” the Initial

Registration Statement, (2) the fifth (5th) Business Day after the date the Company is notified (orally or in writing, whichever

is earlier) by the SEC that the Initial Registration Statement will not be “reviewed” or will not be subject to further review

(the “Effectiveness Deadline”); provided, however that (i) any Business Day that the SEC is not open because of a

shutdown of the government or otherwise shall not count against the ninety (90) calendar day period and (ii) if Cy Biopharma has not

delivered the financial statements required to be included in the Initial Registration Statement pursuant to the rules and regulations

of the SEC to Company by seventy-five (75) days after closing of the Merger, such Effectiveness Deadline shall be extended by one calendar

day for each day that Cy Biopharma has not delivered such financial statements. The Company shall notify the Investors by e-mail as promptly

as practicable, and in any event, within 24 hours, after the Registration Statement is declared effective or is supplemented and shall

provide the Investors with copies of any Prospectus to be used in connection with the sale or other disposition of the securities covered

thereby. The Company shall use commercially reasonable efforts to keep the Initial Registration Statement continuously effective pursuant

to Rule 415 promulgated under the Securities Act and available for the resale by the Investors of all of the Registrable Securities covered

thereby at all times until the earliest to occur of the following events: (i) the date on which the Investors shall have resold all the

Registrable Securities covered thereby; and (ii) the date on which the Registrable Securities may be resold by the Investors without

registration and without regard to any volume or manner-of-sale limitations by reason of Rule 144, without the requirement for the Company

to be in compliance with the current public information requirement under Rule 144 under the Securities Act or any other rule of similar

effect (the “Registration Period”). The Initial Registration Statement (including any amendments or supplements thereto

and prospectuses contained therein) shall not contain any untrue statement of a material fact or omit to state a material fact required

to be stated therein, or necessary to make the statements therein, in light of the circumstances in which they were made, not misleading.

Number of Shares Registered. In the event the number of shares available under the Initial Registration Statement at any time is

insufficient to cover the Registrable Securities, the Company shall, to the extent necessary and permissible, use its commercially reasonable

efforts to amend the Initial Registration Statement or file a new registration statement (together with any prospectuses or prospectus

supplements thereunder, a “New Registration Statement”), so as to cover all of such Registrable Securities as soon

as reasonably practicable, but in any event not later than ten (10) Business Days after the necessity therefor arises (the “New

Registration Filing Deadline”). The Company shall use its commercially reasonable efforts to have such amendment and/or New

Registration Statement become effective as soon as reasonably practicable following the filing thereof but no later than the earlier

of the ninetieth (90th) calendar day following the initial filing date of the New Registration Statement if the SEC notifies

the Company that it will “review” the New Registration Statement and (b) the fifth (5th) Business Day after the

date the Company is notified (orally or in writing, whichever is earlier) by the SEC that the New Registration Statement will not be

“reviewed” or will not be subject to further review (the earlier of such dates, the “New Registration Effectiveness

Deadline”). The provisions of Section 2(a) and (b) shall apply to the New Registration Statement, except as modified

hereby.

(d) Liquidated

Damages. If (i) the Initial Registration Statement has not been filed by the Filing Deadline, (ii) the Initial Registration Statement

has not been declared effective by the Effectiveness Deadline, (iii) the New Registration Statement has not been filed by the New Registration

Filing Deadline, (iv) the New Registration Statement has not been declared effective by the New Registration Effectiveness Deadline or

(v) after any Registration Statement has been declared effective by the SEC, sales cannot be made pursuant to such Registration Statement

for any reason (including without limitation by reason of a stop order, or the Company’s failure to update such Registration Statement),

but excluding any Allowed Delay (as defined below) or, if the Registration Statement is on Form S-1, for a period of 20 days following

the date on which the Company files a post-effective amendment to incorporate the Company’s Annual Report on Form 10-K (a “Maintenance

Failure”), then the Company will make pro rata payments to each Investor then holding Registrable Securities, as liquidated damages

and not as a penalty, in an amount equal to 1.0% of the aggregate amount paid pursuant to the Purchase Agreement by such Investor for

such Registrable Securities then held by such Investor for each 30-day period or pro rata for any portion thereof during which the failure

continues (the “Blackout Period”), provided that no liquidated damages shall be payable (i) if as of the relevant date, the

Registrable Securities may be sold by the Investor without volume or manner of sale restrictions under Rule 144, as determined by counsel

to the Company pursuant to a written opinion letter to such effect, addressed and reasonably acceptable to the Investor and the Company’s

transfer agent (regardless of whether the restrictive legend has been actually removed from the certificates representing such Registrable

Securities), (ii) to an Investor in the event it is unable to lawfully sell any of its Registrable Securities because of possession of

material non-public information, (iii) if and to the extent to, despite best efforts by the Company to avoid a breach hereof, the Company’s

failure was caused by a government shutdown resulting in the SEC’s inability to review or declare effective the Registration Statement,

(iv) to an Investor causing an event that relates to or is caused by any action or inaction taken by such Investor, or (v) with respect

to any period after the expiration of the Registration Period. The Company shall not be liable for liquidated damages under this Agreement

as to any Registrable Securities which are not permitted by the SEC to be included in a Registration Statement due solely to SEC Guidance;

in such case, the liquidated damages shall be calculated to only apply to the percentage of Registrable Securities which are permitted

in accordance with SEC Guidance to be included in such Registration Statement. Such payments shall constitute the Investors’ exclusive

monetary remedy for such events, but shall not affect the right of the Investors to seek injunctive relief. The amounts payable as liquidated

damages pursuant to this paragraph shall be paid in cash no later than twenty (20) Business Days after each such 30-day period following

the commencement of the Blackout Period until the termination of the Blackout Period (the “Blackout Period Payment Date”).

Interest shall accrue at the rate of 0.5% per month (pro rated for any period less than a month) on any such liquidated damages payments

that shall not be paid by the Blackout Period Payment Date until such amount is paid in full. Notwithstanding the above, in no event

shall the aggregate amount of liquidated damages (or interest thereon) paid under this Agreement to any Investor exceed, in the aggregate,

5.0% of the aggregate purchase price of the Shares purchased by such Investor under the Purchase Agreement. Notwithstanding anything

in this Section 2(d) to the contrary, during any periods that the Company is unable to meet its obligations hereunder with respect to

the registration of the Registrable Securities because any Investor fails to furnish information required to be provided pursuant to

Section 2(a) or Section 4(a) within three Business Days of the Company’s request, any liquidated damages that would otherwise accrue

as to such Investor only shall be tolled until such information is delivered to the Company. The Effectiveness Deadline or New Registration

Effectiveness Deadline, as applicable, shall be extended without default or liquidated damages hereunder in the event that the Company’s

failure to obtain the effectiveness of the Registration Statement on a timely basis results from the failure of such Investor to timely

provide the Company with information requested by the Company and necessary to complete the Registration Statement.

(e) Allowable

Delays. On no more than two occasions and for not more than sixty (60) consecutive calendar days or for a total of not more than

ninety (90) calendar days in any twelve (12) month period, the Company may delay the effectiveness of the Initial Registration Statement

or any other Registration Statement, or suspend the use of any Prospectus, in the event that the Company or Board of Directors determines,

in good faith and upon advice of legal counsel, that such delay or suspension is necessary to (A) delay the disclosure of material non-public

information concerning the Company, the disclosure of which at the time is not, in the good faith opinion of the Company, in the best

interests of the Company or (B) amend or supplement the affected Registration Statement or the related Prospectus so that such Registration

Statement or Prospectus shall not include an untrue statement of a material fact or omit to state a material fact required to be stated

therein or necessary to make the statements therein, in the case of the Prospectus in light of the circumstances under which they were

made, not misleading (an “Allowed Delay”); provided, that the Company shall promptly (a) notify each Investor in writing

of the commencement of an Allowed Delay, but shall not (without the prior written consent of an Investor) disclose to such Investor any

material non-public information giving rise to an Allowed Delay, (b) advise the Investors in writing to cease all sales under the applicable

Registration Statement until the end of the Allowed Delay and (c) use commercially reasonable efforts to terminate an Allowed Delay as

promptly as practicable.

(f) Rule

415; Cut-back. If at any time the SEC takes the position that (1) the offering of some or all of the Registrable Securities in any

Registration Statement is not eligible to be made on a delayed or continuous basis under the provisions of Rule 415 (provided, however,

the Company shall be obligated to use commercially reasonable efforts to advocate with the SEC for the registration of all of the Registrable

Securities) or (2) certain Registrable Securities cannot be registered until stockholder approval has been obtained, or the SEC requires

any Investor to be named as an “underwriter,” the Company shall (i) promptly notify each holder of Registrable Securities

thereof and (ii) make commercially reasonable efforts to persuade the SEC that the offering contemplated by such Registration Statement

is a valid secondary offering and not an offering “by or on behalf of the issuer” as defined in Rule 415 and that none of

the Investors is an “underwriter.” The Investors shall have the right to select one legal counsel, which counsel shall be

selected by the Required Investors, to review and oversee any registration or matters pursuant to this Section 2(f), including

participation in any meetings or discussions with the SEC regarding the SEC’s position and to comment on any written submission

made to the SEC with respect thereto. No such written submission with respect to this matter shall be made to the SEC to which any Investor’s

counsel reasonably objects. In the event that, despite the Company’s commercially reasonable efforts and compliance with the terms

of this Section 2(f), the SEC refuses to alter its position, the Company shall (i) remove from such Registration Statement such

portion of the Registrable Securities and/or (ii) agree to such restrictions and limitations on the registration and resale of the Registrable

Securities as the SEC may require to assure the Company’s compliance with the requirements of Rule 415 (collectively, the “SEC

Restrictions”); provided, however, that the Company shall not name any Investor as an “underwriter” in such Registration

Statement without the prior written consent of such Investor (provided that, in the event an Investor withholds such consent, the Company

shall have no obligation hereunder to include any Registrable Securities of such Investor in any Registration Statement covering the

resale thereof until such time as the SEC no longer requires such Investor to be named as an “underwriter” in such Registration

Statement or such Investor otherwise consents in writing to being so named). Any cut-back imposed on the Investors pursuant to this Section

2(f) shall be allocated among the Investors on a pro rata basis and shall be applied first to any of the Registrable Securities of

such Investor as such Investor shall designate, unless the SEC Restrictions otherwise require or provide or the Investors otherwise agree.

3. RELATED COMPANY

OBLIGATIONS.

With

respect to the Registration Statement and whenever any Registrable Securities are to be Registered pursuant to Section 2, including

on the Initial Registration Statement or on any New Registration Statement, the Company shall use its commercially reasonable efforts

to effect the registration of the Registrable Securities in accordance with the intended method of disposition thereof and, pursuant

thereto, the Company shall have the following obligations:

(a) Notifications.

The Company will promptly notify the Investors of the time when any subsequent amendment to the Initial Registration Statement or any

New Registration Statement, other than documents incorporated by reference, has been filed with the SEC and/or has become effective or

where a receipt has been issued therefor or any subsequent supplement to a Prospectus has been filed and of any request by the SEC for

any amendment or supplement to the Registration Statement, any New Registration Statement or any Prospectus or for additional information.

(b) Amendments.

The Company will prepare and file with the SEC any amendments, post-effective amendments or supplements to the Initial Registration Statement,

any New Registration Statement or any Prospectus, as applicable, that, (a) as may be necessary to keep such Registration Statement effective

for the Registration Period and to comply with the provisions of the Securities Act and the Exchange Act with respect to the distribution

of all of the Registrable Securities covered thereby, or (b) in the reasonable opinion of the Investors and the Company, as may be necessary

or advisable in connection with any acquisition or sale of Registrable Securities by the Investors.

Review. The Company will not file any amendment or supplement to the Registration Statement, any New Registration Statement or any

Prospectus, other than documents incorporated by reference, relating to the Investors, the Registrable Securities or the transactions

contemplated hereby unless (A) the Investors and their counsel shall have been advised and afforded the opportunity to review and comment

thereon at least three (3) Business Days prior to filing with the SEC and (B) the Company shall have given reasonable due consideration

to any comments thereon received from the Investors or their counsel.

(d) Copies

Available. The Company will furnish to any Investor whose Registrable Securities are included in any Registration Statement and its

counsel copies of the Initial Registration Statement, any Prospectus thereunder (including all documents incorporated by reference therein),

any Prospectus supplement thereunder, any New Registration Statement and all amendments to the Initial Registration Statement or any

New Registration Statement that are filed with the SEC during the Registration Period (including all documents filed with or furnished

to the SEC during such period that are deemed to be incorporated by reference therein), each letter written by or on behalf of the Company

to the SEC or the staff of the SEC, and each item of correspondence from the SEC or the staff of the SEC, in each case relating to such

Registration Statement (other than any portion thereof which contains information for which the Company has sought confidential treatment)

and such other documents as Investor may reasonably request in order to facilitate the disposition

of the Registrable Securities owned by Investor that are covered by such Registration Statement, in each case as soon as reasonably

practicable upon such Investor’s request and in such quantities as such Investor may from time to time reasonably request; provided,

however, that the Company shall not be required to furnish any document to the Investor to the extent such document is available on EDGAR.

(e) Notification

of Stop Orders; Material Changes. The Company shall use commercially reasonable efforts to (i) prevent the issuance of any stop order

or other suspension of effectiveness and, (ii) if such order is issued, obtain the withdrawal of any such order as soon as practicable.

The Company shall advise the Investors promptly (but in no event later than twenty-four (24) hours) and shall confirm such advice in

writing, in each case: (A) of the Company’s receipt of notice of any request by the SEC or any other federal or state governmental

authority for amendment of or a supplement to the Registration Statement or any Prospectus or for any additional information; (B) of

the Company’s receipt of notice of the issuance by the SEC or any other federal or state governmental authority of any stop order

suspending the effectiveness of the Initial Registration Statement or prohibiting or suspending the use of any Prospectus or Prospectus

supplement, or any New Registration Statement, or of the Company’s receipt of any notification of the suspension of qualification

of the Registrable Securities for offering or sale in any jurisdiction or the initiation or contemplated initiation of any proceeding

for such purpose; and (C) of the Company becoming aware of the happening of any event, which makes any statement of a material fact made

in any Registration Statement or any Prospectus untrue or which requires the making of any additions to or changes to the statements

then made in any Registration Statement or any Prospectus in order to state a material fact required by the Securities Act to be stated

therein or necessary in order to make the statements then made therein (in the case of any Prospectus, in light of the circumstances

under which they were made) not misleading, or of the necessity to amend any Registration Statement or any Prospectus to comply with

the Securities Act or any other law. The Company shall not be required to disclose to the Investors (and shall not so disclose to any

Investor without such Investor’s prior written consent) the substance of specific reasons of any of the events set forth in clauses

(A) to (C) of the immediately preceding sentence (each, a “Suspension Event”), but rather, shall only be

required to disclose that the event has occurred; provided that the Company shall not provide any material non-public information to

the Investors in such notice.. If at any time the SEC, or any other federal or state governmental authority shall issue any stop order

suspending the effectiveness of any Registration Statement or prohibiting or suspending the use of any Prospectus or Prospectus supplement,

the Company shall use its commercially reasonable efforts to obtain the withdrawal of such order at the earliest practicable time. The

Company shall furnish to the Investors, without charge, a copy of any correspondence from the SEC or the staff of the SEC, or any other

federal or state governmental authority to the Company or its representatives relating to the Initial Registration Statement, any New

Registration Statement or any Prospectus, or Prospectus supplement as the case may be. In the event of a Suspension Event set forth in

clause (C) of the first sentence of this Section 3(e), the Company will use its commercially reasonable efforts to publicly

disclose such event as soon as reasonably practicable, or otherwise resolve the matter such that sales under Registration Statements

may resume; provided, however, that if the Company has a bona fide business purpose for not making such information public, the Company

may suspend the use of all Registration Statements for up to sixty (60) consecutive calendar days; provided, further, that the Company

may not suspend the use of all Registration Statements more than twice, or for more than ninety (90) total calendar days, in each case

during any twelve (12)-month period. The Company shall not provide any specific information regarding the Suspension Event unless requested

by the Investor, which in any event shall not include any material nonpublic information unless such specific information constitutes

material non-public information.

(f) Confirmation

of Effectiveness. If reasonably requested by an Investor at any time in respect of any Registration Statement, the Company shall

deliver to such Investor a written confirmation (email being sufficient) from Company’s counsel of whether or not the effectiveness

of such Registration Statement has lapsed at any time for any reason (including, without limitation, the issuance of a stop order) and

whether or not such Registration Statement is currently effective and available to the Company for sale of Registrable Securities.

(g) Listing.

The Company shall use reasonable best efforts to cause all Registrable Securities covered by a Registration Statement to be listed on

the Nasdaq Capital Market.

(h) Compliance.

The Company shall otherwise use best efforts to comply with all applicable rules and regulations of the SEC under the Securities Act

and the Exchange Act, including, without limitation, Rule 172, file any final prospectus, including any supplement or amendment thereof,

with the SEC pursuant to Rule 424, promptly inform the Investor in writing if, at any time during the Registration Period, the Company

does not satisfy the conditions specified in Rule 172 and, as a result thereof, the Investor is required to deliver a prospectus in connection

with any disposition of Registrable Securities and take such other actions as may be reasonably necessary to facilitate the registration

of the Registrable Securities hereunder, and make available to its security holders, as soon as reasonably practicable, but not later

than the Availability Date (as defined below), an earnings statement covering a period of at least twelve (12) months, beginning after

the effective date of each Registration Statement, which earnings statement shall satisfy the provisions of Section 11(a) of the Securities

Act, including Rule 158 promulgated thereunder (for the purpose of this Section 3(h), “Availability Date” means

the forty-fifth (45th) calendar day following the end of the fourth (4th) fiscal quarter that includes the effective

date of such Registration Statement, except that, if such fourth (4th) fiscal quarter is the last quarter of the Company’s

fiscal year, “Availability Date” means the ninetieth (90th) calendar day after the end of such fourth (4th)

fiscal quarter).

(i) Blue-Sky.

The Company shall register or qualify or cooperate with the Investor and their counsel in connection with the registration or qualification

of such Registrable Securities for the offer and sale under the securities or blue sky laws of such jurisdictions reasonably requested

by the Investor; provided, however, that the Company shall not be required in connection therewith or as a condition thereto to (i) qualify

to do business in any jurisdiction where it would not otherwise be required to qualify but for this Section 3(i), (ii) subject

itself to general taxation in any jurisdiction where it would not otherwise be so subject but for this Section 3(i), or (iii)

file a general consent to service of process in any such jurisdiction.

(j) Rule

144. With a view to making available to the Investors the benefits of Rule 144 (or its successor rule) and any other rule or regulation

of the SEC that may at any time permit the Investors to sell shares of Common Stock to the public without registration, the Company covenants

and agrees to: use commercially reasonable efforts to (i) make and keep adequate current public information available, as those terms

are understood and defined in Rule 144, until the earlier of (A) six (6) months after such date as all of the Registrable Securities

may be sold without restriction by the holders thereof pursuant to Rule 144 or any other rule of similar effect or (B) such date as there

are no longer Registrable Securities; and (ii) file with the SEC in a timely manner all reports and other documents required of the Company

under the Exchange Act; (iii) furnish electronically to each Investor upon request, as long as such Investor owns any Registrable Securities,

(A) a written statement by the Company that it has complied with the reporting requirements of the Exchange Act, (B) a copy of or electronic

access to the Company’s most recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q, and (C) such other information

as may be reasonably requested in order to avail such Investor of any rule or regulation of the SEC that permits the selling of any such

Registrable Securities without registration.

(k) Cooperation.

The Company shall cooperate with the holders of the Registrable Securities to facilitate the timely preparation and delivery of certificates

or uncertificated shares representing the Registrable Securities to be sold pursuant to such Registration Statement or Rule 144 free

of any restrictive legends and representing such number of shares of Common Stock and registered in such names as the holders of the

Registrable Securities may reasonably request to the extent permitted by such Registration Statement or Rule 144 to effect sales of Registrable

Securities; for the avoidance of doubt, the Company may satisfy its obligations hereunder without issuing physical stock certificates

through the use of The Depository Trust Company’s Direct Registration System.

(l) Removal

of Restrictive Legends. Without limiting Section 5.5 of the Purchase Agreement, the Company shall use reasonable best efforts to cause

the Company’s transfer agent to remove any restrictive legend from any Registrable Securities, as promptly as practicable following

effectiveness of the applicable Registration Statement, without any request for removal being required from any holder of Registrable

Securities.

4. OBLIGATIONS OF

THE INVESTORS.

(a) Investor

Information. Each Investor shall provide a completed Investor Questionnaire in the form attached hereto as Exhibit B in connection

with the registration of the Registrable Securities. If the Company has not received such completed Questionnaire from an Investor within

three (3) Business Days of the Company’s request, the Company may file the Registration Statement without including such Investor’s

Registrable Securities.

(b) Suspension

of Sales. Each Investor, severally and not jointly with any other Investor, agrees that, upon receipt of any notice from the Company

of the existence of an Allowed Delay or a Suspension Event as set forth in Section 2(d) and Section 3(e), the Investor

will promptly discontinue disposition of Registrable Securities pursuant to any Registration Statement covering such Registrable Securities

until the Investor’s receipt of a notice from the Company confirming the resolution of such Allowed Delay or Suspension Event and

that such dispositions may again be made; provided, for the avoidance of doubt, that the foregoing shall not limit the right of the Investor

to sell or otherwise dispose of the Registrable Securities pursuant to Rule 144 or any other exemption from the registration requirements

of the Securities Act or to settle a transaction pursuant to a Registration Statement as to which a contract for such sale was entered

into prior to such Investor’s receipt of the notice from the Company of the existence of the Allowed Delay or Suspension Event.

Cooperation. Each Investor, severally and not jointly with any other Investor, agrees to cooperate with the Company as reasonably

requested by the Company in connection with the preparation and filing of any amendments and supplements to any Registration Statement

or New Registration Statement hereunder, unless such Investor has notified the Company in writing of its election to exclude all of its

Registrable Securities from such Registration Statement.

5. EXPENSES

OF REGISTRATION.

All

Registration Expenses incurred in connection with registrations pursuant to this Agreement shall be borne by the Company. All Selling

Expenses relating to securities registered on behalf of the Investors shall be borne by the Investors pro rata on the basis of the number

of Registrable Securities so registered.

6. INDEMNIFICATION.

(a) To

the fullest extent permitted by law, the Company will, and hereby does, indemnify, hold harmless and defend the Investors, each Person,

if any, who controls the Investors, the members, the directors, officers, partners, employees, members, managers, agents, representatives

and advisors of the Investors and each Person, if any, who controls the Investors within the meaning of the Securities Act or the Exchange

Act (each, an “Indemnified Person”), against any losses, obligation, claims, damages, liabilities, contingencies,

judgments, fines, penalties, charges, costs (including, without limitation, court costs and costs of preparation), reasonable and documented

attorneys’ fees, amounts paid in settlement or reasonable and documented expenses (collectively, “Claims”) reasonably

incurred in investigating, preparing or defending any action, claim, suit, inquiry, proceeding, investigation or appeal taken from the

foregoing by or before any court or governmental, administrative or other regulatory agency or body or the SEC, whether pending or threatened,

whether or not an indemnified party is or may be a party thereto (“Indemnified Damages”), to which any of them may

become subject insofar as such Claims (or actions or proceedings, whether commenced or threatened, in respect thereof) arise out of or

are based upon: (i) any untrue statement or alleged untrue statement or omission or alleged omission of any material fact contained in

any Registration Statement, any preliminary prospectus or final prospectus, or any amendment or supplement thereof, or (ii) any violation

or alleged violation by the Company or any of its Subsidiaries of the Securities Act, Exchange Act or any other state securities or other

“blue sky” laws of any jurisdiction in which Registrable Securities are offered or any rule or regulation promulgated thereunder

applicable to the Company or its agents and relating to action or inaction required of the Company in connection with such registration

of the Registrable Securities (the matters in the foregoing clauses (i) and (ii) being, collectively, “Violations”).

The Company shall reimburse each Indemnified Person promptly as such expenses are incurred and are due and payable, for any reasonable

out-of-pocket legal fees or other reasonable and documented expenses incurred by them in connection with investigating or defending any

such Claim. Notwithstanding anything to the contrary contained herein, the indemnification agreement contained in this Section 6(a):

(A) shall not apply to a Claim by an Indemnified Person arising out of or based upon a Violation which occurs in reliance upon and in

conformity with information furnished in writing to the Company by the Investors or such Indemnified Person specifically for use in such

Registration Statement or prospectus and was reviewed and approved in writing by such Investor or such Indemnified Person expressly for

use in connection with the preparation of any Registration Statement, any prospectus or any such amendment thereof or supplement thereto,

in each case if the foregoing was timely made available by the Company; (B) with respect to any superseded prospectus, shall not inure

to the benefit of any such Person from whom the Person asserting any such Claim purchased the Registrable Securities that are the subject

thereof (or to the benefit of any other Indemnified Person) if the untrue statement or omission of material fact contained in the superseded

prospectus was corrected in the revised prospectus, as then amended or supplemented, and the Indemnified Person was promptly advised

in writing not to use the outdated, defective or incorrect prospectus prior to the use giving rise to a Violation; (C) shall not apply

to amounts paid in settlement of any Claim if such settlement is effected without the prior written consent of the Company, which consent

shall not be unreasonably withheld, conditioned or delayed. Such indemnity shall remain in full force and effect regardless of any investigation

made by or on behalf of the Indemnified Person and shall survive the transfer of the Registrable Securities by the Investor pursuant

to Section 8.

(b) In

connection with the Initial Registration Statement, any New Registration Statement or any prospectus, the Investors, severally and not

jointly, agree to indemnify, hold harmless and defend, the Company, each of its directors, each of its officers who signed the Initial

Registration Statement or signs any New Registration Statement, each Person, if any, who controls the Company within the meaning of the

Securities Act or the Exchange Act (each, an “Indemnified Party”), against any losses, claims, damages, liabilities

and expense (including reasonable attorney fees) resulting from any Violation, in each case to the extent, and only to the extent, that

such Violation occurs in reliance upon and in conformity with information about an Investor furnished in writing by such Investor to

the Company and reviewed and approved in writing by such Investor or such Indemnified Person expressly for use in connection with the

preparation of the Registration Statement, any New Registration Statement, any prospectus or any such amendment thereof or supplement

thereto. In no event shall the liability of an Investor be greater in amount than the U.S. dollar amount of the proceeds (net of all

expense paid by such Investor in connection with any claim relating to this Section 6 and the amount of any damages such Investor

has otherwise been required to pay by reason of such untrue statement or omission) received by such Investor upon the sale of the Registrable

Securities included in such Registration Statement giving rise to such indemnification obligation. Notwithstanding anything to the contrary

contained herein, the indemnification agreement contained in this Section 6(b), shall not apply to amounts paid in settlement of any

Claim if such settlement is effected without the prior written consent of such Investor, which consent shall not be unreasonably withheld,

conditioned or delayed. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of

such Indemnified Party and shall survive the transfer of the Registrable Securities by any Investor pursuant to Section 8.

after receipt by an Indemnified Person or Indemnified Party under this Section 6 of notice of the commencement of any action or

proceeding (including any governmental action or proceeding) involving a Claim, such Indemnified Person or Indemnified Party shall, if

a Claim in respect thereof is to be made against any party with an indemnification obligation under this Section 6 (an “Indemnifying

Party”), deliver to the Indemnifying Party a written notice of the commencement thereof, and the Indemnifying Party shall have

the right to participate in, and, to the extent the Indemnifying Party so desires, jointly with any other Indemnifying Party similarly

noticed, to assume control of the defense thereof with counsel mutually satisfactory to the Indemnifying Party and the Indemnified Person

or the Indemnified Party, as the case may be, and upon such notice, the Indemnifying Party shall not be liable to the Indemnified Person

or the Indemnified Party for any legal or other expenses subsequently incurred by the Indemnified Person or the Indemnified Party in

connection with the defense thereof; provided, however, that an Indemnified Person or Indemnified Party (together with all other Indemnified

Persons and Indemnified Parties that may be represented without conflict by one counsel) shall have the right to retain one counsel with

the reasonable fees and expenses to be paid by the Indemnifying Party, if, in the reasonable opinion of counsel retained by the Indemnifying

Party, the representation by such counsel of the Indemnified Person or Indemnified Party and the Indemnifying Party would be inappropriate

due to a material conflict of interest being likely to exist if the same counsel were to represent the Indemnified Party and the Indemnifying

Party or any other party represented by such counsel in such proceeding (in which case, if such Indemnified Party notifies the Indemnifying

Party in writing that the Indemnified Party elects to employ separate counsel at the expense of the Indemnifying Party, the Indemnifying

Party shall not have the right to assume the defense thereof and the reasonable fees and expenses of no more than one separate counsel

shall be at the expense of the Indemnifying Party). The Indemnified Party or Indemnified Person shall cooperate with the Indemnifying

Party in connection with any negotiation or defense of any such action or claim by the Indemnifying Party and shall furnish to the Indemnifying

Party all information reasonably available to the Indemnified Party or Indemnified Person which relates to such action or claim. The

Indemnifying Party shall keep the Indemnified Party or Indemnified Person fully apprised as to the status of the defense or any settlement

negotiations with respect thereto. No Indemnifying Party shall be liable for any settlement of any action, claim or proceeding effected

without its written consent, provided, however, that the Indemnifying Party shall not unreasonably withhold, delay or condition its consent.

No Indemnifying Party shall, without the consent of the Indemnified Party or Indemnified Person, consent to entry of any judgment or

enter into any settlement or other compromise unless such judgment or settlement (i) imposes no liability or obligation on, (ii) includes

as an unconditional term thereof the giving of a complete, explicit and unconditional release from the party bringing such indemnified

claims of all liability of the Indemnified Party or Indemnified Person in respect to or arising out of such claim or litigation in favor

of, and (iii) does not include any admission of fault, culpability, wrongdoing or malfeasance by or on behalf of, the Indemnified Party

or Indemnified Person. Following indemnification as provided for hereunder, the Indemnifying Party shall be subrogated to all rights

of the Indemnified Party or Indemnified Person with respect to all third parties, firms or corporations relating to the matter for which

indemnification has been made. The failure to deliver written notice to the Indemnifying Party within a reasonable time of the commencement

of any such action shall not relieve such Indemnifying Party of any liability to the Indemnified Person or Indemnified Party under this

Section 6, except to the extent that the Indemnifying Party is prejudiced in its ability to defend such action.

(d) The

indemnification required by this Section 6 shall be made by periodic payments of the amount thereof during the course of the investigation

or defense, as and when bills are received or Indemnified Damages are incurred. Any Person receiving a payment pursuant to this Section

6 which person is later determined to not be entitled to such payment shall return all such payments (including reimbursement of

expenses) to the person making it.

(e) The

indemnity agreements contained herein shall be in addition to (i) any cause of action or similar right of the Indemnified Party or Indemnified

Person against the Indemnifying Party or others, and (ii) any liabilities the Indemnifying Party may be subject to pursuant to the law.

7. CONTRIBUTION.

the indemnification under Section 6 is unavailable to an Indemnified Party or insufficient to hold an Indemnified Party harmless

for any damages, then each Indemnifying Party shall contribute to the amount paid or payable by such Indemnified Party, in such proportion

as is appropriate to reflect the relative fault of the Indemnifying Party and Indemnified Party in connection with the actions, statements

or omissions that resulted in such damages as well as any other relevant equitable considerations. The relative fault of such Indemnifying

Party and Indemnified Party shall be determined by reference to, among other things, whether any action in question, including any untrue

or alleged untrue statement of a material fact or omission or alleged omission of a material fact, has been taken or made by, or relates

to information supplied by, such Indemnifying Party or Indemnified Party, and the parties’ relative intent, knowledge, access to

information and opportunity to correct or prevent such action, statement or omission. The amount paid or payable by a party as a result

of any damages shall be deemed to include, subject to the limitations set forth in this Agreement, any reasonable attorneys’ or

other fees or expenses incurred by such party in connection with any proceeding to the extent such party would have been indemnified

for such fees or expenses if the indemnification provided for in this Section was available to such party in accordance with its terms.

The

parties hereto agree that it would not be just and equitable if contribution pursuant to this Section 7 were determined by pro

rata allocation or by any other method of allocation that does not take into account the equitable considerations referred to in the

immediately preceding paragraph. In no event shall the contribution obligation of an Investor be greater in amount than the dollar amount

of the proceeds (net of all expenses paid by such Investor in connection with any claim relating to this Section 7 and the amount

of any damages such Investor has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged

omission) received by it upon the sale of the Registrable Securities giving rise to such contribution obligation.

8. ASSIGNMENT OF REGISTRATION

RIGHTS.

The

Company shall not assign this Agreement or any rights or obligations hereunder (whether by operation of law or otherwise) without the

prior written consent of the Required Investors; provided, however, that in any transaction, whether by merger, reorganization, restructuring,

consolidation, financing or otherwise, whereby the Company is a party and in which the Registrable Securities are converted into the

equity securities of another Person, from and after the effective time of such transaction, such Person shall, by virtue of such transaction,

be deemed to have assumed the obligations of the Company hereunder, the term “Company” shall be deemed to refer to such Person

and the term “Registrable Securities” shall be deemed to include the securities received by the Investor in connection with

such transaction unless such securities are otherwise freely tradable by the Investor after giving effect to such transaction, and the

prior written consent of the Required Investors shall not be required for such transaction. An Investor may transfer or assign its rights

hereunder, in whole or from time to time in part, to one or more Persons in connection with the transfer of not fewer than 75,000 (subject

to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization) Registrable

Securities by such Investor to such Person, provided that such Investor complies with all laws applicable thereto, and the provisions

of the Purchase Agreement, and provides written notice of assignment to the Company promptly after such assignment is effected, and such

Person agrees in writing to be bound by all of the provisions contained herein. The provisions of this Agreement shall be binding upon

and inure to the benefit of the Investor and its successors and permitted assigns.

9. AMENDMENTS AND

WAIVERS.

The

provisions of this Agreement, including the provisions of this Section 9, may be amended, modified or supplemented, or waived

only by a written instrument executed by (i) the Company and (ii) the Required Investors, provided that (1) any party may give a waiver

as to itself, (2) any amendment, modification, supplement or waiver that disproportionately and adversely affects the rights and obligations

of any Investor relative to the comparable rights and obligations of the other Investors shall require the prior written consent of such

adversely affected Investor or each Investor, as applicable, and (3) any amendments to Section 6 or to the definitions of “Filing

Deadline,” “Effectiveness Deadline,” or “Registration Period” shall require the written consent of each

Investor. Notwithstanding the foregoing, a waiver or consent to depart from the provisions hereof with respect to a matter that relates

exclusively to the rights of one or more Investors and that does not adversely directly or indirectly affect the rights of other Investors

may be given by Investors holding all of the Registrable Securities to which such waiver or consent relates.

10. MISCELLANEOUS.

(a) Notices.

Any notices or other communications required or permitted to be given hereunder shall be in writing and shall be deemed to be given (a)

when delivered if personally delivered to the party for whom it is intended, (b) when delivered, if sent by electronic mail during normal

business hours of the recipient, and if not sent during normal business hours, then on the recipient’s next Business Day, (c) three

(3) calendar days after having been sent by certified or registered mail, return-receipt requested and postage prepaid, or (d) one (1)

Business Day after deposit with a nationally recognized overnight courier, freight prepaid, specifying next Business Day delivery, with

written verification of receipt:

i. If

to the Company, addressed as follows:

Ensysce

Biosciences, Inc.

7946

Ivanhoe Avenue, Suite 201

Jolla, CA 92037

Attention:

Dr. Lynn Kirkpatrick

Email:

with

a copy (which shall not constitute notice):

Troutman

Pepper Locke LLP

Union

Trust Building

501

Grant Street, Suite 300

Pittsburgh,

PA 15219

Attention:

Eric D. Kline

Email:

ii. If

to any Investor, at its e-mail address or address set forth on its signature page to the Purchase Agreement or to such e-mail address,

or address as subsequently modified by written notice given in accordance with this Section 10.

Any

Person may change the address to which notices and communications to it are to be addressed by notification as provided for herein.

(b) Consent

to Electronic Notice. Each Investor consents to the delivery of any stockholder notice pursuant to the Delaware General Corporation

Law (the “DGCL”), as amended or superseded from time to time, by e-mail pursuant to Section 232 of the DGCL (or any

successor thereto) at the e-mail address set forth below the Investor’s name on the signature page or Exhibit A of the Purchase

Agreement, as updated from time to time by notice to the Company. To the extent that any notice given by means of e-mail is returned

or undeliverable for any reason, the foregoing consent shall be deemed to have been revoked until a new or corrected e-mail address has

been provided, and such attempted electronic notice shall be ineffective and deemed to not have been given. Each party agrees to promptly

notify the other parties of any change in its e-mail address, and that failure to do so shall not affect the foregoing.

No waiver of any term, provision or condition of this Agreement, whether by conduct or otherwise, in any one or more instances, shall

be deemed to be, or be construed as, a further or continuing waiver of any such term, provision or condition or as a waiver of any other

term, provision or condition of this Agreement.

(d) Governing

Law. The provisions of Section 8.6 of the Purchase Agreement are incorporated by reference herein mutatis mutandis.

(e) Headings.

The titles, subtitles and headings in this Agreement are for convenience of reference and shall not form part of, or affect the interpretation

of, this Agreement.

(f)  Counterparts.

This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and

shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile or

pdf signature including any electronic signatures complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com shall be

considered due execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original,

not a facsimile or pdf (or other electronic reproduction of a) signature.

(g) Further

Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute

and deliver all such other agreements, certificates, instruments and documents as the other party may reasonably request in order to

carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

(h) Contract

Interpretation. This Agreement is the joint product of each Investor and the Company and each provision hereof has been subject to

the mutual consultation, negotiation and agreement of such parties and shall not be construed for or against any party hereto.

(i)  No

Third Party Beneficiaries. Except as set forth in Section 6, nothing in this Agreement, express or implied, is intended to confer

on any Person other than the parties to this Agreement any rights, remedies, claims, benefits, obligations or liabilities under or by

reason of this Agreement, and no Person that is not a party to this Agreement (including, without limitation, any partner, member, shareholder,

director, officer, employee or other beneficial owner of any party to this Agreement, in its own capacity as such or in bringing a derivative

action on behalf of a party to this Agreement) shall have any standing as a third party beneficiary with respect to this Agreement or

the transactions contemplated hereby.

(j)  Severability.

If any part or provision of this Agreement is held unenforceable or in conflict with the applicable laws or regulations of any jurisdiction,

the invalid or unenforceable part or provisions shall be replaced with a provision which accomplishes, to the extent possible, the original

business purpose of such part or provision in a valid and enforceable manner, and the remainder of this Agreement shall remain binding

upon the parties hereto.

(k) Non-Recourse.

Notwithstanding anything that may be expressed or implied in this Agreement, the Company covenants, agrees and acknowledges that no recourse

under this Agreement or any documents or instruments delivered in connection with this Agreement shall be had against any current or

future director, officer, employee, stockholder, general or limited partner or member of the Investors or of any affiliates or assignees

thereof, whether by the enforcement of any assessment or by any legal or equitable proceeding, or by virtue of any statute, regulation

or other applicable law, it being expressly agreed and acknowledged that no personal liability whatsoever shall attach to, be imposed

on or otherwise be incurred by any current or future director, officer, employee, stockholder, general or limited partner or member of

the Investors or of any affiliates or assignees thereof, as such for any obligation of the Investors under this Agreement or any documents

or instruments delivered in connection with this Agreement for any claim based on, in respect of or by reason of such obligations or

their creation.

(l)  Specific

Performance. In addition to any and all other remedies that may be available at law in the event of any breach of this Agreement,

each Investor shall be entitled to seek specific performance of the agreements and obligations of the Company hereunder and to such other

injunction or other equitable relief as may be granted by a court of competent jurisdiction.

(m)            Cumulative

Remedies. The remedies provided herein are cumulative and not exclusive of any remedies provided by law.

[Signature

Page Follows]

WITNESS WHEREOF, the parties have caused this Registration Rights Agreement to be duly executed as of date first written above.

COMPANY:

Ensysce Biosciences, INC.

By:

Name:

Dr. Lynn Kirkpatrick

Title:

President and Chief Executive Officer

[Signature

Page to Registration Rights Agreement]

WITNESS WHEREOF, the parties have caused this Registration Rights Agreement to be duly executed as of date first written above.

INVESTOR:

[NAME]

By:

Name:

Title:

[Signature

Page to Registration Rights Agreement]

Exhibit

PLAN

OF DISTRIBUTION

Exhibit

INVESTOR

QUESTIONNAIRE

EX-10.3

Filename: ex10-3.htm · Sequence: 7

Exhibit

10.3

FORM

OF REGISTRATION RIGHTS AGREEMENT

This

Registration Rights Agreement (this “Agreement”) is dated as of August 5, 2026, by and between Ensysce Biosciences,

Inc., a Delaware corporation (the “Company”), and the undersigned signatories hereto.

This

Agreement is made in connection with that Agreement and Plan of Merger, dated as of the date hereof, by and among the Company, Cy Biopharma,

Inc., a Delaware corporation (“Cy Biopharma”), and certain other parties thereto (as amended, restated, supplemented

or otherwise modified from time to time, the “Merger Agreement”), whereby as consideration for the transactions contemplated

by the Merger Agreement (collectively, the “Merger”), the Company has agreed to issue shares of the Company’s

Series C Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the “Preferred Shares”), to the equityholders

of Cy Biopharma.

addition, in connection with the Merger Agreement, the Company has also entered into that certain Omnibus Amendment and Termination Agreement

with 3i, LP (“3i”), whereby as consideration for the transactions contemplated thereby, the Company has agreed to

issue Preferred Shares to 3i.

NOW,

THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt

and adequacy of which are hereby acknowledged, the Company and the Holders agree as follows:

Definitions. Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the

Merger Agreement. As used in this Agreement, the following terms shall have the following meanings:

1.1

“Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is

controlled by, or is under common control with such Person, including without limitation any general partner, managing member, officer,

director or trustee of such Person, or any venture capital fund or registered investment company now or hereafter existing that is controlled

by one or more general partners, managing members or investment adviser of, or shares the same management company or investment adviser

with, such Person.

1.2

“Board of Directors” means the board of directors of the Company.

1.3

“Business Day” means any day other than Saturday, Sunday, or other day on which commercial banks in The City of New

York are authorized or required by law to remain closed.

1.3

“Common Stock” means shares of the Company’s common stock, par value $0.0001 per share, and any other capital

stock of the Company into which such common stock is reclassified or reconstituted.

1.4

“Damages” means any loss, damage, claim or liability (joint or several) to which a party hereto may become subject

under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action

in respect thereof) arises out of or is based upon: (i) any untrue statement or alleged untrue statement of a material fact contained

in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments

or supplements thereto; (ii) an omission or alleged omission to state therein a material fact required to be stated therein, or necessary

to make the statements therein not misleading; or (iii) any violation or alleged violation by the indemnifying party (or any of its agents

or Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities

Act, the Exchange Act, or any state securities law.

1.5

“Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

1.6

“Form S-1” means such form under the Securities Act as in effect on the date hereof or any successor registration

form under the Securities Act subsequently adopted by the SEC.

1.7

“Form S-3” means such form under the Securities Act as in effect on the date hereof or any registration form under

the Securities Act subsequently adopted by the SEC that permits forward incorporation of substantial information by reference to other

documents filed by the Company with the SEC.

1.8

“Holder” means any holder of shares of Registrable Securities who is a party to this Agreement.

1.9

“Immediate Family Member” means a child, stepchild, grandchild, parent, stepparent, grandparent, spouse, sibling,

mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including, adoptive relationships, of a

natural person referred to herein.

1.10

“Initiating Holders” means, collectively, Holders who properly initiate a registration request under this Agreement.

1.11

“Misstatement” shall mean an untrue statement of a material fact or an omission to state a material fact required

to be stated in a registration statement or prospectus or necessary to make the statements in a registration statement or prospectus

in the light of the circumstances under which they were made not misleading.

1.12

“Person” means any individual, corporation, partnership, trust, limited liability company, association or other entity.

1.13

“Registrable Securities” means (i) the Preferred Shares; (ii) shares of Common Stock issuable or issued upon conversion

of Preferred Shares; and (iii) any securities of the Company issued with respect to the securities referenced in clauses (i) and (ii)

by way of any stock dividend or stock split or in connection with any merger, combination, recapitalization, share exchange, consolidation,

reorganization or other similar transaction, excluding in all cases, however, any Registrable Securities sold by a Person in a transaction

in which the applicable rights under this Agreement are not assigned pursuant to Section 3.1, provided that, with respect to a

particular Holder, such Holder’s Common Stock referenced in the preceding clause (ii) shall cease to be Registrable Securities

upon a sale pursuant to a registration statement or Rule 144 (in which case, only such security sold by the Holder shall cease to be

a Registrable Security).

1.14

“Registrable Securities then outstanding” means the number of shares determined by adding the number of shares of

outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant

to then exercisable and/or convertible securities that are Registrable Securities.

1.15

“Registration” shall mean a registration effected by preparing and filing a registration statement or similar document

in compliance with the requirements of the Securities Act, and the applicable rules and regulations promulgated thereunder, and such

registration statement becoming effective.

1.16

“Rule 144” means Rule 144 promulgated by the SEC under the Securities Act.

1.17

“Rule 415” means Rule 415 promulgated by the SEC under the Securities Act.

1.18

“SEC” means the Securities and Exchange Commission.

1.19

“SEC Guidance” means any publicly-available written or oral guidance, comments, requirements or requests of the SEC

staff under the Securities Act; provided, that any such oral guidance, comments, requirements or requests are reduced to writing by the

SEC.

1.20

“Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

1.21

“Selling Expenses” means (a) all underwriting discounts, selling commissions, and stock transfer taxes applicable

to the sale of Registrable Securities, and (b) fees and disbursements of counsel for any Holder, except for the fees and disbursements

of Selling Holder Counsel borne and paid by the Company as provided in Section 2.7.

Registration Rights. The Company covenants and agrees as follows:

2.1

Registration Statement Filing.

(a)

The Company shall, as promptly as reasonably practicable and in any event no later than ninety (90) calendar days after the Closing Date

(the “Filing Deadline”), prepare and file with the SEC an initial Registration Statement (the “Initial Registration

Statement”) covering the resale of all Registrable Securities for an offering to be made on a continuous basis pursuant to

Rule 415; provided, however, if Cy Biopharma has not delivered the financial statements required to be included in the Initial Registration

Statement pursuant to the rules and regulations of the SEC to the Company by seventy-five (75) days after closing of the Merger, such

Filing Deadline shall be extended by one calendar day for each day that Cy Biopharma has not delivered such financial statements. The

Initial Registration Statement shall be on Form S-3 (except if the Company is then ineligible to register for resale the Registrable

Securities on Form S-3, in which case such registration shall be on such other form available to register for resale the Registrable

Securities as a secondary offering) subject to the provisions of Section 2.1(e). Notwithstanding the registration obligations

set forth in this Section 2.1, in the event the SEC informs the Company that all of the Registrable Securities cannot, as a result

of the application of Rule 415, be registered for resale as a secondary offering on a single registration statement, the Company agrees

to promptly (i) inform each of the Holders thereof and use its commercially reasonable efforts to file amendments to the Initial Registration

Statement as required by the SEC and/or (ii) withdraw the Initial Registration Statement and file a new registration statement (a “New

Registration Statement”), in either case covering the maximum number of Registrable Securities permitted to be registered by

the SEC, on Form S-3 or, if the Company is ineligible to register the Registrable Securities on Form S-3, such other form available to

register for resale the Registrable Securities for sale by the Holders; provided, however, that prior to filing such amendment

or New Registration Statement, the Company shall be obligated to use its commercially reasonable efforts to advocate with the SEC for

the registration of all of the Registrable Securities as a secondary offering in accordance with the SEC Guidance. Notwithstanding any

other provision of this Agreement, if the SEC or any SEC Guidance sets forth a limitation of the number of Registrable Securities permitted

to be registered on a particular registration statement (and notwithstanding that the Company used diligent efforts to advocate with

the SEC for the registration of all or a greater number of Registrable Securities), unless otherwise directed in writing by a Holder

as to its Registrable Securities, the number of Registrable Securities to be registered on such registration statement will be reduced

in proportion (as nearly as practicable) to the number of Registrable Securities owned by each Holder, subject to a determination by

the SEC that certain Holders must be reduced first based on the number of Registrable Securities held by such Holders. In the event of

a cutback hereunder, the Company shall notify the Holder in writing as soon as practicable, and in any event within (1) Business Day

of such determination, together with the calculations as to such Holder’s allotment. In the event the Company amends the Initial

Registration Statement or files a New Registration Statement, as the case may be, in accordance with the foregoing, the Company will

use its commercially reasonable efforts to file with the SEC, as promptly as allowed by the SEC or SEC Guidance provided to the Company

or to registrants of securities in general, one or more registration statements on Form S-3 or such other form available to register

for resale those Registrable Securities that were not registered for resale on the Initial Registration Statement, as amended, or the

New Registration Statement (the “Remainder Registration Statements”). No Holder shall be named as an “underwriter”

in any registration statement without such Holder’s prior written consent.

(b)

The Company shall use its commercially reasonable efforts to have the Initial Registration Statement and any amendment declared effective

by the SEC at the earliest possible date but no later than the earlier of (1) the ninetieth (90th) calendar day following the initial

filing date of the Initial Registration Statement if the SEC notifies the Company that it will “review” the Initial Registration

Statement, (2) the fifth (5th) Business Day after the date the Company is notified (orally or in writing, whichever is earlier) by the

SEC that the Initial Registration Statement will not be “reviewed” or will not be subject to further review (the “Effectiveness

Deadline”); provided, however that any Business Day that the SEC is not open because of a shutdown of the government or otherwise

shall not count against the ninety (90) calendar day period. The Company shall use commercially reasonable efforts to keep the Initial

Registration Statement continuously effective pursuant to Rule 415 promulgated under the Securities Act and available for the resale

by the Holders of all of the Registrable Securities covered thereby at all times until the earliest to occur of the following events:

(i) the date on which the Holders shall have resold all the Registrable Securities covered thereby; and (ii) the date on which the Registrable

Securities may be resold by the Holders without registration and without regard to any volume or manner-of-sale limitations by reason

of Rule 144, without the requirement for the Company to be in compliance with the current public information requirement under Rule 144

under the Securities Act or any other rule of similar effect (the “Effectiveness Period”). The Company shall request

effectiveness of a registration statement as of 4:00 P.M. New York City time on a Business Day. The Company shall promptly notify the

Holders via e-mail of the effectiveness of a registration statement or any post-effective amendment thereto on the same Business Day

that the Company telephonically confirms effectiveness with the SEC, which date of confirmation shall initially be the date requested

for effectiveness of such registration statement. The Company shall, by 9:30 A.M. New York City time on the first Business Day after

the Effective Date, file a final prospectus with the SEC, as required by Rule 424(b) and shall provide the Holders with copies of the

final prospectus to be used in connection with the sale or other disposition of the securities covered thereby. The Company shall promptly

inform each Holder in writing if, at any time during the Effectiveness Period, the Company does not satisfy the conditions specified

in Rule 172 and, as a result thereof, the Holder is required to deliver a prospectus in connection with any disposition of Registrable

Securities.

(c)

On no more than two occasions and for not more than sixty (60) consecutive calendar days or for a total of not more than ninety (90)

calendar days in any twelve (12) month period, the Company may delay the effectiveness of the Initial Registration Statement or any other

Registration Statement, or suspend the use of any prospectus, in the event that the Company or Board of Directors determines, in good

faith and upon advice of legal counsel, that such delay or suspension is necessary to (A) delay the disclosure of material non-public

information concerning the Company, the disclosure of which at the time is not, in the good faith opinion of the Company, in the best

interests of the Company or (B) amend or supplement the affected Registration Statement or the related prospectus so that such Registration

Statement or prospectus shall not include an untrue statement of a material fact or omit to state a material fact required to be stated

therein or necessary to make the statements therein, in the case of the prospectus in light of the circumstances under which they were

made, not misleading (an “Allowed Delay”); provided, that the Company shall promptly (a) notify each Holder in writing

of the commencement of an Allowed Delay, but shall not (without the prior written consent of an Investor) disclose to such Investor any

material non-public information giving rise to an Allowed Delay, (b) advise the Holders in writing to cease all sales under the applicable

Registration Statement until the end of the Allowed Delay and (c) use commercially reasonable efforts to terminate an Allowed Delay as

promptly as practicable.

(d)

Each Holder of Registrable Securities to be sold agrees to furnish to the Company a completed form of questionnaire in the form attached

hereto as Exhibit A, or equivalent information, provided to the Company in connection with the preparation of a registration statement

(the “Selling Shareholder Questionnaire”) not less than five (5) Business Days prior to the anticipated filing date

of such registration statement. Each Holder further agrees that it shall not be entitled to be named as a selling securityholder in the

registration statement or use the prospectus for offers and resales of Registrable Securities at any time, unless such Holder has provided

such information to the Company and responded to any reasonable requests for further information. Each Holder acknowledges and agrees

that the information in the Selling Shareholder Questionnaire or any request for further information as described in this Section

2.1(d) will be used by the Company in the preparation of the registration statement and hereby consents to the inclusion of such

information in the registration statement (subject to such Holder’s right to timely review the registration statement as set forth

herein).

(e) In

the event that Form S-3 ceases to be available for the registration of the resale of Registrable Securities hereunder, the Company shall

(i) register the resale of the Registrable Securities on another appropriate form reasonably acceptable to the Holders and (ii) undertake

to register the Registrable Securities on Form S-3 promptly after such form is available, provided that the Company shall maintain

the effectiveness of the registration statement then in effect until such time as a registration statement on Form S-3 covering the Registrable

Securities has been declared effective by the SEC.

(f)

Registrations effected by the Company pursuant to this Section 2.1 shall not be counted as demand registrations effected pursuant

to Section 2.2 hereof.

2.2

Demand Registration.

(a)

Form S-1 Demand. If, at any time after February 1, 2027, the Company is not eligible to use a Form S-3 registration statement

and the Company receives a request from Holders of at least forty percent (40%) of the Registrable Securities then outstanding, then

the Company shall file a Form S-1 registration statement with respect to at least forty percent (40%) of the Registrable Securities then

outstanding as further described below. In such case, the Company shall (x) within five (5) days after the date such request is given,

give notice thereof (the “Demand Notice”) to all Holders other than the Initiating Holders (if any); and (y) as soon

as practicable, and in any event within forty-five (45) days after the date such request is given by the Initiating Holders, file a Form

S-1 registration statement under the Securities Act covering the resale of all Registrable Securities that the Initiating Holders requested

to be registered and, if applicable, any additional Registrable Securities requested to be included in such registration by any other

Holders, as specified by notice given by each such Holder to the Company within ten (10) days of the date the Demand Notice is given

and, in each case, subject to the limitations of Sections 2.2(c) and 2.4. The Company shall use its commercially reasonable

efforts to cause such registration statement to become effective as soon as practicable after filing, but no later than the earlier of

(i) forty-five (45) calendar days after the filing of such registration statement (or seventy-five (75) calendar days after the filing

of such registration statement if the SEC notifies the Company that it will “review” such registration statement) and (ii)

five (5) Business Days after the Company is notified (orally or in writing, whichever is earlier) by the SEC that such registration statement

will not be “reviewed” or will not be subject to further review.

(b)

Form S-3 Demand. If, at any time after February 1, 2027, the Company is eligible to use a Form S-3 registration statement and

the Company receives a request from Holders of at least thirty percent (30%) of the Registrable Securities then outstanding, then the

Company shall file a Form S-3 registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated

aggregate offering price, net of Selling Expenses, of at least $20,000,000 as further described below. In such case, the Company shall

(i) within five (5) days after the date such request is given, give a Demand Notice to all Holders other than the Initiating Holders

(if any); and (ii) as soon as practicable, and in any event within fifteen (15) days after the date such request is given by the Initiating

Holders, file a Form S-3 registration statement under the Securities Act covering the resale of all Registrable Securities that the Initiating

Holders requested to be registered and, if applicable, any additional Registrable Securities requested to be included in such registration

by any other Holders, as specified by notice given by each such Holder to the Company within five (5) days of the date the Demand Notice

is given and, in each case, subject to the limitations of Sections 2.2(c) and 2.4. The Company shall use its commercially

reasonable efforts to cause such registration statement to become effective as soon as practicable after filing, but no later than the

earlier of (i) thirty (30) calendar days after the filing of such registration statement (or forty-five (45) calendar days after the

filing of such registration statement if the SEC notifies the Company that it will “review” such registration statement)

and (ii) five (5) Business Days after the Company is notified (orally or in writing, whichever is earlier) by the SEC that such registration

statement will not be “reviewed” or will not be subject to further review.

(c)

Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this Section

2.2 a certificate signed by the Company’s Chief Executive Officer stating that, in the good faith judgment of the Board of

Directors, it would be materially detrimental to the Company and its stockholders for such registration statement to either become effective

or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would

(i) materially interfere with a significant acquisition, corporate reorganization or other similar transaction involving the Company;

(ii) require premature disclosure of material information that the Company has a bona fide business purpose for preserving as confidential;

or (iii) render the Company unable to comply with requirements under the Securities Act or the Exchange Act, then the Company shall have

the right to defer taking action with respect to such filing for a period of not more than forty-five (45) days after the request of

the Initiating Holders is given; provided, however, that the Company may not invoke this right more than twice in any twelve (12)

month period.

(d)

The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Section 2.2(a) (i)

after the Company has effected three (3) registrations pursuant to Section 2.2(a); or (ii) if the Initiating Holders propose to

dispose of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Section 2.2(b).

The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Section 2.2(b) (i)

if the Company has effected two registrations pursuant to Section 2.2(b) within the twelve (12) month period immediately preceding

the date of such request.

(e)

Notwithstanding the provisions of Section 2.2 or any other part of this Agreement, a Registration pursuant to Section 2.2(a)

or (b) shall not count as a Registration unless and until (i) the registration statement filed with the SEC with respect to a

Registration pursuant to Section 2.2(a) or (b) has been declared effective by the SEC and remains effective for not less

than 180 days (or such shorter period as shall terminate when all Registrable Securities covered by such registration statement have

been sold or withdrawn), or if such registration statement relates to an underwritten offering, such longer period as, in the opinion

of counsel for the managing underwriter, a prospectus is required by law to be delivered in connection with sales of Registrable Securities

by an underwriter or dealer and (ii) the Company has complied with all of its obligations under this Agreement with respect thereto;

provided, further, however, that if, after such registration statement has been declared effective, an offering of Registrable

Securities in a Registration pursuant to Section 2.2(a) or (b) is subsequently interfered with by any stop order or injunction

of the SEC, federal or state court or any other governmental agency, the registration statement with respect to such Registration shall

be deemed not to have been declared effective unless and until (i) such stop order or injunction is removed, rescinded or otherwise terminated,

and (ii) a majority-in-interest of the Initiating Holders initiating such request for registration under Section 2.2(a) or (b)

thereafter affirmatively elect to continue with such Registration and accordingly notify the Company in writing, but in no event later

than five (5) days, of such election.

2.3

Company Registration. If the Company proposes to register (including, for this purpose, a registration effected by the Company

for stockholders of the Company other than the Holders) any of its securities under the Securities Act in connection with the public

offering of such securities solely for cash, then the Company shall give written notice of such proposed filing to all of the Holders

of Registrable Securities as soon as practicable but not less than ten (10) days before the anticipated filing date of such registration

statement, which notice shall (A) describe the amount and type of securities to be included in such offering, the intended method(s)

of distribution, and the name of the proposed managing underwriter(s), if any, in such offering, and (B) offer to all of the Holders

of Registrable Securities the opportunity to register the sale of such number of Registrable Securities as such Holders may request in

writing within five (5) days after receipt of such written notice (such Registration a “Piggyback Registration”).

Upon the request of each Holder the Company shall, subject to the provisions of Section 2.4, cause to be registered all of the

Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate

or withdraw any registration initiated by it under this Section 2.3 before the effective date of such registration, whether or

not any Holder has elected to include Registrable Securities in such registration. The expenses (other than Selling Expenses) of such

withdrawn registration shall be borne by the Company in accordance with Section 2.7. Any Registration effected pursuant to this

Section 2.3 shall not be counted as a Registration pursuant to a demand registration effected under Section 2.2 hereof,

and there shall be no limit on the number of Piggyback Registrations.

2.4

Underwriting Requirements.

(a)

If, pursuant to Section 2.2, the Initiating Holders intend to distribute the Registrable Securities covered by their request by

means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Section 2.2, and the Company

shall include such information in the Demand Notice. The underwriter(s) will be selected by the Holders of a majority of the Registrable

Securities to be included in such underwritten offering and shall be reasonably acceptable to the Company. The right of any Holder to

include such Holder’s Registrable Securities in such registration shall be conditioned upon such Holder’s participation in

such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein.

All Holders proposing to distribute their securities through such underwriting shall (together with the Company as provided in Section

2.5(d)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding

any other provision of this Section 2.4, if the underwriter(s) advise(s) the Initiating Holders in writing that the dollar amount

or number of Registrable Securities to be underwritten, exceeds the maximum dollar amount or maximum number of equity securities that

can be sold in the underwritten offering without adversely affecting the proposed offering price, the timing, the distribution method,

or the probability of success of such offering (such maximum dollar amount or maximum number of such securities, as applicable, the “Maximum

Number of Securities”), then the Company shall so advise all Holders of Registrable Securities that otherwise would be underwritten

pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated as follows: (i)

first, the Registrable Securities of each participating Holder, if any, that has requested in writing to be included in such underwritten

offering in proportion (as nearly as practicable) to the number of Registrable Securities owned by each such Holder or in such other

proportion as shall mutually be agreed to by all such selling Holders that can be sold without exceeding the Maximum Number of Securities;

(ii) second, to the extent that the Maximum Number of Securities has not been reached under the foregoing clause (i), Common Stock or

other equity securities that the Company desires to sell, which can be sold without exceeding the Maximum Number of Securities; and (iii)

third, to the extent that the Maximum Number of Securities has not been reached under the foregoing clauses (i) and (ii), Common Stock

or other equity securities of other persons or entities that the Company is obligated to register in a Registration pursuant to separate

written contractual arrangements with such persons and that can be sold without exceeding the Maximum Number of Securities.

(b)

In connection with any offering involving an underwriting of shares of the Company’s capital stock pursuant to Section 2.2,

the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders

accept the terms of the underwriting as agreed upon between the Company and its underwriters.

(c)

If the underwriter(s) in an underwritten offering that is to be a Piggyback Registration, in good faith, advise the Company and the Holders

of Registrable Securities participating in the Piggyback Registration in writing that the dollar amount or number of equity securities

that the Company desires to sell, taken together with (i) Common Stock and other equity securities, if any, as to which Registration

has been demanded pursuant to separate written contractual arrangements with persons or entities other than the Holders of Registrable

Securities hereunder, (ii) the Registrable Securities as to which registration has been requested pursuant to Section 2.2(a) or

(b) hereof, and (iii) Common Stock and other equity securities, if any, as to which Registration has been requested pursuant to

separate written contractual piggy-back registration rights of other shareholders of the Company, exceeds the Maximum Number of Securities,

then

(i)

If the Registration is undertaken for the Company’s account, the Company shall include in any such Registration (A) first,

Common Stock or other equity securities that the Company desires to sell, which can be sold without exceeding the Maximum Number of

Securities; (B) second, to the extent that the Maximum Number of Securities has not been reached under the foregoing clause (A), the

Registrable Securities of all Holders who have requested in writing to be included in such Piggyback Registration, in proportion (as

nearly as practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be

agreed to by all such selling Holders that can be sold without exceeding the Maximum Number of Securities; and (C) third, to the

extent that the Maximum Number of Securities has not been reached under the foregoing clauses (A) and (B), Common Stock and equity

securities, if any, as to which Registration has been requested pursuant to written contractual piggy-back registration rights of

other shareholders of the Company, which can be sold without exceeding the Maximum Number of Securities; and

(ii)

If the Registration is pursuant to a request by persons or entities other than the Holders of Registrable Securities, then the

Company shall include in any such Registration (A) first, Common Stock or other equity securities, if any, of such requesting

persons or entities, other than the Holders of Registrable Securities, which can be sold without exceeding the Maximum Number of

Securities; (B) second, to the extent that the Maximum Number of Securities has not been reached under the foregoing clause (A), the

Registrable Securities of all Holders who have requested in writing to be included in such Piggyback Registration, in proportion (as

nearly as practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be

agreed to by all such selling Holders that can be sold without exceeding the Maximum Number of Securities; (C) third, to the extent

that the Maximum Number of Securities has not been reached under the foregoing clauses (A) and (B), Common Stock or other equity

securities that the Company desires to sell, which can be sold without exceeding the Maximum Number of Securities; and (D) fourth,

to the extent that the Maximum Number of Securities has not been reached under the foregoing clauses (A), (B) and (C), Common Stock

or other equity securities for the account of other persons or entities that the Company is obligated to register pursuant to

separate written contractual arrangements with such persons or entities, which can be sold without exceeding the Maximum Number of

Securities.

For

the purposes of the provisions in Section 2.1, and 2.4(a), (b) and (c) concerning apportionment, for any

selling Holder that is a partnership, limited liability company or corporation, the partners, members, retired partners, retired members,

stockholders and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members

and retired members and any trusts for the benefit of any of the foregoing Persons, shall be deemed to be a single “selling Holder,”

and any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate number of Registrable

Securities owned by all Persons included in such “selling Holder,” as defined in this sentence.

2.5

Obligations of the Company. Whenever required under this Section 2 to effect the registration of any Registrable Securities,

the Company shall, as expeditiously as reasonably possible:

(a)

prepare and file with the SEC such amendments, post-effective amendments and supplements to such registration statement, and the prospectus

used in connection with such registration statement as may be reasonably requested by the Holders or any underwriter of Registrable Securities,

or as may be necessary to comply with the Securities Act, in order to enable the disposition of all securities covered by such registration

statement;

(b)

furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities

Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities;

(c)

use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other

securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company

shall not be required to qualify to do business or to file a general consent to service of process in any such states or jurisdictions,

unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act;

(d)

in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and

customary form, with the underwriter(s) of such offering;

(e)

use its commercially reasonable efforts to cause all such Registrable Securities covered by such registration statement to be listed

on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities

issued by the Company are then listed;

(f)

provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number

for all such Registrable Securities, in each case not later than the effective date of such registration;

(g)

promptly make available for inspection by the selling Holders, any underwriter(s) participating in any disposition pursuant to such registration

statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial

and other records, pertinent corporate documents and properties of the Company, and cause the Company’s directors, officers, employees

and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant or agent,

in each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate

due diligence in connection therewith;

(h)

notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been

declared effective or a supplement to any prospectus forming a part of such registration statement has been filed;

(i)

after such registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or supplement

such registration statement or prospectus;

(j)

promptly advise each selling Holder of Registrable Securities after it shall receive notice or obtain knowledge thereof, of the issuance

of any stop order by the SEC suspending the effectiveness of such registration statement or the initiation or threatening of any proceeding

for such purpose and promptly use its commercially reasonable efforts to prevent the issuance of any stop order or to obtain its withdrawal

if such stop order should be issued;

(k)

notify each of the Holders in writing if a registration statement or prospectus contains a Misstatement. and promptly prepare and file

any required supplement or amendment correcting any Misstatement promptly after the time of such notice and, if necessary, request the

immediate effectiveness thereof;

(l)

obtain a “cold comfort” letter from the Company’s independent registered public accountants in the event of an underwritten

offering, in customary form and covering such matters of the type customarily covered by “cold comfort” letters as the managing

underwriter(s) may reasonably request, and reasonably satisfactory to a majority-in-interest of the participating Holders and such managing

underwriter;

(m)

on the date the Registrable Securities are delivered for sale pursuant to a registration statement, in the event of an underwritten offering,

obtain an opinion, dated such date, of counsel representing the Company for the purposes of such registration of Registrable Securities,

addressed to the underwriter(s), covering such legal matters with respect to the registration of the Registrable Securities in respect

of which such opinion is being given as the underwriter(s) may reasonably request and as are customarily included in such opinions and

negative assurance letters; and

(n)

if a registration of Registrable Securities, including an underwritten offering, involves the registration of Registrable Securities

with anticipated gross proceeds in excess of $1,000,000, use its reasonable efforts to make available senior executives of the Company

to participate in customary “road show” presentations that may be reasonably requested by the underwriter(s) in any underwritten

offering.

addition, the Company shall ensure that, at all times after any registration statement covering a public offering of securities of the

Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company’s directors

may implement a trading program under Rule 10b5-1 of the Exchange Act.

2.6

Furnish Information. It shall be a condition precedent to the obligations of the Company to take any action pursuant to this Section

2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information

regarding itself, the Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably required

to effect the registration of such Holder’s Registrable Securities.

2.7

Expenses of Registration. All expenses (other than Selling Expenses) incurred in connection with registrations, filings or qualifications

pursuant to Section 2, including all registration fees, filing fees (including fees with respect to filings required to be made

with the Financial Industry Regulatory Authority, Inc.), fees of the securities exchange on which Common Stock is then listed and any

other qualification fees; printers’ and accounting fees; fees and disbursements of counsel for the Company; and the reasonable

fees and disbursements, not to exceed $25,000, of one counsel for the selling Holders (“Selling Holder Counsel”),

shall be borne and paid by the Company; provided, however, that the Company shall not be required to pay for any expenses of any

registration proceeding begun pursuant to Section 2.2 if the registration request is subsequently withdrawn at the request of

the Holders of a majority of the Registrable Securities to be registered (in which case all selling Holders shall bear such expenses

pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless the Holders

of a majority of the Registrable Securities agree to forfeit their right to one registration pursuant to Sections 2.2(a) or 2.2(b),

as the case may be; provided further that if, at the time of such withdrawal, the Holders shall have learned of a material adverse

change in the condition, business, or prospects of the Company from that known to the Holders at the time of their request and have withdrawn

the request with reasonable promptness after learning of such information, then the Holders shall not be required to pay any of such

expenses and shall not forfeit their right to one registration pursuant to Sections 2.2(a) or 2.2(b), as the case may be.

All Selling Expenses set forth in clause (a) of the definition of Selling Expenses, relating to Registrable Securities registered pursuant

to this Section 2, shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities registered

on their behalf. The obligations of the Company and Holders under this Section 2.7 shall survive the completion of any offering

of Registrable Securities in a Registration under this Section 2, and otherwise shall survive the termination of this Agreement.

2.8

Delay of Registration. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any registration

pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of

this Section 2.

2.9

Indemnification. If any Registrable Securities are included in a registration statement under this Section 2:

(a)

To the extent permitted by law, the Company will indemnify and hold harmless each selling Holder, and the partners, members, directors,

officers and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the

Securities Act) for each such Holder; and each Person, if any, who controls such Holder or underwriter within the meaning of the Securities

Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person or other

aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim

or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained

in this Section 2.9(a) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected

without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the Company be liable for any Damages

to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information

furnished by or on behalf of any such Holder, underwriter, controlling Person or other aforementioned Person expressly for use in connection

with such registration.

(b)

To the extent permitted by law, each selling Holder, severally and not jointly, will indemnify and hold harmless the Company, and each

of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within

the meaning of the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act),

any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other Holder,

against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance

upon and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection with

such registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses

reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such

expenses are incurred; provided, however, that the indemnity agreement contained in this Section 2.9(b) shall not

apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Holder,

which consent shall not be unreasonably withheld; provided further that in no event shall the aggregate amounts payable by any

Holder by way of indemnity or contribution under Sections 2.9(b) and 2.9(d) exceed the proceeds from the offering received

by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder.

(c)

Promptly after receipt by an indemnified party under this Section 2.9 of notice of the commencement of any action (including any

governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect

thereof is to be made against any indemnifying party under this Section 2.9, give the indemnifying party notice of the commencement

thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires,

participate jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel

mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties

that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses

to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would

be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such

counsel in such action. The failure to give notice to the indemnifying party within a reasonable time of the commencement of any such

action shall relieve such indemnifying party of any liability to the indemnified party under this Section 2.9, to the extent that

such failure materially prejudices the indemnifying party’s ability to defend such action. The failure to give notice to the indemnifying

party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Section 2.9.

(d)

To provide for just and equitable contribution to joint liability under the Securities Act in any case in which either: (i) any party

otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Section 2.9 but it is judicially

determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the

denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this Section

2.9 provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any party

hereto for which indemnification is provided under this Section 2.9, then, and in each such case, such parties will contribute

to the aggregate losses, claims, damages, liabilities or expenses to which they may be subject (after contribution from others) in such

proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in connection

with the statements, omissions or other actions that resulted in such loss, claim, damage, liability or expense, as well as to reflect

any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined

by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged

omission of a material fact, relates to information supplied by the indemnifying party or by the indemnified party and the parties’

relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided, however,

that, in any such case (x) no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable

Securities offered and sold by such Holder pursuant to such registration statement, and (y) no Person guilty of fraudulent misrepresentation

(within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such

fraudulent misrepresentation; provided further that in no event shall a Holder’s liability pursuant to this Section 2.9(d),

when combined with the amounts paid or payable by such Holder pursuant to Section 2.9(b), exceed the proceeds from the offering

received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of willful misconduct or fraud by such

Holder.

(e)

Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in an underwriting agreement

entered into in connection with an underwritten public offering are in conflict with the foregoing provisions, the provisions in such

underwriting agreement shall control.

(f)

Unless otherwise superseded by an underwriting agreement entered into in connection with an underwritten public offering, the obligations

of the Company and Holders under this Section 2.9 shall survive the completion of any offering of Registrable Securities in a

registration under this Section 2, and otherwise shall survive the termination of this Agreement.

2.10

Reporting Obligations. As long as any Holder shall own Registrable Securities, the Company, at all times while it shall be a reporting

company under the Exchange Act, covenants to file timely (or obtain extensions in respect thereof and file within the applicable grace

period) all reports required to be filed by the Company after the date hereof pursuant to Sections 13(a) or 15(d) of the Exchange Act

and to, upon request, promptly furnish the Holders with true and complete copies of all such filings. The Company further covenants that

it shall take such further action as any Holder may reasonably request, all to the extent required from time to time to enable such Holder

to sell Registrable Securities held by such Holder without registration under the Securities Act within the limitation of the exemptions

provided by Rule 144 promulgated under the Securities Act (or any successor rule promulgated thereafter by the SEC), including using

commercially reasonable efforts to provide any legal opinions (including any opinion of outside counsel to the Company), instruction

letters and certificates to the Company’s transfer agent (i) in connection with a sale of such Holder’s Registrable Securities

in compliance with the requirements of Rule 144, and (ii) as soon as reasonably practicable and legally permissible to do so, removing

any restrictive legends from such Holder’s Registrable Securities and facilitating the transfer of such securities to a brokerage

account. Upon the request of any Holder, the Company shall deliver to such Holder a written certification of a duly authorized officer

as to whether it has complied with such requirements.

2.11

“Market Stand-off” Agreement. Each Holder hereby agrees that it will not, without the prior written consent of the

managing underwriter, during the period commencing on the date of the final prospectus relating to the registration by the Company for

its own behalf, in connection with an underwritten offering, of shares of its Common Stock or securities convertible into or exercisable

or exchangeable for Common Stock under the Securities Act on a registration statement on Form S-1 or Form S-3, and ending on the date

specified by the Company and the managing underwriter (such period not to exceed ninety (90) days), (i) lend; offer; pledge; sell; contract

to sell; sell any option or contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase;

or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable

or exchangeable (directly or indirectly) for Common Stock (whether such shares or any such securities are then owned by the Holder or

are thereafter acquired) or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the

economic consequences of ownership of such securities, whether any such transaction described in clause (i) or (ii) above is to be settled

by delivery of Common Stock or other securities, in cash, or otherwise, subject to exceptions to be agreed in connection with the applicable

underwritten offering. The underwriters in connection with such registration are intended third-party beneficiaries of this Section

2.11 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. Each Holder

further agrees to execute such agreements as may be reasonably requested by the underwriters in connection with such registration that

are consistent with this Section 2.11, or that are necessary to give further effect thereto, or that are customary under the circumstances.

Any discretionary waiver or termination of the restrictions of any or all of such agreements by the Company or the underwriters shall

apply pro rata to all Company stockholders that are subject to such agreements, based on the number of shares subject to such agreements.

2.12

Limitations on Registration Rights. As of the date hereof, neither the Company nor any of its subsidiaries has entered into any

agreement with respect to its securities that would have the effect of impairing the rights granted to the Holders in this Agreement

or otherwise conflicts with the provisions hereof. The Company shall not hereafter enter into any agreement with respect to its securities

which is inconsistent with or violates the rights granted to the Holders of Registrable Securities in this Agreement and in the event

of any conflict between any such agreement or agreements and this Agreement, the terms of this Agreement shall prevail.

Miscellaneous.

3.1

Successors and Assigns. The rights under this Agreement may be assigned (but only with all related obligations) by a Holder to

a transferee of Registrable Securities that (i) is an Affiliate of a Holder; (ii) is a Holder’s Immediate Family Member or trust

for the benefit of an individual Holder or one or more of such Holder’s Immediate Family Members; or (iii) after such transfer,

holds at least 100,000 shares of Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends, combinations,

and other recapitalizations); provided, however, that (x) the Company is, within a reasonable time after such transfer,

furnished with written notice of the name and address of such transferee and the Registrable Securities with respect to which such rights

are being transferred; and (y) such transferee agrees in a written instrument delivered to the Company to be bound by and subject to

the terms and conditions of this Agreement, including the provisions of Section 2.11. For the purposes of determining the number

of Registrable Securities held by a transferee, the holdings of a transferee (1) that is an Affiliate or stockholder of a Holder; (2)

who is a Holder’s Immediate Family Member; or (3) that is a trust for the benefit of an individual Holder or such Holder’s

Immediate Family Member shall be aggregated together and with those of the transferring Holder; provided further that all transferees

who would not qualify individually for assignment of rights shall, as a condition to the applicable transfer, establish a single attorney-in-fact

for the purpose of exercising any rights, receiving notices, or taking any action under this Agreement. The terms and conditions of this

Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this

Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and

permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided

herein.

3.2

Governing Law. This Agreement shall be governed by the internal law of the State of Delaware, without regard to conflict of law

principles that would result in the application of any law other than the law of the State of Delaware.

3.3

Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all

of which together shall constitute one and the same instrument. Counterparts may be delivered via electronic mail (including pdf or any

electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and

any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

3.4

Titles and Subtitles. The titles and subtitles used in this Agreement are for convenience only and are not to be considered in

construing or interpreting this Agreement.

3.5

Notices.

(a)

All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given

upon the earlier of actual receipt or (i) personal delivery to the party to be notified; (ii) when sent, if sent by electronic mail during

the recipient’s normal business hours, and if not sent during normal business hours, then on the recipient’s next business

day; (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv) one

(1) business day after the business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next-day

delivery, with written verification of receipt. All communications shall be sent to the respective parties at their addresses as set

forth on the signature pages hereto, or to the principal office of the Company and to the attention of the Chief Financial Officer, in

the case of the Company, or to such email address or address as subsequently modified by written notice given in accordance with this

Section 3.5. If notice is given to the Company, a copy shall also be sent to Troutman Pepper Locke LLP, Union Trust Building,

501 Grant Street, Suite 300, Pittsburgh, PA 15219 Attn: Eric D. Kline; Email: .

(b)

Consent to Electronic Notice. Each Holder consents to the delivery of any stockholder notice pursuant to the Delaware General

Corporation Law (the “DGCL”), as amended or superseded from time to time, by e-mail pursuant to Section 232 of the DGCL (or

any successor thereto) at the e-mail address set forth below the Holder’s name on the signature page hereto, as updated from time

to time by notice to the Company. To the extent that any notice given by means of e-mail is returned or undeliverable for any reason,

the foregoing consent shall be deemed to have been revoked until a new or corrected e-mail address has been provided, and such attempted

electronic notice shall be ineffective and deemed to not have been given. Each party agrees to promptly notify the other parties of any

change in its e-mail address, and that failure to do so shall not affect the foregoing.

3.6

Amendments and Waivers. Any term of this Agreement may be amended, modified or terminated and the observance of any term of this

Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written

consent of the Company and the Holders of a majority of the Registrable Securities then outstanding; provided that any provision

hereof may be waived by a Holder of Registrable Securities on such party’s own behalf, without the consent of any other party.

Notwithstanding the foregoing, (a) this Agreement may not be amended, modified or terminated and the observance of any term hereof may

not be waived with respect to any Holder without the written consent of such Holder, unless such amendment, modification, termination,

or waiver applies to all Holders in the same fashion. Any amendment, modification, termination, or waiver effected in accordance with

this Section 3.6 shall be binding on all parties hereto, regardless of whether any such party has consented thereto. No waivers

of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed

as a further or continuing waiver of any such term, condition, or provision.

3.7

Severability. If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any rule

of law or public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so

long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner materially adverse to any

party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto

shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in a

mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated to the fullest

extent possible.

3.8

Aggregation of Stock. All Registrable Securities held or acquired by Affiliates shall be aggregated together for the purpose of

determining the availability of any rights under this Agreement and such Affiliates may apportion such rights as among themselves in

any manner they deem appropriate.

3.9

Confidentiality. Pending any required public disclosure and subject to applicable legal requirements, the parties will maintain

appropriate confidentiality of their discussions and any notifications regarding a prospective Registration or offering of Registrable

Securities.

3.10

Entire Agreement. This Agreement (including any Schedules and Exhibits hereto) constitutes the full and entire understanding and

agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject

matter hereof existing between the parties is expressly canceled.

3.11

Dispute Resolution. In any action of proceeding between any of the parties arising out of or relating to this Agreement, each

of the parties (a) hereby irrevocably and unconditionally consent and submit to the exclusive jurisdiction and venue of the Court of

Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the United States District

Court for the District of Delaware or, to the extent that neither of the foregoing courts has jurisdiction, the Superior Court of the

State of Delaware; (b) agree that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance

with clause (a) of this Section 3.11, and (c) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise,

in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that

its property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum,

that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced

in or by such court.

Waiver

of Jury Trial: EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS

AGREEMENT, THE OTHER TRANSACTION DOCUMENTS, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED

TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION,

INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND

STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY

EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL,

AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL.

3.12

Delays or Omissions. No delay or omission to exercise any right, power, or remedy accruing to any party under this Agreement,

upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching

or nondefaulting party, nor shall it be construed to be a waiver of or acquiescence to any such breach or default, or to any similar

breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or

default theretofore or thereafter occurring. All remedies, whether under this Agreement or by law or otherwise afforded to any party,

shall be cumulative and not alternative.

[Remainder

of Page Intentionally Left Blank]

WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the date first written above.

ENSYSCE BIOSCIENCES, INC.

By:

Name:

Dr. Lynn Kirkpatrick

Title:

President and Chief Executive Officer

[Registration

Rights Agreement]

WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the date first written above.

HOLDER:

[NAME]

By:

Name:

Title:

ADDRESS FOR NOTICE

[Registration

Rights Agreement]

Exhibit

SELLING

SECURITY HOLDER QUESTIONNAIRE

EX-10.4

Filename: ex10-4.htm · Sequence: 8

Exhibit

10.4

OMNIBUS

AMENDMENT AND TERMINATION AGREEMENT

This

Omnibus Amendment and Termination Agreement (this “Termination”) is entered into effective as of August 5, 2026 (the

“Effective Date”) by and among Ensysce Biosciences, Inc., a Delaware corporation on behalf of itself and its subsidiaries

(the “Company”) and 3i, LP (“3i” and together with the Company, the “Parties”),

whose signatures are set forth on the signature pages hereto.

RECITALS

WHEREAS,

the Company wishes to acquire 100% of the outstanding equity interests of Cy Biopharma, Inc., a Delaware corporation (together with its

subsidiaries, “Target”) for shares of common stock, par value $.0001 (“Common Stock”) and Series

C Preferred Stock, par value $.0001 (“Series C Preferred Stock”) of the Company (the “Transaction”), with

the date and time that the Transaction occurs to be referred to as the “Closing” for purposes of this Termination;

WHEREAS,

as a condition to the Transaction, the parties to the Transaction require that all instruments and understandings governing the relationship

between the Company and 3i, with the exception of the agreements set forth below, be terminated; and

WHEREAS,

the Parties desire to satisfy that condition for the Transaction to occur.

NOW,

THEREFORE, in consideration of the mutual promises and covenants set forth herein, the Parties agree as follows:

1. Termination.

Subject to Section 2, the Parties hereby agree:

(a)

to terminate all continuing requirements under all agreements and understandings between the Company, subsidiaries of the Company

and 3i, including, but not limited to, those referenced in the form attached as Exhibit A;

(b) that

the Company is authorized and granted power of attorney to terminate all existing liens, security interests and guarantees held by 3i,

including those held through Patent Security Agreements filed with the Patent and Trademark Office under 35 U.S.C. Section 261 and Security

Agreements and Subsidiary Guarantees recorded under the Article 9 of the Uniform Commercial Code in any states where currently filed,

with respect to the Company and its subsidiaries that were granted beginning in 2021. 3i represents that it has not assigned any of its

rights with respect to the Company and the Company’s subsidiaries;

this Termination constitutes a written consent without a meeting by 3i, voting separately as a single class, to amend the Certificate

of Designation of Series B preferred stock, par value $0.0001 of the Company (the “Series B Preferred Stock”) to eliminate

such certificate upon conversion or cancellation of such Series B Preferred Stock; and

(d) that

certain Securities Purchase Agreement dated November 13, 2025, between the Company and 3i, including without limitation, all rights that

3i has to purchase additional shares of Common Stock and warrants of the Company thereunder shall be cancelled. Provided, however, that

the Company shall use reasonable efforts to keep any existing registration statement covering existing Common Stock effective.

2. Consideration.

The Parties agree that the following shall apply:

(a) all

outstanding shares of the Series B Preferred Stock owned by 3i and/or any affiliate, including shares issuable upon accrual of dividends

and otherwise, shall be converted into 3,229,276 shares of Common Stock, of which 910,905 shall be issued to 3i at Closing, and 2,318,371

shall be issued to a bona fide financial institution in an abeyance account at Closing;

(b)

all outstanding warrants exercisable for shares of Common Stock, as set forth on Exhibit A, shall be converted into 7,182,517

shares of Series C Preferred Stock at an initial conversion ratio of Series C Preferred Stock to Common Stock of 1:1; provided further,

that if any additional rights are vested in the Series C Preferred Stock in the Securities Purchase Agreement between the Company and

Target in the Transaction (the “Series C Preferred Agreement”), a similar right shall apply to the Series C Preferred

Stock issued hereunder.

Company will pay 3i Two Hundred Fifty Thousand Dollars ($250,000) at Closing; and

(d) to

the extent that 3i’s right to receive shares of Common Stock pursuant to this Termination would result in 3i’s exceeding

a beneficial ownership limitation equal to 4.99% (or up to 9.99%, which increase shall not take effect until 61 days after 3i delivers

a written notice for such increase to the Company) of the number of shares of Common Stock outstanding immediately after giving effect

to such issuance (“Beneficial Ownership Limitation”), then 3i shall not be entitled to receive such shares to such

extent (or in the beneficial ownership of any shares of Common Stock as a result of such rights in contract or otherwise to such extent)

and the portion of such issuance shall be held in abeyance for the benefit of 3i until such time, if ever, as its right thereto would

not result in 3i exceeding the Beneficial Ownership Limitation.

The

Company hereby represents to 3i that as of the date hereof, the Company has 16,227,518 shares of Common Stock issued and outstanding.

3. Support

Agreement. 3i shall execute the support agreement in the form attached as Exhibit

4. Registration

Rights Agreement; Freely Tradable Shares.

(a) 3i

shall execute the registration rights agreement with respect to its Series C Preferred Stock, in the form attached as Exhibit C.

(b) On

or after the date of the Closing and in the event that 3i converts any of its shares of Series C Preferred Stock into shares of Common

Stock, the Company shall, within five (5) Business Days after the receipt of notice for any such conversion, (i) cause such shares of

Common Stock be issued in electronic form and credited by the Company to 3i or its designee’s specified DWAC account with DTC under

the DTC/FAST Program, or any similar program hereafter adopted by DTC performing substantially the same function, which shares of Common

Stock, upon issuance, shall be freely tradable and transferable and without restriction on resale, and (ii) cause its counsel to issue

a legal opinion, in form and substance reasonably satisfactory to 3i, to the effect that the shares of Common Stock converted may be

issued without any restrictive legends.

5. Third-Party

Beneficiary. 3i shall be a third-party beneficiary of the representations and warranties

of the Company in Section 3 of the Series C Agreement and the covenants of the Company in

Section 5 of the Series C Agreement.

6. Mutual

General Releases.

(a) Release

of 3i. In consideration of the promises set forth in this Termination, the Company, on behalf of its respective members, partners,

representatives, attorneys, executors, administrators, successors, and assigns, hereby releases, acquits, withdraws, and forever discharges

3i and all of its respective members, partners, representatives, attorneys, executors, administrators, successors, and assigns, from

any and all actions, causes of action, obligations, costs, expenses, damages, losses, claims, liabilities, suits, debts, demands, and

benefits (including actual attorneys’ fees and costs), of whatever character, in law or equity, known or unknown, suspected or

unsuspected, matured or unmatured, of any kind or nature whatsoever, now existing or arising in the future, based on any act, omission,

event, occurrence or nonoccurrence from the beginning of time to the date of full execution of this Termination, arising from or related

to this Termination or the Transaction (other than for the matters expressly set forth herein).

(b) Release

of Company. In consideration of the promises set forth in this Agreement, 3i, on behalf of its respective members, partners, representatives,

attorneys, executors, administrators, successors, and assigns, hereby releases, acquits, withdraws, and forever discharges the Company

and all of its members, partners, representatives, attorneys, executors, administrators, successors, and assigns, from any and all actions,

causes of action, obligations, costs, expenses, damages, losses, claims, liabilities, suits, debts, demands, and benefits (including

actual attorneys’ fees and costs), of whatever character, in law or equity, known or unknown, suspected or unsuspected, matured

or unmatured, of any kind or nature whatsoever, now existing or arising in the future, based on any act, omission, event, occurrence

or nonoccurrence from the beginning of time to the date of full execution of this Termination, arising from or related to this Termination

or the Transaction (other than for the matters expressly set forth herein).

7. California

Civil Code Section 1542. The Parties hereby acknowledge that they have been advised to

consult with legal counsel and are familiar with the provisions of California Civil Code

Section 1542, a statute that otherwise prohibits the release of unknown claims, which provides

as follows:

“A

GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR

AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE

DEBTOR OR RELEASED PARTY.”

8. Entire

Agreement. This Termination and the other documents referenced herein embody the entire

agreement and understanding among the Parties with respect to the subject matter hereof and

supersede all prior oral or written agreements and understandings relating to the subject

matter hereof.

9. Governing

Law. This Termination shall be deemed to be a contract made under, and shall be construed

in accordance with, the laws of the State of Delaware. In any action or proceeding between

any of the Parties arising out of or relating to this Agreement each of the Parties irrevocably

and unconditionally consents and submits to the exclusive jurisdiction and venue of the Courts

of Chancery of the State of Delaware, and waives any objection to laying venue in any such

action or proceeding in such courts, waives any objection that such courts are an inconvenient

forum or do not have jurisdiction over any Party, agrees that service of process upon such

Party in any such action or proceeding shall be effective if notice is given in accordance

with Section 10, and irrevocably and unconditionally waives the right to trial by jury.

10. Notices.

All notices and other communications hereunder shall be in writing and shall be deemed to

have been duly delivered and received hereunder (a) one business day (being any day other

than a Saturday, Sunday or other day on which the banks in New York, NY, are authorized or

obligated by applicable law to be closed) (“Business Day”) after being

sent for next Business Day delivery, fees prepaid, via a reputable international overnight

courier service, (b) upon delivery in the case of delivery by hand, or (c) on the date delivered

in the place of delivery if sent by email (with a written or electronic confirmation of delivery)

prior to 5:00 p.m. Eastern Time, otherwise on the next succeeding Business Day, in each case

to the intended recipient as set forth below:

to Ensysce Biosciences, Inc:

Ensysce

Biosciences, Inc.

7946

Ivanhoe Avenue, Suite 201

Jolla, California 92037

to 3i LP:

3i,

Wooster Street, 2nd Floor

New

York, NY 10013

Attention:

Alex Hauff

Email:

ahauff@3ifund.com

11. Other.

This Termination may be executed in multiple counterparts, each of which shall be deemed

an original, but all of which together shall constitute one and the same instrument. Counterparts

may be delivered via electronic mail (including .pdf) or other transmission method and any

counterpart so delivered shall be deemed to have been duly delivered and be valid and effective

for all purposes.

12. This

Termination shall be null and void if the Closing has not occurred within thirty (30) days

of the date hereof.

[SIGNATURE

PAGE FOLLOWS]

WITNESS WHEREOF, the Parties have each executed this Termination as of the Effective Date.

COMPANY:

ENSYSCE BIOSCIENCES, INC.

By: /s/

Print Name: Dr. Lynn Kirkpatrick

Print Title: Chief Executive Officer

[Omnibus

Amendment and Termination Agreement]

3i, LP:

By: /s/

Print Name: Maier J. Tarlow

Print Title: Manager

[Omnibus

Amendment and Termination Agreement]

Exhibit

1,233

shares of Series B Preferred Stock; and

10,037,366

warrants exercisable for shares of Common Stock:

Securities

Purchase Agreement, dated as of September 24, 2021, as well as such other agreements entered into in connection with such agreement and

related warrants issued to 3i on September 24, 2021, November 5, 2021 and August 8, 2022, with such warrants amended May 10, 2023;

Securities

Purchase Agreement, dated as of June 30, 2022, as well as such other agreements entered into in connection with such agreement and related

warrants issued to 3i on June 30, 2022 and August 8, 2022, with such warrants amended May 10, 2023;

Warrants

issued to 3i as of February 6, 2023, the Securities Purchase Agreement, dated as of February 2, 2023, as well as such other agreements

entered into in connection with such agreement and warrants;

Warrants

issued to 3i as of May 12, 2023, warrants amended as of May 10, 2023 that had been issued to 3i in 2021 and 2022, the Securities Purchase

Agreement, dated as of May 10, 2023, as well as such other agreements entered into in connection with such agreement, warrants and amended

warrants;

Warrants

issued to 3i in October 2023 and November 2023, the Securities Purchase Agreement, dated as of October 23, 2023, as well as such other

agreements entered into in connection with such agreement and warrants;

Warrants

issued to 3i as of February 14, 2024, as well as such other agreements entered into in connection with such warrants;

Warrants

issued to 3i as of August 29, 2024, the Securities Purchase Agreement, dated as of August 28, 2024, as well as such other agreements

entered into in connection with such agreement and warrants;

Warrants

issued to 3i as of March 31, 2025, to the Securities Purchase Agreement, dated as of March 30, 2025, as well as such other agreements

entered into in connection with such agreement and warrants;

Warrants

issued to 3i as of April 24, 2025 as well as such other agreements entered into in connection with such warrants;

Warrants

issued to 3i as of November 14, 2025, the Securities Purchase Agreement, dated as of November 13, 2025, as well as such other agreements,

including a Certificate of Designation of Series B Preferred Stock, entered into in connection with such agreement and warrants;

Warrants

issued to 3i as of April 6, 2026, a Subsequent Purchase Notice dated as of April 2, 2026, as well as such other agreements entered into

in connection with such notice and warrants; and

Provided

further, that any shares of Series B Preferred Stock, Warrants exercisable for Common Stock or agreements between the parties not expressly

set forth above shall be deemed to be set forth above.

EX-99.1

Filename: ex99-1.htm · Sequence: 9

Exhibit 99.1

Ensysce

Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing

Acquisition

includes clinical-stage neuroplastogenic therapy with U.S. FDA Orphan Drug Designation for the treatment of Complex Regional Pain Syndrome

(CRPS)

$21.5

million in private placement financing at initial close plus $17.1 million of Cy Biopharma’s cash and cash equivalents from a pre-acquisition

convertible note financing and up to $38.6 million upon achievement of clinical trial milestone

Pro

forma cash expected to fund CY-200 through Phase 2 proof-of-concept data and into registrational development

SAN

DIEGO, CA, August 6, 2026 — Ensysce Biosciences, Inc. (NASDAQ: ENSC) (“Ensysce” or the “Company”)

today announced it has completed the acquisition of Cy Biopharma, Inc. (“Cy Biopharma”), a privately held clinical-stage

biotechnology company developing novel neuroplastogenic therapies for Complex Regional Pain Syndrome (“CRPS”). Concurrent

with the acquisition that brought in $17.1 million in cash from a pre-acquisition convertible note financing, Ensysce entered into a

definitive agreement for the sale of Series C non-voting convertible preferred stock (with a conversion ratio of preferred to common

at 1:1,000) (the “Series C Preferred Stock”) in a private placement financing, which is expected to result in gross proceeds

to the Company of approximately $21.5 million at the initial close before deducting placement agent fees and other offering and transaction

expenses, and includes up to a $38.6 million follow-on tranche that is expected to fund development of CY-200 into 2028.

The

private placement financing was led by Ally Bridge Group and included participation from Perceptive Advisors, Dellora Investments, Ikarian

Capital and Adage Capital Partners, L.P.

The

proceeds from the investment will support the advancement of CY-200 as a novel approach to treating CRPS Type 1, which has received U.S.

Food and Drug Administration (FDA) Orphan Drug Designation. The funds are expected to carry CY-200 through key clinical milestones, including

topline data from a randomized Phase 2 clinical trial assessing the efficacy, safety and tolerability of CY-200 for symptom alleviation

in participants with CRPS Type 1, and to prepare for registrational development. Importantly, the Company believes the Orphan Drug Designation

will provide critical regulatory and commercial advantages.

“Cy

Biopharma’s neuroplastogenic approach to CRPS was the most compelling opportunity we evaluated, and the Board of Directors of Ensysce

believes this acquisition represents a significant value creation opportunity for Ensysce stockholders. The clinical data supporting

CY-200 and Cy Biopharma’s approach to treating the devastating condition of Complex Regional Pain Syndrome reinforced our conviction

for this program. The concurrent private placement financing was intentionally sized to support Cy Biopharma’s immediate strategic

objectives while maintaining financial discipline, and allow Cy Biopharma to progress its lead candidate in a pain market valued over

$1 billion for which there is currently no approved therapy. Concurrently, Ensysce intends to continue progressing PF614-MPAR, which

represents what we believe is a fundamentally new approach to opioid safety, through its PF614-MPAR-102 study with the financial support

of the National Institute on Drug Abuse,” said Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce.

CRPS

is among the most severe chronic pain disorders, with few effective treatment options and significant physical, psychological and socioeconomic

burden. Cy Biopharma has developed therapies designed to address the underlying neurobiology of CRPS rather than simply managing symptoms.

Cy Biopharma’s development strategy combines rigorous clinical science with an efficient regulatory pathway intended to accelerate

the delivery of innovative therapies to patients with significant unmet medical need.

“Our

mission has always been straightforward: to develop a therapy capable of meaningfully changing the lives of patients living with Complex

Regional Pain Syndrome,” said James Morrison, Founder and Chief Executive Officer of Cy Biopharma. “This transaction provides

the capital, public market platform and strategic flexibility to help us execute that mission. We believe the upcoming Phase 2 topline

data for CY-200 will demonstrate the potential of this approach for patients who today have no approved treatment option. Beyond CY-200,

our pipeline of differentiated new chemical entities is designed to increase stress resilience, strengthen descending pain control and

promote neuroplasticity. We believe we are entering the public markets at the point where clinical execution – not financing –

can be our primary near-term focus, and we are looking forward to an exciting second half of the year.”

Management

and Organization

Following

completion of the transaction, James Morrison, Founder and Chief Executive Officer of Cy Biopharma, will serve as President of the Company

and will join its Board of Directors.

About

the Acquisition and Private Placement Financing

The

acquisition is structured as a stock-for-stock merger, pursuant to which all outstanding equity interests of Cy Biopharma will be exchanged

based on a fixed exchange ratio for an aggregate of 282,122 shares of Series C Preferred Stock (representing 282,122,000 shares on an

as-converted-to-common basis and without giving effect to any beneficial ownership limitations). Concurrent with the acquisition, the

Company entered into a definitive agreement for a private placement financing to raise an aggregate of approximately $43 million in gross

proceeds over two tranches, in which the investors will be issued an aggregate of 120,260 shares of Series C Preferred Stock (representing

120,260,000 shares on an as-converted-to-common basis and without giving effect to any beneficial ownership limitations) at a price of

$321.79 per share (or $0.32179 per share on an as-converted basis) for the initial tranche of 66,811 shares of Series C Preferred Stock,

and a price of $402.24 per share (or $0.40224 per share on an as-converted basis) for the second tranche of up to 53,449 shares of Series

C Preferred Stock (the “Milestone Closing”). The first tranche of the private placement is expected to close on August 7,

2026, and the Milestone Closing will close subject to achievement of a clinical trial milestone. Concurrently, the Company also resolved

all existing contractual matters with a third party in exchange for the conversion of its outstanding Series B Preferred Stock and warrants

into common stock and Series C Preferred Stock, subject to beneficial ownership limitations. Subject to Company stockholder approval

in accordance with Nasdaq listing rules, each share of Series C Preferred Stock will automatically convert into 1,000 shares of common

stock, subject to beneficial ownership limitations. Following stockholder approval, ownership of the Company, on a fully diluted basis

not including any shares that may be issued in the Milestone Closing, will be approximately 73.86% for Cy Biopharma’s former equityholders,

approximately 7.57% for the Company and approximately 17.49% for new investors in the private placement with a combined fully diluted

equity value of approximately $101.4 million (excluding transaction fees).

The

acquisition was approved by the Board of Directors of the Company and the Board of Directors and stockholders of Cy Biopharma. The closings

of the acquisition and the private placement are not subject to the approval of the Company’s stockholders. The approval of the

Company’s stockholders is required, among other things, under Nasdaq listing rules in order for the Series C Preferred Stock to

be converted into shares of Company common stock, and the Company is required under the terms of the financing to hold a stockholder

meeting to obtain this vote.

Advisors

Troutman

Pepper Locke LLP served as legal counsel to Ensysce. Orrick, Herrington & Sutcliffe LLP served as legal counsel to Cy Biopharma.

Wedbush Securities Inc. served as the exclusive financial advisor to Cy Biopharma. Tungsten Advisors served as the exclusive financial

advisor to Ensysce. H.C. Wainwright provided the fairness opinion for the transaction.

Cantor

and UBS Investment Bank served as placement agents for the private placement financing. Mintz, Levin, Cohn, Ferris, Glovsky and Popeo,

P.C. served as legal counsel to the placement agents.

About

Ensysce Biosciences

Ensysce

Biosciences is a clinical-stage company with a goal of disrupting the analgesic landscape by introducing a new class of highly novel

opioids for the treatment of severe pain. Leveraging its Trypsin-Activated Abuse Protection (TAAP™) and Multi-Pill Abuse Resistance

(MPAR®) platforms, the Company is developing unique, tamper-proof treatment options for pain that minimize the risk of both drug

abuse and overdose. Ensysce’s products are anticipated to provide safer options to treat patients suffering from severe pain and

assist in preventing deaths caused by medication abuse. For more information, please visit www.ensysce.com.

About

Cy Biopharma

Biopharma is a clinical-stage biotechnology company developing novel neuroplastogenic therapies for severe chronic pain disorders. The

company is advancing innovative treatments designed to address the underlying mechanisms of Complex Regional Pain Syndrome with the goal

of delivering durable clinical benefit for patients with significant unmet medical need. For more information, please visit www.cybiopharma.com.

Forward-Looking

Statements

contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the

safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting

the foregoing, the use of words such as “may,” “intends,” “might,” “will,” “expect,”

“plan,” “possible,” “believe” and other similar expressions are intended to identify forward-looking

statements. All forward-looking statements are based upon management’s estimates and forecasts and reflect the current views, assumptions,

expectations and opinions of the Company as of the date hereof. All forward-looking statements are subject to risks and uncertainties

that may cause actual results to differ materially from those expected, including (i) possible Nasdaq delisting; (ii) failure to obtain

stockholder approval for the conversion of the Series C non-voting convertible preferred stock into shares of common stock of the combined

company; (iii) risks related to the combined company’s ability to manage its operating expenses and its expenses associated with

the acquisition; (iv) unexpected costs, charges or expenses resulting from the acquisition; (v) potential adverse reactions or changes

to business relationships resulting from the announcement or completion of the acquisition; (vi) the uncertainties associated with the

combined company’s product candidates, as well as risks associated with the clinical development and regulatory approval of product

candidates, including potential delays in the commencement and completion of clinical trials, studies and evaluations; (vii) risks related

to the inability of the combined company to obtain sufficient additional capital, including the continuation of government funding, to

continue to advance these or other product candidates; (viii) failure to achieve the clinical trial milestone for the Milestone Closing;

(ix) uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; (x)

risks related to the failure to realize any value from product candidates currently being developed and anticipated to be developed in

light of inherent risks and difficulties involved in successfully bringing product candidates to market; and (xi) risks associated with

the possible failure to realize certain anticipated benefits of the acquisition, including with respect to future financial and operating

results. These statements are also subject to risks and uncertainties described in Ensysce’s most recent annual report on Form

10-K and quarterly report on Form 10-Q and in other filings that it makes with the U.S. Securities and Exchange Commission (the “SEC”),

available at www.sec.gov. Any forward-looking statement speaks only as of the date on which it was made. Ensysce undertakes no obligation

to publicly update or revise any forward-looking statement, except as required under applicable law.

Offer or Solicitation; Important Information About the Acquisition and Where to Find It

This

press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect

of the acquisition and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of the Company or Cy

Biopharma, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale

would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities

shall be made, except by means of a prospectus meeting the requirements of Section 10 of the Securities Act or an exemption therefrom.

The

Company expects to file a proxy statement with the SEC relating to the approval of the conversion of the Series C Preferred Stock and

other matters related to the conversion of the Series C Preferred Stock. The definitive proxy statement will be sent to all Company stockholders.

Before making any voting decision, investors and security holders of the Company are urged to read the proxy statement and all other

relevant documents filed or that will be filed with the SEC in connection with the approval of the conversion of the Series C Preferred

Stock and other matters related to the conversion of the Series C Preferred Stock as they become available because they will contain

important information. Stockholders will be able to obtain free copies of the proxy statement and all other relevant documents filed

or that will be filed with the SEC by the Company through the website maintained by the SEC at www.sec.gov.

Participants

in Solicitation

The

Company, Cy Biopharma, and their respective directors, executive officers and employees may be deemed to be participants in the solicitation

of proxies in respect of the acquisition. Information regarding the persons who may, under the rules of the SEC, be deemed participants

in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained

in the proxy statement and other relevant materials to be filed with the SEC when they become available.

Ensysce

Biosciences Company Contact:

Lynn Kirkpatrick, Ph.D.

Chief Executive Officer

(858) 263-4196

Ensysce Biosciences Investor Relations

Contact:

Shannon Devine

MZ North America

Main: 203-741-8811

ENSC@mzgroup.us

Source: Ensysce

Biosciences Inc.

EX-99.2

Filename: ex99-2.htm · Sequence: 10

Exhibit 99.2

GRAPHIC

Filename: ex99-2_001.jpg · Sequence: 11

Binary file (53761 bytes)

Download ex99-2_001.jpg

GRAPHIC

Filename: ex99-2_002.jpg · Sequence: 12

Binary file (238235 bytes)

Download ex99-2_002.jpg

GRAPHIC

Filename: ex99-2_003.jpg · Sequence: 13

Binary file (120316 bytes)

Download ex99-2_003.jpg

GRAPHIC

Filename: ex99-2_004.jpg · Sequence: 14

Binary file (126125 bytes)

Download ex99-2_004.jpg

GRAPHIC

Filename: ex99-2_005.jpg · Sequence: 15

Binary file (176196 bytes)

Download ex99-2_005.jpg

GRAPHIC

Filename: ex99-2_006.jpg · Sequence: 16

Binary file (103268 bytes)

Download ex99-2_006.jpg

GRAPHIC

Filename: ex99-2_007.jpg · Sequence: 17

Binary file (69086 bytes)

Download ex99-2_007.jpg

GRAPHIC

Filename: ex99-2_008.jpg · Sequence: 18

Binary file (96405 bytes)

Download ex99-2_008.jpg

GRAPHIC

Filename: ex99-2_009.jpg · Sequence: 19

Binary file (96442 bytes)

Download ex99-2_009.jpg

GRAPHIC

Filename: ex99-2_010.jpg · Sequence: 20

Binary file (94443 bytes)

Download ex99-2_010.jpg

GRAPHIC

Filename: ex99-2_011.jpg · Sequence: 21

Binary file (101154 bytes)

Download ex99-2_011.jpg

GRAPHIC

Filename: ex99-2_012.jpg · Sequence: 22

Binary file (99639 bytes)

Download ex99-2_012.jpg

GRAPHIC

Filename: ex99-2_013.jpg · Sequence: 23

Binary file (164208 bytes)

Download ex99-2_013.jpg

GRAPHIC

Filename: ex99-2_014.jpg · Sequence: 24

Binary file (133412 bytes)

Download ex99-2_014.jpg

GRAPHIC

Filename: ex99-2_015.jpg · Sequence: 25

Binary file (127426 bytes)

Download ex99-2_015.jpg

GRAPHIC

Filename: ex99-2_016.jpg · Sequence: 26

Binary file (71912 bytes)

Download ex99-2_016.jpg

GRAPHIC

Filename: ex99-2_017.jpg · Sequence: 27

Binary file (94591 bytes)

Download ex99-2_017.jpg

GRAPHIC

Filename: ex99-2_018.jpg · Sequence: 28

Binary file (129645 bytes)

Download ex99-2_018.jpg

GRAPHIC

Filename: ex99-2_019.jpg · Sequence: 29

Binary file (135808 bytes)

Download ex99-2_019.jpg

GRAPHIC

Filename: ex99-2_020.jpg · Sequence: 30

Binary file (109166 bytes)

Download ex99-2_020.jpg

GRAPHIC

Filename: ex99-2_021.jpg · Sequence: 31

Binary file (116823 bytes)

Download ex99-2_021.jpg

GRAPHIC

Filename: ex99-2_022.jpg · Sequence: 32

Binary file (46866 bytes)

Download ex99-2_022.jpg

GRAPHIC

Filename: ex99-2_023.jpg · Sequence: 33

Binary file (69298 bytes)

Download ex99-2_023.jpg

GRAPHIC

Filename: ex99-2_024.jpg · Sequence: 34

Binary file (145009 bytes)

Download ex99-2_024.jpg

GRAPHIC

Filename: ex99-2_025.jpg · Sequence: 35

Binary file (121014 bytes)

Download ex99-2_025.jpg

GRAPHIC

Filename: ex99-2_026.jpg · Sequence: 36

Binary file (105119 bytes)

Download ex99-2_026.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 41

v3.26.1

Cover

Aug. 05, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 05, 2026

Current Fiscal Year End Date

--12-31

Entity File Number

001-38306

Entity Registrant Name

Ensysce

Biosciences, Inc.

Entity Central Index Key

0001716947

Entity Tax Identification Number

82-2755287

Entity Incorporation, State or Country Code

Entity Address, Address Line One

7946

Ivanhoe Avenue

Entity Address, Address Line Two

Suite 201

Entity Address, City or Town

Jolla

Entity Address, State or Province

Entity Address, Postal Zip Code

92037

City Area Code

(858)

Local Phone Number

263-4196

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, par value $0.0001 per share

Trading Symbol

ENSC

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name:

dei_CurrentFiscalYearEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:gMonthDayItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration